[
    {
        "Gene name":"SLC29A1",
        "Genomic Position":"6:44191363-44201888(+) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"SLC29A1_Overexpression",
        "Disease":"Pancreatic Adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine",
        "Description":"Surgically resected PDACs were used to create tissue microarrays, which were scored for antibody staining of hENT1 (SLC29A1). For patients treated with gemcitabine (n=243), high levels of hENT1 were associated with longer survival time in Kaplan-Meier survival analysis (HR 0.43, 95% CI 0.29-0.63, P < .0001) and by multivariate proportional hazards model (HR 0.34, 95% CI 0.22-0.53, P < .0001). For patients treated with surgery alone (n=142), there was no association with survival.",
        "rs value":null,
        "pmid":"PubMed:22705007",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PML",
        "Genomic Position":"15:74287058-74339112(+) | 15q24.1",
        "CDS Mutation":null,
        "AA Mutation":"PML_PML::RARA",
        "Disease":"Acute Promyelocytic Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tretinoin",
        "Description":"Fusion protein degradation is accelerated upon ATRA treatment of acute promyelocytic cells at pharmalogical concentrations.",
        "rs value":null,
        "pmid":"PubMed:8674046",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PML",
        "Genomic Position":"15:74287058-74339112(+) | 15q24.1",
        "CDS Mutation":null,
        "AA Mutation":"PML_PML::RARA",
        "Disease":"Acute Promyelocytic Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tretinoin,Arsenic Trioxide",
        "Description":"ATRA\/Arsenic combined with standard chemotherapy has been shown to induce a complete remission rate of greater than 75% of patients with acute promyelocytic leukemia harboring the PML-RARa fusion.",
        "rs value":null,
        "pmid":"PubMed:11704842",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PML",
        "Genomic Position":"15:74287058-74339112(+) | 15q24.1",
        "CDS Mutation":null,
        "AA Mutation":"PML_B2_DOMAIN_MUTATION",
        "Disease":"Acute Promyelocytic Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tretinoin",
        "Description":"Mutations in the B2 domain of PML in the PML-RARa fusion have been shown to be associated with resistance to standard ATRA treatment in patients with acute promyelocytic leukemia.",
        "rs value":null,
        "pmid":"PubMed:23670176",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PML",
        "Genomic Position":"15:74287058-74339112(+) | 15q24.1",
        "CDS Mutation":null,
        "AA Mutation":"PML_PML::RARA_A216V",
        "Disease":"Acute Promyelocytic Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Arsenic Trioxide",
        "Description":"Five point mutations were identified in the PML B2 domain of PML-RARA transcripts in 9 patients diagnosed with APL and resistant to arsenic. DNA from these 9 patients was cloned into flag-tagged pCag expression vectors. Immunoblotting analyses demonstrated that after the addition of arsenic, the A216V, S214L, and A216T mutants experienced no change in expression or degradation when compared to wild type cells, indicating that these mutants were not inhibited by arsenic and demonstrate resistance. Immunofluorescent measurements indicated arsenic treatment did not alter the nuclear localization pattern of mutants A216V, S214L, or A216T, but had an effect on the localization of other mutants as well as wild type cells.",
        "rs value":null,
        "pmid":"PubMed:26537301",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PML",
        "Genomic Position":"15:74287058-74339112(+) | 15q24.1",
        "CDS Mutation":null,
        "AA Mutation":"PML-RARA_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Belinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00351975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PML",
        "Genomic Position":"15:74287058-74339112(+) | 15q24.1",
        "CDS Mutation":null,
        "AA Mutation":"PML_PML::RARA_A216V",
        "Disease":"Acute Promyelocytic Leukemia",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Tretinoin",
        "Description":"The mutation A216V in the B2 domain of PML in the PML-RARa fusion was seen in a patient with ATRA-resistant acute promyelocytic leukemia.",
        "rs value":null,
        "pmid":"PubMed:21613260",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PML",
        "Genomic Position":"15:74287058-74339112(+) | 15q24.1",
        "CDS Mutation":null,
        "AA Mutation":"PML_PML::RARA_L218P",
        "Disease":"Acute Promyelocytic Leukemia",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Tretinoin",
        "Description":"The PML L218P mutation in the PML-RARa fusion was observed in a patient with previously ATRA-treated, relapsed acute promyelocytic leukemia refractory to arsenic trioxide.",
        "rs value":null,
        "pmid":"PubMed:21613260",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PML",
        "Genomic Position":"15:74287058-74339112(+) | 15q24.1",
        "CDS Mutation":null,
        "AA Mutation":"PML_PML::RARA",
        "Disease":"Acute Promyelocytic Leukemia",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tretinoin",
        "Description":"A 39-year old woman who presented with acute myeloid leukemia revealed a complicated genetic profile using conventional metaphase cytogenetics and FISH analysis.  Whole genome sequencing elucidated a PML-RARA fusion, which can be successfully treated with ATRA. Uncovering this mutation prevented an unnecessary allogeneic transplant and the patient remained in remission 15 months post-treatment (date of publication).",
        "rs value":null,
        "pmid":"PubMed:21505136",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_Amplification",
        "Disease":"Liposarcoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":"In a phase 2 clinical trial, NCT01209598, 30 patients with CDK4-amplified and RB-expressing well differentiated and dedifferentiated liposarcomas (WDLS\/DDLS) were treated with a selective CDK 4\/6 inhibitor, PD0332991. Treatment with PD0332991 was associated with favorable progression free survival rates (66% PFS rate, primary end point being greater than 40%) suggesting that CDK4 amplification is predictive of sensitivity to CDK4 inhibitor therapy.",
        "rs value":null,
        "pmid":"PubMed:23569312",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"bone | chordoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03110744",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03242382",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"soft tissue | liposarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02571829",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03238196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified_or_CDK6_unspecified_or_CDKN2A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04591431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"soft tissue | liposarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03096912",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03239015",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"skin | malignant melanoma | acral lentiginous",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03454919",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02806648",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"central nervous system | glioma | oligodendroglioma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02530320",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03890952",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04074785",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"soft tissue | liposarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01209598",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_Amplification",
        "Disease":"Liposarcoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":"A total of 59 patients with well-differentiated or dedifferentiated liposarcomas were enrolled in a phase 2 study to evaluate palbociclib efficacy. Half of the patients had received prior treatment and half were treatment naive. Of the 59 patients, at least 34 conferred CDK4 amplification and the remaining were not tested for CDK4 amplification. In the initial cohort (n=28), where all patients had confirmed CDK4 amplification, at least 14 of the patients were progression free at 12 weeks. Overall progression-free survival at 12 weeks was 57.2% and overall median PFS was 17.9 weeks. There was 1 complete response. Toxic effects were primarily hematologic and included neutropenia (grade 3, n\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd20 [33%]; grade 4, n\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd2 [3%]) b",
        "rs value":null,
        "pmid":"PubMed:27124835",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03238196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03237390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified_or_CDK6_unspecified_or_CDKN2A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02645149",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03784014",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02187783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified_and_CDK6_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05432518",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dalpiciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02671513",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04594005",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03310879",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abiraterone acetate + Prednisone + TQB3616",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05156450",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PF-07220060 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04557449",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified_and_MDM2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALRN-6924",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02264613",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"soft tissue | liposarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SPH4336",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05580588",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + LY3214996",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04391595",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified_and_CDK6_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05159245",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04393285",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified_or_CDK6_unspecified_or_CDKN2A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride + Pazopanib + Siremadlin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05180695",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"soft tissue | liposarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib + Siremadlin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02343172",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"soft tissue | liposarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Milademetan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04979442",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALRN-6924 + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03725436",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALRN-6924 + Cytarabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03654716",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Idasanutlin ",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01462175",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BI 907828 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03449381",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"soft tissue | liposarcoma | dedifferentiated",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BI 907828 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05218499",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALRN-6924",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02264613",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BI 907828 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05512377",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Milademetan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05012397",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"central nervous system | NS | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SGT-53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03554707",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"soft tissue | liposarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"APG115 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03611868",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Idasanutlin ",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01773408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Idasanutlin ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04589845",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idasanutlin ",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01773408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM2",
        "Genomic Position":"12:69201956-69239214(+) | 12q15",
        "CDS Mutation":null,
        "AA Mutation":"MDM2_EXPRESSION",
        "Disease":"Malignant Pleural Mesothelioma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Pemetrexed,Cisplatin",
        "Description":"72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated with cisplatin and pemetrexed (standard of care therapy).",
        "rs value":null,
        "pmid":"PubMed:25668009",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":0,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01205828",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Cisplatin + Olaparib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02121990",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"pancreas | carcinoma | ductal carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04666740",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04858334",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Chemotherapy + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03326193",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Navitoclax + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05358639",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_RAD51_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Selumetinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02677038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abiraterone acetate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03732820",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02734004",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03810105",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_BAP1_unspecified_or_MSH2_unspecified_or_PALB2_unspecified_or_BRIP1_unspecified_or_ABL1_unspecified_or_ATR_unspecified_or_ATRX_unspecified_or_BARD1_unspecified_or_BRD4_unspecified_or_CCND1_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_DOT1L_unspecified_or_FANCC_unspecified_or_FANCE_unspecified_or_FANCG_unspecified_or_FANCL_unspecified_or_IKBKE_unspecified_or_MEN1_unspecified_or_MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_MUTYH_unspecified_or_NPM1_unspecified_or_PMS2_unspecified_or_POLD1_unspecified_or_POLE_unspecified_or_RAD51_unspecified_or_SMARCB1_unspecified_or_STK11_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03375307",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03012321",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_FANCL_unspecified_or_PALB2_unspecified_or_RAD51B_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_RAD5L_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05262608",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00989651",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin + Paclitaxel + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03462212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_CD274_unspecified_or_ERCC1_unspecified_or_KEAP1_unspecified_or_SLFN11_unspecified_or_STK11_unspecified_or_TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib + Platinum-doublet chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05568212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Buparlisib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01623349",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_PALB2_unspecified_or_FANCA_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03570476",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_CHEK2_unspecified_or_MLH1_unspecified_or_MRE11_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03434158",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abiraterone acetate + Olaparib + Prednisone",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03012321",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab biosimilar Mvasi + Chemotherapy + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05183984",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01874353",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02502266",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Chemotherapy + Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03737643",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03534453",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02987543",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01844986",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_ATR_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_BLM_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_GEN1_unspecified_or_FANCA_unspecified_or_FANCD2_unspecified_or_MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_MRE11A_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PMS2_unspecified_or_POLE_unspecified_or_RAD50_unspecified_or_RAD51_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_XRCC2_unspecified",
        "Disease":"biliary tract | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05222971",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride liposome + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03161132",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_CCNE_unspecified_or_FANCB_unspecified_or_PALB2_unspecified_or_PTEN_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Selumetinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02511223",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01078662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Olaparib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04261465",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04034927",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03278717",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02264678",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03579316",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04377087",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_PALB2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02029001",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04090567",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abiraterone acetate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05171816",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"LHRH agonist + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05498272",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin + Paclitaxel + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03462212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"NUV-868 + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05252390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02734004",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02446600",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | serous carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00753545",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02184195",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04548752",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01661868",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02446600",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin + Doxorubicin hydrochloride liposome + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01459380",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02345265",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride liposome + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT03161132",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02571725",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02446600",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride liposome + Olaparib + Trabectedin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03470805",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02282020",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01623349",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03025035",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Cisplatin + Olaparib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02121990",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05498155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03394885",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05332561",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin + Paclitaxel + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03462212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05457257",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA1 patients specifically, the hazard ratio was 0.54, 95% CI 0.37-0.79).",
        "rs value":null,
        "pmid":"PubMed:28578601",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03297606",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2\ufffd\ufffd\ufffdnegative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy ",
        "rs value":null,
        "pmid":"PubMed:28792849",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER\/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo. Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).",
        "rs value":null,
        "pmid":"PubMed:34081848",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Durvalumab + Olaparib + Stereotactic radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04711824",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_ATR_unspecified_or_ATRX_unspecified_or_BLM_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_CTIP_unspecified_or_ERCC2_unspecified_or_ERCC3_unspecified_or_ERCC4_unspecified_or_ERCC5_unspecified_or_ERCC6_unspecified_or_FANCA_unspecified_or_FANCB_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCG_unspecified_or_MDC1_unspecified_or_MRE11A_unspecified_or_MUTYH_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_POLE_unspecified_or_POLQ_unspecified_or_RAD50_unspecified_or_RAD51_unspecified_or_RAD51B_unspecified_or_RAD51D_unspecified_or_RAD51C_unspecified_or_RAD52_unspecified_or_RAD54L_unspecified_or_RECQL4_unspecified_or_WRN_unspecified_or_XRCC2_unspecified_or_XRCC3_unspecified_or_XRCC4_unspecified_or_XRCC5_unspecified_or_XRCC6_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03448718",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT03117933",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03009682",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02484404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00679783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02849496",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00679783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03150576",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05201612",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03286842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02502266",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Ovarian Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undifferentiated ovarian cancer.",
        "rs value":null,
        "pmid":"PubMed:23346317",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01116648",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05209529",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02032823",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Pancreatic Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Twenty-three patients with pancreatic cancer havoring BRCA1\/2 germline mutations received olaparib. Five (21.7%) patients had a BRCA1 mutation. All but one had received prior gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%.",
        "rs value":null,
        "pmid":"PubMed:25366685",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02000622",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05659914",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02734004",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02681562",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04330040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02345265",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin + Doxorubicin hydrochloride liposome + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01459380",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01874353",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01844986",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01116648",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03967938",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride liposome + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03161132",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Irinotecan + Mitomycin C + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01296763",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04330040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02476968",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02477644",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Sapacitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03641755",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03330847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02446600",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03330847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Dostarlimab + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03806049",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05629429",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Pamiparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05044871",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05498155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"(BRCA1_unspecified_or_BRCA2_unspecified)_and_CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00989651",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"(BRCA1_unspecified_or_BRCA2_unspecified)_and_CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01540565",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02734004",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02561832",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02264678",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01623349",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01844986",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_FANCL_unspecified_or_PALB2_unspecified_or_PPP2R2A_unspecified_or_RAD51B_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_RAD54L_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02987543",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02502266",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01116648",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03239015",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03931551",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA_2_unspecified_or_ATM_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_FANCI_unspecified_or_FANCL_unspecified_or_PALB2_unspecified_or_RAD51B_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_RAD54L_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02546661",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA_2_unspecified_or_ATM_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_FANCL_unspecified_or_HDAC2_unspecified_or_PALB2_unspecified_or_PPP2R2A_unspecified_or_RAD51B_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_RAD54L_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03432897",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05482074",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02418624",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"(BRCA1_unspecified_or_BRCA2_unspecified)_and_CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02953457",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Fulvestrant + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04053322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_FANCL_unspecified_or_MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PALB2_unspecified_or_PMS2_unspecified_or_PPP2RA_unspecified_or_RAD51B_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_RAD54L_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04592211",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05033756",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00989651",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Buparlisib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01623349",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Ovarian Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were randomized 2:1 to receive olaparib or placebo. The olaparib arm had 191 patients with BRCA1 mutation, 66 BRCA2, and 3 patients with both BRCA1 and BRCA2, while the placebo arm had 91 BRCA1 and 40 BRCA2 mutant patients. Analysis of PFS by blinded independent review found freedom from disease progression or death at 3 years was 69% in the olaparib arm compared with 35% in the placebo arm (hazard ratio for disease progression or death, 0.28; 95% CI, 0.20 to 0.39; P<0.001).",
        "rs value":null,
        "pmid":"PubMed:30345884",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02855697",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin + Doxorubicin hydrochloride liposome + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01459380",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02983799",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Ovarian Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were randomized 2:1 to receive olaparib or placebo. Two patients were found to have somatic BRCA1\/2 mutations. Analysis of PFS by blinded independent review found freedom from disease progression or death at 3 years was 69% in the olaparib arm compared with 35% in the placebo arm (hazard ratio for disease progression or death, 0.28; 95% CI, 0.20 to 0.39; P<0.001).",
        "rs value":null,
        "pmid":"PubMed:30345884",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Prostate Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). The study found that in men with mCRPC who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). For 15 patients with BRCA1 mutations specifically, PFS HR 0.41 [0.13-1.39]. . Based on the results of this study, on May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone.",
        "rs value":null,
        "pmid":"PubMed:32343890",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Olaparib",
        "Description":"In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.",
        "rs value":null,
        "pmid":"PubMed:21862407",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Ovarian Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7\/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11\/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.",
        "rs value":null,
        "pmid":"PubMed:21862407",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01874353",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Cisplatin + Olaparib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02121990",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"In this phase 1 trial, 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1\/2 mutation carriers. 19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation.",
        "rs value":null,
        "pmid":"PubMed:19553641",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Ovarian Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib,Cediranib",
        "Description":"46 women with platinum-sensitive, high-grade, BRCA1\/2+ ovarian cancer received either olaparib monotherapy or olaparib\/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).",
        "rs value":null,
        "pmid":"PubMed:25218906",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Pancreatic Adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"In the phase 3 POLO trial patients who had germline BRCA1\/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to maintenance olaparib or placebo. BRCA1\/2 mutation was determine by the BRAC-Analysis CDx test. Median progression free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% CI, 0.35 to 0.82; p=0.004). BRCA1 mutations were present in 29\/92 patients in the olaparib group and 16\/62 patients in the placebo group, while one patient receiving olaparib had both BRCA1 and BRCA2 germline mutations. Responses were seen in 18 (20%) patients in the olaparib group, including two complete responses. The safety profile of olaparib was similar to that observed in other patient populations.",
        "rs value":null,
        "pmid":"PubMed:31157963",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER\/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo.  Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).",
        "rs value":null,
        "pmid":"PubMed:34081848",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified_or_CHEK2_unspecified_or_ATM_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03601923",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00664781",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03329937",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"biliary tract | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil + Irinotecan hydrochloride liposome + Leucovorin calcium + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03337087",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03824704",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04423185",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04171700",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02354586",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02354586",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03551171",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_RAD51_unspecified_or_RAD51B_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03533946",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCB_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCG_unspecified_or_FANCI_unspecified_or_FANCL_unspecified_or_FANCM_unspecified_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03413995",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05519670",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Copanlisib + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03586661",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01074970",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02505048",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Copanlisib + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03586661",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04423185",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03759600",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02826512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04493060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03462212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03992131",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03598270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03140670",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03462212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Best supportive care + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03945084",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abiraterone acetate + Niraparib + Prednisone",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03748641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_HDAC2_unspecified_or_PALB2_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abiraterone acetate + Niraparib + Prednisone",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03748641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT02975934",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03522246",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_RAD51_unspecified_or_RAD54L_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04276376",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Ovarian Cancer",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":"A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA mutant (BRCA1 or BRCA2) patients, 14 had homozygous somatic BRCA1 mutation or deletion. Confirmed objective response was seen in 71% (10\/14) of the somatic BRCA1 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7\/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).",
        "rs value":null,
        "pmid":"PubMed:27908594",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02042378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Aromatase inhibitors + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04240106",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03598270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Copanlisib + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03586661",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Ovarian Cancer",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":"A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 14 had germline BRCA1 mutation, 13 of which were homozygous mutation and one with unknown zygosity. Confirmed objective response was seen in 86% (12\/14) of the germline BRCA1 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7\/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).",
        "rs value":null,
        "pmid":"PubMed:27908594",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil + Irinotecan hydrochloride liposome + Leucovorin calcium + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03337087",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"M4344 + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04655183",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00664781",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04915755",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01905592",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03598270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03759587",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Mirvetuximab Soravtansine + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03552471",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Placebo + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03522246",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified_or_ATM_unspecified_or_ARID1A_unspecified_or_GEN1_unspecified_or_BARD1__unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_NBN_unspecified_or_RAD51_unspecified_or_RAD51B_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_RAD54L_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03840967",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02855944",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01968213",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03759600",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01847274",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib + Pamiparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05038839",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03759600",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil + Irinotecan hydrochloride liposome + Leucovorin calcium + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03337087",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"pancreas | carcinoma | ductal carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04673448",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03759587",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Mirvetuximab Soravtansine + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03552471",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03759587",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03598270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_RAD51_unspecified_or_RAD54L_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04276376",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT02975934",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03598270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Mirvetuximab Soravtansine + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03552471",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03462212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Copanlisib + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03586661",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03598270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04673448",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_PALB2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Docetaxel + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03442556",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04716686",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04673448",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03845296",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04673448",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCD2_unspecified_or_FANCL_unspecified_or_GEN1_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD51_unspecified_or_RAD51c_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04030559",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_RAD51_unspecified_or_RAD54L_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04276376",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_CHEK2_unspecified_or_PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"HX008 + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04508803",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02952534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation_OR_BRCA2_Mutation",
        "Disease":"Ovary Epithelial Cancer",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":"In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enrolled. Of the 553 enrolled, 203 had germline BRCA1\/2 mutations and 350 had non-germline BRCA1\/2 mutations (including both somatic mutant and wildtype BRCA1\/2); BRCA1\/2 mutation status was determined via BRACAnalysis testing (Myriad Genetics). The patients were randomized in a 2:1 ratio to receive niraparib 300 mg or placebo once daily. Patients in the niraparib group had a significantly longer median duration of progression-free survival than the placebo group: 21.0 vs. 5.5 months in the gBRCA cohort (hazard ratio, 0.27; 95% CI: 0.17 - 0.41; p < 0.001) and 9.3 months vs. 3.9 months in the overall non-gBRCA cohort (hazard ratio, 0.45; 95% CI: 0.34 - 0.61; p < 0.001).",
        "rs value":null,
        "pmid":"PubMed:27717299",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04439227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03767075",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01630226",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cellectra 2000 + INO5401 + INO9012",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04367675",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib + ZEN003694",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05327010",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SC10914",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02940132",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05479487",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Pancreatic Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Oxaliplatin,Cisplatin",
        "Description":"Patients with BRCA1\/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)",
        "rs value":null,
        "pmid":"PubMed:25072261",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_CD274_unspecified_or_ERCC1_unspecified_or_KEAP1_unspecified_or_SLFN11_unspecified_or_STK11_unspecified_or_TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05568212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pidnarulex",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04890613",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Onalespib lactate + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02627430",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03565991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03330405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03990896",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04755868",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"FOLFOX-6 + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01489865",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04296370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02836028",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Novobiocin sodium",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05687110",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04598321",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_CD274_unspecified_or_ERCC1_unspecified_or_KEAP1_unspecified_or_SLFN11_unspecified_or_STK11_unspecified_or_TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Platinum-doublet chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05568212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ascorbic acid + Autologous Hematopoietic Stem Cell Transplantation + Carmustine + Ethanol + Melphalan + Vitamin B12B",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04150042",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02282345",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01506609",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride liposome + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01145430",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02286687",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01282333",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"FOLFIRI + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02890355",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02836028",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03499353",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"NUV-868",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05252390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enzalutamide + NUV-868",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05252390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TSL-1502",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05420779",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HWH340",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03415659",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03579316",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Onalespib lactate + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02627430",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02034916",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Trabectedin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00580112",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00892736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cellectra 2000 + INO5401",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04367675",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AK112",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04870177",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Onalespib lactate + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02627430",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KRAS peptide vaccine + poly ICLC",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05013216",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Docetaxel + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04664972",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Mercaptopurine + Methotrexate",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01432145",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01506609",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01149083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01399840",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02163694",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01282333",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03330405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Onalespib lactate + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02627430",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA_2_unspecified_or_ATM_unspecified_or_ATR_unspecified_or_CHEK2_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Prexasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02873975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01989546",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03509636",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03330405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radiotherapy + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03968406",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Denosumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04711109",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05597527",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05097599",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD9574",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05417594",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01306032",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | serous carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03933761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dalpiciclib + Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04355858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02595905",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02836028",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Epirubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04499118",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03575065",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01585805",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01585805",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01472783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"pancreas | carcinoma | ductal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chlorambucil ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04692740",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Senaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04822961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03148795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05327621",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Choriogonadotropin alfa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03495609",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01009788",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afuresertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04374630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04978012",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abiraterone acetate + Prednisone",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03012321",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ART4215",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04991480",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"VTP-850",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05617040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01306032",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Epacadostat + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03432676",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02326844",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SC10914",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04486937",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afuresertib + LAE001 + Prednisone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04060394",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cyclophosphamide + Paclitaxel + Veliparib + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02032277",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01306032",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SC10914",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02940132",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02836028",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Denosumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03382574",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Prophylactic contralateral breast irradiation",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04960839",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"fallopian tube | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01306032",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01351909",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | carcinosarcoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03933761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lurbinectedin",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02454972",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_CHEK2_unspecified_or_MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PALB2_unspecified_or_PMS2_unspecified_or_PTEN_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03040791",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin,Carboplatin",
        "Description":"In an evaluation of 77 patients, those who had BRCA1\/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.",
        "rs value":null,
        "pmid":"PubMed:25847936",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Stereotactic Body Radiation Therapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04593381",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02836028",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Mercaptopurine + Methotrexate",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01432145",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Senaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04089189",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"peritoneum | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02836028",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01282333",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04499118",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Ovarian Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Platinum Compound",
        "Description":"In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1\/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1\/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum-based therapy.",
        "rs value":null,
        "pmid":"PubMed:24240112",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_ATR_unspecified_or_BAP1_unspecified_or_BLM_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_DSS1_unspecified_or_EMSY_unspecified_or_ERCC3_unspecified_or_FANCA_unspecified_or_HDAC2_unspecified_or_LIG4_unspecified_or_LIG3_unspecified_or_MRE11_unspecified_or_MLH3_unspecified_or_MLH1_unspecified_or_MDC1_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PARP1_unspecified_or_PRKDC_unspecified_or_RAD50_unspecified_or_RAD51_unspecified_or_XRCC6_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04187833",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Mitomycin C",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04747717",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Famitinb + Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03805399",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SC10914",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04556292",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04499118",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01251874",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride liposome + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01145430",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"biliary tract | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01282333",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01945775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Underexpression",
        "Disease":"Ovarian Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Platinum Compound,Taxane Compound",
        "Description":"Absent\/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%CI 1.10-5.55, p=0.029).",
        "rs value":null,
        "pmid":"PubMed:21920589",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Ovarian Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg\/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.",
        "rs value":null,
        "pmid":"PubMed:28242752",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg\/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.",
        "rs value":null,
        "pmid":"PubMed:28242752",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Ovarian Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Platinum Compound",
        "Description":"In a study of ovarian carcinomas, 81% of tumors with germline BRCA1\/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1\/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.",
        "rs value":null,
        "pmid":"PubMed:24240112",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Veliparib + Vinorelbine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01104259",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_CHEK2_unspecified_or_EPCAM_unspecified_or_MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PALB2_unspecified_or_PMS2_unspecified_or_RAD51B_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03581292",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Pancreatic Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin,Gemcitabine,Veliparib",
        "Description":"In Phase I study for pancreatic cancer patients GEM 600 mg\/m2 + CDDP 25 mg\/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7\/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.",
        "rs value":null,
        "pmid":"PubMed:29338080",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Prostate Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"1\/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study.",
        "rs value":null,
        "pmid":"PubMed:26510020",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Q1467*",
        "Disease":"Ovarian Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1\/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1\/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).",
        "rs value":null,
        "pmid":"PubMed:27908594",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AKT2",
        "Genomic Position":"19:40736224-40791302(-) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AKT2_EXPRESSION",
        "Disease":"Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab",
        "Description":"In HER2+ metastatic breast cancer treated with trastuzumab (n = 74 patients), the expression of AKT2 and pAkt-Thr308 and\/or pAkt-Ser473 localized in nucleus+cytoplasm was associated with an improved time to progression (TTP) and overall survival (OS) compared to AKT2 negative tumors as measured by immunohistochemistry.",
        "rs value":null,
        "pmid":"PubMed:22842582",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AKT2",
        "Genomic Position":"19:40736224-40791302(-) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AKT2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT2",
        "Genomic Position":"19:40736224-40791302(-) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AKT2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03310541",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT2",
        "Genomic Position":"19:40736224-40791302(-) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AKT2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT2",
        "Genomic Position":"19:40736224-40791302(-) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AKT2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04632992",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT2",
        "Genomic Position":"19:40736224-40791302(-) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AKT2_Amplification",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus,Vandetanib",
        "Description":"Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET, as well as an AKT2 gene amplification. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET\/CT showed systemic response as well.",
        "rs value":null,
        "pmid":"PubMed:25982012",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":"c.2606T>G",
        "AA Mutation":"p.L869R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31867841",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S310Y",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31543779",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IKZF1",
        "Genomic Position":"7:50348318-50470264(+) | 7p12.2",
        "CDS Mutation":null,
        "AA Mutation":"IKZF1_Deletion",
        "Disease":"B-lymphoblastic Leukemia|lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib,Methotrexate,Fludarabine,Cytarabine,Daunorubicin",
        "Description":"This prospective study reports on the prognosis of patients with B-ALL and an IKZF1 deletion and the impact of intensification of treatment in this subgroup.  In 50 patients from the MS2003 cohort, the 5-year cumulative risk for relapse (CIR) associated with IKZF1 deletion was significantly higher than those without the deletion (CIR= 30.4% vs. 8.1%, p=8.7x10^-7).  Of those with IKZF1 deletions, the study showed improvement in CIR and CID in both BCR-ABL1 positive, who were treated with imatinib and intensification therapy (CIR decreased from 66.7% to 20%), and BCR-ABL1 negative, who were treated with intensification therapy only (CIR decreased from 20.5% to 11.4%). Overall survival was also significantly improved for patients with IKZF1 deletion in both groups. Intensification therapy was achieved with higher doses of methotrexate 5g\/m2, more blocks of delayed intensification, and for HR patients, two fludarabine-cytarabine-daunorubicin blocks. The study was not randomized, did not include IKZF1 mutation status, and did not consider all substratifications of IKZF1.",
        "rs value":null,
        "pmid":"PubMed:30044693",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"IKZF1",
        "Genomic Position":"7:50348318-50470264(+) | 7p12.2",
        "CDS Mutation":null,
        "AA Mutation":"IKZF1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03709719",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IKZF1",
        "Genomic Position":"7:50348318-50470264(+) | 7p12.2",
        "CDS Mutation":null,
        "AA Mutation":"IKZF1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin hydrochloride + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03020030",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HSPH1",
        "Genomic Position":"13:31710765-31736064(-) | 13q12.3",
        "CDS Mutation":null,
        "AA Mutation":"HSPH1_T17_DELETION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Oxaliplatin,Fluorouracil",
        "Description":"329 consecutive patients with stage II\ufffd\ufffd\ufffdIII colorectal tumors with MSI after surgical resection at tertiary medical centers were screened for HSP110 T(17) by PCR. Patients underwent adjuvant chemotherapy with 5-fluorouracil and oxaliplatin. Patients with large HSP110 T(17) deletions (\ufffd\ufffd\ufffd5 bp; 18 of 77 patients, 23.4%) had longer times of relapse-free survival than patients with small or no deletions (\ufffd\ufffd\ufffd4 bp; 59 of 77 patients, 76.6%) in multivariate analysis (hazard ratio, 0.16; 95% confidence interval, 0.012\ufffd\ufffd\ufffd0.8; P = .03). A significant interaction between chemotherapy and T17 delet",
        "rs value":null,
        "pmid":"PubMed:24512910",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_Amplification",
        "Disease":"Skin Melanoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel,Carboplatin,Sorafenib",
        "Description":"Retrospective analysis of somatic mutations and copy number changes in 119 patient treated with carboplatin, paclitaxel, \ufffd\ufffd sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors with CCND1 gene copy gains (HR, 0.45; P = 0.0",
        "rs value":null,
        "pmid":"PubMed:26307133",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02154490",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_ESR1_unspecified_or_PGR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Letrozole + Palbociclib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05429684",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03237390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CCND2_unspecified_or_CDK4_unspecified_or_CDK6_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01037790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CCND3_unspecfied_or_CDK4_unspecified_or_CDK6_unspecified_or_CDKN2A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib + Siremadlin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04116541",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02187783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CCND3_unspecified_or_CDK2_unspecified_or_CDK4_unspecified_or_CDK6_unspecified_or_CDKN2A_unspecified_or_RB1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02414724",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03088059",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Dexamethasone + Doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00872521",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CDK4_unspecified_or_CDKN2A_unspecified_or_SMARCA4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03297606",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"central nervous system | glioma | oligodendroglioma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02530320",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Docetaxel + Erlotinib + Pegfilgrastim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01557959",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"skin | malignant melanoma | acral lentiginous",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03454919",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02645149",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_EGFR_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Fluorouracil + Oxaliplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01561014",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Dexamethasone + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00872521",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CDKN2A_unspecified_or_CDK4_unspecified_or_CDK6_unspecified)_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Letrozole + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01740427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CCNE1_unspecified_or_CCNE2_unspecified_or_PTEN_unspecified_or_RARB_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Isotretinoin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01103375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CCND2_unspecified_or_CCND3_unspecified_(and_RB1_unspecified)",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CCND2_unspecified_or_CCND3_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01880567",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02806648",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CCND2_unspecified_or_CCND3_unspecified_or_CDK4_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02785939",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | HER-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02774681",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CCND2_unspecified_or_CCND3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04439201",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bendamustine + Obinutuzumab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03872180",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acalabrutinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03946878",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03356223",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dalpiciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02671513",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Zotatifin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04092673",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CCND2_unspecified_or_CCND3_unspecified_or_CDK4_unspecified_or_CDK6_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04040205",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CD5_unspecified_or_MS4A1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Prednisone + Ublituximab + Umbralisib + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04692155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CDKN2A_unspecified_or_RB1_unspecified_or_TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04169074",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CCND2_unspecified_or_CCND3_unspecified_or_CDK4_unspecified_or_CDK6_unspecified",
        "Disease":"bone | osteosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04040205",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CCND2_unspecified_or_CCND3_unspecified_or_CDK4_unspecified_or_CDK6_unspecified",
        "Disease":"bone | chondrosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04040205",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02936206",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04594005",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CCND2_unspecified_or_CCND3_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Docetaxel + Fluorouracil + Radiotherapy + Surgery",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02290145",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribavirin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03585725",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03310879",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04393285",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | HER-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Inetetamab + Pyrotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04681911",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PF-07220060 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04557449",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Riviciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00835419",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_Overexpression",
        "Disease":"Estrogen-receptor Positive Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tamoxifen",
        "Description":"The authors performed a tissue microarray analysis of 167 postmenopausal breast cancers that had been randomized to treatment with or without tamoxifen.  ER +ve patients with high CCND1 tumor expression did not show any difference in survival between tamoxifen and no treatment.",
        "rs value":null,
        "pmid":"PubMed:15138475",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T878A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Enzalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27401243",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.2632A>G",
        "AA Mutation":"p.T878A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Enzalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25712683",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.2146G>A",
        "AA Mutation":"p.V716M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Flutamide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19366804",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.2632A>G",
        "AA Mutation":"p.T878A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Abiraterone",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26537258",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.2632A>G",
        "AA Mutation":"p.T878A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Androgen",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25712683",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.2632A>G",
        "AA Mutation":"p.T878A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Flutamide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12860943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.2632A>G",
        "AA Mutation":"p.T878A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Abiraterone",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25320358",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.2632A>G",
        "AA Mutation":"p.T878A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Flutamide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14618630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.1921C>T",
        "AA Mutation":"p.Q641*",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Flutamide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14618630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.2632A>G",
        "AA Mutation":"p.T878A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"LHRH",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:10363963",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.2632A>G",
        "AA Mutation":"p.T878A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Ketoconazole",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25320358",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.2633C>G",
        "AA Mutation":"p.T878S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Abiraterone",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26537258",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.2629T>C",
        "AA Mutation":"p.F877L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Enzalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25712683",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.2146G>A",
        "AA Mutation":"p.V716M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Androgen",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:8145761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":"c.2633C>G",
        "AA Mutation":"p.T878S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Flutamide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:7723794",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATRX",
        "Genomic Position":"X:76760356-77041702(-) | Xq21.1",
        "CDS Mutation":null,
        "AA Mutation":"ATRX_unspecified_or_CDNK2A_unspecified_or_FGFR1_unspecified_or_H3F3A_unspecified_or_MYB_unspecified_or_MYBL1_unspecified_or_NTRK2_unspecified_or_PTPN11_unspecified_or_RAF1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Vinblastine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02840409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATRX",
        "Genomic Position":"X:76760356-77041702(-) | Xq21.1",
        "CDS Mutation":null,
        "AA Mutation":"ATRX_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATRX",
        "Genomic Position":"X:76760356-77041702(-) | Xq21.1",
        "CDS Mutation":null,
        "AA Mutation":"ATRX_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"M4344",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02278250",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATRX",
        "Genomic Position":"X:76760356-77041702(-) | Xq21.1",
        "CDS Mutation":null,
        "AA Mutation":"ATRX_unspecified_or_IDH1_unspecified_or_MGMT_unspecified_or_TERT_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"NOVOTTF-200A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03450850",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATRX",
        "Genomic Position":"X:76760356-77041702(-) | Xq21.1",
        "CDS Mutation":null,
        "AA Mutation":"ATRX_Underexpression",
        "Disease":"Malignant Astrocytoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PCV Regimen,Temozolomide",
        "Description":"A retrospective tumor sample study found that the loss of ATRX expression (less than 10% of nuclei) in IDH-mutant astrocytomas treated with temozolomide or a combination of procarbazine, lomustine and vincristine (PCV) was associated with better outcomes. Patients with IDH-mutant tumors and ATRX expression loss (n=40) experienced greater time to treatment failure (55.6 months vs. 31.8 months; P = 0.0168) and a greater progression-free survival (37.1 months vs. 18.1 months; P = 0.038) compared to patients with IDH-mutant tumors with ATRX expression (n=9).",
        "rs value":null,
        "pmid":"PubMed:23904111",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22718859",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25735500",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31758409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28284172",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20043176",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.H687Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31758409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.2525A>T",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12949711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.2525A>T",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14645423",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16954519",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18955458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26130666",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.2525A>T",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28768491",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15930355",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.2525A>T",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20568982",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.D842",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28284172",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.2525A>T",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.I843",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28284172",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":"c.2525A>T",
        "AA Mutation":"p.D842V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Crenolanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28768491",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RB1",
        "Genomic Position":"13:48877911-49056122(+) | 13q14.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?Xfs*?",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31758409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC2",
        "Genomic Position":"16:2097466-2138713(+) | 16p13.3",
        "CDS Mutation":null,
        "AA Mutation":"TSC2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05125523",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC2",
        "Genomic Position":"16:2097466-2138713(+) | 16p13.3",
        "CDS Mutation":null,
        "AA Mutation":"TSC2_Q1178*",
        "Disease":"Thyroid Gland Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":"The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months.",
        "rs value":null,
        "pmid":"PubMed:25295501",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TSC2",
        "Genomic Position":"16:2097466-2138713(+) | 16p13.3",
        "CDS Mutation":null,
        "AA Mutation":"TSC2_W358*",
        "Disease":"soft tissue | perivascular epithelioid cell tumour (PEComa) | NS",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NF2",
        "Genomic Position":"22:29999547-30094587(+) | 22q12.2",
        "CDS Mutation":"c.592C>T",
        "AA Mutation":"p.R198*",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24813888",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NF2",
        "Genomic Position":"22:29999547-30094587(+) | 22q12.2",
        "CDS Mutation":"c.811-2A>T",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24813888",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRD4",
        "Genomic Position":"19:15347647-15391262(-) | 19p13.12",
        "CDS Mutation":null,
        "AA Mutation":"BRD4_BRD4::NUTM1",
        "Disease":"NUT Midline Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Birabresib",
        "Description":"In the clinic, compassionate use of the BET inhibitor birabresib (also known as OTX015 or MK-8628) induced rapid tumor regression in 2 of 4 patients with confirmed BRD4-NUTM1 fusions and significant disease stabilization in a third patient.  This study provides the first clinical evidence that a BET inhibitor can induce impressive and rapid antitumor activity in this  rare and exceptionally aggressive disease.",
        "rs value":null,
        "pmid":"PubMed:26976114",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MTHFR",
        "Genomic Position":"1:11845780-11863302(-) | 1p36.22",
        "CDS Mutation":null,
        "AA Mutation":"MTHFR_A222V",
        "Disease":"Stomach Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil",
        "Description":"The MTHFR C667T variant was associated with significantly lower relapse-free survival and overall survival in stomach cancer patients treated with 5-Fluorouracil-based therapies. 116 Chinese patients with histologically confirmed gastric cancer were used in this study, and all patients had radical surgery before treatment.",
        "rs value":null,
        "pmid":"PubMed:18704422",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MTHFR",
        "Genomic Position":"1:11845780-11863302(-) | 1p36.22",
        "CDS Mutation":null,
        "AA Mutation":"MTHFR_A222V",
        "Disease":"Rectum Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil",
        "Description":"Patients with the wild type (C\/C) MTHFR gene are 2.91 times (95% CI: [1.23, 6.89]) more likely to have a positive response to neoadjuvant CRT and  3.25 times more likely not to experience relapse (95% CI: [1.37, 7.72]) than patients with the heterozygous  MTHFR [rs1801133 (C>T)] mutation or  the homzygous (T\/T).",
        "rs value":null,
        "pmid":"PubMed:26693073",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTPRD",
        "Genomic Position":"9:8314246-10033790(-) | 9p24.1-p23",
        "CDS Mutation":null,
        "AA Mutation":"PTPRD_V253I",
        "Disease":"Ewing Sarcoma Of Bone",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Teprotumumab,Cixutumumab",
        "Description":"Report of complete response to IGF1-R antibody, with or without mTOR inhibitor tensirolimus in 2\/3 Ewing Sarcoma patients with germline PTPRD mutations (V253I and W775*, R995C). The third patient had stable disease (T781A mutant). Four wildtype patients had stable or progressive disease.",
        "rs value":null,
        "pmid":"PubMed:23800680",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FLCN",
        "Genomic Position":"17:17115526-17140453(-) | 17p11.2",
        "CDS Mutation":null,
        "AA Mutation":"FLCN_c.1285dupC",
        "Disease":"Renal Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":"A case study showed that the mTOR inhibitor everolimus exhibited a relatively long-term effect in a patient with renal cell carcinoma and a FLCN germline mutation (c. 1285dupC, likely loss of function).",
        "rs value":null,
        "pmid":"PubMed:23995526",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"SMARCA4",
        "Genomic Position":"19:11071677-11172958(+) | 19p13.2",
        "CDS Mutation":null,
        "AA Mutation":"SMARCA4_Underexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vinorelbine,Cisplatin",
        "Description":"SMARCA4 expression was determined with gene expression microarray in 133 patients. Improved five-year disease-specific survival (DSS) was noted only in patients with low SMARCA4 expression when treated with adjuvant cisplatin\/vinorelbine (n=36) (HR=0.1, 95% CI: 0.0-0.5, P=0.002 [low]; HR 1.0, 95% CI: 0.5-2.3, P=0.92 [high]) compared to patients in the observation arm (N=30).",
        "rs value":null,
        "pmid":"PubMed:26671993",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"SMARCA4",
        "Genomic Position":"19:11071677-11172958(+) | 19p13.2",
        "CDS Mutation":null,
        "AA Mutation":"SMARCA4_absent",
        "Disease":"soft tissue | rhabdoid tumour | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03012620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PROM1",
        "Genomic Position":"4:15969857-16085324(-) | 4p15.32",
        "CDS Mutation":null,
        "AA Mutation":"PROM1_EXPRESSION",
        "Disease":"Hepatocellular Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sorafenib",
        "Description":"CD133 (PROM1) expression in 39 samples of hepatocellular carcinomas was correlated with JNK activity. Both were more highly expressed in patients not responding to sorafenib. CD133+ cells (sorted) were xenografted into mice, producing larger, more JNK inhibitor responsive tumors than CD133- xenografts.",
        "rs value":null,
        "pmid":"PubMed:22596232",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTCH1",
        "Genomic Position":"9:98205262-98270943(-) | 9q22.32",
        "CDS Mutation":null,
        "AA Mutation":"PTCH1_unspecified",
        "Disease":"central nervous system | primitive neuroectodermal tumour-medulloblastoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib + Sonidegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03434262",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTCH1",
        "Genomic Position":"9:98205262-98270943(-) | 9q22.32",
        "CDS Mutation":null,
        "AA Mutation":"PTCH1_unspecified",
        "Disease":"bone | chondrosarcoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01267955",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTCH1",
        "Genomic Position":"9:98205262-98270943(-) | 9q22.32",
        "CDS Mutation":null,
        "AA Mutation":"PTCH1_unspecified_or_SMO_unspecified",
        "Disease":"meninges | meningioma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02523014",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTCH1",
        "Genomic Position":"9:98205262-98270943(-) | 9q22.32",
        "CDS Mutation":null,
        "AA Mutation":"PTCH1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03297606",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTCH1",
        "Genomic Position":"9:98205262-98270943(-) | 9q22.32",
        "CDS Mutation":null,
        "AA Mutation":"PTCH1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTCH1",
        "Genomic Position":"9:98205262-98270943(-) | 9q22.32",
        "CDS Mutation":null,
        "AA Mutation":"PTCH1_unspecified_or_SMO_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04591431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTCH1",
        "Genomic Position":"9:98205262-98270943(-) | 9q22.32",
        "CDS Mutation":null,
        "AA Mutation":"PTCH1_Mutation",
        "Disease":"Cancer",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vismodegib",
        "Description":"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Twenty-one patients had mutations in the Hedgehog pathway (PTCH-1, n = 18; SMO, n = 3). Three patients with PTCH1 mutations had PRs to vismodegib (17%; unknown primary cancer, n = 1; squamous skin cancer, n = 1; salivary gland cancer, n = 1).",
        "rs value":null,
        "pmid":"PubMed:29320312",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTCH1",
        "Genomic Position":"9:98205262-98270943(-) | 9q22.32",
        "CDS Mutation":null,
        "AA Mutation":"PTCH1_LOH",
        "Disease":"Medulloblastoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vismodegib",
        "Description":"Loss-of-heterozygosity in SHH-driven medulloblastoma was associated with increased PFS under therapy with vismodegib (AKA HhAntag691, GDC0449, GDC-0449). 43 patients total were enrolled for this study.",
        "rs value":null,
        "pmid":"PubMed:26169613",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTCH1",
        "Genomic Position":"9:98205262-98270943(-) | 9q22.32",
        "CDS Mutation":null,
        "AA Mutation":"PTCH1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Taladegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05199584",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTCH1",
        "Genomic Position":"9:98205262-98270943(-) | 9q22.32",
        "CDS Mutation":null,
        "AA Mutation":"PTCH1_unspecified_or_SMO_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sonidegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02002689",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTCH1",
        "Genomic Position":"9:98205262-98270943(-) | 9q22.32",
        "CDS Mutation":null,
        "AA Mutation":"PTCH1_Mutation",
        "Disease":"Medulloblastoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sonidegib",
        "Description":"133 sonic-hedghog driven medulloblastomas were sequenced for alterations (WGS or WES). 60 cases exhibited PTCH1 mutations, most of which were likely loss-of-function (spread across the gene and of types including: stop gain, splice site, frameshift, etc.). Functional models also showed PTCH1 mutant xenografts to be sensitive to SHH inhibition with sonidegib.",
        "rs value":null,
        "pmid":"PubMed:24651015",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"B2M",
        "Genomic Position":"15:45003675-45011075(+) | 15q21.1",
        "CDS Mutation":null,
        "AA Mutation":"B2M_S14FS",
        "Disease":"Skin Melanoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Pembrolizumab",
        "Description":"Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab. A B2M frame-shift deletion in exon 1 was identified as the only new homozygous mutation among 24 new relapse-specific mutations. Immunohistochemistry revealed loss of MHC1 outer-membrane localization.",
        "rs value":null,
        "pmid":"PubMed:27433843",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_Mutation",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Pembrolizumab,Atezolizumab,Nivolumab",
        "Description":"In a retrospective analysis in two separate datasets (Stand Up To Cancer 2 Cohort and Checkmate-057), patients with concomitant KRAS and STK11 mutations had significantly worse response rates, PFS and OS compares to KRAS only and KRAS-TP53 Mutant Patients. This work identifies STK11\/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets.",
        "rs value":null,
        "pmid":"PubMed:29773717",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bemcentinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03184571",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04173507",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + PBF-1129",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05234307",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed + Telaglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04265534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Sarilumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05704634",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sirpiglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04471415",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05469178",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_S69*",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_D194E",
        "Disease":"Pancreatic Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":"Case study of a 46-year old male patient with Peutz-Jeghers Syndrome and pancreatic cancer. A germline STK11 D194E mutation was identified with LOH in the tumor sample. phospho-S6 ribosomal protein staining was observed in the tumor indicating mTOR pathway activation. Everolimus treatement led to partial response (but no change in phospho-S6 ribosomal protein staining) for 9 months.",
        "rs value":null,
        "pmid":"PubMed:21189378",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FOS",
        "Genomic Position":"14:75745477-75748933(+) | 14q24.3",
        "CDS Mutation":null,
        "AA Mutation":"FOS_Overexpression",
        "Disease":"Colon Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irbesartan",
        "Description":"A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.  Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway. The patient was treated with Irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.  Her 10 month CEA was 1.4.",
        "rs value":null,
        "pmid":"PubMed:27022066",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_Loss-of-function",
        "Disease":"Bladder Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":"Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity to everolimus than their wild-type counterparts.",
        "rs value":null,
        "pmid":"PubMed:22923433",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_unspecified_or_TSC2_unspecified_or_RICTOR_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02546661",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_unspecified_or_TSC2_unspecified_or_MTOR_unspecified_or_PIK3CA_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Samotolisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03213678",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_unspecified_or_TSC2_unspecified_or_MTOR_unspecified_or_PIK3CA_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Samotolisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03155620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_unspecified_or_TSC2_unspecified_or_MTOR_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02201212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_unspecified_or_TSC2_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sapanisertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03047213",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_unspecified_or_TSC2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nab-rapamycin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05103358",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sapanisertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03166176",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04185831",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02352844",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_unspecified_or_TSC2_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03082833",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_Frameshift_Truncation",
        "Disease":"Invasive Bladder Transitional Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":"A patient with metastatic bladder cancer that responded well to the mTOR inhibitor everolimus was shown to harbor a TSC1 frameshift truncation mutation (c.1907_1908del, p.Glu636fs) and a nonsense NF2 mutation. 2\/3 additional patients with TSC1 mutations also had mild responses to everolimus.",
        "rs value":null,
        "pmid":"PubMed:22923433",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19589612",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2389T>G",
        "AA Mutation":"p.C797G",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28396313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28104619",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26400668",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23912954",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23180674",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22215752",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21921847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21062933",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19381876",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2375T>G",
        "AA Mutation":"p.L792R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24369725",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2374C>T",
        "AA Mutation":"p.L792F",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2374C>T",
        "AA Mutation":"p.L792F",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31632838",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2153T>A",
        "AA Mutation":"p.L718Q",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27257132",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26862733",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21430269",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18676761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27304188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2390G>C",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23886554",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17192902",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2153T>A",
        "AA Mutation":"p.L718Q",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32777674",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22052230",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21430269",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29110836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20682976",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31542322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2239",
        "AA Mutation":"p.L747P",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29673089",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24034463",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16983123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2153T>A",
        "AA Mutation":"p.L718Q",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31632838",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24752053",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21315472",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18379370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25982275",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17020982",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2281G>T",
        "AA Mutation":"p.D761Y",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17085664",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29807405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2389T>A",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27257132",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2386G>A",
        "AA Mutation":"p.G796S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23079729",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27553514",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31632838",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29128427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28978102",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21921847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2152C>G",
        "AA Mutation":"p.L718V",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29110836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24781527",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28104619",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2386G>A",
        "AA Mutation":"p.G796S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17085664",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20146086",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18992959",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28572531",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20871262",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C797G",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29807405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26612314",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25939061",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25120654",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25130612",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2389T>G",
        "AA Mutation":"p.C797G",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31542322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2390G>C",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19238633",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31761448",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27304188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26746366",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24029120",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23037472",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17335935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20686428",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2374C>T",
        "AA Mutation":"p.L792F",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17085664",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21995391",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16014893",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16198442",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23466741",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31561203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19596957",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18509184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29106415",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24468202",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17973572",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17332333",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2156G>C",
        "AA Mutation":"p.G719A",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2375T>A",
        "AA Mutation":"p.L792H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2375T>A",
        "AA Mutation":"p.L792H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22993320",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22228822",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21030498",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18271876",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L718Q",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29807405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23407566",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31157314",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28274743",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22108465",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31543779",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31542322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19181917",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24457237",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31561203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2386G>C",
        "AA Mutation":"p.G796R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19155283",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24942894",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24636847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22815900",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19692934",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21573178",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2386G>C",
        "AA Mutation":"p.G796R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19272767",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31761448",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2375T>A",
        "AA Mutation":"p.L792H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31632838",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21623281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24813888",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2375T>C",
        "AA Mutation":"p.L792P",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23139670",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17180521",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:33260286",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29120087",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.M766Q",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31254668",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2389T>A",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27895763",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675505",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22108465",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15728811",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2374C>G",
        "AA Mutation":"p.L792V",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17699786",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24729716",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28031840",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G796D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28572531",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26424310",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24555578",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22895145",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2389T>A",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31632838",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23579627",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22071596",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17145836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22773810",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24035188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21135146",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23542356",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24105277",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25939061",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27528220",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28818608",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21921847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28104619",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30711944",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31761448",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31561203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"XL647",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722787",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2390G>C",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"HM61713",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26749488",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Icotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31558230",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"POLD1",
        "Genomic Position":"19:50887596-50921271(+) | 19q13.3",
        "CDS Mutation":null,
        "AA Mutation":"POLD1_unspecified_or_POLE_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03297606",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"POLD1",
        "Genomic Position":"19:50887596-50921271(+) | 19q13.3",
        "CDS Mutation":null,
        "AA Mutation":"POLD1_unspecified_or_POLE_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"POLD1",
        "Genomic Position":"19:50887596-50921271(+) | 19q13.3",
        "CDS Mutation":null,
        "AA Mutation":"POLD1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03767075",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"POLD1",
        "Genomic Position":"19:50887596-50921271(+) | 19q13.3",
        "CDS Mutation":null,
        "AA Mutation":"POLD1_C284Y",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":"In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious (as determined by Polyphen or SIFT) C284Y mutation and a high nonsynonymous mutation burden, treated with pembrolizumab monotherapy, was associated with a durable clinical benefit; POLD1 deleterious mutation was not identified in any patients who did not experience a durable clinical benefit.",
        "rs value":null,
        "pmid":"PubMed:25765070",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"POLD1",
        "Genomic Position":"19:50887596-50921271(+) | 19q13.3",
        "CDS Mutation":null,
        "AA Mutation":"POLD1_E374K",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":"In a retrospective study of 34 non-small cell lung cancer patients, a patient, who never smoked, with POLD1 deleterious E374K mutation (as determined by Polyphen or SIFT) and a high nonsynonymous mutation burden, treated with pembrolizumab monotherapy, was associated with a durable clinical benefit; POLD1 deleterious mutation was not identified in patients who did not experience a durable clinical benefit.",
        "rs value":null,
        "pmid":"PubMed:25765070",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERCC1",
        "Genomic Position":"19:45916692-45926824(-) | 19q13.32",
        "CDS Mutation":null,
        "AA Mutation":"ERCC1_Underexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine,Carboplatin",
        "Description":"As part of a randomized phase III trial (USO-03012) in advanced NSCLC of gemcitabine vs. combination gemcitabine and carboplatin, protein expression levels for RRM1 (n=69) and ERCC1 (n=65) were evaluated using fluorescence-based IHC. RRM1 levels were significantly inversely correlated with response (r = \ufffd\ufffd\ufffd0.41; P = .001, n=58), as were ERCC1 levels (r = \ufffd\ufffd\ufffd0.39; P = .003, n=55). RRM1 and ERCC1 levels were correlated with each other (r = 0.36; P = .003, n=65). There was no significant interaction with treatment arm (P = .64 for RRM1; P = .79 for ERCC1). The authors conclude that RRM1 and ERCC1 expression levels are predictive of response to gemcitabine, and gemcitabine and ",
        "rs value":null,
        "pmid":"PubMed:19884554",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERCC1",
        "Genomic Position":"19:45916692-45926824(-) | 19q13.32",
        "CDS Mutation":null,
        "AA Mutation":"ERCC1_Underexpression",
        "Disease":"Ovary Epithelial Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Platinum Compound",
        "Description":"Ovarian epithelial tumours (n=235) were used to create TMAs and IHC results were scored for ERCC1 (n=114 low, n=121 high). For platinum sensitive patients (n=250 in supplementary table, but not all have ERCC1 levels available), low ERCC1 was associated with better PFS (p = 0.034, HR 1.9, 95% CI 1.1-3.6). For platinum resistant patients (n=26 in supplementary table, but not all have ERCC1 levels available), there was no significant association (p = 0.550, HR 0.5, 95% CI 0.1-4.3).",
        "rs value":null,
        "pmid":"PubMed:30797591",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERCC1",
        "Genomic Position":"19:45916692-45926824(-) | 19q13.32",
        "CDS Mutation":null,
        "AA Mutation":"ERCC1_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bryostatin + Cisplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00006942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IGF1R",
        "Genomic Position":"15:99192200-99507759(+) | 15q26.3",
        "CDS Mutation":null,
        "AA Mutation":"IGF1R_NUCLEAR_EXPRESSION",
        "Disease":"Sarcoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IGF1R Monoclonal Antibody",
        "Description":"IGF-1R nuclear immunostaining (IHC) was observed in 9 out of 16 samples of patients with different sarcomas (osteosarcoma, ewing sarcoma, liposarcoma, synovialsarcoma, desmoplastic tumor, rhabdomyosarcoma). Exclusive nuclear immunostaining was associated with better progression free survival and overall survival after therapy with IGF1R antibodies (R1507, IMC-A12, SCH 717454 and CP-751.871).",
        "rs value":null,
        "pmid":"PubMed:22682017",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"IGF1R",
        "Genomic Position":"15:99192200-99507759(+) | 15q26.3",
        "CDS Mutation":null,
        "AA Mutation":"IGF1R_Overexpression",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Exemestane,Metformin",
        "Description":"A randomized phase III trial of hormone sensitive (ER or PR positive) early stage breast cancer (Dutch TEAM cohort, n=2,446) examined the addition of metformin to exemestane for 155 patients. IGF1R IHC was performed and patients classified as IGF1R high (n=105) or low (n=50). In IGF1R-high patients, combining metformin with exemestane was associated with significant RFS (HR 1.12, 95% CI 0.57\ufffd\ufffd\ufffd2.23 for sequential treatment with metformin, HR 0.73 95% CI 0.56\ufffd\ufffd\ufffd0.94 for exemestane only, and HR 0.32, 95% CI 0.10\ufffd\ufffd\ufffd1.00 for exemestane with metformin, p = 0.02, compared to the sequential treatment arm). There was also significant association with OS (HR for OS 1.72, 95% CI 0.96\ufffd\ufffd\ufffd3.08 for sequential treatment with metformin, HR 0.80, 95% CI 0.62\ufffd\ufffd\ufffd1.03 for exemestane only, and HR 0.67, 95% CI 0.31\ufffd\ufffd\ufffd1.45 for exemestane with metformin, p = 0.03, compared to the sequential treatment arm). The authors conclude that adding metformin to exemestane for patients with IGF1R-high e",
        "rs value":null,
        "pmid":"PubMed:26706833",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FBXW7",
        "Genomic Position":"4:153242410-153457253(-) | 4q31.3",
        "CDS Mutation":null,
        "AA Mutation":"FBXW7_Mutation",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab,Panitumumab",
        "Description":"65 patients were retrospectively analyzed for mutational profiles predictive of response to EGFR-inhibitors (cetuximab or panitumumab). FBXW7 mutation was found to be more prevalent in non-responders (5 mutations) than responders (1 mutation).",
        "rs value":null,
        "pmid":"PubMed:26508446",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FBXW7",
        "Genomic Position":"4:153242410-153457253(-) | 4q31.3",
        "CDS Mutation":null,
        "AA Mutation":"FBXW7_Mutation",
        "Disease":"Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MTOR Inhibitor",
        "Description":"418 patients with advanced cancer were screened for FBXW7 mutations using a multiplex gene panel. 17 FBXW7 mutations were detected (isolated mutation in 2 patients). Ten patients were treated with an mTOR inhibitor with 7 patients having stable disease as best responses and a median time to treatment failure of 2.8 months, two patients had prolonged stable disease of >16 weeks.",
        "rs value":null,
        "pmid":"PubMed:24586741",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FBXW7",
        "Genomic Position":"4:153242410-153457253(-) | 4q31.3",
        "CDS Mutation":null,
        "AA Mutation":"FBXW7_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FBXW7",
        "Genomic Position":"4:153242410-153457253(-) | 4q31.3",
        "CDS Mutation":null,
        "AA Mutation":"FBXW7_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tegavivint",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04851119",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FBXW7",
        "Genomic Position":"4:153242410-153457253(-) | 4q31.3",
        "CDS Mutation":null,
        "AA Mutation":"FBXW7_unspecified_or_NOTCH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic T cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crenigacestat + Dexamethasone",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02518113",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CXCR4",
        "Genomic Position":"2:136871919-136873813(-) | 2q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CXCR4_cterm_del_and_MYD88_L273P",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | lymphoplasmacytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Ixazomib + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02400437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CXCR4",
        "Genomic Position":"2:136871919-136873813(-) | 2q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CXCR4_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | lymphoplasmacytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carfilzomib + Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04263480",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CXCR4",
        "Genomic Position":"2:136871919-136873813(-) | 2q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CXCR4_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | lymphoplasmacytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rituximab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05099471",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CXCR4",
        "Genomic Position":"2:136871919-136873813(-) | 2q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CXCR4_unspecified_and_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | lymphoplasmacytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carfilzomib + Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04263480",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CXCR4",
        "Genomic Position":"2:136871919-136873813(-) | 2q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CXCR4_unspecified_and_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | lymphoplasmacytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rituximab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05099471",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CXCR4",
        "Genomic Position":"2:136871919-136873813(-) | 2q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CXCR4_EXPRESSION",
        "Disease":"Gastric Adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Docetaxel",
        "Description":"CXCR4 expression as assessed by microarray analysis, was associated with resistance to docetaxel in 11 cancer cell lines (R^2 = 0.23, p = 0.019). Expression levels (by qtPCR) were also higher in resistant tumors among 25 patient samples.",
        "rs value":null,
        "pmid":"PubMed:20651371",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CXCR4",
        "Genomic Position":"2:136871919-136873813(-) | 2q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CXCR4_cterm_del_and_MYD88_L273P",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | lymphoplasmacytic lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Mavorixafor",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04274738",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNAS",
        "Genomic Position":"20:57427769-57486247(+) | 20q13.32",
        "CDS Mutation":null,
        "AA Mutation":"GNAS_c.393T>C",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib,Erlotinib",
        "Description":"The disease control rate of patients with GNAS1 T393C CC genotype was lower than that of patients with variant genotype (TT or CT) (46.2% vs 73.8%, P=0.039). Univariate analysis identified gender, smoking history, histology and GNAS1 T393C polymorphism as predictive marker of PFS (P=0.04, P<0.001, P<0.001 and P=0.005). Multivariate analysis of factors, including smoking history, performance status score, histology, GNAS1 T393C polymorphism demonstrated that GNAS1 T393C polymorphism was correlated independently with PFS (P=0.007). The data suggests the role of GNAS1 T393C CC genotype as a poor predictive marker both of DCR and PFS in advanced NSCLC patients treated with tyrosine kinase inhibitor.",
        "rs value":null,
        "pmid":"PubMed:24758907",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNAS",
        "Genomic Position":"20:57427769-57486247(+) | 20q13.32",
        "CDS Mutation":null,
        "AA Mutation":"GNAS_c.393T>C",
        "Disease":"Esophageal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Cisplatin,Fluorouracil",
        "Description":"Overall, 63% of the patients in the T-allele group (TT + CT), i.e with the T393C genotype, were minor responders with more than 10% residual vital tumor cells in resection specimens, whereas T(-) genotypes (CC) showed a major histopathological response with less than 10% residual vital tumor cells in 80%.",
        "rs value":null,
        "pmid":"PubMed:19274060",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNAS",
        "Genomic Position":"20:57427769-57486247(+) | 20q13.32",
        "CDS Mutation":null,
        "AA Mutation":"GNAS_R201C",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab,Irinotecan,Vemurafenib",
        "Description":"Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient acquired a novel GNAS1 R201C mutation at disease progression.",
        "rs value":null,
        "pmid":"PubMed:27729313",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNAS",
        "Genomic Position":"20:57427769-57486247(+) | 20q13.32",
        "CDS Mutation":null,
        "AA Mutation":"GNAS_R201H",
        "Disease":"Thyroid Gland Follicular Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radioactive Iodine",
        "Description":"A 79 year old patient with prior history of graves' disease presented with follicular thyroid carcinoma. Two mutations NRAS p.Q61K and GNAS p.R201H were detected. The thyroid cancer manifested as a 13.5 cm mass. There were minimal lung, humerus and T9 spine metastases, and exhibited a very good response to the radioactive iodine treatment after he had underwent total thyroidectomy and bilateral neck dissection. They also screened other 23 fatal cases and revealed that none of them had GNAS p.R201H mutation. But two of them had NRAS p.Q61K mutation.",
        "rs value":null,
        "pmid":"PubMed:26788326",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDKN1B",
        "Genomic Position":"12:12870058-12875305(+) | 12p13.1",
        "CDS Mutation":null,
        "AA Mutation":"CDKN1B_EXPRESSION",
        "Disease":"Head And Neck Squamous Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin,Fluorouracil",
        "Description":"41 HNSSC were analyzed by IHC for expression of EGFR, p53, CCND1, p16, p21, p27 (CDKN2B), p-AKT, HIF-1a, Caspase 3 and BCL2. p27 was the only protein that served as a predictive biomarker of response after multivariate analysis (p=0.025; n=41 patients).",
        "rs value":null,
        "pmid":"PubMed:24239278",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CHEK2",
        "Genomic Position":"22:29083751-29137826(-) | 22q12.1",
        "CDS Mutation":null,
        "AA Mutation":"CHEK2_mutation",
        "Disease":"Prostate Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). The study found that in men with mCRPC who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). For 17 patients with CHEK2 mutations specifically, PFS HR 0.87 [0.23-4.13]. Based on the results of this study, on May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone.",
        "rs value":null,
        "pmid":"PubMed:32343890",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CHEK2",
        "Genomic Position":"22:29083751-29137826(-) | 22q12.1",
        "CDS Mutation":null,
        "AA Mutation":"CHEK2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02576444",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK2",
        "Genomic Position":"22:29083751-29137826(-) | 22q12.1",
        "CDS Mutation":null,
        "AA Mutation":"CHEK2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK2",
        "Genomic Position":"22:29083751-29137826(-) | 22q12.1",
        "CDS Mutation":null,
        "AA Mutation":"CHEK2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK2",
        "Genomic Position":"22:29083751-29137826(-) | 22q12.1",
        "CDS Mutation":null,
        "AA Mutation":"CHEK2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK2",
        "Genomic Position":"22:29083751-29137826(-) | 22q12.1",
        "CDS Mutation":null,
        "AA Mutation":"CHEK2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK2",
        "Genomic Position":"22:29083751-29137826(-) | 22q12.1",
        "CDS Mutation":null,
        "AA Mutation":"CHEK2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK2",
        "Genomic Position":"22:29083751-29137826(-) | 22q12.1",
        "CDS Mutation":null,
        "AA Mutation":"CHEK2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04336943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK2",
        "Genomic Position":"22:29083751-29137826(-) | 22q12.1",
        "CDS Mutation":null,
        "AA Mutation":"CHEK2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Testosterone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05011383",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK2",
        "Genomic Position":"22:29083751-29137826(-) | 22q12.1",
        "CDS Mutation":null,
        "AA Mutation":"CHEK2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02952534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TUBB3",
        "Genomic Position":"16:89989687-90002505(+) | 16q24.3",
        "CDS Mutation":null,
        "AA Mutation":"TUBB3_EXPRESSION",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Taxane Compound",
        "Description":"High expression of betaIII-tubulin, as assessed in 85 breast cancers by IHC, was associated with better pathological response.",
        "rs value":null,
        "pmid":"PubMed:23218766",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_G13V",
        "Disease":"skin | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03722407",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Ficlatuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03422536",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Siremadlin + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03714958",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03784014",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02643056",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02645149",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02383927",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Ficlatuzumab + Intensity modulated radiation therapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02277184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04997902",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_Mutation",
        "Disease":"Head And Neck Squamous Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":"In a phase II HNSCC trial, an objective response rate of 55% was seen in HRAS-mutant patients (11 of 20) treated with the farnesyltransferase inhibitor tipifarnib with a PFS of 5.6 months and an OS of 15.6 months (providing the allele fraction was at least 20%).",
        "rs value":null,
        "pmid":"PubMed:33750196",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03719690",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04284774",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03155620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02383927",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03496766",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02535650",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KO-947",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03051035",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_Mutation",
        "Disease":"Bladder Urothelial Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":"4 of 16 patients with urothelial carcinoma harboring HRAS hotspot point mutations and 1 patient with an HRAS frameshift insertion had a partial response to the farnesyltransferase inhibitor tipifarnib while none of the 6 patients with wild-type HRAS responded.",
        "rs value":null,
        "pmid":"PubMed:32636318",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_G13D",
        "Disease":"Skin Squamous Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":"In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy, a patient harboring HRAS G13D co-mutation (n=1) was reported to be resistant to vemurafenib treatment.",
        "rs value":null,
        "pmid":"PubMed:22256804",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_G13D",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor",
        "Description":"Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanism in the same study.",
        "rs value":null,
        "pmid":"PubMed:26561417",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"liver | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Icaritin + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03236649",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576444",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03212274",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04281498",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03878095",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03953898",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03878095",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03212274",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"bone | chondrosarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03212274",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Enasidenib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05401097",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Enasidenib + Ixazomib + Pomalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03732703",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cedazuridine + Decitabine + Enasidenib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04774393",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Quizartinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04687761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Quizartinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04687761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04092179",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cedazuridine + Decitabine + Ivosidenib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04774393",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02428855",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01915498",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelofibrosis",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03303950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03683433",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03744390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01546038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02273739",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TQB3455",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04340427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03303950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_R140_or_IDH2_R172",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | clonal cytopenia of undetermined significance",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05102370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03839771",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_Mutation",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib",
        "Description":"A first-in-human phase 1\/2 trial assessing the pharmacology, safety and activity of Enasidenib in IDH2-mutant myeloid hematoblastosis patients. In the AML subgroup (n=176, (n=130 R140; n=45 R172; n=1 Other)) of included patients (n=239) the overall response rate was 40.3%, with median response duration of 5.8 months. Responses were associated with cellular differentiation and maturation, typically without evidence of aplasia. Median overall survival among relapsed\/refractory patients was 9.3 months, and for the 34 patients (19.3%) with complete response was 19.7 months.",
        "rs value":null,
        "pmid":"PubMed:28588020",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Pevonedistat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04090736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02632708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Telaglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02071862",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"(IDH2_R140_or_IDH2_R172)_and_CBL_unspecified_or_KRAS_unspecified_or_NF1_unspecified_or_NRAS_unspecified_or_PTPN11_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cobimetinib + Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05441514",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04203316",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02632708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03557359",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02677922",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02677922",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03728335",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03515512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04051996",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"liver | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chloroquine + Metformin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02496741",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idasanutlin ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02545283",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HMPL306",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04762602",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_R172",
        "Disease":"central nervous system | glioma | astrocytoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radiotherapy + Telaglenastat + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03528642",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03383575",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04740190",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Intensity modulated radiation therapy + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03180502",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Proton beam radiation therapy + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03180502",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"bone | chondrosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chloroquine + Metformin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02496741",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib + Fedratinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04955938",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03881735",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vorasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02481154",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CPX-351 + Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03825796",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + BI 836858",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03013998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT04176393",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chloroquine + Metformin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02496741",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lomustine + Procarbazine + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02333513",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03925246",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03666559",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"bone | chondrosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Belinostat + Guadecitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04340843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT02577406",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SH1573",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04806659",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"bone | chondrosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ASTX727 + Belinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04340843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03914742",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Icapamespib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04782609",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"LY3410738",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04603001",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04522895",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718767",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vorasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04164901",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DC vaccine loaded with glioma stem-like cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01567202",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vorasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02492737",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HMPL306",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04764474",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03749187",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vorasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02481154",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03839771",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HMPL306",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04272957",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH2",
        "Genomic Position":"15:90626277-90645736(-) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"IDH2_Mutation",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Venetoclax",
        "Description":"In this case series, 7 elderly patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA (including 1 patient with antecedent myeloproliferative neoplasm) were treated with venetoclax monotherapy. Three of 7 patients showed response. Of these: 2 patients achieved complete remission (1 of which was mutated for IDH2). One patient with IDH1 mutation showed PB blast clearance (derived anti-leukemic benefit) but BM was not performed to evaluate response. Venetoclax responders had high BCL\ufffd\ufffd\ufffd2 and\/or BIM expression levels in myeloblasts, and the response was significantly associated with OS. BCL-2 and BIM expression levels can potentially identifer venetoclax respo",
        "rs value":null,
        "pmid":"PubMed:30725494",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BARD1",
        "Genomic Position":"2:215590370-215674428(-) | 2q35",
        "CDS Mutation":null,
        "AA Mutation":"BARD1_Mutation",
        "Disease":"Prostate Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). The study found that in men with mCRPC who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). A total of 4 patients had BARD1 mutations, 3 olaparib arm and 1 control arm. Based on the results of this study, on May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone.",
        "rs value":null,
        "pmid":"PubMed:32343890",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BARD1",
        "Genomic Position":"2:215590370-215674428(-) | 2q35",
        "CDS Mutation":null,
        "AA Mutation":"BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_FANCL_unspecified_or_PALB2_unspecified_or_RAD51B_unspecified_or_RAD51C_unspecified_or_RAD51D_unspeciifed_or_RAD54L_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04038502",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BARD1",
        "Genomic Position":"2:215590370-215674428(-) | 2q35",
        "CDS Mutation":null,
        "AA Mutation":"BARD1_unspecified_or_BRIP1_unspecified_or_FANCA_unspecified_or_NBN_unspecified_or_RAD51_unspecified_or_RAD51B_unspecified_or_RAD51D_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04171700",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BARD1",
        "Genomic Position":"2:215590370-215674428(-) | 2q35",
        "CDS Mutation":null,
        "AA Mutation":"BARD1_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCL_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PPP2R2A_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_RAD54L_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":null,
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05787587",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BARD1",
        "Genomic Position":"2:215590370-215674428(-) | 2q35",
        "CDS Mutation":null,
        "AA Mutation":"BARD1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BARD1",
        "Genomic Position":"2:215590370-215674428(-) | 2q35",
        "CDS Mutation":null,
        "AA Mutation":"BARD1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BARD1",
        "Genomic Position":"2:215590370-215674428(-) | 2q35",
        "CDS Mutation":null,
        "AA Mutation":"BARD1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BARD1",
        "Genomic Position":"2:215590370-215674428(-) | 2q35",
        "CDS Mutation":null,
        "AA Mutation":"BARD1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BARD1",
        "Genomic Position":"2:215590370-215674428(-) | 2q35",
        "CDS Mutation":null,
        "AA Mutation":"BARD1_unspecified_or_FANCA_unspecified_or_BRIP1_unspecified_or_PALB2_unspecified_or_RAD51_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib + ZEN003694",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05327010",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VEGFA",
        "Genomic Position":"6:43738444-43752346(+) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"VEGFA_Decreased_Peri-therapeutic_Expression",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab,Levoleucovorin,Irinotecan,Fluorouracil",
        "Description":"Decreased peri- and post-therapeutic expression of VEGFA were significantly associated with response to FOLFIRI plus bevacizumab in 57 patients with metastatic CRC.",
        "rs value":null,
        "pmid":"PubMed:25973082",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"VEGFA",
        "Genomic Position":"6:43738444-43752346(+) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"VEGFA_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VEGFA",
        "Genomic Position":"6:43738444-43752346(+) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"VEGFA_unspecified",
        "Disease":"meninges | meningioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01125046",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VEGFA",
        "Genomic Position":"6:43738444-43752346(+) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"VEGFA_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VEGFA",
        "Genomic Position":"6:43738444-43752346(+) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"VEGFA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VEGFA",
        "Genomic Position":"6:43738444-43752346(+) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"VEGFA_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02117167",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CRBN",
        "Genomic Position":"3:3191695-3221394(-) | 3p26.2",
        "CDS Mutation":null,
        "AA Mutation":"CRBN_Mutation",
        "Disease":"Multiple Myeloma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Lenalidomide,Pomalidomide",
        "Description":"A 37 year old, heavily pretreated (including thalidomide and lenalidomide) patient with IgG-kappa multiple myeloma was sequenced following extramedullary relapse. A high number of alterations were observed including 38 rearrangements, 35 translocations, 4 indels, and 271 nonsynonymous point mutations. Two mutations altering CRBN (Q99* and R283K), a gene previously described as being necessary for immunomodulatory drug response, were observed and thought to be responsible for resistance to the pomalidomide and dexamethasone treatment she received but failed to respond to following sequencing.",
        "rs value":null,
        "pmid":"PubMed:23480694",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FOXP3",
        "Genomic Position":"X:49106897-49121288(-) | Xp11.23",
        "CDS Mutation":null,
        "AA Mutation":"FOXP3_EXPRESSION",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Epirubicin",
        "Description":"1,097 patients with breast cancer were evaluated for FOXP3 expression by IHC. FOXP3 expression was found in 405 tumor samples and associated with improved OS in patients treated with anthracycline-based adjuvant chemotherapy (6 cycles of 'FEC100' aka epirubicin + cyclophosphamide + 5-fluorouracil) but not in patients treated with sequential anthracycline->taxane (3 cycles of FEC100 followed by 3 cycles of docetaxel). In-vitro experiments confirmed that FOXP3 expression enhance anthracycline efficacy. The in vitro data consisted of testing the sensitivity of various breast cancer cell lines to anthracyclines after treatment with valproic acid (which increases FOXP3 expression). The authors observed that, while valproic acid has no intrinsic cytotoxic effect on tumor cells, it enhanced the cytotoxic effect of epirubicin specifically in cell lines where FOXP3 expression was increased.",
        "rs value":null,
        "pmid":"PubMed:22431701",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TFF3",
        "Genomic Position":"21:43731777-43735761(-) | 21q22.3",
        "CDS Mutation":null,
        "AA Mutation":"TFF3_EXPRESSION",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Aminoglutethimide,Tamoxifen",
        "Description":"TFF3 expression was assessed by IHC in 75 patients, 187 patients were identified for the validation cohort. TFF3 expression was associated with response to endocrine therapy (tamoxifen, aminoglutethimide or oophorectomy) and outperformed ER, PR and TFF1 as biomarkers.",
        "rs value":null,
        "pmid":"PubMed:25900183",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GSTP1",
        "Genomic Position":"11:67351066-67354131(+) | 11q13.2",
        "CDS Mutation":null,
        "AA Mutation":"GSTP1_I105V",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"FOLFOX Regimen",
        "Description":"Patients with the GSTP1 I105V variant had greater response to FOLFOX-4 treatment, longer progression-free survival, and longer overall survival. 166 Chinese patients with metastatic colorectal carcinoma who had been treated with FOLFOX-4 were used in this study.",
        "rs value":null,
        "pmid":"PubMed:19922504",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"HMOX1",
        "Genomic Position":"22:35776828-35790207(+) | 22q12.3",
        "CDS Mutation":null,
        "AA Mutation":"HMOX1_EXPRESSION",
        "Disease":"Renal Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sunitinib,Sorafenib",
        "Description":"In 66 patients with advanced renal cell carcinoma, high expression of heme oxygenase-1 (HO-1) was associated with poor overall response rate (2.6% versus 53.6%, P<0.01), clinical benefit rate (47.4% versus 92.9%, P<0.01), shorter progression-free survival (4.4 versus 42 months, P=0.022) and poor overall survival (\ufffd\ufffd (2)=4.775, P=0.029) in patients receiving sorafenib or suniti",
        "rs value":null,
        "pmid":"PubMed:26309414",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MSH6",
        "Genomic Position":"2:48010221-48037240(+) | 2p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH6_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH6",
        "Genomic Position":"2:48010221-48037240(+) | 2p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH6_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03005002",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH6",
        "Genomic Position":"2:48010221-48037240(+) | 2p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH6_unspecified",
        "Disease":"stomach | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Fluorouracil",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03485196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH6",
        "Genomic Position":"2:48010221-48037240(+) | 2p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH6_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KRAS peptide vaccine + poly ICLC",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05013216",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH6",
        "Genomic Position":"2:48010221-48037240(+) | 2p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH6_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03767075",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH6",
        "Genomic Position":"2:48010221-48037240(+) | 2p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH6_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104893",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH6",
        "Genomic Position":"2:48010221-48037240(+) | 2p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH6_LOSS",
        "Disease":"Transitional Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-PD-1 Monoclonal Antibody MEDI0680,Durvalumab",
        "Description":"Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel sequencing as well as loss of expression of these genes as confirmed by IHC. Testing also revealed a high mutational load as well as 2+ PD-L1 expression in 80% of the cells. The patient was treated with anti-PD-L1 inhibitor MEDI4736 and MEDI0680 in a phase 1 trial and had a complete remission within 2 months of treatment that was ongoing after 11 months.",
        "rs value":null,
        "pmid":"PubMed:26674132",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00330564",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pazopanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01436227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01168440",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01015300",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00330564",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00673816",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carfilzomib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01775930",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fludeoxyglucose F 18 + Tanespimycin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00088374",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ranibizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00089765",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | clear cell renal cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PT2385",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03108066",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01266070",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Belzutifan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03401788",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Montanide + von Hippel-Lindau peptide vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00001703",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pegaptanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00056199",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04068831",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00566995",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"autonomic ganglia | paraganglioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Belzutifan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04924075",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pegpleranib + Ranibizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02859441",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"kidney | carcinoma | clear cell renal cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01372813",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vorinostat",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02108002",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_Mutation",
        "Disease":"Renal Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":"A randomized, open-label phase 2 study, encompassing 85 patients, to compare the efficacy of dual PIK3\/mTOR Inhibitor Apitolisib and mTORC1 inhibitor Everolimus in patients who progressed on or after antiangiogenetic therapy (VEGFR). There was a trend towards association between deleterious VHL alterations and progression-free-survival in the Everolimus arm only.",
        "rs value":null,
        "pmid":"PubMed:26951309",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_unspecified",
        "Disease":"soft tissue | haemangioblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vatalanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00052013",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VHL",
        "Genomic Position":"3:10182692-10193904(+) | 3p25.3",
        "CDS Mutation":null,
        "AA Mutation":"VHL_R200W_(c.598C>T)",
        "Disease":"Chuvash Polycythemia",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ruxolitinib",
        "Description":"Homozygous VHL R200W mutations result in a rare congenital polycythemia known as Chuvash polycythemia. Treatment of 3 patients with this disease with the JAK1\/2 inhibitor ruxolitinib led to symptomatic and hematologic improvements in all patients through 21-78 weeks of treatment.",
        "rs value":null,
        "pmid":"PubMed:27518686",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BIRC5",
        "Genomic Position":"17:76210267-76221717(+) | 17q25.3",
        "CDS Mutation":null,
        "AA Mutation":"BIRC5_Overexpression",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"13 HER2 breast cancer patients were treated with trastuzumab and then trastuzumab + docetaxel prior to surgery. Pretreatment biopsies and post-treatment surgical samples were obtained, and microarray performed. 5 of 13 patients responded to treatment, and pretreatment biopsies from non-responders showed significantly higher survivin (BIRC5) mRNA (p=0.026) levels than responders. In HER2 positive, trastuzumab-sensitive BT474 cells, overexpression of survivin blunted sensitivity to trastuzumab. In HER2 positive trastuzumab-resistant breast cancer cell lines, knockdown of survivin with RNAi or with YM155 induced growth inhibition and apoptosis.",
        "rs value":null,
        "pmid":"PubMed:23204226",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BIRC5",
        "Genomic Position":"17:76210267-76221717(+) | 17q25.3",
        "CDS Mutation":null,
        "AA Mutation":"BIRC5_NUCLEAR_EXPRESSION",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Taxane Compound,Platinum Compound",
        "Description":"Patients with nuclear survivin (BIRC5) expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P < 0.001) in a retrospective analysis of 48 patients with non-small cell lung cancer.",
        "rs value":null,
        "pmid":"PubMed:24961465",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BCL2L11",
        "Genomic Position":"2:111878506-111926024(+) | 2q13",
        "CDS Mutation":null,
        "AA Mutation":"BCL2L11_Deletion_Polymorphism",
        "Disease":"Chronic Myeloid Leukemia",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":"DNA sequencing was performed in five Ph+ CML samples with sensitivity or resistance to imatinib. A structural variation in BIM2 (BCL2L11) with an identical 2,903-bp genomic deletion was identified in all three resistant samples. 2,597 healthy individuals were screened and the deletion polymorphism was identified in 12.3% of East Asian Population but 0% in African or European Population. In-vitro, imatinib-induced apoptosis was reduced in cells harboring the BIM deletion polymorphism. Two East Asian CML cohorts (n=203) treated with imatinib were analzed for the polymorphism. Overall odds ratio for resistant disease among subjects with the deletion polymorphism compared to those without it was 2.94 (P = 0.02, 95% CI 1.17\ufffd\ufffd\ufffd7.43). Patients with the polymorphism, compared to those without, were more likely to be resistant without BCR-ABL mutations than resistant with BCR-ABL mutation or sensitive (odds ratio = 1.90, 95% CI 1.08\ufffd",
        "rs value":null,
        "pmid":"PubMed:22426421",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BCL2L11",
        "Genomic Position":"2:111878506-111926024(+) | 2q13",
        "CDS Mutation":null,
        "AA Mutation":"BCL2L11_unspecified_or_BCL2_unspecified_or_MCL1_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Riluzole + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01303341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2L11",
        "Genomic Position":"2:111878506-111926024(+) | 2q13",
        "CDS Mutation":null,
        "AA Mutation":"BCL2L11_unspecified_and_EGFR_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + EGFR-TKI",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2L11",
        "Genomic Position":"2:111878506-111926024(+) | 2q13",
        "CDS Mutation":null,
        "AA Mutation":"BCL2L11_unspecified_and_EGFR_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gefitinib + Vorinostat",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02151721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2L11",
        "Genomic Position":"2:111878506-111926024(+) | 2q13",
        "CDS Mutation":null,
        "AA Mutation":"BCL2L11_unspecified_or_BCL2_unspecified_or_MCL1_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Riluzole + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01303341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2L11",
        "Genomic Position":"2:111878506-111926024(+) | 2q13",
        "CDS Mutation":null,
        "AA Mutation":"BCL2L11_unspecified_or_BCL2_unspecified_or_MCL1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Riluzole + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01303341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2L11",
        "Genomic Position":"2:111878506-111926024(+) | 2q13",
        "CDS Mutation":null,
        "AA Mutation":"BCL2L11_Deletion_Polymorphism",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor",
        "Description":"The BIM (BCL2L11) deletion polymorphism was identified in an EGFR Mutant NSCLC cell line with resistance to EGFR-TKI (HCC2779). Introduction of this polymorphism in a previously EGFR-inhibitor sensitive cell line led to TKI-resistance. In 141 NSCLC patients with EGFR mutations, the presence of the polymorphism (N=26) was predictive of a significantly shorter PFS under treatment with EGFR-TKI (6.6 months vs. 11.9 months, p = 0.0027). Patients received either gefitinib only (N=136) or erlotinib only (N=5).",
        "rs value":null,
        "pmid":"PubMed:22426421",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132",
        "Disease":"High Grade Glioma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib,Bevacizumab",
        "Description":"In a clinical study of 63 recurrent glioma patients, the combined cohort of patients treated with either bevacizumab or sunitinib showed that those harboring IDH1 codon 132 mutation were associated with improved overall survival (OS 7.53 vs. 4.83 months; P=0.04), as compared to patients with wild-type IDH1.",
        "rs value":null,
        "pmid":"PubMed:22199315",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576444",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04147533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"bone | chondrosarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03212274",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03878095",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03953898",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132H",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03991832",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03212274",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | oligodendroglioma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02530320",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03212274",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03991832",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03878095",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132H",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03212742",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05188508",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03561870",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03991832",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03434262",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"liver | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Icaritin + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03236649",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03069352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05406700",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified_or_ATRX_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05076513",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03471260",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Quizartinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04687761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02428855",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cedazuridine + Decitabine + Enasidenib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04774393",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cedazuridine + Decitabine + Ivosidenib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04774393",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Ivosidenib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05401097",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Quizartinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04687761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02677922",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02074839",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"bone | chondrosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Belinostat + Guadecitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04340843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"bone | chondrosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04278781",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02768792",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"(IDH1_unspecified_or_IDH2_unspecified)_and_1p\/19q_deletion",
        "Disease":"central nervous system | glioma | oligodendroglioma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lomustine + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05331521",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"LY3410738",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04603001",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02209428",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132H",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IDH1 R132H peptide vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02771301",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY 2402234",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05061251",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132H",
        "Disease":"central nervous system | glioma | astrocytoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vorasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05484622",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"bone | chondrosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chloroquine + Metformin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02496741",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04051996",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Retifanlimab + Tretinoin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05345002",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD9574 + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05417594",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04056910",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03503409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02073994",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04044209",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132H",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + IDH1 R132H peptide vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03893903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Telaglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02071862",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_and_IDH2_unspecified_and_SRSF2_unspecified_and_TET2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Lenalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00352001",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + BI 836858",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03013998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_and_IDH2_unspecified_and_KRAS_unspecified_and_TET2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Lenalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00352001",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1436032",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03127735",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Diphtheria and tetanus toxoids adsorbed + IDH1 R132H peptide vaccine + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02193347",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Telaglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02071862",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Olutasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02719574",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ASTX727 + Olutasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04013880",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Icapamespib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04782609",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Safusidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05577416",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"(IDH1_unspecified_or_IDH2_unspecified)_and_(FGFR1_unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified)",
        "Disease":"central nervous system | NS | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05267106",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03303950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Olutasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03684811",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Debio 0123 + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05765812",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_Mutation",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":"I phase 1 trial for patients with IDH1-mutated AML, patients who received ivosidenib (AG-120). The rate of complete remission was 21.6%, the over all response rate was 30.4%.",
        "rs value":null,
        "pmid":"PubMed:29860938",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01546038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"liver | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HuaChanSu",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03236636",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1436032",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02746081",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132C",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":"In a clinical study of 17 relapsed or refractory AML patients harboring IDH1 mutations, these patients were associated with response to AG-120 monotherapy; 4\/7 patients who achieved a response experienced complete remission.",
        "rs value":null,
        "pmid":"PubMed:25583779",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radiotherapy + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00626990",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IDH1 R132H peptide vaccine + Vorasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05609994",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelofibrosis",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03303950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vorasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02481154",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | clonal cytopenia of undetermined significance",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05030441",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT04176393",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Safusidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04458272",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radiotherapy + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05565521",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified_or_IDH2_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Zotiraciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05588141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132",
        "Disease":"Cholangiocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":"The multicenter randomized double-blind phase 3 study included patients with IDH1-mutant cholangiocarcinoma who had progressed on previous therapy. Patients were randomly assigned to Ivosidenib or placebo. Placebo to Ivosidenib crossover was permitted on radiological progression. The primary endpoint was progression-free survival by independent central review. Progression-free survival was significantly improved with Ivosidenib compared with the placebo (median 2.7, vs 1.4 months; hazard ratio 0.37; 95% CI 0.25-0.54; one-side p<0.0001). Median overall survival was 10.8 months for the Ivosidenib group versus 9.7 months for the placebo group (HR 0.69 [95% CI 0.44-1.10]; p=0.060) in which 35 patients were crossover from the placebo group. In a prespecified exploratory analysis, the rank-preserving structural failure time (RPSFT) method was used to reconstruct the survival curve for patients receiving a placebo as if crossover had never occurred. RPSFT assumes that the treatment effect is the same for all patients, regardless of when the treatment is given. The RPSFT-adjusted median overall survival was 6.0 months for the placebo group (HR 0.46 [95% CI 0.28-0.75]; p=0.0008).",
        "rs value":null,
        "pmid":"PubMed:32416072",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02677922",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Glasdegib + Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04655391",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02632708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chloroquine + Metformin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02496741",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"liver | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chloroquine + Metformin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02496741",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03749187",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"liver | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Olutasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03684811",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03914742",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vorasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02481154",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"bone | chondrosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Olutasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03684811",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CPX-351 + Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04493164",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olutasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02719574",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_Mutation",
        "Disease":"Cholangiocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":"In a phase1 trial, 73 patients with cholangiocarcinoma harboring IDH1 mutations were treated with mutant IDH1 inhibitor ivosidenib. The response rate was 5%, median progression free survival was 3.8 months, and median overall survival was 13.8 months.",
        "rs value":null,
        "pmid":"PubMed:31300360",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IDH305",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02826642",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132H",
        "Disease":"central nervous system | glioma | astrocytoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Vorasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05484622",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04740190",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02632708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03343197",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lomustine + Procarbazine + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02333513",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04673448",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132H",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IDH1 R132H peptide vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02454634",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vorasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03343197",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132C",
        "Disease":"Brain Glioma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide",
        "Description":"In a study of 189 low-grade gliomas, IDH (IDH1 or IDH2) mutations were found in 132 patients (70%). IDH mutations were associated with improved rate of response to temozolomide as compared to patients with wildtype IDH (61%  vs. 17% , P=0.01).",
        "rs value":null,
        "pmid":"PubMed:20975057",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fedratinib + Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04955938",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04088188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Proton beam radiation therapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01358058",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01534845",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ralimetinib + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02364206",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic eosinophilic leukaemia-hypereosinophilic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03564821",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HMPL306",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04272957",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HMPL306",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04764474",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03839771",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vorasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02492737",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132",
        "Disease":"central nervous system | glioma | astrocytoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radiotherapy + Telaglenastat + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03528642",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Filgrastim + Fludarabine + Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04250051",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02074839",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DC vaccine loaded with glioma stem-like cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01567202",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Extended-release flucytosine + Vocimagene amiretrorepvec",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02414165",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03173248",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olutasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02719574",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03839771",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Olutasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02719574",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olutasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03684811",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"NovoTTF-200A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03450850",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idasanutlin ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02545283",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03013998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vorasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04164901",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HMPL306",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04762602",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"bone | chondrosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ASTX727 + Belinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04340843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Safusidenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03030066",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04088188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1436032",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02746081",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02989857",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"LY3410738",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04521686",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03666559",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IDH305",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02987010",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718767",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03741244",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03557359",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04056910",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IDH305",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02977689",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Safusidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05303519",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olutasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03684811",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Proton beam radiation therapy + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03180502",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Intensity modulated radiation therapy + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03180502",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"NTX-301 + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04851834",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04195555",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03925246",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_R132",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IDH305",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02381886",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IDH1",
        "Genomic Position":"2:209100989-209119046(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"IDH1_Mutation",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Venetoclax",
        "Description":"In this case series, 7 elderly patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA (including 1 patient with antecedent myeloproliferative neoplasm) were treated with venetoclax monotherapy. Three of 7 patients showed response. Of these: 2 patients achieved complete remission (1 of which was mutated for IDH2). One patient with IDH1 mutation showed PB blast clearance (derived anti-leukemic benefit) but BM was not performed to evaluate response. Venetoclax responders had high BCL\ufffd\ufffd\ufffd2 and\/or BIM expression levels in myeloblasts, and the response was significantly associated with OS. BCL-2 and BIM expression levels can potentially identifer venetoclax respo",
        "rs value":null,
        "pmid":"PubMed:30725494",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AURKA",
        "Genomic Position":"20:54944445-54967351(-) | 20q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AURKA_Overexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Cisplatin",
        "Description":"High levels of Aurora-A expression (retrospectively assessed by IHC in 102 NSCLC patients) predicted poorer overall survival and progression free survival in a population treated with surgery and cisplatin-based chemotherapy. In-vitro data confirmed these results and overexpression or knockdown of AURKA decreased or increased in-vitro sensitivity to cisplatin.",
        "rs value":null,
        "pmid":"PubMed:25082261",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AURKA",
        "Genomic Position":"20:54944445-54967351(-) | 20q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AURKA_Overexpression",
        "Disease":"Ovarian Serous Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Platinum Compound",
        "Description":"A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (P\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd0.001; HR 0.14) and platinum therapy resistance (P < 0.001). Expression of AURKA was measured using immunohistochemical techniques on tu",
        "rs value":null,
        "pmid":"PubMed:27209210",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AURKA",
        "Genomic Position":"20:54944445-54967351(-) | 20q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AURKA_EXPRESSION",
        "Disease":"Esophagus Squamous Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radiation Therapy,Cisplatin,Fluorouracil",
        "Description":"A retrospective study examining the expression of AURKA in tumor samples of 78 esophageal squamous cell carcinoma patients found that positive expression of AURKA (>10% of cells by IHC) was correlated with increased clinical response to chemoradiation therapy consisting of cisplatin, 5-fluorouracil, and 40 gy radiation (P = 0.0003).",
        "rs value":null,
        "pmid":"PubMed:25924824",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_Underexpression",
        "Disease":"Stomach Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel,Olaparib",
        "Description":"A randomized phase 2 trial investigating the efficiency of Olaparib plus Paclitaxel vs. Placebo plus Paclitaxel in recurrent or metastatic gastric cancer patients. 123 patients received treatment. Combination treatment did not significantly improve ORR (26,4% vs 19,1%) or PFS (3,91m vs 3,55 m) but OS (13,8 m vs. 8,3 m) in the overall cohort.  A subcohort of ATM low expressing tumours (14%) experienced a greater improvement of OS (not reached vs. 8,2 m) and a trend towards improved PFS (5,29 m vs 3,68 m).",
        "rs value":null,
        "pmid":"PubMed:26282658",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"stomach | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01063517",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02576444",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03155620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_or_MRE11A_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03344965",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03009682",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04336943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_BLM_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FAM175A_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_NBN_unspecified_or_RAD50_unspecified_or_RAD51_unspecified_or_RAD51C_unspecified_or_RTEL1_unspecified",
        "Disease":"pancreas | carcinoma | ductal carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04666740",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Trastuzumab Deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04704661",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_BARD1_unspecified_or_CHEK2_unspecified_or_FANCC_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_SLX4_unspecified_or_XRCC2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05033756",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_ATR_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_BLM_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CDK12_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_MRE11_unspecified_or_NBN_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_WRN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"HX008 + Niraparib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04508803",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"lung | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02264678",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_POT1_unspecified_or_SF3B1_unspecified_or_TP53_unspecified_or_XPO1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + RP-3500",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05405309",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_Mutation",
        "Disease":"Prostate Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"This study (PMID 32343890) by de Bono et al, is a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone).The study found that in men with mCRPC who had disease progression while receiving enzalutamide or abiraterone and who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient- reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). For patients with ATM mutations specifically, PFS HR 1.04 [0.61-1.87]. Based on the results of this study, On May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone.",
        "rs value":null,
        "pmid":"PubMed:32343890",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_FANCL_unspecified_or_PALB2_unspecified_or_PP2R2A_unspecified_or_RAD51B_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_RAD54L_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03786796",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT02975934",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_EPCAM_unspecified_or_EXO1_unspecified_or_MLH1_unspecified_or_MLH3_unspecified_or_MSH2_unspecified_or_MSH3_unspecified_or_MSH6_unspecified_or_PMS1_unspecified_or_PMS2_unspecified_or_POLE_unspecified_or_POLD1_unspecified_or_POLR1C_unspecified_or_RFC1_unspecified_or_RFC2_unspecified_or_RFC3_unspecified_or_RFC4_unspecified_or_RFC5_unspecified_or_RPA1_unspecified_or_RPA2_unspecified_or_SSBP1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02952534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irinotecan + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05694715",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01244009",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Peposertib + Tuvusertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05687136",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Elimusertib + Irinotecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04514497",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Elimusertib + Topotecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04514497",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"RP-3500 + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05566574",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_ATRX_unspecified_or_ARID1A_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_or_MRE11A_unspecified_or_MSH2_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD51_unspecified_or_RAD51B_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ATG-018",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05338346",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04564027",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05010031",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1895344 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04095273",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_EPCAM_unspecified_or_EXO1_unspecified_or_MLH1_unspecified_or_MLH3_unspecified_or_MSH2_unspecified_or_MSH3_unspecified_or_MSH6_unspecified_or_PCNA_unspecified_or_PMS1_unspecified_or_PMS2_unspecified_or_POLE_unspecified_or_POLD1_unspecified_or_POLD2_unspecified_or_POLD3_unspecified_or_POLD4_unspecified_or_POLQ_unspecified_or_PRKDC_unspecified__or_RFC1_unspecified_or_RFC2_unspecified_or_RFC3_unspecified_or_RFC4_unspecified_or_RFC5_unspecified_or_RPA1_unspecified_or_SSBP1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05525858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"stomach | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Elimusertib + FOLFIRI",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04535401",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trifluridine and tipiracil hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04166604",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"stomach | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1895344 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04095273",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SC10914",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02940132",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Elimusertib + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04491942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03565991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1895344 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04095273",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04054167",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1895344 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04095273",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Testosterone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05011383",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"stomach | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Ceralasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02264678",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_ATR_unspecfied_or_BRCA1_unspecified_or_BRCA2_unspecified_or_CDK12_unspecified_or_CHEK2_unspecified_or_FANCA_unspecfied_or_MLH1_unspecified_or_MRE11A_unspecified_or_NBN_unspecified_or_RAD51C_unspecfied",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD51_unspecified_or_RAD51B_unspecified_or_RAD54L_unspecified_or_RPA1_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03377556",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCG_unspecified_or_FANCL_unspecified_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02401347",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03148795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03330405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Berzosertib + Carboplatin + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04216316",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01955668",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alvocidib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00377104",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"M4344",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02278250",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02286687",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"APG115 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03611868",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ART0380",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04657068",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04564027",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03682289",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell neoplasm unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PARP\/Tankyrase inhibitor 2X-121",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01618136",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Elimusertib + FOLFIRI",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04535401",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1895344",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03188965",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_S2289*",
        "Disease":"Prostate Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4\/6 patients (3\/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic frameshift mutation (ATM V2288fs*1) predicted to result in truncation prior to the PI3K catalytic domain and other domains for p53 recognition and response to DNA damage. No other alterations in ATM were observed; however, this patient also had frameshift mutations in MLH3, MRE11 and NBN.",
        "rs value":null,
        "pmid":"PubMed:26510020",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_Mutation",
        "Disease":"Prostate Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Response to olaparib was observed in 4 of 5 with prostate cancer patients with ATM aberrations (2 germline).",
        "rs value":null,
        "pmid":"PubMed:26510020",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_N2875H",
        "Disease":"Prostate Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4\/6 patients (3\/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic missense mutation (ATM N2875H) and no other alterations in ATM or other DNA repair genes.",
        "rs value":null,
        "pmid":"PubMed:26510020",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_Overexpression",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":"High expression of ERBB3 (her3) was associated with shorter overall survival (OS) from Cetuximab treatment in patients with metastatic colorectal cancer. Gene expression measures (qRT-PCR) were available for 103 patients.",
        "rs value":null,
        "pmid":"PubMed:25520391",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Neratinib + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03065387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03810872",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_V104M",
        "Disease":"Transitional Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib",
        "Description":"In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg\/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and\/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.",
        "rs value":null,
        "pmid":"PubMed:27044931",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_G284R",
        "Disease":"Transitional Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib",
        "Description":"In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg\/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and\/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.",
        "rs value":null,
        "pmid":"PubMed:27044931",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_R103G",
        "Disease":"Transitional Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib",
        "Description":"In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg\/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and\/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.",
        "rs value":null,
        "pmid":"PubMed:27044931",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Neratinib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03065387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pertuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01684878",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Patritumab deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04965766",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Patritumab deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02980341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GSK2849330",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01966445",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Varlitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03499626",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pertuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01684878",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Patritumab deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04610528",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"pING-hHER3FL",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03832855",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Loperamide + Neratinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01953926",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SI-B001",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05044897",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus + Neratinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03065387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Patritumab deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04479436",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFB",
        "Genomic Position":"22:39619364-39640756(-) | 22q13.1",
        "CDS Mutation":null,
        "AA Mutation":"PDGFB_COL1A1::PDGFB",
        "Disease":"Dermatofibrosarcoma Protuberans",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":"A 37-year-old man presented with dermatofibrosarcoma protuberans (DFSP). Post resection, multiple nodular metastases were found in both lungs and the disease progressed following treatments with cytotoxic agents and microwave ablation. Overexpression of PDGFRB was detected by IHC and a COL1A1-PDGFB fusion was detected by RT-PCR. Increased PDGFRB is activated by the COL1A1-PDGFB fusion product, which promotes the overactivation of downstream PDGFRB signaling pathways. Imatinib treatment failed as stable disease was followed by disease spread and progression. The patient was then treated with a daily oral dose of sunitinib (a multi-tyrosine kinase inhibitor) for 4 consecutive weeks, followed by a 2-week rest period. After 2 months on sunitinib, the patient experienced overall shrinkage of the body\ufffd\ufffd\ufffds tumor mass (reduction of tumor in arm and partial response in lung and pancreas metastases). Sunitinib resulted in 9 months of progression free survival and improved quality of life. Ultimately, the disease ssed and the patient died 46 months after diagnosis.",
        "rs value":null,
        "pmid":"PubMed:29760553",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PMS2",
        "Genomic Position":"7:6012870-6048756(-) | 7p22.1",
        "CDS Mutation":null,
        "AA Mutation":"PMS2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PMS2",
        "Genomic Position":"7:6012870-6048756(-) | 7p22.1",
        "CDS Mutation":null,
        "AA Mutation":"PMS2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03005002",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PMS2",
        "Genomic Position":"7:6012870-6048756(-) | 7p22.1",
        "CDS Mutation":null,
        "AA Mutation":"PMS2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03767075",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PMS2",
        "Genomic Position":"7:6012870-6048756(-) | 7p22.1",
        "CDS Mutation":null,
        "AA Mutation":"PMS2_unspecified",
        "Disease":"stomach | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Fluorouracil",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03485196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PMS2",
        "Genomic Position":"7:6012870-6048756(-) | 7p22.1",
        "CDS Mutation":null,
        "AA Mutation":"PMS2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104893",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PMS2",
        "Genomic Position":"7:6012870-6048756(-) | 7p22.1",
        "CDS Mutation":null,
        "AA Mutation":"PMS2_K706FS*19",
        "Disease":"Glioblastoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":"Two siblings (6 and 3.5 years) from nonconsanguineous parents were diagnosed with glioblastoma multiforme. Both tumors harbored TP53 mutations and lack of MGMT promoter hypermethylation as poor prognostic markers. Germline homozygous c.2117delA, p. Lys706SerfsX19 mutation in PMS2, loss of PMS2 staining in the tumor and normal tissue confirmed a diagnosis of biallelic mismatch repair deficiency (bMMRD). Both tumors harbored driver mutations in POLE and were found to harbor 24,680 and 21,919 mutations per exome. Neoantigen load was assessed in 37 bMMRD patients and all malignant tumors had high numbers of predicted neoantigens (7-16x as high as in melanoma, lung or other immunoresponsive cancers). Treatment with nivolumab was begun and both patients had radiologic response. After 9 and 5 months of therapy, respectively, the patient and her brother resumed normal schooling and daily activities.",
        "rs value":null,
        "pmid":"PubMed:27001570",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"STMN1",
        "Genomic Position":"1:26211931-26232957(-) | 1p36.11",
        "CDS Mutation":null,
        "AA Mutation":"STMN1_EXPRESSION",
        "Disease":"Endometrial Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Paclitaxel",
        "Description":"33 patients were retrospectively analyzed for Stathmin expression by IHC. High protein expression was correlated with poor response to paclitaxel but not other chemotherapy. The authors supported this conclusion with pre-clinical studies that showed that knock-down of stathmin improved sensitivity to paclitaxel in endometrial carcinoma cell lines with both naturally higher and lower sensitivity to paclitaxel.",
        "rs value":null,
        "pmid":"PubMed:24587245",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"HLA-DRA",
        "Genomic Position":"6:32407619-32412823(+) | 6p21.32",
        "CDS Mutation":null,
        "AA Mutation":"HLA-DRA_EXPRESSION",
        "Disease":"Skin Melanoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab,Nivolumab,Atezolizumab",
        "Description":"Melanoma patients treated with Anti-PD1 or anti-PD-L1(nivolumab, pembrolizumab, MPDL3280A) therapy were analyzed for expression of HLA-DRA (the primary antigen-presenting molecule of the MHC-II pathway). In a discovery cohort, 30 patients underwent IHC for HLA-DRA. 11\/14 (79%) patients with positive HLA-DR staining, had complete (n=3) or partial (n=8) response. 6\/16 (38%) HLA-DR non-expressing melanomas responded to therapy (overall response rate 79 versus 38%, Fisher\ufffd\ufffd\ufffds exact test P=0.033). This finding was confirmed in a second independent data set of 23 melanoma patients with 6\/8 (75%) of HLA-DR(+) tumours in comparison to 4\/15 (27%) HLA-DR(\ufffd\ufffd\ufffd) responding (Fisher\ufffd\ufffd\ufffds exact test P=0.025). Preclinical models con",
        "rs value":null,
        "pmid":"PubMed:26822383",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":"c.1731C>A",
        "AA Mutation":"p.N577K",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30914635",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK1",
        "Genomic Position":"11:125496236-125527031(+) | 11q24.2",
        "CDS Mutation":null,
        "AA Mutation":"CHEK1_Mutation",
        "Disease":"Prostate Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). The study found that in men with mCRPC who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). A total of 3 patients had CHEK1 mutations, 2 in olaparib arm and 1 in control arm. Based on the results of this study, on May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone.",
        "rs value":null,
        "pmid":"PubMed:32343890",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CHEK1",
        "Genomic Position":"11:125496236-125527031(+) | 11q24.2",
        "CDS Mutation":null,
        "AA Mutation":"CHEK1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK1",
        "Genomic Position":"11:125496236-125527031(+) | 11q24.2",
        "CDS Mutation":null,
        "AA Mutation":"CHEK1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK1",
        "Genomic Position":"11:125496236-125527031(+) | 11q24.2",
        "CDS Mutation":null,
        "AA Mutation":"CHEK1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TYMS",
        "Genomic Position":"18:657604-673578(+) | 18p11.32",
        "CDS Mutation":null,
        "AA Mutation":"TYMS_5'_TANDEM_REPEAT",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Irinotecan,Fluorouracil",
        "Description":"The TYMS 5' 3TPR germline variant was significantly correlated with lower response to irinotecan plus 5-fluorouracil treatment in colorectal cancer patients. 149 metastatic CRC patients treated with irinotecan\/5FU as first-line chemotherapy were followed in this study.",
        "rs value":null,
        "pmid":"PubMed:20628391",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TYMS",
        "Genomic Position":"18:657604-673578(+) | 18p11.32",
        "CDS Mutation":null,
        "AA Mutation":"TYMS_Overexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Pemetrexed",
        "Description":"mRNA expression of thymidylate synthase (TYMS) in 62 NSCLC patients correlated with response rate to pemetrexed mono- or combination therapy. Response rate with low TYMS expression was 0.29 compared with 0.03 in patients with overexpression (P = 0.025). Patients with low expression exhibited a benefit in time to progression (average TTP = 56 vs. 23 months, P = 0.001) and in overall survival (average OS = 60 vs. 25 months, P = 0.002).",
        "rs value":null,
        "pmid":"PubMed:26502926",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TYMS",
        "Genomic Position":"18:657604-673578(+) | 18p11.32",
        "CDS Mutation":null,
        "AA Mutation":"TYMS_Amplification",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Pemetrexed",
        "Description":"TYMS copy number was lower in clinical samples responding to pemetrexed in combination with platinum (n=25). The same was found in 17 cell lines.",
        "rs value":null,
        "pmid":"PubMed:23645741",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TYMS",
        "Genomic Position":"18:657604-673578(+) | 18p11.32",
        "CDS Mutation":null,
        "AA Mutation":"TYMS_Underexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemetrexed",
        "Description":"49 tumor specimens from 268 NSCLC patients treated with pemetrexed were evaluated for expression of TYMS and DHFR by IHC and compared to treatment outcomes. Patients with low TS (\ufffd\ufffd\ufffd150) expression had a longer median progression-free survival (PFS) than those with high TS (>150) expression (4.8 vs. 3.4 months; p=",
        "rs value":null,
        "pmid":"PubMed:21367480",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TYMS",
        "Genomic Position":"18:657604-673578(+) | 18p11.32",
        "CDS Mutation":null,
        "AA Mutation":"TYMS_Overexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Pemetrexed",
        "Description":"mRNA levels of TYMS, DHFR and GARFT were assessed (rt-PCR) in 50 patient samples of NSCLC. TYMS mRNA levels were lower in responders compared to non-responders to pemetrexed (1.671 \ufffd\ufffd 0.844 versus 5.978 \ufffd\ufffd 1.895, p=",
        "rs value":null,
        "pmid":"PubMed:23060591",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TYMS",
        "Genomic Position":"18:657604-673578(+) | 18p11.32",
        "CDS Mutation":null,
        "AA Mutation":"TYMS_Overexpression",
        "Disease":"Gastric Adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Raltitrexed",
        "Description":"In 125 gastric tumors, plasma and tissue mRNA levels of TYMS were lower in the raltitrexed sensitive group compared to the resistant group (p = 0.007 and 0.013, respectively).",
        "rs value":null,
        "pmid":"PubMed:22422354",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TYMS",
        "Genomic Position":"18:657604-673578(+) | 18p11.32",
        "CDS Mutation":null,
        "AA Mutation":"TYMS_RS34743033",
        "Disease":"Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Methotrexate",
        "Description":"499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The TYMS rs34743033 tandem repeat polymorphism was the only significant predictor of stomatitis in a multiple regression model considering sex, age, MRD class, WBC, MTX AUC0-48h, and genotypes as independent variables (B = \ufffd\ufffd\ufffd0.48; 95% CI, \ufffd\ufffd\ufffd0.84, \ufffd\ufffd\ufffd0.12; R2 = 0.018; P = .009). Stomatitis toxicity was reduced with increasing *3 (3R) alleles as the *2\/*2 (2R\/2R) genotype displayed the highest incidence of stomatitis, *2\/*3 (2R\/3R) showed intermediate toxicity, and *3\/*3 (3R\/3R) had the lowest incide",
        "rs value":null,
        "pmid":"PubMed:23652803",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TYMS",
        "Genomic Position":"18:657604-673578(+) | 18p11.32",
        "CDS Mutation":null,
        "AA Mutation":"TYMS_Underexpression",
        "Disease":"Prostate Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemetrexed",
        "Description":"Case report of a patient with metastatic prostate cancer and underexpression of TYMS who showed a nonspecified response to pemetrexed for at least 4 months.",
        "rs value":null,
        "pmid":"PubMed:24782778",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ETS2",
        "Genomic Position":"21:40177231-40196879(+) | 21q22.2",
        "CDS Mutation":null,
        "AA Mutation":"ETS2_RS461155",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel,Cisplatin",
        "Description":"Eighty SNPs in miRNA binding sites of cancer related genes selected from 18,500 miRNA:target bindings in crosslinking, ligation, and sequencing of hybrids (CLASH) data were investigated in 379 advanced NSCLC patients using a sequenom mass spectrometry-based genotype assay. 16 SNPs were significantly associated with the clinical outcomes after chemotherapy with paclitaxel-cisplatin: ETS2 SNP: OR = 1.34, 95% CI = 1.00\ufffd\ufffd\ufffd1.81, P = 0.05; aHR = 0.80, 95% CI = 0.69\ufffd\ufffd\ufffd0.94, P = 0.006, under additive model. ETS2 rs461155A>G was significantly associated with decreased ETS2 mRNA expression in both tumor and paired normal lung tissues (Ptrend = 4 \ufffd\ufffd 10-7, and 3 \ufffd\ufffd ",
        "rs value":null,
        "pmid":"PubMed:26893365",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Dexamethasone + Doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00872521",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04550624",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Dexamethasone + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00872521",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_fusions_FGFR3-TACC3_or_FGFR3-BAIAP2L1",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02365597",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04917809",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Erdafitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02952573",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04172675",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03732703",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_G370C_or_FGFR3_R248C_or_FGFR3_S249C_or_FGFR3_Y373C",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02365597",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_G370C_or_FGFR3_R248C_or_FGFR3_S249C_or_FGFR3_Y373C_or_FGFR3-TACC3_fusions_(Therascreen_FGFR)",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03390504",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02272998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03210714",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03827850",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_Mutation",
        "Disease":"Transitional Cell Carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib",
        "Description":"In a phase 2 trial, patients with locally advanced and unresectable or metastatic urothelial carcinoma harboring FGFR3 mutation or FGFR2\/3 fusion were treated with Erdafitinib. All the patients had a history of disease progression during or after at least one course of chemotherapy. The response rate in patients receiving continuous daily 8 or 9mg Erdafitinib treatment was 40% (40\/99). Within this treatment group, the response rate of patients with FGFR3 mutation was 49% (36\/74). FGFR3 mutations included G370C, R248C, S249C, and Y373C.",
        "rs value":null,
        "pmid":"PubMed:31340094",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_FGFR3::TACC3",
        "Disease":"Cancer",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib",
        "Description":"Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 5 partial responses (PR) and 16 with stable disease were seen. In patients harboring FGFR3-TACC3, there were 2 urothelial cancer patients with PRs, 1 endometrial cancer patient with PR (also had FGFR2-BICC1\/FGFR2-OFD1 fusions), and tumor shrinkage in a patient with adrenal carcinoma (also had FGFR2-CCDC6 fusion).",
        "rs value":null,
        "pmid":"PubMed:26324363",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_K650E",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Infigratinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04424966",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PRN1371",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02608125",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Vofatamab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02925533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Epacadostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04586244",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified_or_FGFR1_fusions_or_FGFR2_fusions",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547 + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02546661",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00790426",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Vofatamab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02401542",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Futibatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03784014",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Vofatamab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03123055",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04096417",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rogaratinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04040725",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02872714",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Futibatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04601857",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02278978",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04004975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"[111In]-FPI-1967 + [225Ac]-FPI-1966",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05363605",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Epacadostat + Retifanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04586244",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_S249C",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02965378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01732107",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Infigratinib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT04228042",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Infigratinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04197986",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3-TACC3_fusion",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Infigratinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01975701",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3-TACC3_fusion",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Infigratinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04424966",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03822117",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04003610",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR-TACC_fusion",
        "Disease":"central nervous system | NS | medulloblastoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02824133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02154490",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_Mutation",
        "Disease":"Bladder Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Infigratinib",
        "Description":"Phase 1 study evaluated 132 patients who had advanced cancer with FGFR-aberrations treated with FGFR-inhibitor BGJ398. In the subgroup of eight patients with FGFR3-mutated bladder\/urothelial cancer treated at doses \ufffd\ufffd\ufffd 100 mg, the disease control rate (SD + PR) was 75%. Three patients achieved partial response and 3 patients had stable disease. Of the six patients with disease control, the time on treatment ranged from 15.1 to \ufffd\ufffd\ufffd 101 weeks, with one ongoing at ",
        "rs value":null,
        "pmid":"PubMed:27870574",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"soft tissue | gastrointestinal stromal tumour | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rogaratinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04595747",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04003610",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rogaratinib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02592785",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03914794",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib + Retifanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04586244",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Retifanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04586244",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rogaratinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01976741",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Infigratinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01004224",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04586244",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rogaratinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04595747",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vofatamab + [111In]-FPI-1967 + [225Ac]-FPI-1966",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05363605",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TYRA-300",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05544552",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3-TACC3_fusion",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Intensity modulated radiation therapy + Metformin + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04945148",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3-TACC3_fusion",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT04004975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_G370C_or_FGFR3_R248C_or_FGFR3_S249C_or_FGFR3_Y373C_or_FGFR3_fusions_or_FGFR2_fusions",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ABSK121-NX",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05627063",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"LOXO-435 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05614739",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04088188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ICP192",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04565275",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Futibatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04189445",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Futibatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02052778",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"LOXO-435",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05614739",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Rogaratinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04077255",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Infigratinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04233567",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"FGFR inhibitor debio 1347",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03834220",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"LY3076226",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02529553",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04088188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"central nervous system | NS | medulloblastoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Infigratinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01975701",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_Mutation",
        "Disease":"Urinary Bladder Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin,Gemcitabine",
        "Description":"In this study, 52 patients with Muscle Invasive Bladder Cancer (MIBC) were randomly selected and administered neoadjuvant cisplatin and gemcitabine chemotherapy. 39 out of 52 patients showed pathological response (partial & complete) and 13 patients were resistant to neoadjuvant chemotherapy.35.9% (14\/39) patients that responded to neoadjuvant chemotherapy had the following FGFR3 somatic mutations - p.S249C,p.V372C, p.G299S, p.V411M. FGFR3 somatic mutations exclusively occurred in the responder group.The somatic FGFR3 mutation frequency in the responder group was also compared with three unselected bladder cancer populations from TCGA, Kim et al.study and Guo et al. studies.This analysis revealed that FGFR3 somatic mutations were significantly enriched in the responder cohort compared with the unselected bladder cancer cohorts.",
        "rs value":null,
        "pmid":"PubMed:29941343",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3-TACC3_fusion",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01703481",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_FGFR3::TACC3",
        "Disease":"Transitional Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Infigratinib",
        "Description":"In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or more prior antineoplastic therapies. An overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization. No clear differences between type of FGFR3 aberration and response could be seen. Four of five patients with FGFR3-TACC3 fusions had response data, with three achieving stable disease and one having a complete response. The authors conclude that BGJ398 appears to have moderate anticancer activity in patients with metastatic urothelial carcinoma, that response rates and disease control rate exceed outcomes with most agents in this setting, and that enriching for patients with activating FGFR3 mutations together with the high specificity of BGJ398 for FGFR3 likely explains this improved response.",
        "rs value":null,
        "pmid":"PubMed:29848605",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_S249C",
        "Disease":"Transitional Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pazopanib",
        "Description":"Case report of a 67 year old woman with high-grade papillary urothelial carcinoma. The patient underwent chemotherapy and palliative cystectomy followed by tumor progression and pulmonary lesion enlargement. Genomic profiling of the cystectomy specimen identified FGFR3, CCND1 and FGF19 amplification as well as an FGFR3 S249C mutation (allele frequency 58%). Pazopanib was initiated on the basis of these findings and a partial response was achieved for >6 months.",
        "rs value":null,
        "pmid":"PubMed:25766722",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_Fusion",
        "Disease":"Adrenal Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib",
        "Description":"Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. Tumor shrinkage was observed in a patient with adrenal carcinoma and FGFR3-TACC3\/FGFR2-CCDC6 fusions.",
        "rs value":null,
        "pmid":"PubMed:26324363",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGF3",
        "Genomic Position":"11:69624992-69633792(-) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"FGF3_Amplification",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":"81 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib. Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, respectively. 3 of these 4 patients also had FGFR1 amplifications (\ufffd\ufffd\ufffd6 copies by qPCR) and the fourth presented with FGFR1-gene gain (3.4 copies of FGFR1 by qPCR and SISH nega",
        "rs value":null,
        "pmid":"PubMed:23658459",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_p16_Expression",
        "Disease":"Head And Neck Squamous Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":"Phase III trial to compare afatinib or metothrexate in recurrent or metastatic head and neck squamous cell carcinoma. 483 patients were randomized to either afatinib (n=322) or methotrexate (n=161). 285 patients were assessed for p16 Status (IHC). In the post-hoc analysis, benefit of afatinib compared with methotrexate was more pronounced in p16-negative disease (HR 0\ufffd\ufffd69 [95% CI 0\ufffd\ufffd50\ufffd\ufffd\ufffd0\ufffd\ufffd96], p=0.022) than in p16-positive disease (HR 0\ufffd\ufffd95 [CI 0\ufffd\ufffd51\ufffd\ufffd\ufffd1\ufffd\ufffd75]",
        "rs value":null,
        "pmid":"PubMed:25892145",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified_or_CDKN2B_unspecified_or_CDK4_unspecified_or_CDK6_unspecified_or_PTEN_unspecified_or_PIK3CA_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus + Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03834740",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Encorafenib + Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02159066",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02187783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04423185",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04966481",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"bone | chordoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03110744",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"biliary tract | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"central nervous system | glioma | oligodendroglioma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02530320",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02645149",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04423185",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03237390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified_and_RB1_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02334527",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Intensity modulated radiation therapy + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03389477",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Intensity modulated radiation therapy + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03389477",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01291017",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"skin | malignant melanoma | acral lentiginous",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03454919",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04074785",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"soft tissue | gastrointestinal stromal tumour | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01907607",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_p16_Expression",
        "Disease":"Head And Neck Squamous Cell Carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":"In this retrospective analysis of p16 status as surrogate marker for HPV in the SPECTRUM trial, p16 (CDKN2A) expression was not associated with improved response to EGFR-directed therapy (Panitumumab) in combination with chemotherapy compared to chemotherapy alone.",
        "rs value":null,
        "pmid":"PubMed:23746666",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_p16_Expression",
        "Disease":"Head And Neck Squamous Cell Carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panitumumab",
        "Description":"p16-negative patients (HPV negative) have a longer overall survival under panitumumab\/chemotherapy in comparison to chemotherapy alone.",
        "rs value":null,
        "pmid":"PubMed:23746666",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"(CDKN2A_unspecified_and_TP53_unspecified)_or_MYC_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02688907",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"(CDKN2A_unspecified_and_TP53_unspecified)_or_MYC_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02593019",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_deletion",
        "Disease":"NS | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03654833",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03356223",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ilorasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02540876",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Montanide ISA 51 VG + P16_37-63",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01462838",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ilorasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02478320",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_deletion",
        "Disease":"bone | chondrosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04040205",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_deletion",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04040205",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_deletion",
        "Disease":"bone | osteosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04040205",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_deletion_and_PDCD4_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemrametostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04676516",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Montanide ISA 51 VG + P16_37-63",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02526316",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + LY3214996",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04391595",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abiraterone acetate + Prednisone + TQB3616",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05156450",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04393285",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Cisplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02620839",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dalpiciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02671513",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KRAS peptide vaccine + poly ICLC",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05013216",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_Loss",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Letrozole,Palbociclib",
        "Description":"A patient with metastatic ER-positive, her2-negative breast cancer with CDKN2A loss experienced a short-lived (~3-month) clinical response to palbociclib when given in combination with letrozole.",
        "rs value":null,
        "pmid":"PubMed:26715889",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myelomonocytic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03722407",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04147533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myeloproliferative neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00217646",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01253070",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01664897",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00383474",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Sorafenib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04752527",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Mercaptopurine + Methotrexate + Pegaspargase + Prednisone + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03117751",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Omacetaxine mepesuccinate + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04874194",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Mitoxantrone hydrochloride + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04330820",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1-RUNX1T1_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01238211",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic NK cells + Cyclophosphamide + Filgrastim + Fludarabine + Melphalan + Mesna + Mycophenolate mofetil + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05115630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1-RUNX1T1_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02450877",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1-RUNX1T1_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Fludarabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02926586",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01546038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_Mutation",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Cytarabine",
        "Description":"In non-APL patients with AML (age 18-60), those who had mutations in RUNX1 had significantly shorter relapse-free survival following conventional post-remission treatment (repetitive cycles of high-dose cytarabine) than those treated with an allogeneic hematopoietic stem-cell transplantation (N=32) at first remission (4-year RFS; 0% vs 52%; P<0.0001).",
        "rs value":null,
        "pmid":"PubMed:21343560",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Hematopoietic Stem Cell Transplant + Lenalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02038153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1-RUNX1T1_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Topotecan + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00588991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + SCH 900776",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01870596",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Samalizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03013998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1-RUNX1T1_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01139970",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Etoposide + Mitoxantrone hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01260714",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1-RUNX1T1_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Topotecan + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00588991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00658814",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic stem cell transplantation",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00093470",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01361464",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Entinostat",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00313586",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cytarabine + Daunorubicin + Decitabine + Etoposide + Filgrastim + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00416598",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Filgrastim + Fludarabine + KDS-1001 + Melphalan + Mesna + Mycophenolate mofetil + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05115630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04051996",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Azacitidine + Busulfan + Fludarabine + Hematopoietic Stem Cell Transplant + Methotrexate + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01168219",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Deferasirox",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02159040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Belinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00351975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Filgrastim + Fludarabine + Gemtuzumab Ozogamicin + Idarubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00801489",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idarubicin + Lenalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01132586",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RUNX1",
        "Genomic Position":"21:36160098-36421641(-) | 21q22.12",
        "CDS Mutation":null,
        "AA Mutation":"RUNX1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Hematopoietic Stem Cell Transplant + Lenalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01254578",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TIMP1",
        "Genomic Position":"X:47441712-47446188(+) | Xp11.3",
        "CDS Mutation":null,
        "AA Mutation":"TIMP1_Overexpression",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Paclitaxel",
        "Description":"High expression of TIMP-1 was assessed by IHC in 99 primary breast cancers that had not spread beyond the breast after 6 postoperative courses of paclitaxel-based chemotherapy. High TIMP1 levels were associated with worse 5-year disease free survival (71.1%) than low levels (88.5 %; P = 0.020). High TIMP-1 levels were also associated with worse 5-year overall survival (78.9 %) than low levels (96.7 %; P = 0.004).",
        "rs value":null,
        "pmid":"PubMed:22544540",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1544G>C",
        "AA Mutation":"p.C515S",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28235842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1544G>C",
        "AA Mutation":"p.C515S",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24869598",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1544G>C",
        "AA Mutation":"p.C515S",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25082755",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1544G>C",
        "AA Mutation":"p.C515S",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30508305",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1543T>A",
        "AA Mutation":"p.C515S",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28049639",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1543T>A",
        "AA Mutation":"p.C515S",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30508305",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1544G>C",
        "AA Mutation":"p.C515S",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28049639",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1544G>T",
        "AA Mutation":"p.C515F",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30508305",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1048A>G",
        "AA Mutation":"p.T350A",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27626698",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1543T>C",
        "AA Mutation":"p.C515R",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28235842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1544G>A",
        "AA Mutation":"p.C515Y",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30508305",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1543T>A",
        "AA Mutation":"p.C515S",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28235842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1543T>A",
        "AA Mutation":"p.C515S",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24869597",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1544G>C",
        "AA Mutation":"p.C515S",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27199251",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1544",
        "AA Mutation":"p.C515S",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25082755",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1544G>A",
        "AA Mutation":"p.C515Y",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28235842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1544G>T",
        "AA Mutation":"p.C515F",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24869598",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1543T>C",
        "AA Mutation":"p.C515R",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30508305",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1543T>C",
        "AA Mutation":"p.C515R",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28049639",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1544G>C",
        "AA Mutation":"p.C515S",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Acalabrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30508305",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BTK",
        "Genomic Position":"X:100604438-100641183(-) | Xq22.1",
        "CDS Mutation":"c.1544G>T",
        "AA Mutation":"p.C515F",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Acalabrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30508305",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FNTB",
        "Genomic Position":"14:65453438-65529316(+) | 14q23.3",
        "CDS Mutation":null,
        "AA Mutation":"FNTB_RS11623866",
        "Disease":"Ovarian Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lonafarnib",
        "Description":"57 from 105 patients in the AGo-OVAR-15 trial were retrospectively genotyped for FNTB polymorphisms. Resistance to lonafarnib-containing treatment was limited to patients with a FNTB rs11623866 (c.-609G\ufffd\ufffd\ufffd>\ufffd\ufffd\ufffdC) GG genotype (HRPFS 6.2, 95%CI\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd2.01, 19.41, P\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd0.002; HROS 9.6, 95%C",
        "rs value":null,
        "pmid":"PubMed:26033044",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.170A>C",
        "AA Mutation":"p.K57T",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26644315",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.179T>A",
        "AA Mutation":"p.V60E",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.362G>C",
        "AA Mutation":"p.C121S",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21383288",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q56P",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23569304",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.383G>T",
        "AA Mutation":"p.G128V",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.371C>T",
        "AA Mutation":"p.P124L",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.361T>A",
        "AA Mutation":"p.C121S",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.171G>C",
        "AA Mutation":"p.K57N",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.K57E",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23569304",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.E203K",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23569304",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V211D",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Binimetinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31227518",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.169A>G",
        "AA Mutation":"p.K57E",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24463458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.370C>T",
        "AA Mutation":"p.P124S",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F129L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"PD0325901",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22402123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L115P",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"PD0325901",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22402123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.383G>A",
        "AA Mutation":"p.G128D",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25452114",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.371C>T",
        "AA Mutation":"p.P124L",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Selumetinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19915144",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DDR2",
        "Genomic Position":"1:162602255-162757190(+) | 1q23.3",
        "CDS Mutation":null,
        "AA Mutation":"DDR2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01273610",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DDR2",
        "Genomic Position":"1:162602255-162757190(+) | 1q23.3",
        "CDS Mutation":null,
        "AA Mutation":"DDR2_I638F_or_DDR2_L239R_or_DDR2_S768R",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DDR2",
        "Genomic Position":"1:162602255-162757190(+) | 1q23.3",
        "CDS Mutation":null,
        "AA Mutation":"DDR2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04439305",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DDR2",
        "Genomic Position":"1:162602255-162757190(+) | 1q23.3",
        "CDS Mutation":null,
        "AA Mutation":"DDR2_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01491633",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DDR2",
        "Genomic Position":"1:162602255-162757190(+) | 1q23.3",
        "CDS Mutation":null,
        "AA Mutation":"DDR2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01514864",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DDR2",
        "Genomic Position":"1:162602255-162757190(+) | 1q23.3",
        "CDS Mutation":null,
        "AA Mutation":"DDR2_S768R",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib,Dasatinib",
        "Description":"In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response.",
        "rs value":null,
        "pmid":"PubMed:22328973",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RAF1",
        "Genomic Position":"3:12625100-12705725(-) | 3p25.2",
        "CDS Mutation":null,
        "AA Mutation":"RAF1_Amplification",
        "Disease":"Skin Melanoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin,Paclitaxel,Sorafenib",
        "Description":"Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, \ufffd\ufffd sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors that were positive for RAF1 gene copy gains (HR = 0.372; P = 0.0",
        "rs value":null,
        "pmid":"PubMed:26307133",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RAF1",
        "Genomic Position":"3:12625100-12705725(-) | 3p25.2",
        "CDS Mutation":null,
        "AA Mutation":"RAF1_QKI-RAF1",
        "Disease":"Spindle Cell Sarcoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":"Case report of a 27-year old female patient with spindle cell sarcoma. Initial treatment consisted of eight cycles of alternating vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide plus definitive radiation for suspected Ewing's sarcoma. An Archer panel revealed a QKI-RAF1 gene fusion, no EWSR1 and SS18 gene rearrangement were identified and a diagnosis of spindle cell tumor (S100 and CD34 coexpression with recurrent gene fusion) was made. Three months after end of treatment a relapse was diagnosed which progressed under temozolomide-irinotecan. Third-line therapy with trametinib was started which led to a complete metabolic response. The patient died 10months later from septic shock. No tumor progression was noted.",
        "rs value":null,
        "pmid":"PubMed:35050712",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CSF3R",
        "Genomic Position":"1:36931644-36948879(-) | 1p34.3",
        "CDS Mutation":null,
        "AA Mutation":"CSF3R_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02092324",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CSF3R",
        "Genomic Position":"1:36931644-36948879(-) | 1p34.3",
        "CDS Mutation":null,
        "AA Mutation":"CSF3R_T618I",
        "Disease":"Chronic Neutrophilic Leukemia",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ruxolitinib",
        "Description":"Case report of a patient treated with ruxolitinib, an FDA-approved JAK1\/2 inhibitor, which resulted in dramatic improvement of his blood counts. He also had significant reduction of spleen volume and constitutional symptoms.",
        "rs value":null,
        "pmid":"PubMed:25180155",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":"c.1633G>A",
        "AA Mutation":"p.E545K",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25515853",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":"c.1634A>G",
        "AA Mutation":"p.E545G",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERRFI1",
        "Genomic Position":"1:8071779-8086368(-) | 1p36.23",
        "CDS Mutation":null,
        "AA Mutation":"ERRFI1_E384*",
        "Disease":"Cholangiocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib",
        "Description":"An ERRFI1 (E384X) was detected in a patient with metastatic, recurrent\/refractory cholangiocarcinoma (allelic fraction 11%) without any mutations or amplifications in other EGFR signaling members such as EGFR and BRAF. The patient was treated with erlotinib 150 mg orally\/daily. After 3 months, RECIST v1.1 partial response evidenced by a decrease of 58% in the sum of largest diameters was observed.",
        "rs value":null,
        "pmid":"PubMed:24550739",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_Mutation",
        "Disease":"Prostate Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). The study found that in men with mCRPC who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). For 99 patients with CDK12 mutations specifically, PFS HR 0.74 [0.44-1.31]. Based on the results of this study, on May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone.",
        "rs value":null,
        "pmid":"PubMed:32343890",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Vudalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05005728",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04336943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03570619",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03570619",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02952534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Testosterone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05011383",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabazitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abiraterone acetate",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enzalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104893",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04019964",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04751929",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04751929",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabazitaxel + Carboplatin + Vudalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05005728",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DKK1",
        "Genomic Position":"10:54074056-54077417(+) | 10q21.1",
        "CDS Mutation":null,
        "AA Mutation":"DKK1_NUCLEAR_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Irinotecan,Levoleucovorin,Oxaliplatin,Fluorouracil",
        "Description":"Nuclear expression of DICKKOPF-1 was identified in 15% of 699 patients with colorectal cancer and was associated with decreased progression-free survival (PFS) and overall survival (OS) after chemotherapy (FOLFOX, FOLFIRI, or 5-FU) [adjusted HR, 1.65; 95% confidence interval (CI), 1.23-2.21; P = 0.002)].",
        "rs value":null,
        "pmid":"PubMed:25788273",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RAD54L",
        "Genomic Position":"1:46713404-46744144(+) | 1p34.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD54L_Mutation",
        "Disease":"Prostate Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). The study found that in men with mCRPC who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). For 6 patients with RAD54L mutations specifically, PFS HR 0.33 [0.05-2.54]. Based on the results of this study, on May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone.",
        "rs value":null,
        "pmid":"PubMed:32343890",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RAD54L",
        "Genomic Position":"1:46713404-46744144(+) | 1p34.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD54L_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD54L",
        "Genomic Position":"1:46713404-46744144(+) | 1p34.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD54L_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD54L",
        "Genomic Position":"1:46713404-46744144(+) | 1p34.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD54L_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABCB1",
        "Genomic Position":"7:87133175-87342564(-) | 7q21.12",
        "CDS Mutation":null,
        "AA Mutation":"ABCB1_S893T",
        "Disease":"Ovarian Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel",
        "Description":"The ABCB1 G2677T\/A (S893T, rs2032582) homozygous variant was positively correlated with response to paclitaxel treatment in ovarian cancer patients. 51 epithelial and 2 fallopian tube frozen tumors were analyzed for this study.",
        "rs value":null,
        "pmid":"PubMed:16467099",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ABCB1",
        "Genomic Position":"7:87133175-87342564(-) | 7q21.12",
        "CDS Mutation":null,
        "AA Mutation":"ABCB1_I1145I",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin,Carboplatin",
        "Description":"The mutation at codon 3435 (C>T) correlated with a significantly higher response rate to platinum-based chemotherapy in patients with advanced non small cell lung cancer (NSCLC).  103 Chinese patients with NSCLC were evaluated in this study. However, there was not a significant correlation between the mutation and overall survival.",
        "rs value":null,
        "pmid":"PubMed:22296372",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CTAG1B",
        "Genomic Position":"X:153845865-153847522(-) | Xq28",
        "CDS Mutation":null,
        "AA Mutation":"CTAG1B_Overexpression",
        "Disease":"Multiple Myeloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Letetresgene Autoleucel",
        "Description":"Clinical responses to NY-ESO-1\/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and\/or LAGE-1 in this Phase 1\/2a trial showing a median progression free survival of 19.1 months.",
        "rs value":null,
        "pmid":"PubMed:26193344",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CTAG1B",
        "Genomic Position":"X:153845865-153847522(-) | Xq28",
        "CDS Mutation":null,
        "AA Mutation":"CTAG1B_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CHP-NY-ESO-1 vaccine + Picibanil",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00291473",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"POLE",
        "Genomic Position":"12:133200348-133263945(-) | 12q24.33",
        "CDS Mutation":null,
        "AA Mutation":"POLE_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03767075",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"POLE",
        "Genomic Position":"12:133200348-133263945(-) | 12q24.33",
        "CDS Mutation":null,
        "AA Mutation":"POLE_Mutation",
        "Disease":"Glioblastoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":"Case report of a patient with glioblastoma multiforme and POLE germline mutation. The patient was treated with pembrolizumab and lymphocyte infiltration was noted after resection of a spinal metastasis. An objective radiographic response was noted in the intracranial lesion. A high neoantigen load was identified.",
        "rs value":null,
        "pmid":"PubMed:27683556",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"POLE",
        "Genomic Position":"12:133200348-133263945(-) | 12q24.33",
        "CDS Mutation":null,
        "AA Mutation":"POLE_Mutation",
        "Disease":"Endometrial Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":"Case report of a patient with endometrial cancer and exceptional response to pembrolizumab (maintained at 14 months). POLE mutations V411L (exonuclease domain) and R114* were identified in the primary tumor as well as a resected lymph node metastasis. The tumor harbored a high mutational load as assessed by panel sequencing. Analysis of TCGA RNA-seq data revealed an association between POLE mutations and high immune marker expression.",
        "rs value":null,
        "pmid":"PubMed:27159395",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30683630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F1174C",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F1174C",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3604G>A",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31374369",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3604G>A",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27130468",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V1180L",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3367G>A",
        "AA Mutation":"p.G1123S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26134233",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202del",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.I1171S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3538G>C",
        "AA Mutation":"p.V1180L",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25228534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F1174V",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.I1171T",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3604G>C",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31374369",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.I1171S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26464158",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3512T>A",
        "AA Mutation":"p.I1171N",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25393796",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3512T>G",
        "AA Mutation":"p.I1171S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25393796",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F1174L",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3607G>A",
        "AA Mutation":"p.D1203N",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28434515",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3512T>A",
        "AA Mutation":"p.I1171N",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25393798",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T1151R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F1174L",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3467G>A",
        "AA Mutation":"p.C1156Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27045755",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S1206F",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C1156Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S1206Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T1151M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Brigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3512T>C",
        "AA Mutation":"p.I1171T",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25393798",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S1206Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3806G>C",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23434628",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3586C>A",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23344087",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F1174C",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3383G>C",
        "AA Mutation":"p.G1128A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30089600",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3617C>A",
        "AA Mutation":"p.S1206Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22277784",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S1206C",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Brigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.I1171T",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F1174V",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3467G>A",
        "AA Mutation":"p.C1156Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23434628",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3806G>C",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23344087",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Brigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31668326",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3604G>A",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22277784",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S1206Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3586C>A",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23434628",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3586C>A",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22277784",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Brigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31668326",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3520T>G",
        "AA Mutation":"p.F1174V",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24736079",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1203N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Brigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3806G>C",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27045755",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1152R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3806G>C",
        "AA Mutation":"p.G1269A",
        "Disease":"epithelioid_inflammatory_myofibroblastic_sarcoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30675302",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3604G>A",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24736079",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C1156F",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3604G>A",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31749991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3451",
        "AA Mutation":"p.T1151dup",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22277784",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3522C>G",
        "AA Mutation":"p.F1174L",
        "Disease":"inflammatory_myofibroblastic_tumour",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21030459",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.E1210K",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1204V",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29650534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3512T>G",
        "AA Mutation":"p.I1171S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31943796",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3806G>C",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31749991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3604G>A",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31749991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3806G>C",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31943796",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29650534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.I1171N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31616196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1198F",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29650534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29650534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NFE2L2",
        "Genomic Position":"2:178095033-178129859(-) | 2q31.2",
        "CDS Mutation":null,
        "AA Mutation":"NFE2L2_Mutation",
        "Disease":"Lung Squamous Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sapanisertib",
        "Description":"In an NCI-CTEP phase 2 trial, patients with squamous cell lung carcinoma with NFE2L2 mutations were treated with TORC1\/2 inhibitor TAK-228. The response rate was 29% (2\/7\ufffd\ufffd\ufffdand disease control rate was 100%. NFE2L2 mutations included Exon 2 deletion, F37V, D29H, W24C, E79K, G31R, R34G, R34Q, W24R, D77H, and",
        "rs value":null,
        "pmid":"ASCO:174406",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NFE2L2",
        "Genomic Position":"2:178095033-178129859(-) | 2q31.2",
        "CDS Mutation":null,
        "AA Mutation":"NFE2L2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Onatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04518137",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NFE2L2",
        "Genomic Position":"2:178095033-178129859(-) | 2q31.2",
        "CDS Mutation":null,
        "AA Mutation":"NFE2L2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Telaglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03872427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NFE2L2",
        "Genomic Position":"2:178095033-178129859(-) | 2q31.2",
        "CDS Mutation":null,
        "AA Mutation":"NFE2L2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sirpiglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04471415",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NFE2L2",
        "Genomic Position":"2:178095033-178129859(-) | 2q31.2",
        "CDS Mutation":null,
        "AA Mutation":"NFE2L2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed + Telaglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04265534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SGK1",
        "Genomic Position":"6:134490384-134639196(-) | 6q23.2",
        "CDS Mutation":null,
        "AA Mutation":"SGK1_Overexpression",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Alpelisib",
        "Description":"A group of 18 breast cancer patients were treated with PI3Kalpha inhibitor alpelisib (NVP-BYL719) plus an aromatase inhbitor (NCT01870505). 3 out of 3 patients expressing high tumor SGK1 mRNA had disease progression as best response with median progression free survival (PFS) of 56 days, while 15 patients classified with low to medium SGK1 mRNA had median PFS 111 days with 4\/15 having disease progression as best response.",
        "rs value":null,
        "pmid":"PubMed:27451907",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"DPYD",
        "Genomic Position":"1:97543299-98386579(-) | 1p21.3",
        "CDS Mutation":null,
        "AA Mutation":"DPYD_DPYD*2A_HOMOZYGOSITY",
        "Disease":"Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine,Tegafur,Fluorouracil",
        "Description":"The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population.",
        "rs value":null,
        "pmid":"PubMed:23988873",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"DPYD",
        "Genomic Position":"1:97543299-98386579(-) | 1p21.3",
        "CDS Mutation":null,
        "AA Mutation":"DPYD_DPYD*13_HOMOZYGOSITY",
        "Disease":"Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine,Tegafur,Fluorouracil",
        "Description":"The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population.",
        "rs value":null,
        "pmid":"PubMed:23988873",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"DPYD",
        "Genomic Position":"1:97543299-98386579(-) | 1p21.3",
        "CDS Mutation":null,
        "AA Mutation":"DPYD_RS67376798_HOMOZYGOSITY",
        "Disease":"Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil,Capecitabine,Tegafur",
        "Description":"The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population.",
        "rs value":null,
        "pmid":"PubMed:23988873",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"DPYD",
        "Genomic Position":"1:97543299-98386579(-) | 1p21.3",
        "CDS Mutation":null,
        "AA Mutation":"DPYD_EXON_11-19_DELETION",
        "Disease":"Head And Neck Squamous Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Leucovorin,Fluorouracil",
        "Description":"A 69 year old patient diagnosed with HNSCC presented with an unresectable neck mass three months after surgery and adjuvant radiation therapy. A biopsy was taken for whole genome and transcriptome analysis and the patient was started on systemic therapy. After showing resistance to the systemic therapy treatment with 5-FU and leucovorin was initiated based on the discovery of a somatic exon 11-19 in frame deletion in DPYD, which was hypothesized to increase sensitivity to 5-FU in the tumour. A dramatic clinical and radiographic response was sustained for 17 weeks, but following a 3 week treatment break a new nodule appeared. This recurrence showed resistance to re-initiation of treatment with capecitabine (oral 5-FU), and analysis of an additional biopsy provided no evidence as to the mechanism of resistance.",
        "rs value":null,
        "pmid":"PubMed:31871216",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RAD51B",
        "Genomic Position":"14:68286525-69062713(+) | 14q24.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD51B_Mutation",
        "Disease":"Prostate Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). The study found that in men with mCRPC who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). A total of 7 patients had RAD51B mutations, 5 in olaparib arm and 2 in control arm. Based on the results of this study, on May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone.",
        "rs value":null,
        "pmid":"PubMed:32343890",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RAD51B",
        "Genomic Position":"14:68286525-69062713(+) | 14q24.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD51B_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51B",
        "Genomic Position":"14:68286525-69062713(+) | 14q24.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD51B_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51B",
        "Genomic Position":"14:68286525-69062713(+) | 14q24.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD51B_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51B",
        "Genomic Position":"14:68286525-69062713(+) | 14q24.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD51B_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MMP2",
        "Genomic Position":"16:55512883-55540603(+) | 16q12.2",
        "CDS Mutation":null,
        "AA Mutation":"MMP2_SERUM_LEVELS",
        "Disease":"Inflammatory Breast Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab",
        "Description":"MMP2 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. High bMMP2 was correlated with better disease-free survival (DFS, p=0.001) and overall survival (OS, p=0.032). Correlation to DFS was also found after multivariate analysis (p=0.003, Hazard Ratio [HR]: 0.115). bMMP2 was associated with relapse (p=0.002) and death (p=0.049). During treatment, significant increase in MMP2 was observed in 100% of patients.",
        "rs value":null,
        "pmid":"PubMed:26921265",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MMP2",
        "Genomic Position":"16:55512883-55540603(+) | 16q12.2",
        "CDS Mutation":null,
        "AA Mutation":"MMP2_SERUM_LEVELS",
        "Disease":"Brain Glioma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab",
        "Description":"Plasma levels of 11 potential biomarkers were tested at baseline and 2 weeks after bevacizumab initiation in a prospective cohort of 26 patients with recurrent high-grade gliomas. Results were validated in a separate retrospective cohort (n = 50) and also tested in patients treated with cytotoxic agents without bevacizumab (n = 34). MMP2 level was correlated with PFS (hazard ratio, 3.92; 95% confidence interval [CI]:1.46-10.52; P = .007) and OS (hazard ratio, 4.62; 95% CI: 1.58-13.53; P = .005) in the discovery and validation cohorts but not in patients treated without bevacizumab.",
        "rs value":null,
        "pmid":"PubMed:24327581",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PREX2",
        "Genomic Position":"8:68864353-69149265(+) | 8q13.2",
        "CDS Mutation":null,
        "AA Mutation":"PREX2_R172I",
        "Disease":"Melanoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":"In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E\/K (known BRAF inhibitor sensitizing mutations), PREX2 R172I was associated with a case of acquired resistance to BRAF inhibitor (vemurafenib) monotherapy in one patient. This patient was an 83 year old male with stage IV M1c melanoma who took vemurafenib (960mg twice daily). The best overall response was a 5% increase in sum of target lesions, and progression free survival lasted 132 days. Prior to vemurafenib monotherapy, this patient harbored BRAF V600K and no other somatic genetic alterations noted in the baseline tumor. Following relapse, the patient gained PREX2 R172I in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors indicated that the biology behind this potential resistance mutation was unknown.",
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25979954",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1609T>A",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27551012",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>C",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24055055",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1613A>G",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1138G>C",
        "AA Mutation":"p.E380Q",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32723837",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>G",
        "AA Mutation":"p.Y537C",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>C",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1613A>G",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185510",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26434753",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>C",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1607T>A",
        "AA Mutation":"p.L536H",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537C",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26434753",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537C",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26434753",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32723837",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1609T>A",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.L536",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1613A>G",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24217577",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26434753",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1613A>G",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>C",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185510",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1607",
        "AA Mutation":"p.L536Q",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185510",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1609T>A",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>G",
        "AA Mutation":"p.Y537C",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25979954",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":"c.1650T>A",
        "AA Mutation":"p.N550K",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30914635",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":"c.1187T>A",
        "AA Mutation":"p.V396D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30914635",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":"c.1697A>C",
        "AA Mutation":"p.E566A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"BGJ398",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31911531",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":"c.1614G>A",
        "AA Mutation":"p.M538I",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32723837",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":"c.1693G>T",
        "AA Mutation":"p.V565F",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28978722",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":"c.1852T>A",
        "AA Mutation":"p.L618M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"BGJ398",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31911531",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":"c.1650T>A",
        "AA Mutation":"p.N550K",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32723837",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":"c.1648A>C",
        "AA Mutation":"p.N550H",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"INCB054828",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31371345",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Ovarian Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undifferentiated ovarian cancer.",
        "rs value":null,
        "pmid":"PubMed:23346317",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04336943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00679783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03025035",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA2 patients specifically, the hazard ratio was 0.68, 95% CI 0.45-0.1.07.",
        "rs value":null,
        "pmid":"PubMed:28578601",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER\/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo.  Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).",
        "rs value":null,
        "pmid":"PubMed:34081848",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Prostate Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"In phase 3 trial of 387 patients comparing olaparib and new hormonal agent (enzalutamide or abiraterone) therapy for patients with metastatic castration-resistant prostate cancer harboring homologous recombinant repair-related gene mutation detected from a tumor sample, olaparib showed significant PFS benefit in an ITT population (HR [95%CI] 0.49 [0.38, 0.63]). But in subgroup analysis, the treatment effect differed in each mutated genes. Among them, patients with BRCA2 mutations (olaparib: n=92, control: n=53) showed a prominent benefit of olaparib (PFS HR [95%CI] 0.21 [0.13, 0.32]).",
        "rs value":null,
        "pmid":"PubMed:32343890",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03931551",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00679783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Pancreatic Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Twenty-three patients with pancreatic cancer havoring BRCA1\/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation.  In total of patients with BRCA1\/2 mutation , all but one had received prior gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%.",
        "rs value":null,
        "pmid":"PubMed:25366685",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2\ufffd\ufffd\ufffdnegative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy ",
        "rs value":null,
        "pmid":"PubMed:28792849",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Ovarian Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib,Cediranib",
        "Description":"46 women with platinum-sensitive, high-grade, BRCA1\/2+ ovarian cancer received either olaparib monotherapy or olaparib\/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).",
        "rs value":null,
        "pmid":"PubMed:25218906",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER\/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo. Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).",
        "rs value":null,
        "pmid":"PubMed:34081848",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Ovarian Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were randomized 2:1 to receive olaparib or placebo. The olaparib arm had 191 patients with BRCA1 mutation, 66 BRCA2, and 3 patients with both BRCA1 and BRCA2, while the placebo arm had 91 BRCA1 and 40 BRCA2 mutant patients. Analysis of PFS by blinded independent review found freedom from disease progression or death at 3 years was 69% in the olaparib arm compared with 35% in the placebo arm (hazard ratio for disease progression or death, 0.28; 95% CI, 0.20 to 0.39; P<0.001).",
        "rs value":null,
        "pmid":"PubMed:30345884",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Pancreatic Adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"In the phase 3 POLO trial patients who had germline BRCA1\/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to maintenance olaparib or placebo. BRCA1\/2 mutation was determine by the BRAC-Analysis CDx test. Median progression free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% CI, 0.35 to 0.82; p=0.004). BRCA2 mutations were present in 62\/92 patients in the olaparib group and 46\/62 patients in the placebo group, while one patient receiving olaparib had both BRCA1 and BRCA2 germline mutations. Responses were seen in 18 (20%) patients in the olaparib group, including two complete responses. The safety profile of olaparib was similar to that observed in other patient populations.",
        "rs value":null,
        "pmid":"PubMed:31157963",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"In this phase 1 trial 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1\/2 mutation carriers.19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation.",
        "rs value":null,
        "pmid":"PubMed:19553641",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Prostate Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function alleles (biallelic somatic loss or germline mutations in combination with somatic copy loss or copy neutral LOH) demonstrated a clinical response.",
        "rs value":null,
        "pmid":"PubMed:26510020",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Ovarian Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7\/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11\/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.",
        "rs value":null,
        "pmid":"PubMed:21862407",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03140670",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00664781",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00664781",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Ovarian Cancer",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":"A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 5 had somatic BRCA2 mutation, 4 of which were homozygous mutations and one had unknown zygosity. Confirmed objective response was seen in 80% (4\/5) of the somatic BRCA2 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7\/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).",
        "rs value":null,
        "pmid":"PubMed:27908594",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Ovarian Cancer",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":"A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 6 had germline homozygous BRCA2 mutation. Confirmed objective response was seen in 83% (5\/6) of the germline BRCA2 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7\/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).",
        "rs value":null,
        "pmid":"PubMed:27908594",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02034916",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pidnarulex",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04890613",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01149083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Ovarian Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Platinum Compound",
        "Description":"In a study of ovarian carcinomas, 81% of tumors with germline BRCA1\/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1\/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.",
        "rs value":null,
        "pmid":"PubMed:24240112",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg\/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.",
        "rs value":null,
        "pmid":"PubMed:28242752",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Ovarian Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Platinum Compound",
        "Description":"In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1\/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1\/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum therapy.",
        "rs value":null,
        "pmid":"PubMed:24240112",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KRAS peptide vaccine + poly ICLC",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05013216",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00892736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin,Cisplatin",
        "Description":"In an evaluation of 77 patients, those who had BRCA1\/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.",
        "rs value":null,
        "pmid":"PubMed:25847936",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Ovarian Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg\/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.",
        "rs value":null,
        "pmid":"PubMed:28242752",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Pancreatic Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Platinum Compound",
        "Description":"Patients with BRCA1\/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)",
        "rs value":null,
        "pmid":"PubMed:25072261",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Pancreatic Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine,Veliparib,Cisplatin",
        "Description":"In Phase I study for pancreatic cancer patients GEM 600 mg\/m2 + CDDP 25 mg\/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7\/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.",
        "rs value":null,
        "pmid":"PubMed:29338080",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_V159M",
        "Disease":"Ovarian Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1\/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1\/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).",
        "rs value":null,
        "pmid":"PubMed:27908594",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_V211L",
        "Disease":"Ovarian Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1\/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1\/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).",
        "rs value":null,
        "pmid":"PubMed:27908594",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_V211I",
        "Disease":"Ovarian Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1\/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1\/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).",
        "rs value":null,
        "pmid":"PubMed:27908594",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Pancreatic Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Iniparib",
        "Description":"Patient with germline BRCA2 mutation underwent resection of pancreatic cancer. Around three years later, tumor recurrence was detected by MRI and PET-CT confirmed it. She was treated with gemcitabine plus iniparib in clinical trial. Excellent response to therapy was observed and surgery was performed but no residual tumor tissue was detected",
        "rs value":null,
        "pmid":"PubMed:21508395",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_M1R",
        "Disease":"Ovarian Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1\/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1\/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).",
        "rs value":null,
        "pmid":"PubMed:27908594",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_R2336P",
        "Disease":"Ovarian Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1\/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1\/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).",
        "rs value":null,
        "pmid":"PubMed:27908594",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_M1I",
        "Disease":"Ovarian Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1\/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1\/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).",
        "rs value":null,
        "pmid":"PubMed:27908594",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_K3326*",
        "Disease":"Glioblastoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide,Olaparib",
        "Description":"In a case report, a 3\ufffd\ufffd\ufffdyear\ufffd\ufffd\ufffdold girl with glioblastoma harboring a probable germline heterozygous BRCA2 Lys3326Ter (K3326*) nonsense variant. After debulking surgery, the patient received standard\ufffd\ufffd\ufffdof\ufffd\ufffd\ufffdcare treatment with radiation and temozolomide. Nine months later the PARP inhibitor olaparib was administered in combination with temozolomide for 16 cycles. This regimen was well tolerated by the patient and serial imaging showed a ",
        "rs value":null,
        "pmid":"PubMed:32043779",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RAD51D",
        "Genomic Position":"17:33427691-33446832(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"RAD51D_Mutation",
        "Disease":"Prostate Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). The study found that in men with mCRPC who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). A total of 2 patients had RAD51D mutations, both in the olaparib arm. Based on the results of this study, on May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone.",
        "rs value":null,
        "pmid":"PubMed:32343890",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RAD51D",
        "Genomic Position":"17:33427691-33446832(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"RAD51D_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51D",
        "Genomic Position":"17:33427691-33446832(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"RAD51D_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04336943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51D",
        "Genomic Position":"17:33427691-33446832(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"RAD51D_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51D",
        "Genomic Position":"17:33427691-33446832(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51D",
        "Genomic Position":"17:33427691-33446832(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51D",
        "Genomic Position":"17:33427691-33446832(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"RAD51D_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51D",
        "Genomic Position":"17:33427691-33446832(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"RAD51D_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDCD4",
        "Genomic Position":"10:112631565-112659764(+) | 10q25.2",
        "CDS Mutation":null,
        "AA Mutation":"PDCD4_EXPRESSION",
        "Disease":"Lung Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel",
        "Description":"PDCD4 expression was associated with response to paclitaxel in a retrospective analysis of 77 patients after preclinical validation and mechanistic analysis of the biomarker.",
        "rs value":null,
        "pmid":"PubMed:25928036",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":0,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02159040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":0,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Deferasirox",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02159040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bendamustine + Rituximab + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05551936",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myelomonocytic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03722407",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04147533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rituximab + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04762160",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Daratumumab + Dexamethasone + Hyaluronidase-fihj + Pomalidomide + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05205252",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acalabrutinib + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05205252",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Tazemetostat hydrobromide + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04557956",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Mitoxantrone hydrochloride + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04330820",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03854474",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01897571",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"EZH2 inhibitor GSK2816126",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02082977",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"NS | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CPI-0209 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04557956",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"ovary | carcinoma | clear cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CPI-0209 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Valemetostat tosylate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04842877",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03456726",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HH2853",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04390737",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tafasitamab-cxix + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05205252",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_Y646S_OR_EZH2_Y646F_OR_EZH2_Y646H_OR_EZH2_Y646C_OR_EZH2_Y646N_OR_EZH2_A692V_OR_EZH2_A682G",
        "Disease":"Follicular Lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat",
        "Description":"This phase II study involved 17 Japanese adult patients with relapsed\/refractory follicular lymphoma (FL), previously treated with chemotherapy without an available standard therapy. The patients   harbored EZH2 activating mutations and were recruited to test the efficacy and safety of the EZH2 inhibitor- Tazemetostat. Tazemetostat was given at 800 mg dose twice a day for 28-days cycle. The objective response rate in this cohort was 76.5%, including six patients who had a complete response and seven who had partial response. The remaining three patients had stable disease status. Finally, the median progression\ufffd\ufffd\ufffdfree survival was not reached at the median follow\ufffd\ufffd\ufffdup of 12.9 months. The authors highlight the efficacy and manageable safety profile of Tazemetostat in refractory\/",
        "rs value":null,
        "pmid":"PubMed:34159682",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified_or_SMARCB1_unspecified_or_SMARCA4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02601950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05467943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Belinostat + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05627245",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05228158",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_Activating_Mutation",
        "Disease":"Follicular Lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat",
        "Description":"In this phase I study, four Japanese patients with follicular lymphoma were recruited to test the efficacy of EZH2 inhibitor-Tazemetostat. Patients were screened for presence of EZH2 mutations and only one patient had an activating mutation in EZH2. The patients were treated with Tazemetostat at a dose of 800 mg twice a day. Three of the four patients had partial response (including the one with the activating mutation), while one had a stable disease status after the treatment cycle. The authors highlight the treatment's acceptable safety profile and promising antitumor activity in relapsed or refractory B-cell lymphomas.",
        "rs value":null,
        "pmid":"PubMed:33492746",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified_or_SMARCB1_unspecified_or_SMARCA4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03217253",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified_or_SMARCB1_unspecified_or_SMARCA4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01897571",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified_or_SMARCB1_unspecified_or_SMARCA4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1-H\/K-HELP, Survivin-H\/K-HELP,MAGE-A4-H ? K-HELP, MUC1-22 peptide loaded autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04199559",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified_or_SMARCB1_unspecified_or_SMARCA4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03213665",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CPI-0209 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified_or_SMARCB1_unspecified_or_SMARCA4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03155620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CPI-0209 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_Activating_Mutation",
        "Disease":"Follicular Lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat",
        "Description":"Tazemetostat was found to have significantly increased anti-tumor activity in patients with relapsed\/refractory follicular lymphoma with gain-of-function EZH2 mutations (cobas EZH2 Mutation Test; objective response rate of 69%) versus patients with wild-type EZH2 (objective response rate of 35%). Treatment shows good tolerability and durability of response in both groups of patients.",
        "rs value":null,
        "pmid":"PubMed:33035457",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenalidomide + Tafasitamab-cxix + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05205252",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03303950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelofibrosis",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03303950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SHR2554",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03603951",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03456726",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CPI-0209 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_expression",
        "Disease":"Diffuse Large B-cell Lymphoma Germinal Center B-cell Type",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat",
        "Description":"In this phase I study, one patient with germinal center B\ufffd\ufffd\ufffdcell\ufffd\ufffd\ufffdlike (GCB) DLBCL and two with non-GCB DLBCL types were recruited to test the efficacy of EZH2 inhibitor-Tazemetostat in Japanese patients with refractory\/relapsed B-cell lymphomas. The patients were treated with a dose of 800 mg twice a day and an objective response was reached only in the patient with the GCB-DLBCL type (complete response), while the other two had progressive disease status. Since EZH2 is known to be expressed in GC and have a role in cellular proliferation and differentiation, the authors speculate that the the cellular origin of DLBCL might be a key in predicting the efficacy of T",
        "rs value":null,
        "pmid":"PubMed:33492746",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EZH2",
        "Genomic Position":"7:148504477-148581370(-) | 7q36.1",
        "CDS Mutation":null,
        "AA Mutation":"EZH2_Y646H",
        "Disease":"Diffuse Large B-cell Lymphoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat",
        "Description":"A phase I safety and dose-escalation study (NCT01897571) was completed for tazemetostat in relapsed or refractory B-cell non-Hodgkin lymphoma or advanced solid tumors. Durable objective responses, including complete responses, were observed in eight (38%) of 21 patients with B-cell non-Hodgkin lymphoma and two (5%) of 43 patients with solid tumours. EZH2 mutation status was assessed retrospectively. Two DLBCL patients had mutations. One of these (with a Y646H mutation) had a durable partial response before disease progression after 16 months on study. The variant in the second patient was not reported and the duration of therapy for this patient that did not respond was among the shortest in the trial.",
        "rs value":null,
        "pmid":"PubMed:29650362",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_ETV6::NTRK3",
        "Disease":"Congenital Fibrosarcoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"Four out of six patients with infantile fibrosarcoma and a ETV6-NTRK3 fusion had a partial response, the remaining two had a complete response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1\/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response.",
        "rs value":null,
        "pmid":"PubMed:29606586",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_Fusion",
        "Disease":"Solid Tumor",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"This was a Phase 1\/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall response rate was 75% according to independent review and 80% according to investigator assessment. Authors state that Larotrectinib had durable anti tumor activity regardless of age or tumor type. 26\/27 patients with NTRK3-fusion showed maximum percent change in tumor size between -30% and -100%.",
        "rs value":null,
        "pmid":"PubMed:29466156",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_ETV6::NTRK3",
        "Disease":"Solid Tumor",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"In this phase 1 dose-escalation study seventy patients with metastatic solid tumours were enrolled. Eight patient tumours were found to harbour NTRK gene fusions, six of which were ETV6-NTRK3. Treatment with larotrectinib resulted in reduced tumour burden for all patients with NTRK fusions. The average time on treatment was 28.4 months for patients with NTRK fusion cancer, compared to 1.8 months for those without an NTRK fusion.",
        "rs value":null,
        "pmid":"PubMed:30624546",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"XZP-5955",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04996121",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Entrectinib + Resection",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04302025",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_Fusion",
        "Disease":"Solid Tumor",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"Describes a meta-analysis of three separate phase I or II trials: ALKA-372-001, STARTRK-1, and STARTRK-2. All of these evaluate entrectinib in NTRK fusion-positive solid tumours. 31\/54 had objective response (57%; 95% CI 43\ufffd\ufffd2\ufffd\ufffd\ufffd70\ufffd\ufffd8), including 4 CR and 27 PR. 9 had SD. Response by NTRK gene type: 13\/22 NTRK1 fusions [59%; 95% CI 36\ufffd\ufffd4\ufffd\ufffd\ufffd79\ufffd\ufffd3], 18\/31 NTRK3 fusions [58%; 39\ufffd\ufffd1\ufffd\ufffd\ufffd75\ufffd\ufffd5], and 0\/1 NTRK2 fusion. Most frequent tumour types were sarcoma, NSCLC, salivary, breast, thyroid, colorectal. Most common fusions were ETV6-NTR",
        "rs value":null,
        "pmid":"PubMed:31838007",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_Fusion",
        "Disease":"Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1\/2\/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.",
        "rs value":null,
        "pmid":"PubMed:28183697",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_ETV6::NTRK3",
        "Disease":"Congenital Fibrosarcoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"In a pediatric phase 1 trial (NCT02637687) after initial chemotherapy failure, two ETV6-NTRK3 positive children (2 year old and 5 month old) were treated with Larotrectinib, resulting in reduced tumor burden (4 cycles showed ~50% reduction). Treatment was followed up by surgical resection resulting in a disease-free status at the time of last follow-up (>1 year).",
        "rs value":null,
        "pmid":"PubMed:30204247",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_ETV6::NTRK3",
        "Disease":"B-lymphoblastic Leukemia|lymphoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"Case report of a 61-year-old man with B-ALL. An initial analysis detected the ETV6-NTRK3 fusion and a NRASGly12Asp mutation. Initial therapies included chemotherapy and CAR-T infusion. Relapse 6 weeks after initial complete response to these therapies found a large increase in fusion transcripts and NTRK3 rearrangements were detectable by FISH in 50\/50 blast nuclei whereas NRAS mutations were no longer detectable. The patient was treated with oral monotherapy larotrectinib (100mg twice per day). After 4 days on treatment peripheral blood blasts became undetectable; after 6 days on treatment lymphadenopathy and leukemia cutis resolved and a biopsy revealed an ablated bone marrow with only a few scattered blasts. The patient experienced clinical benefit with no apparent side effects during 42 days of larotrectinib treatment, however, patient eventually succumbed to multifocal angioinvasive aspergillosis because of insufficient recovery of normal hematopoiesis. Later sequencing of the NTRK3 kinase domain did not detect any larotrectinib resistance mutations (p.G623R, p.G696A).",
        "rs value":null,
        "pmid":"PubMed:31905241",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_ETV6::NTRK3",
        "Disease":"B-lymphoblastic Leukemia|lymphoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Etoposide,Larotrectinib,Methotrexate",
        "Description":"All lines of conventional therapy (including allogeneic HSCT, blinatumomab, and CAR T cells) were inefficient for a 6-year-old boy with B-cell ALL and CNS infiltration (National Cancer Institute high risk). Conventional cytogenetics, FISH, and an Abbott break-apart probe of a peripheral blood sample collected at diagnosis revealed an unbalance translocation of the ETV6 locus. The patient relapsed twice and RNA sequencing of the initial diagnosis sample revealed a cytogenetically cryptic ETV6-NTRK3 fusion. Treatment with larotrectinib was initiated in combination with etoposide and methotrexate resulted in molecular remission in 66 days in bone marrow and CNS. A third relapse occurred 45 days after Larotrectinib was paused for CAR-T infusions. Larotrectinib was resumed with a dosage increase and again achieved sustained undetectable minimal residual disease after 66 days, and displayed molecular remission through 39 days. The authors suggest larotrectinib as a potential effective treatment for B-cell ALL patients harboring ETV6-NTRK3, including those with CNS infiltration.",
        "rs value":null,
        "pmid":"PubMed:31725893",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_F617L",
        "Disease":"Gastrointestinal Stromal Tumor",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Larotrectinib",
        "Description":"A 58-year-old male with NTRK-fusion positive gastrointestinal stromal tumour (GIST) demonstrated initial response to Larotrectinib but progressed after developing a gatekeeper mutation (TRKC F617L).",
        "rs value":null,
        "pmid":"PubMed:30624546",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_ETV6::NTRK3_G623R",
        "Disease":"Mammary Analogue Secretory Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Entrectinib",
        "Description":"Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an etv6-ntrk3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followed by disease progression. A NTRK3 exon 16 G623R (c.1867G>A) mutation was identified in the progressive tumor. Cell line and structural models revealed that this mutation conferred relative resistance to entrectinib.",
        "rs value":null,
        "pmid":"PubMed:26884591",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_ETV6::NTRK3",
        "Disease":"Congenital Fibrosarcoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"Nagasubramanian et al reports on a case of refractory infantile fibrosarcoma (IFS) with constitutive activation of the tropomyosin\ufffd\ufffd\ufffdrelated kinase (TRK) signaling pathway from an ETS variant gene 6\ufffd\ufffd\ufffdneurotrophin 3 receptor gene (ETV6\ufffd\ufffd\ufffdNTRK3) gene fusion. The patient was diagnosed with IFS at 6 months of age. At 16 months the patient enrolled in a pediatric Phase 1 trial of LOXO\ufffd\ufffd\ufffd101 (Larotrectinib, ARRY-470), an experimental, highly selective inhibitor of TRK. The patient experienced a rapid, radiographic response, demonstrating the potential for LOXO\ufffd\ufffd\ufffd101 to provide benefit for IF",
        "rs value":null,
        "pmid":"PubMed:27093299",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_ETV6::NTRK3",
        "Disease":"Breast Secretory Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"Shukla et al report on a remarkable case study of a 14 year old pediatric patient with refractory secretory breast carcinoma first presenting as a fibroadenoma at 8 yo. Over the next years, she experienced recurrence, multiple rounds of chemotherapy and metastasis -- until her case was presented at a virtual multidisciplinary tumor board organized by the Global Cancer Institute which recommended testing for ETV6-NTRK3 fusion. This fusion was confirmed by RNA-seq, targeted DNA and WGS sequencing as well as immunohistochemistry staining with a TRK antibody. The patient was treated with LOXO-101 (larotrectinib) in a single patient use protocol. Within two months, she experienced near complete resolution of a 10.4 \ufffd\ufffd 8.5 cm fungating chest mass with multiple satellite lesions (See Figure 2). The authors note that TERT promoter mutation and a reciprocal inversion including CDKN2A were also identified, but given what is known about LOXO-101 and ETV6-NTRK3, they  infer ETV6-NTRK3 fusion as the primary mitogenic er in this patient.",
        "rs value":null,
        "pmid":"PubMed:29623306",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_ETV6::NTRK3",
        "Disease":"Mammary Analogue Secretory Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.",
        "rs value":null,
        "pmid":"PubMed:26884591",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERCC2",
        "Genomic Position":"19:45853095-45873876(-) | 19q13.32",
        "CDS Mutation":null,
        "AA Mutation":"ERCC2_K751Q",
        "Disease":"Osteosarcoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Cisplatin",
        "Description":"The ERCC2 K751Q variant was significantly correlated with a lower response to cisplatin chemotherapy in osteosarcoma patients and shorter event-free survival. 91 osteosarcoma patients with a median age of 15 years were followed in this study.",
        "rs value":null,
        "pmid":"PubMed:19434073",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERCC2",
        "Genomic Position":"19:45853095-45873876(-) | 19q13.32",
        "CDS Mutation":null,
        "AA Mutation":"ERCC2_K751Q",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin,Paclitaxel",
        "Description":"The ERCC2 K751Q variant is significantly correlated with increased response to paclitaxel and carboplatin therapies in non small cell lung cancer (NSCLC). The researchers utilized data from three previous clinical trials in Japan and the United States with a total of 526 NSCLC patients.",
        "rs value":null,
        "pmid":"PubMed:19470925",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MTOR",
        "Genomic Position":"1:11166592-11322564(-) | 1p36.22",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28818608",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MTOR",
        "Genomic Position":"1:11166592-11322564(-) | 1p36.22",
        "CDS Mutation":"c.6324C>A",
        "AA Mutation":"p.F2108L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25295501",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MTOR",
        "Genomic Position":"1:11166592-11322564(-) | 1p36.22",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28818608",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MTOR",
        "Genomic Position":"1:11166592-11322564(-) | 1p36.22",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F2108L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Rapamycin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27279227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":0,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALT-801",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01670994",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":0,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Dexamethasone + Doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00872521",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":0,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Dexamethasone + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00872521",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pazopanib + Vorinostat",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01339871",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"17p_deletion_(TP53)",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Obinutuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02264574",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576444",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"17p_deletion_(TP53)",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01578707",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03112174",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Celecoxib + Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02748707",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04853043",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Folfirinox",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01442935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02748707",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + FOLFOX-4",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01442935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Olaparib + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02624973",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576444",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Y220C",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Trastuzumab Deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04704661",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bendamustine + Cytarabine + Rituximab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03567876",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04147533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02232386",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + FOLFIRI",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01442935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05432518",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04510584",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Tisagenlecleucel ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04234061",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04533321",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Cisplatin + Olaparib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04318938",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Fludarabine + Ibrutinib + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02251548",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"17p_deletion_(TP53)_or_TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fludarabine + Ibrutinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03204188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Obinutuzumab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02758665",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03226301",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"17p_deletion_or_TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Obinutuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02264574",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acalabrutinib + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05214183",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Daratumumab + Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03734198",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Cetuximab + Cisplatin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00477711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rituximab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03455517",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Wildtype",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Oxaliplatin,Cetuximab,Capecitabine",
        "Description":"In this retrospective biomarker analysis of the EXPERT-C trial, patients with TP53 wild-type status had a statistically significant better progression free survival (PFS) (89.3% vs 65.0% at 5 years; hazard ratio [HR] = 0.23; 95% confidence interval [CI] = 0.07 to 0.78; two-sided P = .02 by Cox regression) and overall survival (OS) (92.7% vs 67.5% at 5 years; HR = 0.16; 95% CI = 0.04 to 0.70; two-sided P = .02 by Cox regression) when treated with Cetuximab + CAPOX (Capecitabine, Oxaliplatin) than in the control arm without Cetuximab.",
        "rs value":null,
        "pmid":"PubMed:24957073",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Deleterious_Mutation",
        "Disease":"Sarcoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pazopanib",
        "Description":"19 advanced sarcoma patients treated with pazopanib were retrospectively assessed for mutations associated with response using the Foundation one sarcoma\/heme panel. Progression-free survival (PFS) of patients with TP53 mutations (all predicted to be loss of function) was significantly greater than TP53 wild-type tumors with the median PFS of 208 versus 136 days, respectively [P = 0.036, hazards ratio 0.38 (95% confidence interval 0.09-0.83)].",
        "rs value":null,
        "pmid":"PubMed:26646755",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Nivolumab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04277442",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03404193",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Venetoclax + Zanubrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05168930",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_R249M",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03953235",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acalabrutinib + Obinutuzumab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05197192",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Quizartinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04687761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Hematopoietic Stem Cell Transplant + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05528354",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"17p_deletion_(TP53)_or_TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acalabrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02337829",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Quizartinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04687761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02980731",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Eprenetapopt + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT04214860",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alemtuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Quizartinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03661307",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_S127Y",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03953235",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acalabrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04178798",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bendamustine + Ofatumumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01678430",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_K132E",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03953235",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chlorambucil  + Ofatumumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01678430",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_K132N",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03953235",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02756611",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Idelalisib + Ofatumumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01659021",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Magrolimab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04778397",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Siremadlin + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03714958",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acalabrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04660045",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Mitoxantrone hydrochloride + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04330820",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03069352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_R213L",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03953235",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acalabrutinib + Obinutuzumab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04855695",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"17p_deletion_(TP53)",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01889186",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Mutation",
        "Disease":"Chronic Lymphocytic Leukemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alemtuzumab",
        "Description":"Thirty-six patients with CLL were treated with alemtuzumab. Partial or complete response was achieved in 6 of 15 patients with p53 mutations, compared to 4 of 21 without. These findings are not statistically significant, but the authors suggest that alemtuzumab is an effective therapy for patients with p53 mutations or deletions.",
        "rs value":null,
        "pmid":"PubMed:14726385",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00004038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Wildtype",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adjuvant Chemotherapy",
        "Description":"Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA, 1209 patients, median follow-up 5.5 years) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS). Patients with wild-type TP53 had better outcomes with ACT than OBS (HROS=0.77 [0.62-0.95], p=0.02; HRDFS=0.75 [0.62-0.92], p=0.005).",
        "rs value":null,
        "pmid":"PubMed:26899019",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tamoxifen",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Overexpression",
        "Disease":"Ovarian Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Carboplatin,Cisplatin",
        "Description":"In a study involving patients with invasive ovarian carcinoma who had undergone surgery, a subset of 73 patients were classified via response to platinum-based chemotherapy as sensitive or resistant\/refractory and tested for p53 overexpression (>10% postive stained nuclei). 78% of p53 negative patients were classified as sensitive, in compariston to 39% of p53 positive patients (p=0.001).",
        "rs value":null,
        "pmid":"PubMed:11595686",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atorvastatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03560882",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BI 3011441",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04742556",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide + Cytarabine + Decitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03381781",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALRN-6924 + Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05622058",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04695223",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Belinostat + Pevonedistat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03772925",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_R249",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin",
        "Description":"Breast tumors with R175H or R249 mutations are more responsive to doxorubicin than breast tumors with wild type TP53.",
        "rs value":null,
        "pmid":"PubMed:9569050",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03715946",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01556776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Filgrastim + Fludarabine + Interleukin-2 + p53 TCR-transduced lymphocytes",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00393029",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02965950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TVB2640",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02980029",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Prexasertib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02808650",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02435186",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03645200",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"APR-548 + Azacitidine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04638309",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"thymus | thymic carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radioiodine + rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00902122",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALT-801 + Cisplatin",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01029873",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00003167",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Crolibulin",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01240590",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Eprenetapopt",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03931291",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Lenalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01459211",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Decitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04123392",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | peripheral T cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Decitabine + Doxorubicin hydrochloride + Prednisone + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04480099",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enzalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02099864",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Deferasirox",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02159040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00064103",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide + Decitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03855371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + MVAp53",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02275039",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemrametostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02783300",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Lenalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00352001",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ASTX727 + Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05396859",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Eprenetapopt",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03745716",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALT-801",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00496860",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Pevonedistat",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT03268954",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Eprenetapopt",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03588078",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Y220C",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PC14586",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04585750",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02768792",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Eprenetapopt",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03072043",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenalidomide + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04796857",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Filgrastim + Fludarabine + KDS-1001 + Melphalan + Mesna + Mycophenolate mofetil + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05115630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bone marrow transplantation + Cisplatin + Etoposide + Mitomycin C",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene + Docetaxel + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00044993",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bryostatin + Cisplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00006942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide + Transferrin receptor-targeted liposomal p53 cDNA",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02340156",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Celecoxib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02748707",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Filgrastim + Fludarabine + Interleukin-2 + p53 TCR-transduced lymphocytes",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00393029",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"sEphB4-HSA",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04033432",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CEP-11981 + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04159896",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabazitaxel + Prednisone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02961257",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ifosfamide + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04776525",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib + Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01357161",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02159040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"ovary | carcinoma | serous carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride liposome + Eprenetapopt",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03268382",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02645149",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Semustine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00004041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Paclitaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00176241",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Wildtype",
        "Disease":"Esophageal Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy",
        "Description":"Patients with p53 wild type (as defined by low expression and\/or wild-type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 % CI = 1.03-1.16, P = .003; pathological MR: RR = 1.15, 95 % CI = 1.06-1.25, P = .001; total complete response [CR]: RR = 1.08, 95 % CI = 1.00-1.17, P = .040) in this meta-analysis (28 studies, 1497 cases).",
        "rs value":null,
        "pmid":"PubMed:23515910",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02340117",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Y220C",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MVAp53 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02432963",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Irinotecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03641313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_R273H_or_TP53_R175H_or_TP53_R248Q_or_TP53_R249S",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Nab-paclitaxel + PD-1 blocking antibody + TP53\/EPHA2 targetting CAR dendritic cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05631886",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Eprenetapopt",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03072043",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Y220C",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALT-801",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00496860",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MVAp53 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03113487",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Peripheral blood stem cell transplantation  + Prophylactic donor lymphocytes",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03771222",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib + Irinotecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02448329",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"RO5045337",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00623870",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00902083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide + Decitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03377725",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Eprenetapopt",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03588078",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idasanutlin ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02545283",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cenersen + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00967512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Entospletinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03013998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00617409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_DNA_Binding_Domain_Mutation",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tamoxifen",
        "Description":"In a study 202 breast cancer patients undergoing first line tamoxifen treatment, 65 patients had mutations in TP53. Among the p53 wild type population a 66% response rate was reported, where response was considered as complete response, partial response or stable disease. In a patient subgroup with mutations in p53 amino acids that directly interact with DNA, 2 of 11 (18%) of patients responded to tamoxifen.",
        "rs value":null,
        "pmid":"PubMed:10786679",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00378404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03063203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Radioiodine + rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02429037",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00003257",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00017173",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02734537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALRN-6924",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04022876",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene + Tretinoin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00617409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02101775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02418988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Radioiodine + rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00894153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00004225",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | bronchioloalveolar adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00003649",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02509169",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00003588",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00003147",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib + Carboplatin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01164995",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00003450",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03149679",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01574729",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02101775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Wildtype",
        "Disease":"Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"RG7112",
        "Description":"Phase I Trial of RG7112 in 116 heavily pretreated patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type TP53. 96 patients were tested for TP53 mutation and 19 cases of mutation were detected. No sustained clinical improvement or induction of TP53 target genes was observed in patients with mutant TP53.",
        "rs value":null,
        "pmid":"PubMed:26459177",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Mutation",
        "Disease":"Gastric Adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy",
        "Description":"In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and\/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.704; 95% confidence intervals [CI] = 0.550-0.903; P = 0.006).",
        "rs value":null,
        "pmid":"PubMed:24740294",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Deleterious_Mutation",
        "Disease":"Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"RG7112",
        "Description":"Phase I Trial of MDM2 inhibitor RG7112 in 116 patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type TP53. No sustained clinical improvement or induction of TP53 target genes was observed in patients with mutant TP53.",
        "rs value":null,
        "pmid":"PubMed:26459177",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Overexpression",
        "Disease":"Stomach Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin,Etoposide,Mitomycin",
        "Description":"In a Phase II trial of 25 patients with metastaic gastric cancer, patients received preoperative high dose chemotherapy (HDCT) consisting of etoposide, cisplatin and mitomycin. Patients with greater than 50% regression in response to HDCT received surgery. TP53 overexpression was assayed by immunohistochemistry. 14 patients showed p53 overexpression, and 12 of these qualified for resection. Overall survival in patients with p53 overexpression was 17.3 months in contrast to patients with negative p53 immunohistochemistry, where it was 7.2 months (p=0.0003).",
        "rs value":null,
        "pmid":"PubMed:14514923",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_ALTERATION",
        "Disease":"Ovarian Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Cisplatin,Carboplatin",
        "Description":"In a group of patients with invasive ovarian carcinoma who had undergone surgery, a subset of 74 patients treated with platinum based chemotherapy were assessed for  p53 alteration (p53 mutation or p53 overexpression by immunostaining >10% positive). Significant decreased time to progression (p=0.037) was seen in the subset of  patients with p53 alteration (n=54) in comparison to the group with normatl p53 (n=20)",
        "rs value":null,
        "pmid":"PubMed:11595686",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Y220C",
        "Disease":"Stomach Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Etoposide,Cisplatin,Mitomycin",
        "Description":"A male patient taking part in a 25 patient gastric cancer trial was diagnosed at age 50, harbored a TP53 mutation and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score was 2. Resection was performed on patients with >50% size reduction of the lesion. Consistent with response to preoperative chemotherapy, this patient did undergo resection, and had an overall survival of 12.6 months.",
        "rs value":null,
        "pmid":"PubMed:14514923",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Mutation",
        "Disease":"Breast Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Tamoxifen",
        "Description":"In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild-type vs. 31%, odds ratio (OR):0.22, 95CI:0.12-0.42, P<0.0001, univariate analysis; OR:0.29, 95% CI:0.12-0.42, P=0.0014, multivariate analysis). The median survival after start of therapy was shorter in patients with mutations in TP53 than for patients with wild-type TP53 (20mo vs. 29mo, HR:1.99,95% CI:1.43-2.75, P<0.001). Breast cancer patients with TP53 mutations also had a decrease in progression-free survival (HR:2.61, 95% CI:1.90-3.6, P<0.001).",
        "rs value":null,
        "pmid":"PubMed:10786679",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_R282L",
        "Disease":"Stomach Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"EAP Protocol",
        "Description":"In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044).",
        "rs value":null,
        "pmid":"PubMed:14514923",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"NRAS_Q61K_and_TP53_V272M_and_TP53_R273C",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Valproic acid",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_R213P",
        "Disease":"Stomach Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"EAP Protocol",
        "Description":"In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044).",
        "rs value":null,
        "pmid":"PubMed:14514923",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_R273L",
        "Disease":"Ovarian Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cisplatin,Carboplatin",
        "Description":"Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A study of ovarian carcinoma patients (n=178) reported a reduced overall survival (HR:1.59, 95% CI:1.09-2.33, P=0.014) for patients with mutations in TP53.",
        "rs value":null,
        "pmid":"PubMed:11595686",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Mutation",
        "Disease":"Stomach Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin,Cisplatin,Etoposide",
        "Description":"In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044).",
        "rs value":null,
        "pmid":"PubMed:14514923",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_R175H",
        "Disease":"Stomach Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"EAP Protocol",
        "Description":"In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044).",
        "rs value":null,
        "pmid":"PubMed:14514923",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Y234C",
        "Disease":"Ovarian Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Cisplatin,Carboplatin",
        "Description":"Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A study of ovarian carcinoma patients (n=178) reported a reduced overall survival (HR:1.59, 95% CI:1.09-2.33, P=0.014) for patients with mutations in TP53.",
        "rs value":null,
        "pmid":"PubMed:11595686",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"DNMT1",
        "Genomic Position":"19:10244216-10305755(-) | 19p13.2",
        "CDS Mutation":null,
        "AA Mutation":"DNMT1_EXPRESSION",
        "Disease":"Gastric Adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Cisplatin",
        "Description":"High DNMT1 expression was found in 105\/127 (83%) or patients (by qPCR assay). Low DNMT1 expression was associated with improved histopathological and clinical response and OS in patients with gastric cancer  (P=0.03\/P=0.008, P(log-rank)=0.001, respectively). In one cisplatin resistant cell line, DAC treatment and cisplatin had a synergistic effect.",
        "rs value":null,
        "pmid":"PubMed:21458988",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"soft tissue | gastrointestinal stromal tumour | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Spartalizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03609424",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04563338",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Capecitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05609370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Nivolumab + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02873962",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axitinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02133742",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Platinum-based chemotherapy + SG001",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05715840",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB4_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03125928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03082534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03896074",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04605796",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Pembrolizumab + THOR-707",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05061420",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Trastuzumab-emtansine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04740918",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Bevacizumab + CEA-targeted adenoviral vaccine + Capecitabine + FOLFOX",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03050814",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03082534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03434379",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab duocarmazine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04239443",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axitinib + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04459663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Lenvatinib + Oxaliplatin + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04669496",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab + mFOLFOX6",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02997228",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02366143",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03012230",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Prednisolone + Rituximab + Sintilimab + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05280626",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_TP53_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride liposome + Rituximab + Sintilimab + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04023916",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"skin | malignant melanoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axitinib + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03086174",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04523493",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02484404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02484404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03666728",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Pembrolizumab + Ramucirumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04340882",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04834986",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04360941",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_(ALK_unspecified_or_EGFR_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Durvalumab + Intensity modulated radiation therapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02087423",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02681549",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axitinib + Erfonrilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05420220",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + MK-7684A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05007106",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Durvalumab + Intensity modulated radiation therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03051906",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Oxaliplatin + Tegafur-gimeracil-oteracil potassium + Tirelizumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04819971",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04102098",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04282109",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axitinib + SEA-TGT + Sasanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04585815",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03898180",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Capecitabine + LBL-007",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05609370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03038100",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab + Doxorubicin hydrochloride liposome or paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03353831",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_EGFR_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT04426825",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04199104",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05523323",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenalidomide + Nivolumab + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03558750",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05063552",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05433116",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Cyclophosphamide + Docetaxel or Paclitaxel + Epirubicin hydrochloride + Pertuzumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03894007",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin or Cisplatin + Docetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05063552",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03841201",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + MK-7684A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05007106",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Lenvatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04443309",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02873962",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Etoposide + Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05384015",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Olaparib + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04624204",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Nab-paclitaxel + Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05174832",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04949256",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Capecitabine + LBL-007 + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05609370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Trastuzumab + Tucatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04789096",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axitinib + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04394975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | mesothelioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03654833",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04662710",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Paclitaxel + Pertuzumab + Trastuzumab + Trastuzumab-emtansine + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03726879",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sintilimab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05429684",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02484404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axitinib + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03086174",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fruquintinib or Regorafenib + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04483219",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Ramucirumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04040361",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02420821",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03829332",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"skin | malignant melanoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axitinib + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04180995",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Pertuzumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03820141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin + Dostarlimab + Niraparib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03602859",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02973997",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | clear cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05296512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rituximab + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04425824",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"thymus | thymic carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03463460",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Nivolumab + Oxaliplatin + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03366272",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05623319",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Trastuzumab + Vinorelbine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04759248",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pembrolizumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03095352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02129556",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04550624",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04641728",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Paclitaxel + Ramucirumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03966118",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02811861",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04739670",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"AK112 + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04999605",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03740165",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03784014",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin + MK-7684A + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05007106",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axitinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02853331",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Axitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02684006",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel or Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04194203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04676412",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin + Niraparib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03602859",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT03772561",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05116189",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02834013",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Evolocumab + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05144529",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | carcinoma | neuroendocrine carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Sintilimab + Sulfatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05165407",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03225664",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03308942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02519322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01844505",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | carcinoma | neuroendocrine carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05289856",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab + Prednisolone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03563729",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03302234",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02477826",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab + Stereotactic radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03223155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04681469",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil or capecitabine + Ipilimumab + Mitomycin C + Nivolumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05200988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03117309",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02750514",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04013542",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03308942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Ipilimumab + Nivolumab + Prednisolone + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03563729",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03914300",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab + Trabectedin",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03138161",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"soft tissue | malignant peripheral nerve sheath tumour | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04465643",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02750514",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03170960",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abequolixron + Ipilimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02922764",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"skin | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05111574",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04940637",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02741570",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03367741",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03873402",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02553642",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | mesothelioma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02899299",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab + Stereotactic radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03340129",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride liposome + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03409198",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Ipilimumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03430063",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT03036098",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04475939",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03469960",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03351361",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02500797",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04514484",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab + TP-1454",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04328740",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03308942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02998528",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03215706",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03141177",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Encorafenib + Ipilimumab + Nivolumab + Prednisolone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03563729",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04274907",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02231749",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02477826",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02496208",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Pembrolizumab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04284787",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02553642",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"FOLFOX + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03647969",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Ipilimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03515629",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03143153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04230954",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02659059",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab + Platinum-doublet chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02659059",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Ipilimumab + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03515629",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02674061",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MVAp53 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03113487",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02564263",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04243616",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Doxorubicin hydrochloride liposome",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02580058",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cadonilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05522894",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03424005",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02559687",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Pembrolizumab + Trilaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05112536",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride liposome",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03164993",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | sarcomatoid carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Ifosfamide + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04224337",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03582475",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Eribulin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02513472",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02369874",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cyclophosphamide + Decitabine + Doxorubicin hydrochloride + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02957968",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Nab-paclitaxel + Tocilizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03424005",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Penpulimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04974398",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04547088",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + PVX-410 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04634747",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04286958",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02628132",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nab-paclitaxel + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05233696",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03095352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Fluorouracil + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03143153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04548271",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03059667",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02453282",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02252042",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04978012",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02875613",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02437370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BCG vaccine + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03317158",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03715205",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02569242",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Radiotherapy + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03700476",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04642469",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Durvalumab + Oleclumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03616886",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ociperlimab + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04732494",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ASP1951 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03799003",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Fluorouracil + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03189719",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Durvalumab + Fluorouracil + Leucovorin calcium + Oxaliplatin + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05713838",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cadonilimab + Cisplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05522894",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride liposome + Gemcitabine + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03539328",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02504372",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03029598",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PGG beta-glucan + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02981303",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Paclitaxel or Fluorouracil + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03748134",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03598270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Gemcitabine + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04458909",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01848834",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03014648",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"bone | chondrosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04458922",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"biliary tract | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bintrafusp alfa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03833661",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02273375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03841747",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"biliary tract | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Durvalumab + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03875235",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02041533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Tesetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03952325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"skin | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04204837",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02613507",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02366143",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03856411",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02542293",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02685059",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04203485",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"RO7121661",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04785820",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib + Anthracycline + Nab-paclitaxel + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04914390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576574",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03358875",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CMP-001 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04633278",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02560636",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02358031",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02105636",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03134456",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Coxsackievirus A21 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04521621",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Oportuzumab Monatox",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03258593",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05255302",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03125902",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PGG beta-glucan + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05159778",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"biliary tract | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cobimetinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03201458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + SRF617",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04336098",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride + Filgrastim or Pegfilgrastim + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03197935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03358875",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04736173",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Zimberelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04736173",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Domvanalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04736173",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Oleclumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05221840",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Monalizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05221840",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK-7684A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04738487",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04294810",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02580058",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ociperlimab + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04746924",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02625961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radiotherapy + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03812549",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03706690",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Balstilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04943627",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02497508",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02519322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Relatimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02519322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PGG beta-glucan + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02981303",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IO102 + IO103 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05280314",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Vactosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05436990",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02453282",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pexastimogene devacirepvec + Socazolimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04849260",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04203485",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_KRAS_G12C_and_STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"JDQ443",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05445843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02841748",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"bone | chordoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03012620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04300647",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tebentafusp-tebn",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02535078",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04654403",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01704287",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01848834",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Paclitaxel + QL1604",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04864782",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04221945",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Tesetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03952325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tesetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03952325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02478099",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01721772",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tebentafusp-tebn + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02535078",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tebentafusp-tebn + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02535078",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tebentafusp-tebn",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02535078",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01295827",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Socazolimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04849260",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Penpulimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03866967",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Compound Kushen injection + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05259540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01866319",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_TIGIT_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Capecitabine + Oxaliplatin + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04933227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | carcinoma | neuroendocrine carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03167853",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | carcinoma | neuroendocrine carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | carcinoma | neuroendocrine carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03278405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | carcinoma | neuroendocrine carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03278379",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | carcinoma | neuroendocrine carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03728361",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02388906",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nab-paclitaxel + SG001",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05068141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02530489",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Etigilimab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04761198",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Epacadostat + Retifanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04463771",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Carboplatin or Cisplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05151549",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CBT-502 + Carboplatin or Cisplatin + Fluorouracil",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03855384",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04671667",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Genolimzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03808857",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Retifanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05287113",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05156970",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04624113",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tesetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03952325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02207530",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT03193931",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HLX301",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05102214",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Prednisolone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03563729",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03767075",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | carcinoma | neuroendocrine carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sulfatinib + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Fluorouracil + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02358031",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Cisplatin + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04831450",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02125461",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BMS-986012 + Carboplatin + Etoposide + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04702880",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adebrelimab + Cisplatin + Etoposide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05496166",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05266937",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03703297",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03850444",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02864394",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02978404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03012581",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"JTX-8064 + Pimivalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04669899",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Durvalumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03723967",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Lurbinectedin",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04253145",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Danvatirsen + Durvalumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03421353",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04624204",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04393883",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02125461",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04267848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04547504",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Eribulin + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04913571",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PGG beta-glucan + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03246685",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02484404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03703297",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04974944",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05159245",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03816553",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03666143",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02352948",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02411656",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02447003",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Danvatirsen + Durvalumab + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03421353",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Etoposide + Serplulimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04063163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03003962",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03317158",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + S-588210",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04106115",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ociperlimab + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04047862",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"INCA32459-101",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05577182",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Paclitaxel + SCT-200",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05552807",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SCT-200 + SCT-I10A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05552807",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + GDC-1971 + Omeprazole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05487235",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Intensity modulated radiation therapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02775812",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Etoposide",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02763579",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Nab-paclitaxel + Nivolumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05203913",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Carboplatin + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03134872",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_TIGIT_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Capecitabine + Oxaliplatin + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05251948",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Gemcitabine + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02853305",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Capecitabine + Carboplatin + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03371017",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Gemcitabine + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02755272",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02951767",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03513952",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05406713",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335006",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02335424",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin or Cisplatin + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02807636",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + CYT107",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03513952",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03800836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Brachytherapy + Cisplatin + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03738228",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Melanoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab,Nivolumab",
        "Description":"Based on a meta-analysis of 20 trials (1475 patients), of which 7 studies (636 patients) included melanoma, PD-L1 expression was associated with a higher ORR rate in patients with melanoma. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies.",
        "rs value":null,
        "pmid":"PubMed:26086854",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Fluorouracil + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02335411",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04148911",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02425891",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HLX301",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05102214",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Fluorouracil + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02358031",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Feladilimab + Fluorouracil + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT04428333",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03047473",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Radiotherapy + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03899857",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03635567",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03800836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03036098",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Cisplatin + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04514835",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02551159",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Domvanalimab + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05211895",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02255097",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_KRAS_G12C_",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adagrasib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04613596",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01846416",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BNT113 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04534205",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02387996",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04665843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04138628",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03421652",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03317158",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02500121",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"stomach | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01848834",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03212651",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05737199",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03012620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02395172",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04448886",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335006",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03891238",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nab-paclitaxel + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04085276",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02838823",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pelareorep + Retifanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04445844",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03740165",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"stomach | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Serplulimab + Tegafur-gimeracil-oteracil potassium",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05769725",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"stomach | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Docetaxel + Tegafur-gimeracil-oteracil potassium",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04152889",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03800836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"stomach | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Fluorouracil + LP002",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04755543",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03167151",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"penis | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03391479",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abequolixron + Docetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02922764",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02335424",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02628067",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02632409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02256436",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02369874",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HLX301",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05390528",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Tolinapant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05082259",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03765918",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02551159",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Oxaliplatin + Pimurutamab + Serplulimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05246982",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"eye | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02359851",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Nab-paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02382406",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04167774",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04832854",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Nab-paclitaxel + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04153734",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"NC318",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04699123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab + Oxaliplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03813784",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Feladilimab + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04128696",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Famitinb",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05042375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Penpulimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03866980",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03281954",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02926196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IBI315",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04162327",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IMU-131 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05311176",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT04004221",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Cyclophosphamide + Epirubicin hydrochloride + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04770272",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Docetaxel or Paclitaxel + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05013268",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05093387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04754321",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Nab-paclitaxel + Oxaliplatin + Radiotherapy + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05002686",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Guadecitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02935361",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"genital tract | germ cell tumour | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03081923",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03933449",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"RO7247669",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04785820",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02998268",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02807636",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Exemestane + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02997995",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CBT-502 + TQB2618",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05645315",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Eribulin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03237780",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nab-paclitaxel + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04211012",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03113266",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IO102 + IO103 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05077709",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02555657",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Radiotherapy + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04690855",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02256436",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04568304",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02516241",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04251169",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MEDI0680",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02118337",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bintrafusp alfa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04246489",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + MK-7684A + Oxaliplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05007106",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + MEDI0680",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02118337",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MRI-guided laser ablation + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02311582",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KA2507",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03008018",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02516241",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Carboplatin + Nab-paclitaxel + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04722718",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01721746",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03843515",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02339558",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"autonomic ganglia | neuroblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dinutuximab + Irinotecan + Sargramostim + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03794349",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bempegaldesleukin + Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03138889",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02332668",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bempegaldesleukin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03138889",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Paclitaxel + Radiotherapy + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05520619",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04672317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05401279",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cisplatin + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04602078",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Nab-paclitaxel + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04211012",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Cisplatin + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03324282",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01693562",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02437370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04458922",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irinotecan + Pucotenlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04486651",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SG001",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04886700",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CBT-502",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04325763",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CBT-502 + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04325763",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cisplatin + Docetaxel + Paclitaxel + Pemetrexed + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04158440",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Penpulimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03866993",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bintrafusp alfa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03631706",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04550260",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + IMU-131",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05311176",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous PD-1-targeted CSR T cells + Cyclophosphamide + Fludarabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02937844",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_KRAS_G12C_",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adagrasib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05609578",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03800134",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Etoposide + Nivolumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02768558",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04706598",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05681039",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05459129",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02997228",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB4_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Nab-paclitaxel + Pyrotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04872985",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HLX301",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05102214",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05609968",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_POLD1_unspecified_or_POLE_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03491345",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02892201",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05459129",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CBT-502",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04623333",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"autonomic ganglia | neuroblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dinutuximab + Eflornithine hydrochloride + Irinotecan + Sargramostim + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03794349",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK-7684A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05007106",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Gemcitabine + Trilaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04799249",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03800836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bempegaldesleukin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04969861",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | in situ neoplasm | cervical intraepithelial neoplasia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04712851",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + THOR-707",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05061420",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02915432",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05459129",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"OSE-279",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05751798",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Danvatirsen + Durvalumab + Fluorouracil",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03421353",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04701060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | Hodgkin lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01953692",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02318771",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"UV1 telomerase peptide vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05075122",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04999800",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Fluorouracil + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05446467",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PDS0101 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04260126",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bintrafusp alfa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04428047",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Nivolumab + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04882462",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | Hodgkin lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02453594",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK-4830 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03564691",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Nivolumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03984357",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"INBRX-105 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03809624",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03316144",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03117309",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02836834",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05043688",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cobimetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03337698",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01848834",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Carboplatin + Docetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05475678",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03244384",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02853305",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Pemetrexed + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02578680",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02702414",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01953692",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenalidomide + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01953692",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Fluorouracil or capecitabine + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02494583",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Oxaliplatin + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT03745170",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IO102 + IO103 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05280314",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01673867",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01295827",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04866017",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03383094",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04671667",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | NK-T cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Mitoxantrone hydrochloride liposome + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05464433",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02366143",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03088540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02486718",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03095352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | Hodgkin lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03617666",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ociperlimab + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04047862",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01693562",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IO102 + IO103 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05077709",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05009069",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02008227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02409342",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AK112",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05499390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tislelizumab + Zanubrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04705129",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_MET_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02819596",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_MET_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Savolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02819596",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_MET_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Savolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02819596",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02819518",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_EGFR_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Almonertinib + Envafolimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05534113",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03036488",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Stereotactic Body Radiation Therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03469713",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03990961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab + Cryoablation",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04201990",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ociperlimab + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05267054",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01953692",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01953692",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576509",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | peripheral T cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Interleukin-15",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03905135",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | peripheral T cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Sintilimab + Tucidinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04052659",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Lenalidomide + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02906332",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Datopotamab Deruxtecan + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05555732",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01668784",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03142334",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Platinum-based chemotherapy + QL1706",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05487391",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01953692",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab-Vibostolimab + Platinum-doublet chemotherapy + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05298423",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Maveropepimut-S + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04920617",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Interleukin-2 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03260504",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Carboplatin + Paclitaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05043688",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04054518",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + TACE + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04522544",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04605731",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_MET_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02819596",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Fianlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05785767",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"skin | carcinoma | Merkel cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02267603",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03637543",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02787005",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02031458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"placenta | gestational trophoblastic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03135769",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pemetrexed + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04507217",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05281003",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cisplatin + Datopotamab Deruxtecan + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05555732",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Relatimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02750514",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Thermal ablation + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05240404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pegilodecakin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03382899",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01642004",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capmatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04139317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03293680",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ociperlimab + Platinum-doublet chemotherapy + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05791097",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"skin | carcinoma | Merkel cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04291885",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AK112",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04900363",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04210115",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01375842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Cisplatin + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04072107",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"451238",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03602833",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abequolixron + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02922764",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abequolixron",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02922764",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axatilimab + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03238027",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04895358",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04243616",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Decitabine + Doxorubicin hydrochloride + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02957968",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Ulevostinag",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04220866",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03409614",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BPI-371153",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05341557",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02576990",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Platinum-doublet chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02998528",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel or Nab-paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02775435",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | large cell neuroendocrine carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Durvalumab + Etoposide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05262985",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02409342",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axatilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03238027",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Envafolimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05055167",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"stomach | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05535569",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02008227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Zimberelimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03713905",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Maveropepimut-S + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04920617",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_EGFR_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Pemetrexed + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05527808",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Stereotactic Body Radiation Therapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03436056",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"oesophagus | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04533490",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab + Yttrium-90 SIRT",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04522544",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Favezelimab + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05064059",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK-4280A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05600309",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab-Relatlimab-rmbw",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05328908",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erfonrilimab + MAX-40279",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05425602",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03337919",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entinostat + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03838042",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02915432",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IMMH-010",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04343859",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03728361",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ARRY-382 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02880371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Danvatirsen + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03421353",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03012620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IMC-001",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03999658",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Pembrolizumab + Tetrahydrouridine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03233724",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HB0036",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05417321",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03571360",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02564380",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT03191786",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Datopotamab Deruxtecan + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05215340",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Pemetrexed + Sugemalimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03789604",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Nab-paclitaxel + Serplulimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04033354",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05047250",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02409355",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Ociperlimab + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04866017",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"FS118",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03440437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01704287",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cadonilimab + Cisplatin + Gemcitabine + Intensity modulated radiation therapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05587374",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Radiotherapy + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04907370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05027204",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab + Capecitabine + Oxaliplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03813784",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02335411",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04634877",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + mFOLFOX6",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05268510",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + mFOLFOX6",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03488667",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02340975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04777162",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02494583",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_FGFR2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TT-00420",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05253053",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Magrolimab + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04854499",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Danvatirsen + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02983578",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abequolixron + Carboplatin + Pembrolizumab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02922764",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"INCAGN02385 + INCAGN02390 + Retifanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05287113",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02891161",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03869190",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"urinary tract | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02451423",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Stereotactic Body Radiation Therapy + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05459129",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"INCAGN02385 + Retifanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05287113",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_FGFR2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nab-paclitaxel + TT-00420",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05253053",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_FGFR2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + TT-00420",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05253053",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05382286",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cisplatin + Gemcitabine + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05286619",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02362594",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04282109",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bempegaldesleukin + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04936841",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Eftilagimod alpha + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04811027",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cisplatin + Durvalumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03830866",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | nasopharyngeal carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03925090",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"skin | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02760498",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"skin | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02883556",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"skin | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03737721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"soft tissue | alveolar soft part sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03012620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + sEphB4-HSA",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03049618",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02500797",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib + LVGN6051",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05301764",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"soft tissue | desmoplastic small round cell tumour | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03012620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"soft tissue | angiosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04873375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Fluorouracil + Oxaliplatin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04522336",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Mocetinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02805660",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03914612",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"female genital tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AK112",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04870177",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"female genital tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Vigil",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03073525",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02743494",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02872116",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01943461",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bempegaldesleukin + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04410445",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Navoximod",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02471846",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Nivolumab + Pemetrexed + TG4010",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03353675",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PF-07265807 + Sasanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04458259",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04625894",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Fluorouracil + Leucovorin calcium + Oxaliplatin + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05466019",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"LP002",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04755543",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02879617",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02766335",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fruquintinib + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05625737",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Fluorouracil + LP002",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04755543",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01905657",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03019588",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02370498",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Hematopoietic Stem Cell Transplant + Idarubicin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04214249",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AN0025 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04432857",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02836834",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DKY709 + Spartalizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03891953",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DKY709",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03891953",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KAZ954 + Spartalizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04237649",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KAZ954",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04237649",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"JS006 + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05061628",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tebotelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04178460",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TAB004 + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04137900",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TAB004",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04137900",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KAZ954 + NZV930",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04237649",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KAZ954 + Taminadenant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04237649",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01953692",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04342910",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + GEN-001",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05419362",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Oxaliplatin + Sindilizumab + Sintilimab + Tegafur-gimeracil-oteracil potassium",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05216237",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05180734",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03675737",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Hypofractionated radiotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04166734",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TTI-101",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03195699",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"INBRX-105",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03809624",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + FT536 + Fludarabine + Pembrolizumab or Nivolumab, or Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05395052",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Cyclophosphamide + FT536 + Fludarabine + Interleukin-2",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05395052",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02588131",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02399371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SIM0237",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05781360",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TP-1454",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04328740",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"INBRX-105 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03809624",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"JS019",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05374226",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"JS006",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05061628",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BI 754111 + Ezabenlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03156114",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PF-07257876",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04881045",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03666143",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MT-6402",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04795713",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous PD-1-targeted CSR T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02930967",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Envafolimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03101488",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD2936",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04995523",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bintrafusp alfa + Docetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04396535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK-7684A + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05007106",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04925986",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Durvalumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04392505",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Fluorouracil + MK-7684A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05007106",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nab-rapamycin + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03190174",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05661578",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Eribulin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03222856",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Encorafenib + Sasanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04585815",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03620669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous activated NK cells + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03958097",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GEN1046 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05117242",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cibisatamab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03337698",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04716946",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Itacitinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03425006",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"NC318 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04699123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Domvanalimab + Etrumadenant + Zimberelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04791839",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Glumetinib + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04797702",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + IO102 + Pembrolizumab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03562871",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05501665",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Domvanalimab + Zimberelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04262856",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Endostatin + Envafolimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05203276",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03228667",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Zalifrelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03411473",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK-4830 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04165083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + GB1211",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05240131",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Linrodostat + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02750514",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Denosumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03669523",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Accelerated Hypofractionated Radiation Therapy + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03801902",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03523702",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + MK-7684A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05007106",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Durvalumab + Pemetrexed or Vinorelbine + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04765709",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IO102 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03562871",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Domvanalimab + Etrumadenant + Zimberelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04262856",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04164745",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Durvalumab + Oral Restorative Microbiota Therapy + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04105270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04396457",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Platinum-based chemotherapy + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT05244837",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Hypofractionated radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04351256",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + PULSAR",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04889066",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Vactosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04515979",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Standard of care",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04093167",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Stereotactic Body Radiation Therapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03383302",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK-0482 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04165083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Tumor treating fields",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892472",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Radiotherapy + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02888743",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03373760",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04108026",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03304093",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02750514",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03798743",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03083041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03574402",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04252365",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Epacadostat + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03322540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IO102 + IO103 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05077709",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03102242",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03085069",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CIMAvax + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02955290",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04832854",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03563716",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"LN-145",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04614103",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05557591",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Efineptakin alfa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04984811",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HLX301",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05102214",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenalidomide + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02963610",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Docetaxel + Nivolumab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05081674",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02087423",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04499053",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Platinum-doublet chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03480230",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02927301",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04563338",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05565378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Docetaxel + Pembrolizumab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05081674",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Zimberelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04262856",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Icaritin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03236649",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Envafolimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05465733",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib + CBT-502",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT03910127",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02367781",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GAd-PEV + MVA-PEV",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04990479",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anetumab Ravtansine + Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03455556",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pemetrexed + RO7247669",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05775289",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01633970",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sasanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04181788",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GRN-1201 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03417882",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab or Atezolizumab or Cemiplimab + Sargramostim + UV1 telomerase peptide vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05344209",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Envafolimab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05465733",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tislelizumab + Tucidinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05519865",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BNT116 + Cemiplimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05557591",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fruquintinib + Tislelizumab + Vitamin E",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05771181",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab + EOS884448",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05565378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Nab-paclitaxel + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04015778",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BGB-A445 + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05635708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Pemetrexed + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05746481",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bempegaldesleukin + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03729245",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fecal Microbiota Transplant + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05669846",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"LBL-007 + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05635708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Penpulimab",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03866993",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02220894",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02142738",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02007070",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03666143",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + GDC-1971 + Omeprazole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05487235",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Interleukin-2 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05493566",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD7789",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04931654",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Fludarabine + PD-L1 CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03330834",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IBI323",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04916119",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"RO7121661",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03708328",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GEN1046",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05117242",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine oral + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02546986",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Durvalumab + Paclitaxel + Papaverine + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05136846",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05321212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Domvanalimab + FOLFOX + Zimberelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05329766",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Fluorouracil + Leucovorin calcium + Nivolumab + Oxaliplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03647969",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Sirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04348292",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IMU-201",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04432207",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous PD-L1\/CD80\/CD86-targeted CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03060343",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | Hodgkin lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02684292",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GB1275 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04060342",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Oxaliplatin + Pembrolizumab + Tegafur-gimeracil-oteracil potassium",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03382600",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Pembrolizumab + Tegafur-gimeracil-oteracil potassium",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03382600",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + SHR1701",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04950322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Domvanalimab + Zimberelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05329766",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"skin | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03284424",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ES101",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04009460",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Tucidinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04674683",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03083041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT03030131",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab,Pembrolizumab",
        "Description":"Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher ORR rate in patients with NSCLC. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies.",
        "rs value":null,
        "pmid":"PubMed:26086854",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab,Atezolizumab,Avelumab,Nivolumab",
        "Description":"Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1\/PD-L1 monoclonal antibodies. Patients with PD-L1 positive tumors (PD-L1 tumor cell staining \ufffd\ufffd\ufffd1%), had a significantly higher ORR, compared to patients with PD-L1 negative tumors (OR: 2.44; 95% CIs: 1.61-",
        "rs value":null,
        "pmid":"PubMed:26918451",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Head And Neck Squamous Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Radiation Therapy",
        "Description":"Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1. In 3 cohorts of HPV-negative head and neck squamous cell carcinoma patient samples evaluated with different methods [reverse phase protein array (N=68), mRNA expression array (N=97) or immunohistochemistry (N=114), respectively], increased expression of PD-L1 was also correlated with local failure following radiotherapy as compared to the PD-L1\ufffd\ufffd\ufffdlow expression group (P = 0.01, 1.9 \ufffd\ufffd 10\ufffd\ufffd\ufffd3, and 9 \ufffd\ufffd 10",
        "rs value":null,
        "pmid":"PubMed:28476872",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":"Exploratory biomarker analysis from a phase-II randomized trial comparing atezolizumab (PD-L1) and docetaxel in previously treated, advanced or metastatic non-small cell lung cancer. Baseline PD-L1 expression (IHC) was assessed in tumour cells (as percentage of PD-L1-expressing tumour cells TC3\ufffd\ufffd\ufffd50%, TC2\ufffd\ufffd\ufffd5% and <50%, TC1\ufffd\ufffd\ufffd1% and <5%, and TC0<1%) and tumour-infiltrating immune cells (as percentage of tumour area: IC3\ufffd\ufffd\ufffd10%, IC2\ufffd\ufffd\ufffd5% and <10%, IC1\ufffd\ufffd\ufffd1% and <5%, and IC0<1%). Increasing PD-L1 Expression was associated with improved overall survival (TC3 or IC3 HR 0\ufffd\ufffd49 [0\ufffd\ufffd22-1\ufffd\ufffd07; p=0\ufffd\ufffd068], TC2\/3 or IC2\/3 HR 0\ufffd\ufffd54 [0\ufffd\ufffd33-0\ufffd\ufffd89; p=0\ufffd\ufffd014], TC1\/2\/3 or IC1\/2\/3 HR 0\ufffd\ufffd59 [0\ufffd\ufffd40-0\ufffd\ufffd85; p=0\ufffd\ufffd005], TC0 and IC0 HR 1\ufffd",
        "rs value":null,
        "pmid":"PubMed:26970723",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":"Trial NCT00730639 tested monoclonal antibody nivolumab against the PD-1 immune checkpoint receptor in pretreated patients with various cancer types. PD-L1 expression was tested in 42 patients by ICH from tumor FFPE biopsies. (18 melanoma, 10 NSCLC, 7 colorectal cancer, 5 renal cell cancer, 2 prostate cancer). 9 of 25 PD-L1 expressing patients showed objective response, and zero of 17 PD-L1 negative patients showed objective response (p=0.006). Biopsies were optional, and therefore not fully randomized.",
        "rs value":null,
        "pmid":"PubMed:22658127",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":"This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treating NSCLC patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of EGFR or translocation of ALK. Patients in the pembrolizumab group exhibited significantly better progression-free survival and overall survival compared to patients in the chemotherapy group.",
        "rs value":null,
        "pmid":"PubMed:27718847",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab,Atezolizumab,Avelumab,Pembrolizumab,Durvalumab",
        "Description":"In this meta-analysis of 14 studies with 2857 patients, the immunotherapy response rate was higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89).",
        "rs value":null,
        "pmid":"PubMed:28472902",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":"PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab.",
        "rs value":null,
        "pmid":"PubMed:25891174",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_M918T",
        "Disease":"Thyroid Gland Medullary Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":"In a phase 2 clinical trial of sorafenib in patients with hereditary or sporadic advanced medullary thyroid cancer, 10 out of 12 patients genotyped in arm B (sporadic MTC) tested positive for RET mutations. In response to sorafenib, 8 patients with RET M918T mutations had stable disease, 1 RET M918T mutant had partial response, and 1 patient with a RET C634R mutation had stable disease. Prior to study entry, all patients with RET M918T mutations had progressive disease or were newly diagnosed.",
        "rs value":null,
        "pmid":"PubMed:20368568",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"KIF5B-RET_fusion_COSF1231",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01877083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"soft tissue | rhabdomyosarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01502410",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03445000",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00381641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02450123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03131206",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_C634R",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00390325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"autonomic ganglia | paraganglioma | malignant",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03008369",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Regorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05159245",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_M918T",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00390325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03194893",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02314481",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02691793",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03178552",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03131206",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"kidney | Wilms tumour | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01502410",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04591431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01639508",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03838692",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00704730",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"salivary gland | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00859937",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_M918T",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00704730",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Brigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04591431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"salivary gland | carcinoma | adenoid cystic carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00859937",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02272998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03468985",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01813734",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_Fusion",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":"RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. This was an open-label, two-stage, single-centre, phase 2, single-arm trial in the USA in metastatic\/unresectable lung cancer harbouring RET rearrangement. 26 Patients with lung adenocarcinomas were given 60 mg of cabozantinib orally per day. The primary objective was overall response. Confirmed PR was seen in 7\/25 (ORR 28% [95% CI 12\ufffd\ufffd\ufffd49%]) response-evaluable patients, meeting the primary endpoint. KIF5B-RET was the predominant fusion in 16 (62%) pat",
        "rs value":null,
        "pmid":"PubMed:27825636",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03239015",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01838642",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04131543",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_M918T",
        "Disease":"Thyroid Gland Medullary Carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":"In this retrospective analysis of a phase 3 trial of cabozantinib or placebo in 330 patients. Among those, 51.2% were RET mutation-positive (38.2% with RET M918T), 34.8% were RET mutation-unknown, and 13.9% were RET mutation-negative. Sixteen patients were RAS mutation-positive. Cabozantinib appeared to prolong PFS versus the placebo in the RET mutation-positive subgroup (hazard ratio [HR], 0.23; 95% confidence interval [CI], 0.14-0.38; P\ufffd\ufffd\ufffd<\ufffd\ufffd\ufffd.0001).  Patients in a RET mutation-negative population showed relatively smaller benefits from cabozantinib (HR 0.53). The RET M918T subgroup achieved the greatest observed PFS benefit from cabozantinib versus the placeb",
        "rs value":null,
        "pmid":"PubMed:27525386",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"KIF5B-RET_fusion_COSF1231",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_Fusion",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":"RET rearrangements involving RET are found in about 1% of NSCLC and define a unique molecular subset.  This study was a multi-center, open-label, phase II clinical trial to examine the safety and efficacy of Vandetanib (300 mg\/d) in RET positive NSCLC patients (confirmed by FISH), Primary endpoint was the objective response rate. 18 patients were enrolled, the majority were a heavily pretreated population. Among the 17 evaluable patients, three had a partial response (ORR\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd18%) and eight had a stable disease (DCR\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd65%). Among these patients, the PR or SD was durable for more than 6 months in 8 patients. Vandetanib also showed a PFS of 4.5 months, and an OS of 11.6 months during a median follow-u",
        "rs value":null,
        "pmid":"PubMed:27803005",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01823068",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_M918T",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00514046",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Luminespib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01922583",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HS269",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05058352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03157128",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"KIF5B-RET_fusion_COSF1231",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus + Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01582191",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DS-5010 ",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03780517",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04268550",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"LOXO-260",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05241834",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03157128",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pralsetinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03037385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04194944",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radioiodine + Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05668962",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pralsetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04760288",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04280081",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04819100",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04280081",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"CCDC6-RET_fusion_COSF1271",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Agerafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Agerafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03157128",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DS-5010 ",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03780517",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04320888",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"APS03118",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05653869",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pralsetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05170204",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pralsetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04222972",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04280081",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01934335",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DS-5010 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03780517",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"KIF5B-RET_fusion_COSF1231",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02540824",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04280081",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pralsetinib + Resection",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04302025",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04759911",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TAS0953\/HM06",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04683250",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HS10365",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05207787",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GSK3179106",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02798991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GSK3179106",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02727283",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TY-1091",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05675605",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SYHA1815",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05105464",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_Fusion",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":"We aimed to assess the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC. In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged NSCLC continuously received 300 mg of oral vandetanib daily. 1536 patients with EGFR mutation-negative NSCLC were screened, 34 were RET-positive (2%). 19 were enrolled and 17 patients were eligible for primary analysis.   9 patients (53%) achieved an objective response. At data cutoff, median PFS was 4.7 months.",
        "rs value":null,
        "pmid":"PubMed:27825616",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_Fusion",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":"In this phase 1 trial, 57 patients with RET fusion- or mutation positive cancers were treated in 7 dose levels. Among patients with RET-Fusion positive NSCLC, objective response rates were 65% (n = 17\/26). Responses occurred independent of fusion partner (9\/13 KIF5B vs 7\/9 non-KIF5B) and included 3 pts w\/ baseline brain metastases.",
        "rs value":null,
        "pmid":"ASCO:161573",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_Fusion",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":"Patients with RET-fusion positive non-small cell lung cancer were enrolled in this phase 1-2 trial of RET inhibitor selpercatinib. Among 105 consecutively enrolled patients who had previously received at least platinum-based chemotherapy, the percentage with an objective response was 64% (95% confidence interval [CI], 54 to 73). The median duration of response was 17.5 months (95% CI, 12.0 to could not be evaluated), and 63% of the responses were ongoing at a median follow-up of 12.1 months. Among 39 previously untreated patients, the percentage with an objective response was 85% (95% CI, 70 to 94), and 90% of the responses were ongoing at 6 months. Among 11 patients with measurable central nervous system metastasis at enrollment, the percentage with an objective intracranial response was 91% (95% CI, 59 to 100).",
        "rs value":null,
        "pmid":"PubMed:32846060",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Agerafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03784378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:UMIN000010095",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Agerafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03784378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05170204",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DS-5010 ",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03780517",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03157128",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03155620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pemetrexed + Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05364645",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TPX-0046",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04161391",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03899792",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HA121-28",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05117658",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pralsetinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03037385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pralsetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04589845",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pralsetinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03037385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02013089",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01831726",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05099068",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Agerafenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01877811",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pralsetinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03037385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"CCDC6-RET_fusion_COSF1271",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00876460",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_V804M_or_RET_M918T",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"KIF5B-RET_fusion_COSF1231",
        "Disease":"thyroid | carcinoma | medullary carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_KIF5B::RET",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":"A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission in the patient.",
        "rs value":null,
        "pmid":"PubMed:23584301",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_KIF5B::RET",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus,Vandetanib",
        "Description":"Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET\/CT showed systemic response as well.",
        "rs value":null,
        "pmid":"PubMed:25982012",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_Overexpression",
        "Disease":"Papillary Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":"A 78-year-old man presented with oral papillary adenocarcinoma and lung metastases that were refractory to standard treatment.  Tumor sequencing showed increased MAPK activity due to RET over-expression and PTEN deletion, therefore sunitinib (RET inhibitor) was initiated.  After 28 days post-administration, the lung metastases decreased in size by 22% (28mm to 21mm) and no new metastatic lesions had appeared.  After 4 months, the patient grew resistant to treatment.",
        "rs value":null,
        "pmid":"PubMed:20696054",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_Fusion",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alectinib",
        "Description":"Alectinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor (TKI) that also has anti-RET activity in vitro. 4 patients with metastatic RET-rearranged NSCLC were identified. 3 of 4 had received prior RET TKIs, including cabozantinib and experimental RET inhibitors. We observed two (50%) objective radiographic responses after treatment with alectinib (one confirmed and one unconfirmed), with durations of therapy of 6 months and more than 5 months (treatment ongoing). Notably, one of these two patients had his dose of alectinib escalated to 900 mg twice daily and had clinical improvement in central nervous system metastases. In addition, one patient (25%) experienced a best response of stable disease lasting approximately 6 weeks. A fourth patient who was RET TKI-naive had primary progression while receiving alectinib.",
        "rs value":null,
        "pmid":"PubMed:27544060",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_CCDC6::RET",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":"Case report of a 60-year old woman with lung adenocarcinoma. After negative testing for EGFR mutations and ALK translocations and failure of platinum-based chemotherapy she was enrolled on a nintedanib-docetaxel trial. Docetaxel was discontinued after 22 cycles because of edema and fatigue. A total of 48 treatment cycles (26 cycles of nintedanib alone) was administered over 33 months before documentation of disease progression in March 2013. Genomic testing revealed a CCDC6-RET fusion but no other actionable mutations (confirmed by FISH).",
        "rs value":null,
        "pmid":"PubMed:26787234",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_CCDC6::RET",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Agerafenib",
        "Description":"A patient with right-sided, MSI-High and CCDC6-RET positive metastatic colorectal cancer showed complete response to the selective RET inhibitor RXDX-105. The patient remained progression-free after 19 months on treatment.",
        "rs value":null,
        "pmid":"PubMed:29538669",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":"c.402",
        "AA Mutation":"p.M134del",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":"c.1",
        "AA Mutation":"p.0",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.R159S",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25705882",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":"c.1",
        "AA Mutation":"p.0",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28818608",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NF1",
        "Genomic Position":"17:29421945-29704695(+) | 17q11.2",
        "CDS Mutation":"c.7175G>A",
        "AA Mutation":"p.G2392E",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28818608",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.806G>A",
        "AA Mutation":"p.G269E",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11964322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1109T>C",
        "AA Mutation":"p.M370T",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.787A>G",
        "AA Mutation":"p.M263V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1121A>G",
        "AA Mutation":"p.E374G",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26413254",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.787A>G",
        "AA Mutation":"p.M263V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11964322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1109T>C",
        "AA Mutation":"p.M370T",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1109T>C",
        "AA Mutation":"p.M370T",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11964322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>A",
        "AA Mutation":"p.T334N",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20512393",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>G",
        "AA Mutation":"p.F378V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23355941",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1121A>G",
        "AA Mutation":"p.E374G",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1433A>G",
        "AA Mutation":"p.E478G",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.813G>C",
        "AA Mutation":"p.Q271H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11853795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11853795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1244A>C",
        "AA Mutation":"p.H415P",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22299775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.815A>T",
        "AA Mutation":"p.Y272F",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.787A>G",
        "AA Mutation":"p.M263V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.806G>A",
        "AA Mutation":"p.G269E",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1133T>G",
        "AA Mutation":"p.F378C",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.799C>G",
        "AA Mutation":"p.L267V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17008892",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1307C>A",
        "AA Mutation":"p.S436Y",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11964322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>G",
        "AA Mutation":"p.F378V",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11964322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.821A>T",
        "AA Mutation":"p.E274V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1109T>C",
        "AA Mutation":"p.M370T",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.821A>T",
        "AA Mutation":"p.E274V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.937",
        "AA Mutation":"p.K313delinsRGG",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21264552",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.787A>G",
        "AA Mutation":"p.M263V",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22299775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.799C>G",
        "AA Mutation":"p.L267V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11853795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1244A>C",
        "AA Mutation":"p.H415P",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11853795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1109T>C",
        "AA Mutation":"p.M370T",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1218G>C",
        "AA Mutation":"p.L406F",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1000",
        "AA Mutation":"p.T334V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23044928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1008C>G",
        "AA Mutation":"p.F336L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1109T>C",
        "AA Mutation":"p.M370T",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23355941",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.821A>T",
        "AA Mutation":"p.E274V",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11853795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>G",
        "AA Mutation":"p.F378V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1370C>G",
        "AA Mutation":"p.S457C",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.806G>A",
        "AA Mutation":"p.G269E",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.883G>A",
        "AA Mutation":"p.D295N",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.821A>T",
        "AA Mutation":"p.E274V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>G",
        "AA Mutation":"p.F378V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.806G>A",
        "AA Mutation":"p.G269E",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.787A>G",
        "AA Mutation":"p.M263V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>A",
        "AA Mutation":"p.F378I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23044928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1121A>G",
        "AA Mutation":"p.E374G",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.893A>C",
        "AA Mutation":"p.E298A",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1216T>A",
        "AA Mutation":"p.L406M",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25807654",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1006T>G",
        "AA Mutation":"p.F336V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.821A>T",
        "AA Mutation":"p.E274V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.813G>C",
        "AA Mutation":"p.Q271H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11964322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1216T>A",
        "AA Mutation":"p.L406M",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1432G>A",
        "AA Mutation":"p.E478K",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>G",
        "AA Mutation":"p.F378V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1008C>G",
        "AA Mutation":"p.F336L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11964322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.815A>T",
        "AA Mutation":"p.Y272F",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1008C>G",
        "AA Mutation":"p.F336L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1244A>G",
        "AA Mutation":"p.H415R",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1244A>G",
        "AA Mutation":"p.H415R",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12399961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1008C>G",
        "AA Mutation":"p.F336L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11853795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.820G>A",
        "AA Mutation":"p.E274K",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:11853795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.884A>G",
        "AA Mutation":"p.D295G",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1415A>C",
        "AA Mutation":"p.E472A",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1244A>G",
        "AA Mutation":"p.H415R",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.806G>A",
        "AA Mutation":"p.G269E",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25807654",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1514T>C",
        "AA Mutation":"p.F505S",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.799C>G",
        "AA Mutation":"p.L267V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23676790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.813G>T",
        "AA Mutation":"p.Q271H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.815A>T",
        "AA Mutation":"p.Y272F",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12623848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.813G>C",
        "AA Mutation":"p.Q271H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20367437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1244A>G",
        "AA Mutation":"p.H415R",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14745431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1006",
        "AA Mutation":"p.F336R",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23044928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.787A>G",
        "AA Mutation":"p.M263V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>G",
        "AA Mutation":"p.F378V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1008C>A",
        "AA Mutation":"p.F336L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.806G>A",
        "AA Mutation":"p.G269E",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22870928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.800T>G",
        "AA Mutation":"p.L267R",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23044928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.814T>C",
        "AA Mutation":"p.Y272H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.884A>G",
        "AA Mutation":"p.D295G",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1001C>T",
        "AA Mutation":"p.T334I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22870928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.806G>A",
        "AA Mutation":"p.G269E",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1216T>A",
        "AA Mutation":"p.L406M",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1219A>T",
        "AA Mutation":"p.M407L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21895409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABL1",
        "Genomic Position":"9:133589333-133761070(+) | 9q34.12",
        "CDS Mutation":"c.1132T>A",
        "AA Mutation":"p.F378I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23044928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V600E",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29596911",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V600E",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31542322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.1799T>A",
        "AA Mutation":"p.V600E",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.1799T>A",
        "AA Mutation":"p.V600E",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25182956",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.(138+1",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32669268",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.139-?",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.139",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.V47",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29605720",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.139",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24463458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.505-?",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24463458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.1514T>A",
        "AA Mutation":"p.L505H",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25515853",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.139",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25515853",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.139-?",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26101714",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.981-?",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26101714",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25673644",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.139-?",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.139-?",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25705882",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.505-?",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24463458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.139-?",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24463458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.139",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24463458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.139-?",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23645591",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.V47",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Alpelisib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28951457",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.139-?",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265154",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.505-?",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265154",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK2",
        "Genomic Position":"9:87283466-87638505(+) | 9q21.33",
        "CDS Mutation":null,
        "AA Mutation":"NTRK2_Fusion",
        "Disease":"Solid Tumor",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"A pooled analysis of three phase 1\/2 clinical trials investigating the efficacy and safety of larotrectinib in 159 NTRK fusion positive solid tumor patients (1 month - 84 years old) confirmed larotrectinib to be effective and safe in these patients. NTRK2 fusions were found in 4 of the 159 patients. Two cases NTRK2 fusion cases were shown to have reduction in tumor size with another tumor showing only minor growth.",
        "rs value":null,
        "pmid":"PubMed:32105622",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK2",
        "Genomic Position":"9:87283466-87638505(+) | 9q21.33",
        "CDS Mutation":null,
        "AA Mutation":"NTRK2_Fusion",
        "Disease":"Solid Tumor",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"54 patients aged 18 or older with metastatic or locally advanced NTRK-fusion positive solid tumours (including ten tumour types and 19 unique histologies) were enrolled in one of three phase 1 or 2 trials (ALKA-372\ufffd\ufffd\ufffd001, STARTRK-1, and STARTRK-2). The patients were administered a 600 mg dose of entrectinib orally daily, with the primary endpoints being the proportion of patient with an objective response and the median duration of response. 31 of the 54 patients had an objective response (95% CI: 43.2\ufffd\ufffd\ufffd70.8), four of which were complete responses. The median duration of the response was 10 months (95% CI: 7.1 to not estimable). The most common fusions were ETV6-NTRK3 (n = 25), TPM3-NTRK1 (n = 4) and TPR-NTRK1 (n = 4), and only one patient had an NRTK2 fusion (S",
        "rs value":null,
        "pmid":"PubMed:31838007",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK2",
        "Genomic Position":"9:87283466-87638505(+) | 9q21.33",
        "CDS Mutation":null,
        "AA Mutation":"NTRK2_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"XZP-5955",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04996121",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK2",
        "Genomic Position":"9:87283466-87638505(+) | 9q21.33",
        "CDS Mutation":null,
        "AA Mutation":"NTRK2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Entrectinib + Resection",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04302025",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK2",
        "Genomic Position":"9:87283466-87638505(+) | 9q21.33",
        "CDS Mutation":null,
        "AA Mutation":"NTRK2_STRN::NTRK2",
        "Disease":"Sarcoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"One Patient with soft tissue sarcoma and a STRN-NTRK2 fusion had a partial Response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1\/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response.",
        "rs value":null,
        "pmid":"PubMed:29606586",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK2",
        "Genomic Position":"9:87283466-87638505(+) | 9q21.33",
        "CDS Mutation":null,
        "AA Mutation":"NTRK2_ETV6::NTRK2",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"Rearrangements involving the neurotrophic receptor kinase genes (NTRK1, NTRK2, and NTRK3; hereafter referred to as TRK) produce oncogenic fusions in a wide variety of cancers in adults and children. In this manuscript, TRK fusions were screened for in 7,311 patients with a variety of hematologic malignancies. Overall, 8 TRK-fusions were identified including 1 ETV6-NTRK2 fusion in a patient with acute myeloid leukemia (AML) Treatment with TRK-Inhibitor larotrectinib led to a partial Response in an AML patient with ETV6-NTRK2 fusion after sucessful xenograft studies.",
        "rs value":null,
        "pmid":"PubMed:29920189",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK2",
        "Genomic Position":"9:87283466-87638505(+) | 9q21.33",
        "CDS Mutation":null,
        "AA Mutation":"NTRK2_KANK1::NTRK2",
        "Disease":"Anaplastic Ependymoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"An MRI in a previously healthy 6-year-old boy now presenting with neurologic abnormalities and seizers revealed a mass obstructing the foramen of Monro and diffuse leptomeningeal dissemination. The primary tumor was resected and subsequent radiation therapy resulted in moderate cognitive and motor improvements. Seven months later, an MRI detected a recurrence, which led to tumor molecular profiling of patient DNA and RNA. RNA analysis discovered and confirmed an in-frame KANK1::NTRK2 e3::ex16 fusion, which was predicted to preserve NTRK2\ufffd\ufffd\ufffds tyrosine kinase domain. The patient was started on larotrectinib and within 2 weeks demonstrated cognitive and motor improvements. After 2 months of therapy, an MRI showed significant tumor response and by 4 months cognition and memory were near-baseline. Overall, larotrectinib resulted in both sustained clinical and radiographic response through 10 months of treatment with no related tox",
        "rs value":null,
        "pmid":"PubMed:34651095",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK2",
        "Genomic Position":"9:87283466-87638505(+) | 9q21.33",
        "CDS Mutation":null,
        "AA Mutation":"NTRK2_KANK1::NTRK2",
        "Disease":"Glioblastoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"An MRI of 26-year-old man presenting with motor weakness and language difficultly revealed a lesion in the left frontal lobe that extended across the corpus callosum. Histologic analysis of the biopsy characterized the lesion as a glioblastoma wildtype for IDH and was negative for EGFR and MET amplification based on FISH. The biopsy material was analyzed with a DNA based genotyping panel and RNA-based NGS assay. The latter detected a KANK1::NTRK2 e4::e16 fusion that was confirmed by FISH. Following the partial resection of the tumor and six weeks of concurrent temozolomide and radiation therapy, an MRI revealed enhancement of the remaining tumor with no significant disease progression. Larotrectinib (100mg) was administered and after 49 days an MRI displayed significant treatment response as the lesion shrunk (25mm to <10mm) and the patient demonstrated slight motor improvements. By day 106 of Larotrectinib treatment, disease progression was evident. However, molecular analysis of a rebiopsy revealed KANK1::NTRK2 was no longer detectable, but a minor subclone at diagnosis with PDGFRA amplification was driving disease progression. Therefore, the authors conclude the KANK1::NTRK2 clones were effectively targeted by Larotrectinib treatment over several months resulting in a robust clinical response.",
        "rs value":null,
        "pmid":"PubMed:34041811",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RICTOR",
        "Genomic Position":"5:38938021-39074510(-) | 5p13.1",
        "CDS Mutation":null,
        "AA Mutation":"RICTOR_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Onatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04518137",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RICTOR",
        "Genomic Position":"5:38938021-39074510(-) | 5p13.1",
        "CDS Mutation":null,
        "AA Mutation":"RICTOR_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02593019",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RICTOR",
        "Genomic Position":"5:38938021-39074510(-) | 5p13.1",
        "CDS Mutation":null,
        "AA Mutation":"RICTOR_Amplification",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sapanisertib,Onatasertib",
        "Description":"Study describes an 18 year old never smoker patient presenting with lung adenocarcinoma. A genomic profiling assay (FoundationOne) revealed a 7-copy amplification of RICTOR as the only somatic alteration. RICTOR amplification was confirmed via FISH and IHC. On two separate treatments with dual mTOR1\/2 inhibitors patient exhibited stable disease for more than 18 months.",
        "rs value":null,
        "pmid":"PubMed:26370156",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Polatuzumab Vedotin + Prednisone + Rituximab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04790903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Dexamethasone + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02755597",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | AIDS related lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride liposome + Prednisone + Rituximab + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00389818",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Letrozole + Palbociclib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03900884",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Polatuzumab Vedotin + Prednisone + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04479267",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03984448",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Mivavotinib + Prednisolone + Rituximab + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03742258",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fimepinostat + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01742988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Prednisone + Rituximab + Vincristine sulphate + Zanubrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05189197",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Prednisone + Rituximab + Vincristine sulphate + Zanubrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05164770",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Filgrastim + Prednisone + Rituximab + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00001337",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_fusions_and_BCL6_fusions_and_MYC_fusions",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Polatuzumab Vedotin + Prednisone + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04479267",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Lenalidomide + Prednisone + Rituximab + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04842487",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"soft tissue | gastrointestinal stromal tumour | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Oblimersen sodium",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00091078",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Dexamethasone + Doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00872521",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified_and_MS4A1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Parsaclisib + Pegfilgrastim + Prednisone + Rituximab + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04323956",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"RO6870810 + Rituximab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03255096",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified_and_MYC_fusions",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous Hematopoietic Stem Cell Transplantation + Carmustine + Cytarabine + Etoposide + Ibrutinib + Melphalan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02443077",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03749018",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine oral + Cyclophosphamide + Doxorubicin hydrochloride + Prednisone + Rituximab + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04799275",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified_and_MYC_fusions",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Prednisone + Rituximab + Tucidinostat + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04231448",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01388959",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Prednisolone + Rituximab + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00080847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Oblimersen sodium + Prednisone + Rituximab + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00080847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Dexamethasone + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00872521",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Polatuzumab Vedotin + Prednisone + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04231877",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carfilzomib + Dexamethasone + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02899052",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fimepinostat + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01742988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | peripheral T cell lymphoma unspecified",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03552692",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Venetoclax + Vincristine sulfate liposome",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03504644",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ofatumumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02710643",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | peripheral T cell lymphoma unspecified",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Romidepsin + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03534180",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acalabrutinib + Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05583149",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alemtuzumab + Cyclophosphamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03132584",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ARQ 531",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03162536",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + TTI-622",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05507541",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tisagenlecleucel + Zanubrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05202782",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Etoposide + Navitoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00878449",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irinotecan + Oblimersen sodium",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00004870",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DA-EPOCH-R + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03620578",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + TTI-621",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05507541",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + JCAR014",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02706405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sepantronium Bromide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05263583",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + JCAR014",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02706405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axicabtagene ciloleucel + Zanubrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05202782",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bryostatin + Cisplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00006942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Fludarabine + huJCAR014",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03103971",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous stem cell transplantation + Cyclophosphamide + Doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00169130",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Varlilumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03038672",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lisocabtagene maraleucel + Zanubrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05202782",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified_and_EGFR_unspecified",
        "Disease":"lung | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Icotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02044328",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Fludarabine + huJCAR014",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03103971",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Devimistat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03793140",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tegavivint",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05755087",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Oblimersen sodium + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00005032",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Paclitaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00176241",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Interferon alpha-2B + Isotretinoin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00062010",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00378404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"(BCL2_unspecified_or_BCL6_unspecified)_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous Hematopoietic Stem Cell Transplantation + Cytarabine + Etoposide + Loncastuximab Tesirine + Melphalan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05228249",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Navitoclax",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00888108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ABBV-453",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05308654",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lisaftoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05147467",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"t(14;18)_(BCL2)",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | follicular lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribavirin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03585725",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nab-paclitaxel + Oblimersen sodium + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00409383",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fimepinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01742988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Navitoclax",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00887757",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride + Everolimus + Pegaspargase + Prednisone + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01523977",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified_or_BCL6_unspecfied_or_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CT120",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05091541",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Ibritumomab tiuxetan-90Y + Prednisolone + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00386321",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_G101V",
        "Disease":"Chronic Lymphocytic Leukemia|small Lymphocytic Lymphoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Venetoclax",
        "Description":"The effective cohort in this study was 11 CLL patients who were first treated with ibrutinib and then on progression treated with venetoclax until progression. Patient samples were sequenced before and after progression on venetoclax. The previously described BCL2 G101V mutation was observed in 1 patient at progression",
        "rs value":null,
        "pmid":"PubMed:32232486",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_F104I",
        "Disease":"Follicular Lymphoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Venetoclax",
        "Description":"This study identified BCL2 F104I mutation in one Follicular Lymphoma patient who developed resistance to venetoclax. Codon 104 is located at the venetoclax binding site of BCL2.",
        "rs value":null,
        "pmid":"PubMed:31234236",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02428543",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Mitoxantrone hydrochloride + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04330820",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Filgrastim + WT1-specific cytotoxic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00562640",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cyclophosphamide + Paclitaxel + WT1, Cyclin B1, CEF antigen-loaded autologous DC vaccine + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02018458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Montanide + PR1 leukemia peptide vaccine + Sargramostim + WT1 126-134 peptide vaccine ",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00488592",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Keyhole limpet hemocyanin + Sargramostim + WT1 126-134 peptide vaccine ",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00153582",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"pleura | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Nivolumab + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04040231",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01266083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT2725",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01621542",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1, MUC1 peptide loaded autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03114631",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogeneic CD25\/Treg-depleted donor lymphocytes + WT1-A10\/AS01B immunotherapeutic GSK2130579A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01513109",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"kidney | Wilms tumour | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tumor-associated antigen cytotoxic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02789228",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Interleukin-2 + WT1-TCRc4 gene-transduced autologous CD8-positive Tcm\/Tn lymphocytes",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02770820",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"soft tissue | rhabdomyosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tumor-associated antigen cytotoxic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02789228",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Montanide + Nivolumab + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02737787",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Hematopoietic Stem Cell Transplant + WT1-A10\/AS01B immunotherapeutic GSK2130579A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01819558",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Pembrolizumab + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03761914",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + BI 836858",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03013998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Pembrolizumab + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03761914",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tumour lysate loaded autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03114631",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1 mRNA transfected autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00965224",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"p.DOM-WT1-126 + p.DOM-WT1-37",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01334060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride + Epirubicin hydrochloride + Fluorouracil + GSK2302024A + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01220128",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"central nervous system | NS | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tumor-associated antigen cytotoxic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03652545",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Busulfan + Fludarabine + Melphalan + T cell depleted HSCT + WT1-specific allogenic cytotoxic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01758328",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1 mRNA transfected autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01686334",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"pleura | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Montanide + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01265433",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chimeric antigen receptor T cells + WT1-specific DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03291444",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"pleura | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Pemetrexed + WT1 mRNA transfected autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02649829",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Pembrolizumab + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03761914",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1 mRNA transfected autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01291420",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PRAME mRNA transfected autologous DC vaccine + WT1 mRNA transfected autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02405338",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1, NY-ESO-1, PRAME and Survivin-specific allogenic CTLs",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02494167",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1 peptide vaccine OCV-501",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01475370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"bone | Ewing sarcoma-peripheral primitive neuroectodermal tumour | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tumor-associated antigen cytotoxic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02789228",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KLH peptide loaded autologous DC vaccine + MUC1 peptide loaded autologous DC vaccine + WT1 peptide loaded autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00703105",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1, MAGEA3, CT7 autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01995708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Filgrastim + Fludarabine + WT1-specific cytotoxic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00562640",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"bone | osteosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tumor-associated antigen cytotoxic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02789228",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Pembrolizumab + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03761914",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Interleukin-2 + WT1-sensitized allogenic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01640301",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04522895",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1-sensitized allogenic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT00620633",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Multiple pathogen-specific T cells + WT1-specific allogenic cytotoxic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02895412",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"autonomic ganglia | neuroblastoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tumor-associated antigen cytotoxic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02789228",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Pembrolizumab + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03761914",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tumor-associated antigen cytotoxic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02789228",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1, PRAME, Survivin-specific autologous cytotoxic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02475707",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_Exon_7_Mutation",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Cytarabine,Daunorubicin",
        "Description":"WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML.",
        "rs value":null,
        "pmid":"PubMed:18591546",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Interleukin-2 + WT1-TCRc4 gene-transduced autologous CD8-positive Tcm\/Tn lymphocytes",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02408016",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ASP7517",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04837196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1-specific TCR transduced autologous T cell infusion",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01621724",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT2725",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01621542",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ASP7517 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04837196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Fludarabine + Interleukin-2 + WT1-sensitized allogenic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01640301",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1 mRNA transfected autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03083054",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Montanide + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00398138",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05320809",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"NY-ESO-1\/PRAME\/MAGE-A3\/WT-1 peptide vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02750995",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01546038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acetaminophen + Diphenhydramine + Donor lymphocyte infusion + Interleukin-4 + Keyhole limpet hemocyanin + WT1 peptide vaccine + WT1 peptide-loaded allogenic DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00923910",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1 peptide vaccine OCV-501",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01440920",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide + WT1 mRNA transfected autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02649582",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1-A10\/AS01B immunotherapeutic GSK2130579A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00725283",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT2725",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01621542",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"pleura | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Montanide + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01890980",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1-A10\/AS01B immunotherapeutic GSK2130579A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01051063",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1 126-134 peptide vaccine  + poly ICLC",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01842139",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Montanide + WT1 126-134 peptide vaccine ",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01842139",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Basiliximab + WT1 126-134 peptide vaccine ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01842139",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1 mRNA transfected autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00834002",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT2725",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01621542",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Hematopoietic Stem Cell Transplant + Interleukin-2 + WT1-specific allogenic cytotoxic T cells",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00052520",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic NK cells + Cyclophosphamide + Filgrastim + Fludarabine + Melphalan + Mesna + Mycophenolate mofetil + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05115630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1, TERT, Survivin peptide loaded autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05000801",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ROS1",
        "Genomic Position":"6:117609463-117747018(-) | 6q22.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G2032R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30683630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_Fusion",
        "Disease":"Sarcoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"In a Phase 1\/2 study involving 15 pediatric patients with infantile fibrosarcoma or soft tissue sarcoma, 8 patients had NTRK1 fusions. The patients were administered Larotrectinib, and 7 out of 8 patients showed objective response, with 2 complete and 5 partial responses. The patient without objective response had soft tissue sarcoma, and showed stable disease.",
        "rs value":null,
        "pmid":"PubMed:29606586",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"biliary tract | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"salivary gland | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03155620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"central nervous system | NS | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"central nervous system | NS | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02637687",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK3_fusions",
        "Disease":"lung | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib + Radioiodine ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05783323",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_Fusion",
        "Disease":"Solid Tumor",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"This was a Phase 1\/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall response rate was 75% according to independent review and 80% according to investigator assessment. Authors state that Larotrectinib had durable anti tumor activity regardless of age or tumor type. 17\/23 patients with NTRK1-fusion showed maximum percent change in tumor size between -30% and -100%.",
        "rs value":null,
        "pmid":"PubMed:29466156",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Entrectinib + Resection",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04302025",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_unspecified_or_NTRK1_unspecified_or_NTRK2_unspecified_or_NTRK3_unspecified_or_ROS1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02097810",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selitrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03215511",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_unspecified_or_NTRK1_unspecified_or_NTRK2_unspecified_or_NTRK3_unspecified_or_ROS1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TY-2136b",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05769075",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_unspecified_or_NTRK2_unspecified_or_NTRK3_unspecified_or_ROS1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05159245",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_unspecified_or_NTRK1_unspecified_or_NTRK2_unspecified_or_NTRK3_unspecified_or_ROS1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Repotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04094610",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Repotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03093116",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TSR-011",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02048488",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02568267",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions_or_ROS1_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Taletrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02279433",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions_or_ROS1_fusions",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02587650",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02122913",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02568267",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01831726",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02568267",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04589845",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"XZP-5955",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04996121",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ICP-723",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05745623",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_unspecified_or_NTRK1_unspecified_or_NTRK2_unspecified_or_NTRK3_unspecified_or_ROS1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02650401",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ONO-7579",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03182257",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions",
        "Disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Taletrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02279433",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_Fusion",
        "Disease":"Solid Tumor",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"Describes a meta-analysis of three separate phase I or II trials: ALKA-372-001, STARTRK-1, and STARTRK-2. All of these evaluate entrectinib in NTRK fusion-positive solid tumours. 31\/54 had objective response (57%; 95% CI 43\ufffd\ufffd2\ufffd\ufffd\ufffd70\ufffd\ufffd8), including 4 CR and 27 PR. 9 had SD. Response by NTRK gene type: 13\/22 NTRK1 fusions [59%; 95% CI 36\ufffd\ufffd4\ufffd\ufffd\ufffd79\ufffd\ufffd3], 18\/31 NTRK3 fusions [58%; 39\ufffd\ufffd1\ufffd\ufffd\ufffd75\ufffd\ufffd5], and 0\/1 NTRK2 fusion. Most frequent tumour types were sarcoma, NSCLC, salivary, breast, thyroid, colorectal. Most common fusions were ETV6-NTR",
        "rs value":null,
        "pmid":"PubMed:31838007",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions_or_ROS1_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04591431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"VMD-928",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03556228",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_Fusion",
        "Disease":"Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1\/2\/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.",
        "rs value":null,
        "pmid":"PubMed:28183697",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ensartinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03574402",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_Amplification",
        "Disease":"Solid Tumor",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"In a phase I study of larotrectinib in 67 patients with solid tumours, 8 patients were recorded as having objective response. 7 of these harboured NTRK fusions, and one had a NTRK1 amplification. This patient's tumour had a size reduction measured as 45% and a response duration of 3.7 months. It is not stated in the publication whether a survey of amplification status in other patients in the study was done.",
        "rs value":null,
        "pmid":"PubMed:30624546",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_LMNA::NTRK1_G595R_and_G667C",
        "Disease":"Colorectal Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Entrectinib",
        "Description":"A gene fusion between exon 10 of NTRK1 and exon 11 of the LMNA genes was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI\/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months. Longitudinal analysis of ctDNA in plasma samples revealed a p.G595R- and p.G667C mutation in NTRK1 that were absent before treatment initiation but  emerged 4 weeks upon initiation of treatment with entrectinib. These mutations were also validated using xenograft, in vitro and 3D-modeling.",
        "rs value":null,
        "pmid":"PubMed:26546295",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_LMNA::NTRK1_e2-e11",
        "Disease":"Sarcoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors. The tumor of a 41-year-old woman with soft-tissue sarcoma metastatic to the lung was found to harbor an in-frame LMNA-NTRK1 (exon 2 & exon 11) gene fusion encoding a functional LMNA-TRKA fusion oncoprotein. This patient's tumors underwent rapid and substantial tumor regression, with an accompanying improvement in pulmonary dyspnea, oxygen saturation, and plasma tumor markers.",
        "rs value":null,
        "pmid":"PubMed:26216294",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_LMNA::NTRK1_e2-e10",
        "Disease":"Congenital Fibrosarcoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib",
        "Description":"A mass found at birth in a patient\ufffd\ufffd\ufffds left arm became enlarged at age 2 and was resected and characterized as a high-grade spindle cell sarcoma. FISH and RT-PCR did not detect any common sarcoma translocations. A recurrence and a new mass formed after 4 months of therapy, so amputation was performed. Metastatic high-grade sarcoma appeared in the lungs 4 months later followed by multiple recurrences 10 months after treatment. Whole exome and transcriptome sequencing of diagnosis and normal samples were performed and the in-frame LMNA-NTRK1 fusion (exon 2 & exon 10) with the kinase domain intact was discovered. Treatment with Crizotinib was started and a chest CT after 2 months revealed partial response. After 22 months of therapy, chest CT revealed a complete response of lung nodules, which has been sustained >18 months beyond the conclusion of treatment at 31 m",
        "rs value":null,
        "pmid":"PubMed:30709876",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_TPM3::NTRK1",
        "Disease":"Spindle Cell Sarcoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"In a pediatric phase 1 trial (NCT02637687), a 12-year-old boy with TPM3-NTRK1 fusion was treated with Larotrectinib as first line treatment as no standard treatment options were available. Following a significant tumor burden reduction of 31%, he underwent surgical resection, with R0 resection and no evidence for tumor recurrence at the time of last follow-up (>7 months).",
        "rs value":null,
        "pmid":"PubMed:30204247",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_G595R_and_G667S",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Larotrectinib",
        "Description":"A 29-year-old male with NTRK-fusion positive NSCLC demonstrated initial response to Larotrectinib but progressed after devloping solvent-front (TRKA G595R) and xDFG (TRKA G667S) mutations.",
        "rs value":null,
        "pmid":"PubMed:30624546",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_SQSTM1::NTRK1",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1\/2\/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.",
        "rs value":null,
        "pmid":"PubMed:28183697",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_SQSTM1::NTRK1",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"In 1378 cases of NSCLC screened for NTRK1 rearrangements, 2 were identified (frequency 0.1%). One patient with SQSTM1-NTRK1 was treated with entrectinib in a phase 1 study. The patient had resolution of prior dyspnea and pain within 3 weeks. CT scans showed a partial response and complete resolution of brain metastases. The patient has continued treatment for over 6 months with ongoing PR.",
        "rs value":null,
        "pmid":"PubMed:26565381",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_Fusion",
        "Disease":"Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy. This publication reported results from an AACR meeting for an ongoing study that had enrolled six patients with NTRK fusions, three of whom could be evaluated at the time. Each had a different, heavily pretreated advanced disease: soft-tissue sarcoma; gastrointestinal stromal tumor (GIST); and MASC. All three patients experienced partial responses by 3-4 months with resolution of key tumour-related symptoms within two weeks. One of three patients experienced near-complete response by 8 months.",
        "rs value":null,
        "pmid":"PubMed:26603524",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_SQSTM1::NTRK1",
        "Disease":"Congenital Fibrosarcoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"One patient with infantile fibrosarcoma and a NTRK1-SQSTM1 fusion was treated with larotrectinib and exhibited a partial response. Treatment was done within a multicentre, open-label, phase 1\/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response.",
        "rs value":null,
        "pmid":"PubMed:29606586",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_PDE4DIP::NTRK1",
        "Disease":"Sarcoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"One Patient with soft tissue sarcoma and a NTRK1-PDE4DIP fusion was treated with larotrectinib and exhibited a partial response. Treatment was done within a multicentre, open-label, phase 1\/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response.",
        "rs value":null,
        "pmid":"PubMed:29606586",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_LMNA::NTRK1",
        "Disease":"Sarcoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"One Patient with soft tissue sarcoma and a NTRK1-LMNA fusion had a partial response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1\/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response.",
        "rs value":null,
        "pmid":"PubMed:29606586",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_PDE4DIP::NTRK1",
        "Disease":"Sarcoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"In a pediatric phase 1 trial (NCT02637687), a boy aged 15 months with soft tissue sarcoma of the right upper thigh harbored the PDE4DIP-NTRK1 fusion. After resection and the failure of initial chemotherapy, Larotrectinib reduced tumor size by 37% after 2 cycles and 64% after 6 cycles. An R2 resection was performed and Larotrectinib again reduced tumor progression. A second R2 resection was followed by adjuvant radiotherapy and Larotrectinib cycles and the patient remained in complete response at the time of the last follow-up.",
        "rs value":null,
        "pmid":"PubMed:30204247",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_SQSTM1::NTRK1",
        "Disease":"Congenital Fibrosarcoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"In a pediatric phase 1 trial (NCT02637687), a 2 year old with infantile fibrosarcoma of the shoulder harbored the SQSTM1-NTRK1 fusion. After two surgical resections and multiple rounds of chemotherapy, Larotrectinib treatment resulted in 93% tumour reduction. An R1 resection was performed followed by adjuvant Larotrectinib. The patient remained on Larotrectinib without evidence of disease progression at the time of last follow-up.",
        "rs value":null,
        "pmid":"PubMed:30204247",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_LMNA::NTRK1_e11-e10",
        "Disease":"Colorectal Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"A gene fusion between exon 11 of LMNA and exon 10 of NTRK1 was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI\/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months.",
        "rs value":null,
        "pmid":"PubMed:26546295",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_TPM3::NTRK1",
        "Disease":"Sarcoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"Four patients with infantile fibrosarcoma and soft tissue sarcoma and a NTRK1-TPM3 fusion were treated with larotrectinib. Two had a partial, and two had a complete response. Treatment was done within a multicentre, open-label, phase 1\/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response.",
        "rs value":null,
        "pmid":"PubMed:29606586",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_LMNA::NTRK1_e11-e10",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"After disease progression with no objective response to therapy, a 75-year-old with metastatic colorectal cancer that spread to the liver displayed elevated NTRK1 expression in both primary tumor and liver metastasis as measured by immunohistochemistry. FISH of the tumor and patient derived xenograft indicated NTRK1 involvement. 5\ufffd\ufffd\ufffdRACE PCR discovered a novel LMNA-NTRK1 fusion (exon 11 & exon 10), which resulted in the expression of two different fusion splice transcripts (exons 1-10 with exons 10-16 and exons 1-11 with exons 10-16). Fusion expression of both transcripts was confirmed by western blot, and Sanger sequencing revealed the fusion to be in-frame with the kinase domain intact. After 4 weeks of treatment with Entrectinib, CT scan revealed the patient showed a partial response with a 30% reduction of target lesions. This response was maintained for 5 m",
        "rs value":null,
        "pmid":"PubMed:26563355",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TOP2A",
        "Genomic Position":"17:38544768-38574202(-) | 17q21.2",
        "CDS Mutation":null,
        "AA Mutation":"TOP2A_EXPRESSION",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin",
        "Description":"In a retrospective study, TOP2A expression was assessed by IHC for 108 breast cancer patients (from TAX 303 trial). TOP2A expression was associated with a higher probability of response in doxorubicin treated but not in docetaxel treated breast cancer patients.",
        "rs value":null,
        "pmid":"PubMed:15486187",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BAP1",
        "Genomic Position":"3:52435029-52444366(-) | 3p21.1",
        "CDS Mutation":null,
        "AA Mutation":"BAP1_Mutation",
        "Disease":"Renal Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sunitinib,Everolimus",
        "Description":"This study evaluated the effects of everolimus and sunitinib on patients with metastatic renal cell carcinoma. A total of 220 patients with RCC were evaluated for 341 genes at 540x coverage. Of all 220 patients, 19% of had BAP1 mutations. Patients with BAP1 mutations treated with first line everolimus followed by sunitinib (N=87 wildtype, 22 mutant) were associated with shorter progression free survival (median [95% CI] 4.9 [2.9 - 8.1] vs 10.5 [7.3 - 12.9] mo; HR 1.84 [1.1-3.2]; P=0.02). For patients treated with sunitinib followed by everolimus (N=91 wildtype, 20 mutant) were associated with a trend towards shorter progression free survival (median [95% CI] 8.1 [3.1-11.3] vs 11.0 [8.3-13.8] mo; HR 1.69 [0.9-3.2]; P=0.06).",
        "rs value":null,
        "pmid":"PubMed:27751729",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576444",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04862663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_AKT2_unspecified_or_AKT3_unspecified_or_IGF1_unspecified_or_IGFBP3_unspecified_or_IRS1_unspecified_or_IGF1R_unspecified_or_MAPK3_unspecified_or_MAPK1_unspecified_or_MTOR_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00769483",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_AKT2_unspecified_or_AKT3_unspecified_or_IGF1_unspecified_or_IGFBP3_unspecified_or_IRS1_unspecified_or_IGF1R_unspecified_or_MAPK3_unspecified_or_MAPK1_unspecified_or_MTOR_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dalotuzumab + Erlotinib + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00769483",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ipatasertib + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04920708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_CD274_unspecified_or_PIK3CA_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Duvelisib + SG001",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05508659",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib + Uprosertib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01935973",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + FOLFIRI + Floxuridine + Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01312857",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_AKT2_unspecified_or_AKT3_unspecified_or_FBXW7_unspecified_or_FLCN_unspecified_or_MTOR_unspecified_or_NF1_unspecified_or_NF2_unspecified_or_NTRK3_unspecified_or_PIK3CA_unspecified_or_PIK3R1_unspecified_or_PTEN_unspecified_or_RHEB_unspecified_or_STK11_unspecified_or_TSC1_unspecified_or_TSC2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temsirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03297606",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galeterone",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02438007",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ARQ751 + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02761694",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_AKT2_unspecified_or_MTOR_unspecified_or_PIK3CA_unspecified_or_PIK3R1_unspecified_or_PTEN_unspecified_or_RICTOR_unspecified_or_RPTOR_unspecified_or_TSC1_unspecified_or_TSC2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02029001",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_undefined_or_FANCD2_undefined_or_FANCE_undefined_or_FANCF_undefined_or_FANCG_undefined_or_FANCL_undefined_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04768426",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_AKT3_unspecified_or_PTEN_unspecified_or_PIK3CA_unspecified_or_MTOR_unspecified_or_TSC1_unspecified_or_TSC2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MSC2363318A",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01971515",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03310541",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_MTOR_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04591431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05498896",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_AKT2_unspecified_or_AKT3_unspecified_or_IGF1_unspecified_or_IGFBP3_unspecified_or_IRS1_unspecified_or_IGF1R_unspecified_or_MAPK3_unspecified_or_MAPK1_unspecified_or_MTOR_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dalotuzumab + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00769483",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Buparlisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01695473",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ARQ751",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02761694",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_EGFR_unspecified_or_KRAS_unspecified_or_MTOR_unspecified_or_TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01313390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04591431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_CSF1R_unspecified_or_EGFR_unspecified_or_FHIT_unspecified_or_MYC_unspecified_or_PDGFA_unspecified_or_PDGFRA_unspecifed_or_PDGFRB_unspecified_or_PI3KCA_unspecified_or_PTEN_unspecified_or_VHL_unspecified",
        "Disease":"kidney | carcinoma | clear cell renal cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01791387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04650581",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anastrozole + Miransertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02476955",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ARQ751 + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02761694",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_BCL2_unspecified_or_EGFR_unspecified_or_MTOR_unspecified_or_HRAS_unspecified_or_KRAS_unspecified_or_NRAS_unspecified_or_TP53_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01313390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Miransertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02476955",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PTEN_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TAS-117",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03017521",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Miransertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02476955",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_MAP1LC3A_unspecified_or_MTOR_unspecified_or_PI3K_unspecified_or_SQSTM1_unspecified_or_STK11_unspecified_or_ULK1",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Metformin + Sirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02145559",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_MTOR_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sapanisertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03745911",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01306045",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_AKT2_unspecified_or_AKT3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04589845",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04305496",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05172258",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04632992",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05564377",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Miransertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02476955",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_MTOR_unspecified_or_NF1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified_or_VHL_unspecified",
        "Disease":"NS | carcinoma | neuroendocrine carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02315625",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_MTOR_unspecified_or_TSC1_unspecified_or_TSC2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temsirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03337724",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01226316",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_MTOR_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified_or_TSC1_unspecified_or_TSC2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03580239",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01277757",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01283035",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"thymus | thymic carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01306045",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03337724",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Celecoxib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208583",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02117167",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PIK3CG_unspecified_or_PIK3R1_unspecified_or_PIK3R5_unspecified_or_PIK3AP1_unspecified_or_MTOR_unspecified_or_PTEN",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SF1126",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02644122",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"soft tissue | leiomyosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Ipatasertib + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05172245",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"meninges | meningioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02523014",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01226316",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afuresertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04374630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SY-3505",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05257512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01306045",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04486352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1125976",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01915576",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04439123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02162719",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05554380",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01802320",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temsirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02093598",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":"AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363. 58 patients with advanced solid tumors were treated. In patients with AKT1 E17K-mutant tumors (n = 52) and a median of 5 lines of prior therapy, the median PFS was 5.5 months , 6.6 months and 4.2 months in patients with ER+ breast, gynecologic, and other solid tumors, respectively. In an exploratory biomarker analysis, imbalance of the AKT1 E17K-mutant allele, most frequently caused by copy-neutral loss-of-heterozygosity targeting the wild-type allele, was associated with longer PFS as was the presence of coincident PI3K pathway hotspot mutations. Persistent declines in AKT1 E17K in cfDNA were associated with improved PFS and response. Responses were not restricted to patients with detectable AKT1 E17K in pretreatment cfDNA.",
        "rs value":null,
        "pmid":"PubMed:28489509",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"meninges | meningioma | meningothelial",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"Breast Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":"In a phase-I study of AZD5363, partial response was observed in 2 patients with breast and ovarian carcinoma, respectively, and AKT1 E17K mutations. While full study results have not yet been published, this paper highlights in vitro results that further confirm the role of AKT E17K mutation.",
        "rs value":null,
        "pmid":"PubMed:26351323",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_Q79K",
        "Disease":"Melanoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":"In a retrospective study of 44 relapsed melanoma patients with BRAF V600E\/K (known BRAF inhibitor sensitizing mutations), AKT1 Q79K was associated with acquired resistance to BRAF inhibitor (dabrafenib) monotherapy in one patient. This patient was a 38 year old female with stage IV M1a melanoma who took dabrafenib (35 mg twice daily to 100 mg three times a day). The best overall response was a 100% reduction in the sum of target lesions, and progression free survival lasted 119 days. Prior to dabrafenib monotherapy, this patient's baseline tumor harbored BRAF V600K\ufffd\ufffd\ufffdno other somatic alterations were noted. Following relapse, the patient gained AKT1 Q79K in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors hypothesized that disruptions in the PI3K-PTEN-AKT pathway represent a core mechanism of acquired resistance to BRAF inhibitor th",
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MAPK1",
        "Genomic Position":"22:22108789-22221919(-) | 22q11.22",
        "CDS Mutation":null,
        "AA Mutation":"MAPK1_E322K",
        "Disease":"Head And Neck Squamous Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib",
        "Description":"Case report of a patient with stage IVA HNSCC with near-complete histologic response after 13 days of neoadjuvant erlotinib. Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mutation (allelic fraction 0.13). In-vitro studies in two HNSCC cell lines showed enhanced EGFR phosphorylation and erlotinib sensitivity in the mutant line compared with the wild-type line.",
        "rs value":null,
        "pmid":"PubMed:26181029",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CTAG2",
        "Genomic Position":"X:153880246-153881853(-) | Xq28",
        "CDS Mutation":null,
        "AA Mutation":"CTAG2_Overexpression",
        "Disease":"Multiple Myeloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Letetresgene Autoleucel",
        "Description":"Clinical responses to NY-ESO-1\/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and\/or LAGE-1 in this Phase 1\/2a trial showing a median progression free survival of 19.1 months.",
        "rs value":null,
        "pmid":"PubMed:26193344",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"WEE1",
        "Genomic Position":"11:9595228-9610754(+) | 11p15.4",
        "CDS Mutation":null,
        "AA Mutation":"WEE1_RS3910384",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine,Platinum Compound",
        "Description":"The presence of the WEE1 polymorphism rs3910384 correlated with OS and PFS of NSCLC patients treated with platinum-based chemotherapy. Especially the combination of two DNA-damaging agents was associated with efficacy. 663 patients were tested. The authors showed that rs3910384 is closely linked with the putative functional WEE1 promoter at SNPs rs6486433, rs3763869 and rs3763868.",
        "rs value":null,
        "pmid":"PubMed:26057002",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AREG",
        "Genomic Position":"4:75310851-75320726(+) | 4q13.3",
        "CDS Mutation":null,
        "AA Mutation":"AREG_Expression",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":"226 cetuximab-treated patients with colorectal cancer (CRC) were analyzed for mRNA expression (by qPCR) of EGFR and its ligands (EGF, TGFA, AREG and EREG). High AREG mRNA expression in KRAS wild type tumours was a favorable predictor in a multivariate analysis (median survival 33 vs. 15\ufffd\ufffd\ufffdmonths, p=0.0005).   Cetuximab-treated patients with AREG-low KRAS wild type CRC had poor survival, similar to KRAS mutate",
        "rs value":null,
        "pmid":"PubMed:23374602",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AREG",
        "Genomic Position":"4:75310851-75320726(+) | 4q13.3",
        "CDS Mutation":null,
        "AA Mutation":"AREG_Expression",
        "Disease":"Head And Neck Squamous Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab,Docetaxel",
        "Description":"47 HNSCC patients treated with cetuximab\/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tumor cells was associated with reduced overall survival  (hazard ratio: 2.2, P = 0.002) and progression free survival (hazard ratio: 2.2, P = 0.016) compared to patients with low AREG expression score. AREG was an independent prognosticator of OS in multivariate Cox analysis. High EGFRvIII and AREG expression levels identified SCCHN (squamous cell carcinoma, head and neck) patients that were less likely to benefit from combination treatment with cetuximab and docetaxel.",
        "rs value":null,
        "pmid":"PubMed:21653686",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AREG",
        "Genomic Position":"4:75310851-75320726(+) | 4q13.3",
        "CDS Mutation":null,
        "AA Mutation":"AREG_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":"Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions.",
        "rs value":null,
        "pmid":"PubMed:23344087",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AREG",
        "Genomic Position":"4:75310851-75320726(+) | 4q13.3",
        "CDS Mutation":null,
        "AA Mutation":"AREG_Expression",
        "Disease":"Colorectal Cancer",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panitumumab",
        "Description":"Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as \"high expressor\" (either EREG or AREG mRNA level) or \"low expressor\" (neither EREG nor AREG in top tertile).  For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P\ufffd\ufffd\ufffd<\ufffd\ufffd\ufffd.001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd.73; interaction test results were significant [P\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd.01]). Results were less clear for response rate (interaction P\ufffd\ufffd\ufffd",
        "rs value":null,
        "pmid":"PubMed:26867820",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02645149",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03784014",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"central nervous system | glioma | oligodendroglioma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02530320",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04074785",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03239015",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"bone | chordoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03110744",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02187783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03237390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03310879",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03356223",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abiraterone acetate + Prednisone + TQB3616",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05156450",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04393285",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04594005",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_Overexpression",
        "Disease":"Estrogen-receptor Positive Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fulvestrant",
        "Description":"In two cohorts (n=45 and n=46) of ER+ breast cancer patients who had received fulvestrant, CDK6 overexpression correlated with shorter median time to progression in both cohorts (2.5 vs. 8.2 months and 3.4 vs. 8.9 months for CDK6 overexpression vs. normal expression). CDK6 expression did not correlate with other lines of treatment (N=68, tamoxifen or endocrine therapy). Four fulvestrant-resistant cell lines were derived from estrogen responsive and fulvestrant sensitive parental breast cancer cell line MCF-7\/SO.5. Gene expression profiling showed upregulation of CDK6 in the fulvestrant resistant derivatives. Knockdown of CDK6 in these derivative cells resulted in fulvestrant sensitivity.",
        "rs value":null,
        "pmid":"PubMed:27252418",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + LY3214996",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04391595",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HLA-C",
        "Genomic Position":"6:31236526-31239863(-) | 6p21.33",
        "CDS Mutation":null,
        "AA Mutation":"HLA-C_COPY-NEUTRAL_LOSS_OF_HETEROZYGOSITY",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Therapeutic Tumor Infiltrating Lymphocytes",
        "Description":"A patient with metastatic colorectal cancer was enrolled in a phase 2 clinical trial (NCT01174121). 24 cultures of tumor-infiltrating lymphocytes were expanded from 3 lung metastasis resections. After cultures were tested for reactivity, the patient was infused with 1.48 x 10^11 tumor-infiltrating lymphocytes (75% CD8+ T cells) that were specifically reactive to KRAS G12D and HLA-C*08:02. A single lesion that progressed after 9 months still expressed the KRAS G12D mutation. Whole-exome analysis revealed copy-neutral loss of heterozygosity at chromosome 6, encoding the HLA locus and resulting in loss of the targeted HLA-C*08:02 allele.",
        "rs value":null,
        "pmid":"PubMed:27959684",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDKN1A",
        "Genomic Position":"6:36646487-36655108(+) | 6p21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDKN1A_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fluorouracil",
        "Description":"112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1\ufffd\ufffd and ALDH1. High pretreatment p21 (CDKN1A) expression was significantly associated with non-pCR (p\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd0.022) and poor disease free survival (median DFS - low vs high p21: 75.8 vs 58.1 months, p\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd0.002). Multivariate analysis was also significant (p\ufffd\ufffd\ufffd=\ufffd",
        "rs value":null,
        "pmid":"PubMed:24708484",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDKN1A",
        "Genomic Position":"6:36646487-36655108(+) | 6p21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDKN1A_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00378404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN1A",
        "Genomic Position":"6:36646487-36655108(+) | 6p21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDKN1A_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Paclitaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00176241",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMAD4",
        "Genomic Position":"18:48556583-48611409(+) | 18q21.2",
        "CDS Mutation":null,
        "AA Mutation":"SMAD4_Mutation",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab,Cetuximab",
        "Description":"In a retrospective analysis of 65 patients with metastatic colorectal cancer, SMAD4 mutations were more common among patients with no benefit from EGFR-inhibition (cetuximab or panitumumab) (4 patients) than with patients with response to EGFR directed treatment (1 patient).",
        "rs value":null,
        "pmid":"PubMed:26508446",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"SMAD4",
        "Genomic Position":"18:48556583-48611409(+) | 18q21.2",
        "CDS Mutation":null,
        "AA Mutation":"SMAD4_unspecified_",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Cetuximab + Gemcitabine + Oxaliplatin + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00338039",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMAD4",
        "Genomic Position":"18:48556583-48611409(+) | 18q21.2",
        "CDS Mutation":null,
        "AA Mutation":"SMAD4_Deletion",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fluorouracil",
        "Description":"A retrospective study with 202 colorectal cancer patients found that SMAD4 deletion was associated with worse outcomes during 5-fluorouracil treatment. The hazard ratio for disease-free survival was 2.89 times greater for patients with SMAD4 deletion as compared to those  with normal SMAD4 diploidy (P = .045).  For overall survival, the hazard ratio was 3.23 times greater for SMAD4 deletion (P = .056).",
        "rs value":null,
        "pmid":"PubMed:12237773",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"SMAD4",
        "Genomic Position":"18:48556583-48611409(+) | 18q21.2",
        "CDS Mutation":null,
        "AA Mutation":"SMAD4_unspecified_",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Gemcitabine + Nab-paclitaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01921751",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMAD4",
        "Genomic Position":"18:48556583-48611409(+) | 18q21.2",
        "CDS Mutation":null,
        "AA Mutation":"SMAD4_unspecified_",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Hydroxychloroquine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_Mutation",
        "Disease":"Uveal Melanoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":"In total, 77 patients with metastatic melanoma (62% cutaneous, 30% uveal, 8% mucosal) were admitted into a randomized phase II trial assessing the efficacy of Cabozantinib. Patients received cabozantinib 100\ufffd\ufffd\ufffdmg\/d during a 12-week lead-in. Patients with stable disease (SD; RECIST) at week 12 were randomized to cabozantinib or placebo. During lead-in phase, 55% of evaluable patients showed reduction in target lesion size (59% uveal melanoma). Uveal melanoma cohort included 23 patients, 9 with GNAQ (n=5) and GNA11 (n=4) mutations. Responses were reported in mutational patients. In the uveal melanoma cohort, 61% of patients (14\/23) had SD at week 12, and no patient had a PR, resulting in an overall disease control rate of 61%. The median PFS for the 23 patients with uveal melanoma was 4.8 m",
        "rs value":null,
        "pmid":"PubMed:28103611",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified_or_GNAQ_unspecified",
        "Disease":"eye | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib + Uprosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01979523",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified_or_GNAQ_unspecified",
        "Disease":"eye | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01835145",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified_or_GNAQ_unspecified",
        "Disease":"eye | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib + Darovasertib",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03947385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02645149",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified_or_GNAQ_unspecified",
        "Disease":"eye | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02359851",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified_or_GNAQ_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DYP688",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05415072",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_unspecified_or_GNAQ_unspecified",
        "Disease":"eye | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dacarbazine + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01143402",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNA11",
        "Genomic Position":"19:3094408-3124002(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"GNA11_Mutation",
        "Disease":"Uveal Melanoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":"Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses. One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks.",
        "rs value":null,
        "pmid":"PubMed:22805292",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"DNMT3A",
        "Genomic Position":"2:25455845-25565459(-) | 2p23.3",
        "CDS Mutation":null,
        "AA Mutation":"DNMT3A_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04147533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DNMT3A",
        "Genomic Position":"2:25455845-25565459(-) | 2p23.3",
        "CDS Mutation":null,
        "AA Mutation":"DNMT3A_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myelomonocytic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03722407",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DNMT3A",
        "Genomic Position":"2:25455845-25565459(-) | 2p23.3",
        "CDS Mutation":null,
        "AA Mutation":"DNMT3A_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Lenalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00352001",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DNMT3A",
        "Genomic Position":"2:25455845-25565459(-) | 2p23.3",
        "CDS Mutation":null,
        "AA Mutation":"DNMT3A_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cladribine + Cytarabine + Decitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05766514",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DNMT3A",
        "Genomic Position":"2:25455845-25565459(-) | 2p23.3",
        "CDS Mutation":null,
        "AA Mutation":"DNMT3A_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Peripheral blood stem cell transplantation  + Prophylactic donor lymphocytes",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03771222",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DNMT3A",
        "Genomic Position":"2:25455845-25565459(-) | 2p23.3",
        "CDS Mutation":null,
        "AA Mutation":"DNMT3A_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gilteritinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03013998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DNMT3A",
        "Genomic Position":"2:25455845-25565459(-) | 2p23.3",
        "CDS Mutation":null,
        "AA Mutation":"DNMT3A_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04051996",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DNMT3A",
        "Genomic Position":"2:25455845-25565459(-) | 2p23.3",
        "CDS Mutation":null,
        "AA Mutation":"DMT3A_unspecified_or_IDH1_unspecified_or_IDH2_unspecified_or_NPM1_unspecified_or_TET2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01802333",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DNMT3A",
        "Genomic Position":"2:25455845-25565459(-) | 2p23.3",
        "CDS Mutation":null,
        "AA Mutation":"DNMT3A_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01546038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DNMT3A",
        "Genomic Position":"2:25455845-25565459(-) | 2p23.3",
        "CDS Mutation":null,
        "AA Mutation":"DMT3A_unspecified_or_IDH1_unspecified_or_IDH2_unspecified_or_NPM1_unspecified_or_TET2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idarubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01802333",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DNMT3A",
        "Genomic Position":"2:25455845-25565459(-) | 2p23.3",
        "CDS Mutation":null,
        "AA Mutation":"DNMT3A_Mutation",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine",
        "Description":"Among 46 AML patients treated with decitabine, the response rate was 75% (6\/8) among DNMT3A mutated and 34% (13\/38) among DNMT3A wild-type patients (P=.008)",
        "rs value":null,
        "pmid":"PubMed:22124213",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"DNMT3A",
        "Genomic Position":"2:25455845-25565459(-) | 2p23.3",
        "CDS Mutation":null,
        "AA Mutation":"DNMT3A_Mutation",
        "Disease":"Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Nivolumab,Pembrolizumab,Atezolizumab",
        "Description":"A subset of patients receiving PD1\/PD-L1 inhibition appear to be \"hyper-progressors,\" with a greatly accelerated rate of tumor growth and clinical deterioration compared to pre-therapy. The current study investigated potential genomic markers associated with \"hyper-progression\". Consecutive stage IV cancer patients who received immunotherapies (CTLA-4, PD-1\/PD-L1 inhibitors or other [investigational] agents) and had their tumor evaluated by next-generation sequencing Amongst 155 patients, TTF (time to treatment failure) <2 months was seen in 4\/5 individuals harbouring DNMT3A alteration.",
        "rs value":null,
        "pmid":"PubMed:28351930",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"DNMT3A",
        "Genomic Position":"2:25455845-25565459(-) | 2p23.3",
        "CDS Mutation":null,
        "AA Mutation":"DNMT3A_R882",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Idarubicin",
        "Description":"Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.",
        "rs value":null,
        "pmid":"PubMed:22081665",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05310643",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04082572",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02715284",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02563002",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Emepepimut-S + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01507103",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01507103",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_METHYLATION",
        "Disease":"Stomach Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Oxaliplatin",
        "Description":"The methylation status of MLH1 was analyzed in a study of 53 paraffin-embedded gastric cancer samples. No association was found between methylation status and clinical factors. The study showed that MLH1 methylation was associated with resistance to treatment with oxaliplatin.",
        "rs value":null,
        "pmid":"PubMed:24748501",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_methylation",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05550558",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Aspirin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02813824",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02715284",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03005002",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01876511",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified_",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified",
        "Disease":"large intestine | adenoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03631641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified",
        "Disease":"stomach | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Fluorouracil",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03485196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104893",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KRAS peptide vaccine + poly ICLC",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05013216",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02159820",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified",
        "Disease":"biliary tract | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Irinotecan",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01859728",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03767075",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH1",
        "Genomic Position":"3:37034823-37092409(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MLH1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"XRCC1",
        "Genomic Position":"19:44047192-44080158(-) | 19q13.31",
        "CDS Mutation":null,
        "AA Mutation":"XRCC1_R194W",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel,Vinorelbine,Gemcitabine",
        "Description":"The XRCC1 R194W variant was shown to be correlated with increased chance of response to platinum-based chemotherapy in Stage IV Non-small Cell Lung Carcinoma (NSCLC). 82 patients with Stage IV NSCLC who had not previously been treated with chemotherapy were used in this study.",
        "rs value":null,
        "pmid":"PubMed:19157633",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"XRCC1",
        "Genomic Position":"19:44047192-44080158(-) | 19q13.31",
        "CDS Mutation":null,
        "AA Mutation":"XRCC1_Q399R",
        "Disease":"Cervical Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin,Carboplatin",
        "Description":"The XRCC1 R399Q variant was correlated with increased response to platinum-based neoadjuvant chemotherapy in patients with cervical cancer. Tumor samples from 36 patients with Stage IB or IIA bulky (greater than 4 cm in size) cervical carcinomas were used in this study.",
        "rs value":null,
        "pmid":"PubMed:16875718",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.76A>G",
        "AA Mutation":"p.K26E",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31648313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1100G>A",
        "AA Mutation":"p.R367Q",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23377281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.116G>A",
        "AA Mutation":"p.R39Q",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32694622",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.R367Q",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28253933",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1054C>G",
        "AA Mutation":"p.H352D",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32391957",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1100G>A",
        "AA Mutation":"p.R367Q",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32694622",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1100G>A",
        "AA Mutation":"p.R367Q",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27655895",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.712C>T",
        "AA Mutation":"p.R238W",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23377183",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1100G>A",
        "AA Mutation":"p.R367Q",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28157215",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1075A>C",
        "AA Mutation":"p.K359Q",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23377281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.R238W",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32694622",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.713G>T",
        "AA Mutation":"p.R238L",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23377281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1216delinsTCCTCAT",
        "AA Mutation":"p.L406delinsSSF",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31697823",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.712C>G",
        "AA Mutation":"p.R238G",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27655895",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.D396",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28157215",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1220A>C",
        "AA Mutation":"p.D407A",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23377281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1100G>A",
        "AA Mutation":"p.R367Q",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"ATRA",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29795382",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1054C>G",
        "AA Mutation":"p.H352D",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31697823",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1219G>T",
        "AA Mutation":"p.D407Y",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28157215",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1100G>A",
        "AA Mutation":"p.R367Q",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31697823",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1334C>T",
        "AA Mutation":"p.S445F",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27655895",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D407V",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28253933",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.712C>T",
        "AA Mutation":"p.R238W",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28157215",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1360G>A",
        "AA Mutation":"p.V454M",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27655895",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.712C>T",
        "AA Mutation":"p.R238W",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23377281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1100G>A",
        "AA Mutation":"p.R367Q",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32391957",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1100G>A",
        "AA Mutation":"p.R367Q",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31648313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1212G>T",
        "AA Mutation":"p.K404N",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"ATRA",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29795382",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1100G>A",
        "AA Mutation":"p.R367Q",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23377183",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1123C>T",
        "AA Mutation":"p.L375F",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23377281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.871C>T",
        "AA Mutation":"p.R291W",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23377281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1224C>A",
        "AA Mutation":"p.S408R",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23377183",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1434G>C",
        "AA Mutation":"p.R478S",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27655895",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1334C>T",
        "AA Mutation":"p.S445F",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23377183",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1567C>T",
        "AA Mutation":"p.Q523*",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23377281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1211",
        "AA Mutation":"p.K404delinsNQ",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31697823",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.337G>A",
        "AA Mutation":"p.D113N",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31648313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1123C>T",
        "AA Mutation":"p.L375F",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28157215",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.D407",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31697823",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1221C>A",
        "AA Mutation":"p.D407E",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27655895",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1219G>T",
        "AA Mutation":"p.D407Y",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27655895",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1240C>T",
        "AA Mutation":"p.P414S",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28157215",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.1224C>G",
        "AA Mutation":"p.S408R",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31697823",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5C2",
        "Genomic Position":"10:104845940-104953056(-) | 10q24.32-q24.33",
        "CDS Mutation":"c.116G>A",
        "AA Mutation":"p.R39Q",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27655895",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"JUN",
        "Genomic Position":"1:59246465-59249785(-) | 1p32.1",
        "CDS Mutation":null,
        "AA Mutation":"JUN_Overexpression",
        "Disease":"Colorectal Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irbesartan",
        "Description":"A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.  Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway. The patient was treated with irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.  Her 10 month CEA was 1.4.",
        "rs value":null,
        "pmid":"PubMed:27022066",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>C",
        "AA Mutation":"p.G12A",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722830",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>C",
        "AA Mutation":"p.G12A",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.34G>C",
        "AA Mutation":"p.G12R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.38G>A",
        "AA Mutation":"p.G13D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.183A>T",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.34G>T",
        "AA Mutation":"p.G12C",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.183A>C",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.38G>A",
        "AA Mutation":"p.G13D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20361188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.38G>A",
        "AA Mutation":"p.G13D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722830",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.182A>G",
        "AA Mutation":"p.Q61R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20361188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.183A>C",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26644315",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.183A>T",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722830",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.34G>C",
        "AA Mutation":"p.G12R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.181C>G",
        "AA Mutation":"p.Q61E",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>T",
        "AA Mutation":"p.G12V",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>C",
        "AA Mutation":"p.G12A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.34G>T",
        "AA Mutation":"p.G12C",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.34G>C",
        "AA Mutation":"p.G12R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25673644",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.38G>A",
        "AA Mutation":"p.G13D",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25673644",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25137394",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.183A>C",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.34G>A",
        "AA Mutation":"p.G12S",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.38G>A",
        "AA Mutation":"p.G13D",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722830",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.35G>T",
        "AA Mutation":"p.G12V",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.182",
        "AA Mutation":"p.Q61P",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":"c.34G>T",
        "AA Mutation":"p.G12C",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5E",
        "Genomic Position":"6:86159809-86205496(+) | 6q14.3",
        "CDS Mutation":null,
        "AA Mutation":"NT5E_Overexpression",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":"CD73 high expression was identified as a potential marker of improved PFS from cetuximab treatment in patients with metastatic CRC.",
        "rs value":null,
        "pmid":"PubMed:25520391",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NT5E",
        "Genomic Position":"6:86159809-86205496(+) | 6q14.3",
        "CDS Mutation":null,
        "AA Mutation":"NT5E_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Durvalumab + Oleclumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03616886",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD50",
        "Genomic Position":"5:131892630-131979752(+) | 5q31.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD50_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD50",
        "Genomic Position":"5:131892630-131979752(+) | 5q31.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD50_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD50",
        "Genomic Position":"5:131892630-131979752(+) | 5q31.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD50_L1237F",
        "Disease":"Ureter Small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irinotecan,Checkpoint Kinase Inhibitor AZD7762",
        "Description":"A 51-year-old woman with an invasive small-cell cancer of the ureter showed a durable complete response at 3-years when treated with AZD7762 (an ATP-competitive checkpoint kinase inhibitor) and irinotecan (a topoisomerase I inhibitor). Whole genome sequencing of the tumor revealed a somatic RAD50 (L1237F) mutation, which was identified as a potential sensitizing lesion contributing to the profound response. Six rad50-mutant yeast strains and genetically engineered mouse embryonic fibroblasts were established and demonstrated severe sensitivity to camptothecin (Chk1 inhibitor).",
        "rs value":null,
        "pmid":"PubMed:24934408",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"SLCO1B1",
        "Genomic Position":"12:21284136-21392180(+) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"SLCO1B1_RS4149056",
        "Disease":"Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Methotrexate",
        "Description":"499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The SLCO1B1 rs4149056 variant was significantly associated with MTX AUC0-48h and as such associated with increased toxicity.",
        "rs value":null,
        "pmid":"PubMed:23652803",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"SLCO1B1",
        "Genomic Position":"12:21284136-21392180(+) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"SLCO1B1_N130D",
        "Disease":"Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Methotrexate",
        "Description":"499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The SLCO1B1 RS2306283 variant was significantly associated with MTX AUC0-48h and as such associated with increased toxicity.",
        "rs value":null,
        "pmid":"PubMed:23652803",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00373373",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + DS-1594b + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04752163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Venetoclax + Ziftomenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05735184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + DS-1594b + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04752163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Quizartinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04687761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02428543",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03069352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Venetoclax + Ziftomenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05735184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04867928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ixazomib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02030405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Quizartinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04687761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01835288",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DS-1594b + Mini-HCVD",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04752163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KO 539",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04067336",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00927498",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Etoposide + Tretinoin",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01237808",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Revumenib",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT04065399",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Pevonedistat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04712942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Standard of care + Sulfasalazine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05580861",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Flotetuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05063123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Pevonedistat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04712942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Entospletinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03013998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1, PRAME and CMV pp65 transfected TLR7\/8 matured DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01734304",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anastrozole + Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02730923",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04051996",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Ziftomenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05735184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Antifungals + DSP-5336",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04988555",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00860639",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"JNJ-75276617",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04811560",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Pevonedistat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04090736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04689815",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_EXON_12_MUTATION",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Valproic Acid",
        "Description":"For patients with NPM1 mutation that achieved CR following induction therapy, relapse-free survival was improved following treatment with valproic acid.",
        "rs value":null,
        "pmid":"PubMed:24797300",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_EXON_12_MUTATION",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Daunorubicin",
        "Description":"Young patients (18-60) with NPM1 mutations had improved overall survival following high-dose versus standard dose daunorubicin (p=0.01) in univariate analysis. However, the adjusted p-value for multiple testing is 0.11.",
        "rs value":null,
        "pmid":"PubMed:22417203",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idarubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01296178",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Idarubicin + Pegfilgrastim + Tretinoin",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT00893399",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03769532",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02450877",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DS-1594b",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04752163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01546038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DS-1594b",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04752163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idarubicin + Pravastatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01831232",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Gemtuzumab Ozogamicin + Gilteritinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05199051",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide + Cytarabine + Tretinoin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03031249",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anthracycline + Cytarabine + Entospletinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05020665",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NPM1",
        "Genomic Position":"5:170814652-170838141(+) | 5q35.1",
        "CDS Mutation":null,
        "AA Mutation":"NPM1_EXON_12_MUTATION",
        "Disease":"Acute Myeloid Leukemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tretinoin",
        "Description":"ATRA treatment improved overall and relapse-free survival in older (>60) patients with mutant NPM1 and without FLT3-ITD.",
        "rs value":null,
        "pmid":"PubMed:19059939",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RRM1",
        "Genomic Position":"11:4116039-4160106(+) | 11p15.4",
        "CDS Mutation":null,
        "AA Mutation":"RRM1_Underexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin,Gemcitabine",
        "Description":"In the personalized therapy group of this study, patients received chemotherapy based on RRM-1 IHC expression levels, whereas the standard therapy group received non-customized chemotherapy. There were statistically significant improvements between the personalized therapy group versus the standard therapy group in disease control rate (82.9% vs 55.3%, P=0.004), and progression-free survival (median: 5.5 months vs 3.0 months, P=0.005). Besides, the overall survival had a tendency to become more prolonged (median: 16.0 months vs 12.4 months, P=0.286).",
        "rs value":null,
        "pmid":"PubMed:24595080",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RRM1",
        "Genomic Position":"11:4116039-4160106(+) | 11p15.4",
        "CDS Mutation":null,
        "AA Mutation":"RRM1_Underexpression",
        "Disease":"Pancreatic Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine",
        "Description":"There were 68 patients enrolled in this study, 28 of which were treated with gemcitabine.  Of those 28, 14 patients had a low RRM1 expression and 14 had a high RRM1 expression. Only the patients with low RRM1 expression received a significant benefit from gemcitabine (p=0.0010) whereas the benefit for those with a high RRM1 expression was not significantly better (p=0.3309).  The study also tested the role of ERCC1 expression and its correlation to RRM1 expression. It was found that patients with a combined high RRM1 and ERCC1 expression had good prognosis with the highest survival rate (P=0.0127).",
        "rs value":null,
        "pmid":"PubMed:19543324",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RRM1",
        "Genomic Position":"11:4116039-4160106(+) | 11p15.4",
        "CDS Mutation":null,
        "AA Mutation":"RRM1_Underexpression",
        "Disease":"Pancreatic Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine",
        "Description":"In this study, human pancreatic carcinoma cell line MiaPaCa2, which is a gemcitabine-sensitive cell line, was used for the establishment of chemoresistant cells MiaPaCa2-RG. Analysis for identifying genetic alterations relating to gemcitabine resistance revealed that RRM1 was the most upregulated gene with a 4.5 fold expression. RRM1-speci\ufffd\ufffd\ufffdc RNAi transfection significantly reduced the gemcitabine chemoresistance of MiaPaCa2-RG to the same level as that of gemcitabine sensitive MiaPaCa2. Moreover, gemcitabine response of MiaPaCa2 also became more sensitive.  Next, patients with pancreatic cancer were recruited and 18 tissue samples were taken. The patients with a low RRM1 expression had a significantly better outcome after gemcitabine treatment than those patients with high RRM1 expression (P=0",
        "rs value":null,
        "pmid":"PubMed:17131328",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RRM1",
        "Genomic Position":"11:4116039-4160106(+) | 11p15.4",
        "CDS Mutation":null,
        "AA Mutation":"RRM1_Underexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine",
        "Description":"In this study, 229 tumors were analyzed for RRM1 expression. This resulted in 146 that were negative for RRM1 expression and 83 that were positive. These tumors were studied for a relationship between RRM1 expression and chemotherapy regimens, gemcitabine, docetaxel and carboplatin, and vinorelbine and carboplatin. In the patients receiving gemcitabine treatment, the progression-free survival of RRM1-negative patients was significantly higher than that of RRM1-positive patients (8.8 months vs. 7.6 months, P = 0.01). The patients that were positive for RRM1 expression, had a better response to docetaxel or vinorelbine treatment than gemcitabine (P=0.047 and P=0.047). However, there were no differences of response to docetaxel and vinorelbine in regards to RRM1 expression.",
        "rs value":null,
        "pmid":"PubMed:24647522",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RRM1",
        "Genomic Position":"11:4116039-4160106(+) | 11p15.4",
        "CDS Mutation":null,
        "AA Mutation":"RRM1_Underexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vinorelbine,Paclitaxel,Gemcitabine",
        "Description":"The study began with a total of 443 patients that were randomly assigned to either regimen A (Paclitaxel and cisplatin with gemcitabine) or regimen B ( cisplatin and vinorelbine). Of those patients, 261 had tissue available for RRM1 evaluation. In regimen B, survival increased significantly in patients with low RRM1 expression as compared to those with a high expression (P=0.046). However, in regimen A, the increase in survival for patients with low RRM1 expression as opposed to those with a high RRM1 expression was not as significant (P=0.366).",
        "rs value":null,
        "pmid":"PubMed:23038758",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RRM1",
        "Genomic Position":"11:4116039-4160106(+) | 11p15.4",
        "CDS Mutation":null,
        "AA Mutation":"RRM1_Underexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine,Carboplatin",
        "Description":"As part of a randomized phase III trial (USO-03012) in advanced NSCLC of gemcitabine vs. combination gemcitabine and carboplatin, protein expression levels for RRM1 (n=69) and ERCC1 (n=65) were evaluated using fluorescence-based IHC. RRM1 levels were significantly inversely correlated with response (r = \ufffd\ufffd\ufffd0.41; P = .001, n=58), as were ERCC1 levels (r = \ufffd\ufffd\ufffd0.39; P = .003, n=55). RRM1 and ERCC1 levels were correlated with each other (r = 0.36; P = .003, n=65). There was no significant interaction with treatment arm (P = .64 for RRM1; P = .79 for ERCC1). The authors conclude that RRM1 and ERCC1 expression levels are predictive of response to gemcitabine, and gemcitabine and ",
        "rs value":null,
        "pmid":"PubMed:19884554",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ARAF",
        "Genomic Position":"X:47420516-47431299(+) | Xp11.3",
        "CDS Mutation":null,
        "AA Mutation":"ARAF_S214C",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":"In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.",
        "rs value":null,
        "pmid":"PubMed:24569458",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ARAF",
        "Genomic Position":"X:47420516-47431299(+) | Xp11.3",
        "CDS Mutation":null,
        "AA Mutation":"ARAF_S490T",
        "Disease":"Colorectal Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib,Cetuximab,Irinotecan",
        "Description":"Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient had an acquired ARAF S490T mutation that was not identified before treatment initiation.",
        "rs value":null,
        "pmid":"PubMed:27729313",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_Fusion",
        "Disease":"Myeloproliferative Neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":"Twelve patients with BCR-ABL-negative chronic myeloproliferative disease and reciprocal translocations involving PDGFRB received imatinib for a median of 47 months (range, 0.1-60 months). Eleven had prompt responses, 10 had complete resolution of cytogenetic abnormalities and decrease or disappearance of fusion transcripts as measured by reverse transcriptase-polymerase chain reaction (RT-PCR). Updates were sought from 8 further patients previously described in the literature; prompt responses were described in 7 and persist in 6.",
        "rs value":null,
        "pmid":"PubMed:16960151",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_unspecified",
        "Disease":"biliary tract | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01082809",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_unspecified",
        "Disease":"skin | carcinoma | Merkel cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00068783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Pevonedistat + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03862157",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01831726",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Famitinb",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04355858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04004975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_Overexpression",
        "Disease":"Dermatofibrosarcoma Protuberans",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":"A 37-year-old man presented with dermatofibrosarcoma protuberans (DFSP). Post resection, multiple nodular metastases were found in both lungs and the disease progressed following treatments with cytotoxic agents and microwave ablation. Overexpression of PDGFRB was detected by IHC and a COL1A1-PDGFB fusion was detected by RT-PCR. Increased PDGFRB is activated by the COL1A1-PDGFB fusion product, which promotes the overactivation of downstream PDGFRB signaling pathways. Imatinib treatment failed as stable disease was followed by disease spread and progression. The patient was then treated with a daily oral dose of sunitinib (a multi-tyrosine kinase inhibitor) for 4 consecutive weeks, followed by a 2-week rest period. After 2 months on sunitinib, the patient experienced overall shrinkage of the body\ufffd\ufffd\ufffds tumor mass (reduction of tumor in arm and partial response in lung and pancreas metastases). Sunitinib resulted in 9 months of progression free survival and improved quality of life. Ultimately, the disease ssed and the patient died 46 months after diagnosis.",
        "rs value":null,
        "pmid":"PubMed:29760553",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_EBF1::PDGFRB",
        "Disease":"Childhood B-cell Acute Lymphoblastic Leukemia",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":"Two patients with EBF1-PDGFRB positive pediatric B-ALL were treated with induction\/post-induction therapy and Imatinib. Neither patient experienced disease relapse. One patient died of an undefined encephalopathy at 6 mos post-transplant and the other patient was alive in clinical remission at 10 months after diagnosis.",
        "rs value":null,
        "pmid":"PubMed:26872634",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_EBF1::PDGFRB",
        "Disease":"B-lymphoblastic Leukemia|lymphoma, BCR-ABL1\ufffd\ufffd",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib,Chemotherapy",
        "Description":"A 9 year old girl with B-lymphoblastic leukemia\/ lymphoma (2016 WHO) relapsed 15 months post-maintenance chemotherapy. FISH and genomic analysis detected the EBF1-PDGFRB fusion (exon 11 with Exon14). The patient was treated with induction [fludarabine, idarubicin and cytarabine] therapy followed by additional chemotherapy (cyclophosphamide, adriamycin, vincristine, and dexamethasone followed by high-dose methotrexate and cytarabine) plus tyrosine kinase inhibitor (TKI, imatinib). Imatinib was stopped 10 days before cord blood transplant (CBT) with reduced intensity conditional and re-initiated on day 47 until 12 months post-transplant. The EBF1-PDGFRB transcript level measured using reverse-transcriptase polymerase chain reaction remained below detection limit (<2.5x102 copies\/ microgram RNA) for 36 months post CBT. Furthermore, the patient maintained molecular remission during the 24 months post-CBT and the 12 months following completion of TKI administration, based on minimal residual disease (MRD) testing conducted every 6 months.",
        "rs value":null,
        "pmid":"PubMed:32068648",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_EBF1::PDGFRB",
        "Disease":"Childhood B-cell Acute Lymphoblastic Leukemia",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":"A 10-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an EBF1-PDGFRB fusion responded to imatinib plus induction chemotherapy (vincristine, daunorubicin, prednisone, and intrathecal methotrexate). Complete remission was achieved with bone marrow MRD of 0.059% by flow cytometry and normal PDGFRB by FISH. Consolidation therapy with cyclophosphamide, cytarabine, mercaptopurine, and imatinib followed and the patient was still in remission 10 months after beginning imatinib.",
        "rs value":null,
        "pmid":"PubMed:23835704",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_EBF1::PDGFRB",
        "Disease":"Childhood B-cell Acute Lymphoblastic Leukemia",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":"A 16-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an IKZF1 deletion (delta 2-7) and a 5q33 microdeletion resulting in an EBF1-PDGFRB fusion responded to continuous imatinib (400 mg\/d) during consolidation. Following consolidation therapy that included dexamethasone, vincristine, etoposide, cytarabine, and high-dose methotrexate, MRD declined to 10^-5 and the patient underwent bone marrow transplant. MRD performed at 105 days post-BMT found no detectable blasts with a sensitivity of 10^-5.",
        "rs value":null,
        "pmid":"PubMed:24186319",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_EBF1::PDGFRB",
        "Disease":"Childhood B-cell Acute Lymphoblastic Leukemia",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib,Dasatinib",
        "Description":"The EBF1-PDGFRB fusion was detected in leukemia cells of a 7 year old Latino boy who presented with B-ALL and initial WBC of 600,000. He failed to enter remission with 4 drug induction (90% blasts at day 23), and showed testicular involvement. SNP array showed deletion of IKZF1 deletion and gains in 5q32 and 5q33.3 that interrupted the PDGFRB and EBF1 loci, respectively. FISH studies demonstrated an extra PDGFRB signal with suspect EBF1-PDGFRB that needs molecular confirmation. Imatinib, cyclophosphamide and etoposide were commenced with MRD 4.3% after 1 month. Imatinib dose was increased with MRD 0.44% after additional month of treatment. MRD was 0.0226% after two months of dasatinib treatment, and the patient proceeded to matched unrelated donor hematopoietic stem cell transplantation.",
        "rs value":null,
        "pmid":"PubMed:25207766",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MYD88",
        "Genomic Position":"3:38179969-38184510(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MYD88_L265P",
        "Disease":"Lymphoplasmacytic Lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib",
        "Description":"A prospective study of ibrutinib in 63 symptomatic patients with Waldenstr\ufffd\ufffdm's macroglobulinemia who had received at least one previous treatment. The response rates were highest among patients with MYD88(L265P) and CXCR4(WT). The MYD88 L265P mutation was present in 56 patients (8",
        "rs value":null,
        "pmid":"PubMed:25853747",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MYD88",
        "Genomic Position":"3:38179969-38184510(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MYD88_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | lymphoplasmacytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carfilzomib + Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04263480",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYD88",
        "Genomic Position":"3:38179969-38184510(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MYD88_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Emavusertib + Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03328078",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYD88",
        "Genomic Position":"3:38179969-38184510(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MYD88_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenalidomide + Nivolumab + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03558750",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYD88",
        "Genomic Position":"3:38179969-38184510(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MYD88_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous bone marrow transplantation + Chemotherapy + Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02443077",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYD88",
        "Genomic Position":"3:38179969-38184510(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MYD88_L273P",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | lymphoplasmacytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Ixazomib + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02400437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYD88",
        "Genomic Position":"3:38179969-38184510(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MYD88_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | lymphoplasmacytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04273139",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYD88",
        "Genomic Position":"3:38179969-38184510(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MYD88_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | lymphoplasmacytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rituximab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05099471",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYD88",
        "Genomic Position":"3:38179969-38184510(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MYD88_L273P",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bazlitoran",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02252146",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYD88",
        "Genomic Position":"3:38179969-38184510(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MYD88_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pacritinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03601819",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYD88",
        "Genomic Position":"3:38179969-38184510(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MYD88_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | lymphoplasmacytic lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Zanubrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03053440",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYD88",
        "Genomic Position":"3:38179969-38184510(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MYD88_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | lymphoplasmacytic lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Loncastuximab Tesirine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05190705",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYD88",
        "Genomic Position":"3:38179969-38184510(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MYD88_L273P",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | lymphoplasmacytic lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Zanubrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05640102",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYD88",
        "Genomic Position":"3:38179969-38184510(+) | 3p22.2",
        "CDS Mutation":null,
        "AA Mutation":"MYD88_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KT-413",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05233033",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH2",
        "Genomic Position":"2:47630108-47710367(+) | 2p21-p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH2",
        "Genomic Position":"2:47630108-47710367(+) | 2p21-p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03767075",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH2",
        "Genomic Position":"2:47630108-47710367(+) | 2p21-p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH2_unspecified",
        "Disease":"large intestine | adenoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03631641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH2",
        "Genomic Position":"2:47630108-47710367(+) | 2p21-p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03005002",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH2",
        "Genomic Position":"2:47630108-47710367(+) | 2p21-p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Methotrexate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00952016",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH2",
        "Genomic Position":"2:47630108-47710367(+) | 2p21-p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KRAS peptide vaccine + poly ICLC",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05013216",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH2",
        "Genomic Position":"2:47630108-47710367(+) | 2p21-p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH2",
        "Genomic Position":"2:47630108-47710367(+) | 2p21-p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH2_unspecified",
        "Disease":"stomach | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Fluorouracil",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03485196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH2",
        "Genomic Position":"2:47630108-47710367(+) | 2p21-p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH2",
        "Genomic Position":"2:47630108-47710367(+) | 2p21-p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104893",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSH2",
        "Genomic Position":"2:47630108-47710367(+) | 2p21-p16.3",
        "CDS Mutation":null,
        "AA Mutation":"MSH2_Loss",
        "Disease":"Transitional Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab,Anti-PD-1 Monoclonal Antibody MEDI0680",
        "Description":"Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel sequencing as well as loss of expression of these genes as confirmed by IHC. Testing also revealed a high mutational load as well as 2+ PD-L1 expression in 80% of the cells.  The patient was treated with anti-PD-L1 inhibitor MEDI4736 and MEDI0680 in a phase 1 trial and had a complete remission within 2 months of treatment that was ongoing after 11 months.",
        "rs value":null,
        "pmid":"PubMed:26674132",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MS4A1",
        "Genomic Position":"11:60223320-60238233(+) | 11q12.2",
        "CDS Mutation":null,
        "AA Mutation":"MS4A1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Parsaclisib + Pegfilgrastim + Prednisone + Rituximab + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04323956",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MS4A1",
        "Genomic Position":"11:60223320-60238233(+) | 11q12.2",
        "CDS Mutation":null,
        "AA Mutation":"MS4A1_Mutation",
        "Disease":"Diffuse Large B-cell Lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"R-CHOP Regimen",
        "Description":"A targeted sequencing study of 135 relapsed\/refractory DLBCL patients identified an association between missense mutations in MS4A1 and acquired resistance to R-CHOP.",
        "rs value":null,
        "pmid":"PubMed:32589730",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MRE11",
        "Genomic Position":"11:94152895-94227074(-) | 11q21",
        "CDS Mutation":null,
        "AA Mutation":"MRE11_Frameshift",
        "Disease":"Prostate Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11, ATM, MLH3 and NBN genes and showed clinical response to PARP inhibitor olaparib (16 weeks on Treatment).",
        "rs value":null,
        "pmid":"PubMed:26510020",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MRE11",
        "Genomic Position":"11:94152895-94227074(-) | 11q21",
        "CDS Mutation":null,
        "AA Mutation":"MRE11_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MRE11",
        "Genomic Position":"11:94152895-94227074(-) | 11q21",
        "CDS Mutation":null,
        "AA Mutation":"MRE11_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04336943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MRE11",
        "Genomic Position":"11:94152895-94227074(-) | 11q21",
        "CDS Mutation":null,
        "AA Mutation":"MRE11_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03009682",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MRE11",
        "Genomic Position":"11:94152895-94227074(-) | 11q21",
        "CDS Mutation":null,
        "AA Mutation":"MRE11_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRG1",
        "Genomic Position":"8:32405728-32622548(+) | 8p12",
        "CDS Mutation":null,
        "AA Mutation":"NRG1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRG1",
        "Genomic Position":"8:32405728-32622548(+) | 8p12",
        "CDS Mutation":null,
        "AA Mutation":"NRG1_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Patritumab",
        "Description":"In this phase-2 study, 215 patients were randomized to either erlotinib and placebo or erlotinib and HER3 monoclonal antibody patritumab. HRG (NRG1) expression was retrospectively defined as predictive biomarker but prospectively assessed in 102 patients before unblinding. NRG1-high groups demonstrated clinical benefit from additional patritumab with hazard ratios of 0.37 (P = 0.0283) and 0.29 (P = 0.0027) in the high- and low-dose patritumab arms, respectively.",
        "rs value":null,
        "pmid":"PubMed:26137564",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NRG1",
        "Genomic Position":"8:32405728-32622548(+) | 8p12",
        "CDS Mutation":null,
        "AA Mutation":"NRG1_fusions",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Zenocutuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02912949",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRG1",
        "Genomic Position":"8:32405728-32622548(+) | 8p12",
        "CDS Mutation":null,
        "AA Mutation":"NRG1_ATP1B1::NRG1",
        "Disease":"Cholangiocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib",
        "Description":"In a single patient with presumed cholangiocarcinoma a novel ATP1B1-NRG1 gene fusion was detected. Integrative genome analysis was used to assess the potential functional significance of the gene fusion, prioritizing a therapeutic strategy targeting the HER-family of growth factor receptors with afatinib. This patient was treated with the pan HER-family kinase inhibitor afatinib and displayed significant and durable response to treatment.",
        "rs value":null,
        "pmid":"PubMed:28950338",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NRG1",
        "Genomic Position":"8:32405728-32622548(+) | 8p12",
        "CDS Mutation":null,
        "AA Mutation":"NRG1_SDC4::NRG1",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib",
        "Description":"In patient with lung adenocarcinoma an SDC4-NRG1 gene fusion was detected. Integrative genome analysis was used to assess the potential functional significance of the detected gene fusion, prioritizing therapeutic strategies targeting the HER-family of growth factor receptors. This patient was treated with the pan HER-family kinase inhibitor afatinib and displayed a significant and durable response to treatment.",
        "rs value":null,
        "pmid":"PubMed:28950338",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NRG1",
        "Genomic Position":"8:32405728-32622548(+) | 8p12",
        "CDS Mutation":null,
        "AA Mutation":"NRG1_Fusion",
        "Disease":"Pancreatic Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib",
        "Description":"In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberrant ERBB receptor-mediated signaling, and pharmacologic ERBB inhibition resulted in clinical improvement and remission of liver metastases in two patients with NRG1-rearranged tumors that had proved resistant to standard treatment. One patient (30) was treated with afatinib monotherapy and showed improvement at 7 weeks, followed by progression at 3 months after necessary dose reduction.",
        "rs value":null,
        "pmid":"PubMed:29802158",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NRG1",
        "Genomic Position":"8:32405728-32622548(+) | 8p12",
        "CDS Mutation":null,
        "AA Mutation":"NRG1_ATP1B1::NRG1",
        "Disease":"Pancreatic Ductal Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib",
        "Description":"Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3\/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. A 59-year-old metastatic PDAC patient harbored an in-frame fusion of exon 3 of ATP1B1 with exon 2 of NRG1 and no other observed clinically relevant small mutations. Compared to this PDAC cohort, significant overexpression of NRG1 (exons 2-7) was observed in the tumor. Of note, the EGF-like domain of NRG1 (exons 6 & 7), which is required for HER-family kinase activation, is preserved in the fusion. Treatment with afatinib resulted in significant clinical response as measured by imaging, as well as a drastic reduction in CA19-9 levels. Disease progression was noted 5.5 months after treatment initiation.",
        "rs value":null,
        "pmid":"PubMed:31068372",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NRG1",
        "Genomic Position":"8:32405728-32622548(+) | 8p12",
        "CDS Mutation":null,
        "AA Mutation":"NRG1_APP::NRG1",
        "Disease":"Pancreatic Ductal Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib",
        "Description":"Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3\/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. In a 54-year-old with metastatic PDAC, a complex rearrangement involving the insertion of exons 6 and 7 of NRG1 between exons 15 and 16 of APP was found. This in-frame fusion resulted in the preservation and increased expression of the EGF-like domain of NRG1, which is required for HER-family kinase activation. Treatment with afatinib resulted in the resolution of multiple metastases and imaging showed ongoing response 5 months after treatment initiation.",
        "rs value":null,
        "pmid":"PubMed:31068372",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"UGT1A1",
        "Genomic Position":"2:234668894-234681945(+) | 2q37.1",
        "CDS Mutation":null,
        "AA Mutation":"UGT1A1_UGT1A1*28",
        "Disease":"Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Belinostat",
        "Description":"The FDA approved package insert for Belinostat recommends dose adjustment for UGT1A1*28 allele homozygotes.",
        "rs value":null,
        "pmid":"PubMed:26313268",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"UGT1A1",
        "Genomic Position":"2:234668894-234681945(+) | 2q37.1",
        "CDS Mutation":null,
        "AA Mutation":"UGT1A1_UGT1A1*60",
        "Disease":"Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Belinostat",
        "Description":"In a phase 1 trial belinostat (400-800mg\/m2\/24h) was administered to 25 patients in combination with cisplatin and etoposide. Endpoints were associations between genotype of UGT1A1 and pharmacokinetics, toxicities and proteine lysine acetylation. Belinostat AUC and half-life was significantly increased in UGT1A1*60 carriers, and they were at greater risk for thrombocytopenia.",
        "rs value":null,
        "pmid":"PubMed:26313268",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ALCAM",
        "Genomic Position":"3:105085753-105295744(+) | 3q13.11",
        "CDS Mutation":null,
        "AA Mutation":"ALCAM_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fluorouracil",
        "Description":"112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1\ufffd\ufffd and ALDH1. Pretreatment CD166 (ALCAM) expression level was associated with poor disease free survival (p\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd0.003; HR 5.61; 95% ",
        "rs value":null,
        "pmid":"PubMed:24708484",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CTLA4",
        "Genomic Position":"2:204732509-204738683(+) | 2q33.2",
        "CDS Mutation":null,
        "AA Mutation":"CTLA4_CTLA4::CD28",
        "Disease":"Sezary's Disease",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab",
        "Description":"A 67-year-old Caucasian female with stage IVA Sezary syndrome presented refractory to traditional therapy and was enrolled in a whole genome study trial. Sequencing revealed a CTLA4-CD28 fusion protein such that the inhibitory CTLA4 receptor activated a stimulatory CD28 intracellular domain that promoted proliferation. The patient was treated with iplimumab, a CTLA4 receptor inhibitor, and after 10 days, there was a reduction in erythema and ulceration by 50%, a reduction in tumor size by 75%, and overall improved quality of life. However, during the sixth week of therapy, the patient rapidly developed skin tumors and died 3 months later.",
        "rs value":null,
        "pmid":"PubMed:25802883",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"SSTR5",
        "Genomic Position":"16:1128781-1131454(+) | 16p13.3",
        "CDS Mutation":null,
        "AA Mutation":"SSTR5_expression",
        "Disease":"Neuroendocrine Tumor",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pasireotide",
        "Description":"Phase II study of pasireotide in metastatic neuroendocrine tumours enrolled 29 patients. Overall median PFS was 11 months (95% CI, 7.6\ufffd\ufffd\ufffd16 months). High SSTR5 expression (seen in 17\/22 samples measured) was associated with prolonged PFS (P=0.0068). Median PFS for low-SSTR5 tumours was 2.8 months (95% CI, 2.3\ufffd\ufffd\ufffd12.1 months) vs high tumours 19.9 months (95% CI, 7.7\ufffd",
        "rs value":null,
        "pmid":"PubMed:25376618",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15930355",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T670I",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16551858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y823D",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16551858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31758409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31758409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18955458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2466T>G",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18623623",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18623623",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18830121",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2009C>T",
        "AA Mutation":"p.T670I",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16954519",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T670I",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18955458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820G",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18623623",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17875769",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.A829P",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23456621",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y823D",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18955458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.K642E",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20043176",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16551858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23348204",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T670I",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20028860",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16954519",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.1961T>C",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15930355",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y823D",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31758409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16954519",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27997714",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N655T",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27864817",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2460T>A",
        "AA Mutation":"p.D820E",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y823D",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20043176",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C809G",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18452195",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y578C",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2466T>G",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21394667",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T670I",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31758409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.K818",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y823D",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18623623",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.A829P",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18623623",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820G",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16551858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18955458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D816H",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18623623",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16551858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2466T>A",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21394667",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23456621",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.A829P",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18955458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.K642E",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23456621",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820G",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16954519",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.A829P",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26779618",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D816H",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31758409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y823D",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16954519",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18452195",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15930355",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N822Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31758409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C809G",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31758409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y823D",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17875769",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D816H",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16954519",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D816A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18955458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18623623",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2466T>A",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26316776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T670E",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y823D",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27997714",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C809G",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18955458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.1961T>C",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18488000",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D579del",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820E",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18452195",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2466T>A",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18623623",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N822Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18623623",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2464A>T",
        "AA Mutation":"p.N822Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D816H",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18955458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.(P627",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18955458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S709F",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16551858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2458G>T",
        "AA Mutation":"p.D820Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2008",
        "AA Mutation":"p.T670E",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16551858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26779618",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D816E",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16551858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2466T>A",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.A829P",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31758409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.1961T>C",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25182956",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2009C>T",
        "AA Mutation":"p.T670I",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820G",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820G",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18452195",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y823D",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31758409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18955458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18955458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.1924A>G",
        "AA Mutation":"p.K642E",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20043176",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.1961T>C",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T670I",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15930355",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2447A>G",
        "AA Mutation":"p.D816G",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2460T>A",
        "AA Mutation":"p.D820E",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2040T>G",
        "AA Mutation":"p.N680K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2446G>C",
        "AA Mutation":"p.D816H",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20032375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820E",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16954519",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T670I",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18623623",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D816H",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17875769",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T670I",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16954519",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23456621",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S821F",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25735500",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.V569",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886408",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27997714",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.1961T>C",
        "AA Mutation":"p.V654A",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19096980",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D816E",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18452195",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C809G",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17875769",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820G",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18955458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N822Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16954519",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C809G",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16954519",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2146G>A",
        "AA Mutation":"p.D716N",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y823D",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15930355",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.N822K",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17875769",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16551858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820E",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16551858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y823D",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23456621",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D820Y",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27997714",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2447A>G",
        "AA Mutation":"p.D816G",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27068398",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MMP9",
        "Genomic Position":"20:44637547-44645200(+) | 20q13.12",
        "CDS Mutation":null,
        "AA Mutation":"MMP9_SERUM_LEVELS",
        "Disease":"Inflammatory Breast Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Bevacizumab",
        "Description":"MMP9 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Low bMMP9 was correlated with better OS (p=0.022) and non-significantly associated with longer DFS (p=0.071). Correlation to DFS was also found after multivariate analysis (p=0.041, HR: 3.511). bMMP9 was associated with death (p=0.035). During treatment, a significant decrease in MMP9 levels (p<0.001) was observed in 87% of patients.",
        "rs value":null,
        "pmid":"PubMed:26921265",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRIP1",
        "Genomic Position":"17:59758627-59940882(-) | 17q23.2",
        "CDS Mutation":null,
        "AA Mutation":"BRIP1_Mutation",
        "Disease":"Prostate Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). The study found that in men with mCRPC who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). A total of 4 patients had BRIP1 mutations, 2 in each arm. Based on the results of this study, on May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone.",
        "rs value":null,
        "pmid":"PubMed:32343890",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRIP1",
        "Genomic Position":"17:59758627-59940882(-) | 17q23.2",
        "CDS Mutation":null,
        "AA Mutation":"BRIP1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRIP1",
        "Genomic Position":"17:59758627-59940882(-) | 17q23.2",
        "CDS Mutation":null,
        "AA Mutation":"BRIP1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRIP1",
        "Genomic Position":"17:59758627-59940882(-) | 17q23.2",
        "CDS Mutation":null,
        "AA Mutation":"BRIP1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRIP1",
        "Genomic Position":"17:59758627-59940882(-) | 17q23.2",
        "CDS Mutation":null,
        "AA Mutation":"BRIP1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61K",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G12S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61L",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G12D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G60R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G60D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61L",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.182A>G",
        "AA Mutation":"p.Q61R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.37G>C",
        "AA Mutation":"p.G13R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.182A>T",
        "AA Mutation":"p.Q61L",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24553387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61R",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61K",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26101714",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.182A>G",
        "AA Mutation":"p.Q61R",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.182A>G",
        "AA Mutation":"p.Q61R",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21107323",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.181C>A",
        "AA Mutation":"p.Q61K",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.181C>A",
        "AA Mutation":"p.Q61K",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61L",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23569304",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.183A>C",
        "AA Mutation":"p.Q61H",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.181C>A",
        "AA Mutation":"p.Q61K",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21107323",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61K",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26715644",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61L",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61K",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28951457",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.37G>C",
        "AA Mutation":"p.G13R",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61K",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G12R",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61L",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27929064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61K",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23569304",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61K",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30036146",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.182A>G",
        "AA Mutation":"p.Q61R",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.181",
        "AA Mutation":"p.Q61R",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.181C>A",
        "AA Mutation":"p.Q61K",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24463458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G13R",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Alpelisib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28951457",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.181C>A",
        "AA Mutation":"p.Q61K",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25452114",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61R",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61R",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26524482",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61K",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25886620",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G12D",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.35G>A",
        "AA Mutation":"p.G12D",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25452114",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q61K",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26524482",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":"c.181C>A",
        "AA Mutation":"p.Q61K",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.W535L",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759020",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.1376C>T",
        "AA Mutation":"p.A459V",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759019",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D473G",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759020",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F460L",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759020",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.722C>T",
        "AA Mutation":"p.T241M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759019",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D473N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759020",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.1489G>T",
        "AA Mutation":"p.G497W",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25306392",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D473H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759020",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.961G>A",
        "AA Mutation":"p.V321M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25199678",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.1406G>A",
        "AA Mutation":"p.C469Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759019",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.W281C",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759020",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.H231R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759020",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.961G>A",
        "AA Mutation":"p.V321M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759019",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S533N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759020",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.1417G>T",
        "AA Mutation":"p.D473Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25306392",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.W535R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759020",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.1417G>C",
        "AA Mutation":"p.D473H",
        "Disease":"primitive_neuroectodermal_tumour-medulloblastoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19726788",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V321A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759020",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.842G>T",
        "AA Mutation":"p.W281L",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25199678",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q477E",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25759020",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PPP1R15A",
        "Genomic Position":"19:49375649-49379314(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"PPP1R15A_RS557806",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"FOLFIRI Regimen,Bevacizumab",
        "Description":"Exome and RNA sequencing was performed in tumor and matched normal tissue of 19 patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. The variant PPP1R15A (rs557806) showed the most significant association (P = 0.000401) with FOLFIRI-bevacizumab-driven tumor inhibition rate in exome sequencing data and the highest correlation (r = 0.74) with the drug responses in RNA sequencing data. Patients who were homozygous for the reference alleles (GG) of PPP1R15A rs557806 exhibited greater disease control rates and a tendency toward greater overall response rate than those with homozygous or heterozygous substitution alleles (GC and CC; P = 0.027 and 0.073) when treated with bevacizumab-containing regimens. PPP1R15A rs557806 nonsignificantly correlated with DCR in multivariate analysis (P = 0.054). In HCT116 xenograft tumors, tumor growth IR with FRB was 25 % in mock cells, 24 % in clones with reference alleles (G alleles) of PPP1R15A rs557806, and 17 % in clones with substitution alleles (C alleles) of PPP1R15A rs557806 (P = 0.004, day 13). FDG-PET imaging on day 7 showed FDG uptake (mean SUV max) of 0.219 and 0.500 in HCT116 xenografts expressing the reference allele (G) and substitution allele (C) of PPP1R15A rs557806, respectively (P = 0.032).",
        "rs value":null,
        "pmid":"PubMed:27177629",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EREG",
        "Genomic Position":"4:75230860-75254468(+) | 4q13.3",
        "CDS Mutation":null,
        "AA Mutation":"EREG_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":"226 cetuximab-treated patients with CRC were analyzed for mRNA expression of EGFR and its ligands. Favorable predictors in a multivariate analysis were high AREG mRNA in KRAS wild type tumours, high EREG mRNA and low Ephrin A2 receptor mRNA.",
        "rs value":null,
        "pmid":"PubMed:23374602",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"EREG",
        "Genomic Position":"4:75230860-75254468(+) | 4q13.3",
        "CDS Mutation":null,
        "AA Mutation":"EREG_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panitumumab",
        "Description":"Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as \"high expressor\" (either EREG or AREG mRNA level) or \"low expressor\" (neither EREG nor AREG in top tertile). For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P\ufffd\ufffd\ufffd<\ufffd\ufffd\ufffd.001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd.73; interaction test results were significant [P\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd.01]). Results were less clear for response rate (interaction P\ufffd\ufffd\ufffd",
        "rs value":null,
        "pmid":"PubMed:26867820",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"HAVCR2",
        "Genomic Position":"5:156512843-156536725(-) | 5q33.3",
        "CDS Mutation":null,
        "AA Mutation":"HAVCR2_unspecified",
        "Disease":"soft tissue | gastrointestinal stromal tumour | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Spartalizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03609424",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HAVCR2",
        "Genomic Position":"5:156512843-156536725(-) | 5q33.3",
        "CDS Mutation":null,
        "AA Mutation":"HAVCR2_Overexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"PD1 Inhibitor",
        "Description":"In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed after progression under PD-1 antibody. A survival advantage was observed with the addition of a TIM-3 blocking antibody. Two patients who developed adaptive resistance to anti-PD-1 treatment also showed TIM-3 upregulation in blocking antibody-bound T cells at treatment failure.",
        "rs value":null,
        "pmid":"PubMed:26883990",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"JAK2",
        "Genomic Position":"9:4985245-5128183(+) | 9p24.1",
        "CDS Mutation":"c.1641+2T>G",
        "AA Mutation":"p.?",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27433843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EPHB4",
        "Genomic Position":"7:100400187-100425121(-) | 7q22.1",
        "CDS Mutation":null,
        "AA Mutation":"EPHB4_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Bevacizumab",
        "Description":"EPHB4 expression, as assessed by quantitative RT-PCR in 13 colorectal cancer patients treated with bevacizumab, was higher in non-responders (p = 0.048). No difference was observed in a control group without bevacizumab treatment. qRT-PCR results were also shown to correlate with protein expression measured by IHC.",
        "rs value":null,
        "pmid":"PubMed:23579861",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_Mutation",
        "Disease":"Uveal Melanoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":"Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses. One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks.",
        "rs value":null,
        "pmid":"PubMed:22805292",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02645149",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04439357",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib + Darovasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03947385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_Mutation",
        "Disease":"Uveal Melanoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":"Patients with metastatic melanoma (n=77; 48 cutaneous, 23 uveal, 6 mucosal) were enrolled in a phase II randomised discontinuation trial assessing cabozantinib. Patients received 100 mg cabozantinib daily for 12 weeks. Patients with stable disease (SD; RECIST; n=26) were randomly assigned to cabozantinib (n=13) or placebo (n=13). In the uveal melanoma cohort, 61% of patients (14\/23, 61%) had SD at week 12. 9 patients had either a GNAQ (n=5) or GNA11 (n=4) mutation; only 10 patients were analyzed. Patients with GNAQ mutations remained on the study treatment from 1.4-10.3 months. The median PFS for the 23 patients with uveal melanoma was 4.8 months (41% PFS at 6 months) and median OS was 12.6 months. In the entire cohort, median overall PFS was 3.8 months (33% PFS at 6 months). After randomisation, median PFS for cabozantinib patients was 4.1 months and 2.8 months for placebo (HR 0.59, p=0.284).",
        "rs value":null,
        "pmid":"PubMed:28103611",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_unspecified_or_GNA11_unspecified_or_BAP1_unspecified",
        "Disease":"eye | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vorinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01587352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Darovasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03947385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Darovasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03947385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_Q209",
        "Disease":"Uveal Melanoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Refametinib",
        "Description":"Phase 1 study of MAPK1\/2 inhibitor BAY 86-9766. 53 patients were evaluated for efficacy, one patients achieved a PR and 11 patients had stable disease. One ocular melanoma patient with prolonged stable disease, who later went on to complete 28 courses, was positive for GNAQ Q209L and PTEN R173S mutations. The PTEN mutation was identified only in the postdose biopsy and not in the predose biopsy.",
        "rs value":null,
        "pmid":"PubMed:23434733",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNAQ",
        "Genomic Position":"9:80331003-80646374(-) | 9q21.2",
        "CDS Mutation":null,
        "AA Mutation":"GNAQ_Q209P",
        "Disease":"Skin Melanoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":"A 26-year old patient presented with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma. Five of his metastases were evaluated using whole genome sequencing. A GNAQ (Q209P) mutation was identified as unanimously present in all five tumors.",
        "rs value":null,
        "pmid":"PubMed:24504448",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28396313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29596911",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28961830",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28271038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32122695",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28274743",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.L982",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31157314",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29128427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31561203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27694386",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1249Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29128427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29128427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1246H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27987579",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3736G>A",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32234363",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y1248H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27987579",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1181R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28522754",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28522754",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y1248H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28522754",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1246H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29128427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3742T>C",
        "AA Mutation":"p.Y1248H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28396313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3743A>G",
        "AA Mutation":"p.Y1248C",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27666659",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27987579",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32122695",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3736G>A",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27343442",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y1248S",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28522754",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3736G>A",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28396313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y1248H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29128427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30711944",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28818608",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3736G>A",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Capmatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28396313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"PF-04217903",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23610116",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31561203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3742T>C",
        "AA Mutation":"p.Y1248H",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Capmatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28396313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3737A>T",
        "AA Mutation":"p.D1246V",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Savolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27694386",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.2073T>G",
        "AA Mutation":"p.F691L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23969938",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.2503G>C",
        "AA Mutation":"p.D835H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22368270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D835Y",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27908881",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D835X",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22368270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.2503G>T",
        "AA Mutation":"p.D835Y",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23969938",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.2503G>C",
        "AA Mutation":"p.D835H",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23969938",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.2503G>T",
        "AA Mutation":"p.D835Y",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22368270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.2503G>T",
        "AA Mutation":"p.D835Y",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Quizartinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22504184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D835I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Quizartinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27908881",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D835Y",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Quizartinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22354205",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.2073T>G",
        "AA Mutation":"p.F691L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Quizartinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22504184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.2504A>T",
        "AA Mutation":"p.D835V",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Quizartinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22504184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D835I",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Crenolanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27908881",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.2503",
        "AA Mutation":"p.D835F",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Quizartinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22504184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F691L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Crenolanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27908881",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":"c.2073T>G",
        "AA Mutation":"p.F691L",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Quizartinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23392356",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CALR",
        "Genomic Position":"19:13049421-13055303(+) | 19p13.13",
        "CDS Mutation":null,
        "AA Mutation":"CALR_unspecified_or_JAK2_V617F_or_MPL_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelofibrosis",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"PEG-interferon alfa-2a + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02742324",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CALR",
        "Genomic Position":"19:13049421-13055303(+) | 19p13.13",
        "CDS Mutation":null,
        "AA Mutation":"CALR_EXON_9_FRAMESHIFT",
        "Disease":"Essential Thrombocythemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Peginterferon Alfa-2a",
        "Description":"Study explored the hematologic and molecular responses in a cohort of 31 patients presenting with thrombocythemia and CALR exon 9 frameshift mutations. All 31 patients exhibited a hematologic response at the time of followup (European LeukemiaNet criteria). In regards to molecular response, before treatment the CALR mutant allele displayed a median frequency of 41% across the cohort, during treatment a significant decrease was observed in comparison to controls treated with hydroxyurea and aspirin.",
        "rs value":null,
        "pmid":"PubMed:26486786",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CSF1R",
        "Genomic Position":"5:149432854-149492935(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"CSF1R_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CSF1R",
        "Genomic Position":"5:149432854-149492935(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"CSF1R_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03784014",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CSF1R",
        "Genomic Position":"5:149432854-149492935(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"CSF1R_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CSF1R",
        "Genomic Position":"5:149432854-149492935(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"CSF1R_unspecified_or_FGFR1_unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified_or_FLT1_unspecified_or_FLT3_unspecified_or_FLT4_unspecified_or_KDR_unspecified_or_KIT_unspecified_or_PDGFRA_unspecified_or_PDGFRB_unspecified_or_RET_unspecified_or_VHL_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CSF1R",
        "Genomic Position":"5:149432854-149492935(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"CSF1R_unspecified_or_FGFR1_unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified_or_FLT3_unspecified_or_KIT_unspecified_or_PDGFRA_unspecified_or_PDGFRB_unspecified_or_RET_unspecified_or_VEGFR1_unspecified_or_VEGFR2_unspecified_or_VEGFR3__unspecified_or_VHL_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03297606",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CSF1R",
        "Genomic Position":"5:149432854-149492935(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"CSF1R_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01831726",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CSF1R",
        "Genomic Position":"5:149432854-149492935(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"CSF1R_MEF2D::CSF1R",
        "Disease":"B-lymphoblastic Leukemia|lymphoma, BCR-ABL1\ufffd\ufffd",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":"This study describes a cohort of 24 patients with BCR-ABL1-like B-ALL and ABL-class kinase rearrangement exposed to TKI frontline or at relapse, who showed favorable MRD response and outcome. Specifically, one 34-year-old man with MEF2D-CSF1R identified by RNAseq was prescribed an unspecified dose of imatinib as adjuvant to his frontline chemotherapy (protocol GRAALL-2014). His initial MRD analysis at 94 days remained positive for blasts (1 x 10^-4), but was consistent with continuous complete remission at day 147.",
        "rs value":null,
        "pmid":"PubMed:31434701",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MGMT",
        "Genomic Position":"10:131265448-131566271(+) | 10q26.3",
        "CDS Mutation":null,
        "AA Mutation":"MGMT_Promoter_Methylation",
        "Disease":"Glioblastoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide",
        "Description":"In a randomized clinical trial, patients with MGMT promoter methylation benefitted from temozolomide. This benefit was also methylation status dependent, as those without methylation did not see increased survival.",
        "rs value":null,
        "pmid":"PubMed:15758010",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MGMT",
        "Genomic Position":"10:131265448-131566271(+) | 10q26.3",
        "CDS Mutation":null,
        "AA Mutation":"MGMT_Promoter_Methylation",
        "Disease":"Glioblastoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carmustine",
        "Description":"MGMT promoter methylation has been shown to confer sensitivity to alkylating agents, such as carmustine, in glioblastoma cells.",
        "rs value":null,
        "pmid":"PubMed:11070098",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MGMT",
        "Genomic Position":"10:131265448-131566271(+) | 10q26.3",
        "CDS Mutation":null,
        "AA Mutation":"MGMT_RS16906252",
        "Disease":"Glioblastoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide",
        "Description":"The T allele of the rs16906252 SNP was associated with MGMT methylation and low protein expression. Germline presence of the T allele increased the risk of glioblastoma development (adjusted odds ratio, 1.96; P = .013). Temozolomide treatment led to better survival in patients with the rs16906252 T genotype irrespective of methylation status.",
        "rs value":null,
        "pmid":"PubMed:25910840",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MGMT",
        "Genomic Position":"10:131265448-131566271(+) | 10q26.3",
        "CDS Mutation":null,
        "AA Mutation":"MGMT_Underexpression",
        "Disease":"Glioblastoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide",
        "Description":"In this study, patients with low MGMT expression, compared with patients with high MGMT expression, had a significantly higher response rate (55% v 7%, respectively; P = .004) and improved PFS (median, 5.5 v 1.9 months, respectively; P = .009) and OS (median, 16 v 5 months, respectively; P = .003). Among patients with MGMT data available for analysis, radiotherapy was started and completed in 91% of patients with low MGMT expression. In contrast, among patients with high MGMT expression, only 64% started radiotherapy, and 43% completed it. These results suggest that neoadjuvant chemotherapy may be feasible for inoperable glioblastoma patients expressing low levels of MGMT without compromising subsequent treatment with radiotherapy, whereas patients with high MGMT expression are less likely to respond and more likely to experience progression before or during radiotherapy.",
        "rs value":null,
        "pmid":"PubMed:17442989",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MGMT",
        "Genomic Position":"10:131265448-131566271(+) | 10q26.3",
        "CDS Mutation":null,
        "AA Mutation":"MGMT_Underexpression",
        "Disease":"High Grade Glioma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide",
        "Description":"This study showed that low MGMT mRNA expression was strongly predictive for prolonged time to progression, treatment response, and length of survival in univariate and multivariate models (p<0.0001). The degree of MGMT mRNA expression was highly correlated with the MGMT promoter methylation status (p<0.0001); however, discordant findings were seen in 12 glioblastoma patients. Patients with methylated tumors with high MGMT mRNA expression (N = 6) did significantly worse than those with low transcriptional activity (p<0.01). Conversely, unmethylated tumors with low MGMT mRNA expression (N = 6) did better than their counterparts.",
        "rs value":null,
        "pmid":"PubMed:21365007",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MGMT",
        "Genomic Position":"10:131265448-131566271(+) | 10q26.3",
        "CDS Mutation":null,
        "AA Mutation":"MGMT_Underexpression",
        "Disease":"Oligodendroglioma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide",
        "Description":"In this study, loss of chromosome 1p and low MGMT protein expression were associated with objective response (P < .003 and P < .04, respectively). However, only 54% of the study group had evaluation of 1p\/19q status, and MGMT protein expression was studied in only 33%. Therefore, the association between 1p deletion and low MGMT protein expression was statistically significant when evaluated further and verified in the extended group of 31 patients with low-grade oligodendrogliomas.",
        "rs value":null,
        "pmid":"PubMed:16541434",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MGMT",
        "Genomic Position":"10:131265448-131566271(+) | 10q26.3",
        "CDS Mutation":null,
        "AA Mutation":"MGMT_Underexpression",
        "Disease":"Glioblastoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide",
        "Description":"In 41 glioblastomas treated with temozolomide (TMZ) therapy (MGMT-immunopositive: n = 22, negative: n = 19), both progression free survival and overall survival were significantly better in MGMT-immunonegative glioblastomas. (PFS: P = 0.0015, OS: P = 0.0384).",
        "rs value":null,
        "pmid":"PubMed:21331613",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MGMT",
        "Genomic Position":"10:131265448-131566271(+) | 10q26.3",
        "CDS Mutation":null,
        "AA Mutation":"MGMT_Underexpression",
        "Disease":"Neuroendocrine Tumor",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide",
        "Description":"Among those patients who received temozolomide-based therapy in this study, the median progression-free survival for patients whose tumors showed intact MGMT expression was 9.3 months compared with 19.2 months for patients with MGMT-deficient tumors (P = 0.11). The median overall survival for patients whose tumors showed intact MGMT expression was 19.1 months; the median overall survival for patients with MGMT deficient tumors was not reached.",
        "rs value":null,
        "pmid":"PubMed:19118063",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RSF1",
        "Genomic Position":"11:77371041-77532063(-) | 11q14.1",
        "CDS Mutation":null,
        "AA Mutation":"RSF1_Amplification",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tamoxifen",
        "Description":"In retrospective study, 413 patients were assessed for RSF1 amplification. 28 patients with RSF1 amplification did not show a benefit from adjuvant tamoxifen compared to placebo (12 treated vs 16 placebo). 381 patients without amplification did show a benefit compared to placebo (187 treated vs 194 placebo).",
        "rs value":null,
        "pmid":"PubMed:24367492",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AGR2",
        "Genomic Position":"7:16831435-16844704(-) | 7p21.1",
        "CDS Mutation":null,
        "AA Mutation":"AGR2_EXPRESSION",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tamoxifen",
        "Description":"mRNA expression of AGR2 in 61 patients with tamoxifen treated postmenopausal breast cancer was determined by qRT-PCR and was inversely associated with treatment response and progression free survival (p= 0.0011, p = 0.0366 respectively). AGR2 protein expression as assessed by IHC was not significantly associated with treatment outcome.",
        "rs value":null,
        "pmid":"PubMed:24167368",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"HSPA5",
        "Genomic Position":"9:127997132-128003609(-) | 9q33.3",
        "CDS Mutation":null,
        "AA Mutation":"HSPA5_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil",
        "Description":"Expression of GRP78 (HSPA5) in colorectal cancer patients (n=396, by IHC) showed improved benefit from adjuvant chemotherapy in stage III patients (52% vs. 28%; p = 0.026). In vitro, GRP78 inhibition reduced response to 5-FU.",
        "rs value":null,
        "pmid":"PubMed:23456958",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KDR",
        "Genomic Position":"4:55944644-55991756(-) | 4q12",
        "CDS Mutation":"c.2518C>T",
        "AA Mutation":"p.L840F",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29588308",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TOP1",
        "Genomic Position":"20:39657458-39753127(+) | 20q12",
        "CDS Mutation":null,
        "AA Mutation":"TOP1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Trastuzumab Deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04704661",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TOP1",
        "Genomic Position":"20:39657458-39753127(+) | 20q12",
        "CDS Mutation":null,
        "AA Mutation":"TOP1_Amplification",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irinotecan",
        "Description":"FFPE tumor samples from 78 patients with colorectal cancer, who had received irinotecan monotherapy were analyzed with a FISH dual-probe. TOP1 gain was nonsignificantly associated with objective response to irinotecan Odds ratio (OR): 1.62; p = 0.07.",
        "rs value":null,
        "pmid":"PubMed:24256029",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TOP1",
        "Genomic Position":"20:39657458-39753127(+) | 20q12",
        "CDS Mutation":null,
        "AA Mutation":"TOP1_EXPRESSION",
        "Disease":"Ovarian Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Topotecan,Carboplatin,Cyclophosphamide",
        "Description":"Shorter progression free survival was observed in patients with low expression (IHC) of topoisomerase 1 in 16 patients with relapsed or persistent ovarian or peritoneal carcinoma after treatment with topotecan, cyclophosphamide and carboplatin followed by an autologous hematopoietic stem cell transplant.",
        "rs value":null,
        "pmid":"PubMed:19648970",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TOP1",
        "Genomic Position":"20:39657458-39753127(+) | 20q12",
        "CDS Mutation":null,
        "AA Mutation":"TOP1_EXPRESSION",
        "Disease":"Colorectal Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Irinotecan",
        "Description":"498 patients were retrospectively analyzed for topoisomerase 1 expression (IHC). In the subgroup of patients treated with irinotecan (38% of the 498), those patients expressing Topoisomerase I had a better overall survival according to multivariate analysis (HR = 0.47, 95% CI 0.23-0.94, p = 0.033).",
        "rs value":null,
        "pmid":"PubMed:19775480",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"JAK1",
        "Genomic Position":"1:65298912-65432187(-) | 1p31.3",
        "CDS Mutation":"c.1507C>T",
        "AA Mutation":"p.Q503*",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27433843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_Mutation",
        "Disease":"Prostate Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). The study found that in men with mCRPC who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). A total of 8 patients had PALB2 mutations, 4 in each arm. Based on the results of this study, on May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone.",
        "rs value":null,
        "pmid":"PubMed:32343890",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04336943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05232006",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03140670",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02286687",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KRAS peptide vaccine + poly ICLC",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05013216",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pidnarulex",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04890613",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04756765",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05097599",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_Biallelic_Inactivation",
        "Disease":"Pancreatic Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Mitomycin",
        "Description":"In a patient with gemcitabine-refractory pancreatic cancer, a tumor-derived xenograft was found to be responsive to Mitomycin C. After disease progression, the patient was started on a regimen of mitomycin C, and the patient was shown to be asymptomatic after 3 years of follow-up.",
        "rs value":null,
        "pmid":"PubMed:21135251",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_Biallelic_Inactivation",
        "Disease":"Prostate Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"From 14 prostate cancer patients (88%) who had a response to olaparib, 7 patients had BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations), 4 of 5 with had ATM aberrations and one had a biallelic inactivation of PALB2 (frameshift mutation and deletion).",
        "rs value":null,
        "pmid":"PubMed:26510020",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGF19",
        "Genomic Position":"11:69513000-69519410(-) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"FGF19_Overexpression",
        "Disease":"Hepatocellular Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fisogatinib",
        "Description":"In a phase 1 trial, patients with hepatocellular carcinoma were treated with selective FGFR4 inhibitor, fisogatinib (BLU-554). For dose escalation, 25 patients received 140 to 900 mg fisogatinib once daily. FGF19 expression was evaluated by immunohistochemistry. Across doses, the overall response rate was 17% (11\/66) in FGF19 positive patients and 0% (0\/32) in FGF19 negative patients.",
        "rs value":null,
        "pmid":"PubMed:31575541",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"DEFA1",
        "Genomic Position":"8:6835172-6837602(-) | 8p23.1",
        "CDS Mutation":null,
        "AA Mutation":"DEFA1_EXPRESSION",
        "Disease":"Prostate Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel",
        "Description":"Blood mRNA levels of DEFA1, DEFA1B and DEFA3 were associated with response to docetaxel treatment in castration resistant prostate cancer. The discovery cohort consisted of 6 patients, results were validated in 10 patients.",
        "rs value":null,
        "pmid":"PubMed:26261420",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MDM4",
        "Genomic Position":"1:204485511-204527248(+) | 1q32.1",
        "CDS Mutation":null,
        "AA Mutation":"MDM4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALRN-6924 + Cytarabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03654716",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MDM4",
        "Genomic Position":"1:204485511-204527248(+) | 1q32.1",
        "CDS Mutation":null,
        "AA Mutation":"MDM4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALRN-6924 + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03725436",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CRLF2",
        "Genomic Position":"X:1314890-1331527(-) | Xp22.3 and Yp11.3",
        "CDS Mutation":null,
        "AA Mutation":"CRLF2_unspecified_or_DNM2_unspecified_or_EPOR_unspecified_or_IL7R_unspecified_or_JAK1_unspecified_or_JAK2_unspecified_or_JAK3_unspecified_or_PTPN2_unspecified_or_SH2B3_unspecified_or_STAT5B_unspecified_or_USP9X_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Dexamethasone + Ruxolitinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05745714",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DDX3X",
        "Genomic Position":"X:41192651-41209462(+) | Xp11.4",
        "CDS Mutation":null,
        "AA Mutation":"DDX3X_unspecified_or_PTPN2_unspecified_or_TET2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride + Prednisone + Rituximab + Selinexor + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05577364",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDH1",
        "Genomic Position":"16:68771128-68869451(+) | 16q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CDH1_unspecified",
        "Disease":"oesophagus | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib + JMT101",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05164848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDH1",
        "Genomic Position":"16:68771128-68869451(+) | 16q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CDH1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03620643",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCOR",
        "Genomic Position":"X:39910501-39956656(-) | Xp11.4",
        "CDS Mutation":null,
        "AA Mutation":"BCOR_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04147533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R2",
        "Genomic Position":"19:18263928-18281350(+) | 19p13.11",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R2_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TQB3525",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04836663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R2",
        "Genomic Position":"19:18263928-18281350(+) | 19p13.11",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R2_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TQB3525",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04836663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R2",
        "Genomic Position":"19:18263928-18281350(+) | 19p13.11",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R2_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TQB3525",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04836663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RNF43",
        "Genomic Position":"17:56431037-56494894(-) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RNF43_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05525858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RNF43",
        "Genomic Position":"17:56431037-56494894(-) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RNF43_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tegavivint",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04851119",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RNF43",
        "Genomic Position":"17:56431037-56494894(-) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RNF43_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02568267",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RNF43",
        "Genomic Position":"17:56431037-56494894(-) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RNF43_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05770544",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RNF43",
        "Genomic Position":"17:56431037-56494894(-) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RNF43_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCR5",
        "Genomic Position":"3:46411633-46417673(+) | 3p21.31",
        "CDS Mutation":null,
        "AA Mutation":"CCR5_unspecified_and_CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Leronlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03838367",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MST1R",
        "Genomic Position":"3:49924435-49941070(-) | 3p21.31",
        "CDS Mutation":null,
        "AA Mutation":"MST1R_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02612194",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MCL1",
        "Genomic Position":"1:150547032-150552066(-) | 1q21.2",
        "CDS Mutation":null,
        "AA Mutation":"MCL1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride + Everolimus + Pegaspargase + Prednisone + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01523977",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AFP",
        "Genomic Position":"4:74301880-74321891(+) | 4q13.3",
        "CDS Mutation":null,
        "AA Mutation":"AFP_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Best supportive care + Ramucirumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02435433",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CYP2D6",
        "Genomic Position":"22:42522501-42526908(-) | 22q13.2",
        "CDS Mutation":null,
        "AA Mutation":"CYP2D6_unspecified",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tamoxifen citrate",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01124695",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FH",
        "Genomic Position":"1:241660903-241683061(-) | 1q43",
        "CDS Mutation":null,
        "AA Mutation":"FH_unspecified_or_SDHA_unspecified_or_SDHB_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04068831",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FH",
        "Genomic Position":"1:241660903-241683061(-) | 1q43",
        "CDS Mutation":null,
        "AA Mutation":"FH_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05525858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DNTT",
        "Genomic Position":"10:98064153-98098321(+) | 10q24.1",
        "CDS Mutation":null,
        "AA Mutation":"DNTT_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bryostatin + Cisplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00006942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT3",
        "Genomic Position":"1:243665065-244013430(-) | 1q43-q44",
        "CDS Mutation":null,
        "AA Mutation":"AKT3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03310541",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT3",
        "Genomic Position":"1:243665065-244013430(-) | 1q43-q44",
        "CDS Mutation":null,
        "AA Mutation":"AKT3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT3",
        "Genomic Position":"1:243665065-244013430(-) | 1q43-q44",
        "CDS Mutation":null,
        "AA Mutation":"AKT3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04632992",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CTNNB1",
        "Genomic Position":"3:41240930-41281936(+) | 3p22.1",
        "CDS Mutation":"c.98C>G",
        "AA Mutation":"p.S33C",
        "Disease":"malignant_melanoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28421416",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLH3",
        "Genomic Position":"14:75480467-75518235(-) | 14q24.3",
        "CDS Mutation":null,
        "AA Mutation":"MLH3_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104893",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCF",
        "Genomic Position":"11:22644079-22647387(-) | 11p14.3",
        "CDS Mutation":null,
        "AA Mutation":"FANCF_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCF",
        "Genomic Position":"11:22644079-22647387(-) | 11p14.3",
        "CDS Mutation":null,
        "AA Mutation":"FANCF_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SF3B1",
        "Genomic Position":"2:198254508-198299815(-) | 2q33.1",
        "CDS Mutation":null,
        "AA Mutation":"SF3B1_K700E",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + E7107",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00499499",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SF3B1",
        "Genomic Position":"2:198254508-198299815(-) | 2q33.1",
        "CDS Mutation":null,
        "AA Mutation":"SF3B1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02232386",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SF3B1",
        "Genomic Position":"2:198254508-198299815(-) | 2q33.1",
        "CDS Mutation":null,
        "AA Mutation":"SF3B1_K700E",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + E7107",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00459823",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SF3B1",
        "Genomic Position":"2:198254508-198299815(-) | 2q33.1",
        "CDS Mutation":null,
        "AA Mutation":"SF3B1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myelomonocytic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01586195",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SF3B1",
        "Genomic Position":"2:198254508-198299815(-) | 2q33.1",
        "CDS Mutation":null,
        "AA Mutation":"SF3B1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Mitoxantrone hydrochloride + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04330820",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SF3B1",
        "Genomic Position":"2:198254508-198299815(-) | 2q33.1",
        "CDS Mutation":null,
        "AA Mutation":"SF3B1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01586195",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SF3B1",
        "Genomic Position":"2:198254508-198299815(-) | 2q33.1",
        "CDS Mutation":null,
        "AA Mutation":"SF3B1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"H3B-8800",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02841540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SF3B1",
        "Genomic Position":"2:198254508-198299815(-) | 2q33.1",
        "CDS Mutation":null,
        "AA Mutation":"SF3B1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gilteritinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03013998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SF3B1",
        "Genomic Position":"2:198254508-198299815(-) | 2q33.1",
        "CDS Mutation":null,
        "AA Mutation":"SF3B1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myelomonocytic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"H3B-8800",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02841540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SF3B1",
        "Genomic Position":"2:198254508-198299815(-) | 2q33.1",
        "CDS Mutation":null,
        "AA Mutation":"SF3B1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"H3B-8800",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02841540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SF3B1",
        "Genomic Position":"2:198254508-198299815(-) | 2q33.1",
        "CDS Mutation":null,
        "AA Mutation":"SF3B1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Luspatercept",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05732961",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SF3B1",
        "Genomic Position":"2:198254508-198299815(-) | 2q33.1",
        "CDS Mutation":null,
        "AA Mutation":"SF3B1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CA-4948 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04278768",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AXL",
        "Genomic Position":"19:41725108-41767671(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AXL_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoid-endocrine tumour | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib + Lanreotide acetate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04427787",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AXL",
        "Genomic Position":"19:41725108-41767671(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AXL_unspecified_or_MET_unspecified_or_NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01639508",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AXL",
        "Genomic Position":"19:41725108-41767671(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AXL_unspecified_or_MERTK_unspecified_or_MET_unspecified_or_FLT1_unspecified_or_FLT3_unspecified_or_FLT4_unspecified_or_KDR_unspecfied_or_KIT_unspecified_or_NTRK2_unspecied_or_RET_unspecified_or_ROS1_unspecified_or_TEK_unspecified_or_TYRO3_unspecified_or_VEGFA_unspecified_or_VEGFB_unspecified_or_VEGFC_unspecified_or_VEGFD_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04116541",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AXL",
        "Genomic Position":"19:41725108-41767671(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AXL_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"XZP-3621",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05204628",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AXL",
        "Genomic Position":"19:41725108-41767671(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AXL_unspecified_or_CBL_unspecified_or_DDR2_unspecified_or_KDR_unspecified_or_KIT_unspecified_or_MET_unspecified_or_NTRK1_unspecified_or_NTRK2_unspecified_or_NTRK3_unspecified_or_PDGFRA_unspecified_or_RET_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AXL",
        "Genomic Position":"19:41725108-41767671(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AXL_unspecified_or_CBL_unspecified_or_KDR_unspecified_or_KIT_unspecified_or_MET_unspecified_or_NTRK1_unspecified_or_NTRK2_unspecified_or_NTRK3_unspecified_or_PDGFRA_unspecified_or_RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AXL",
        "Genomic Position":"19:41725108-41767671(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AXL_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AXL",
        "Genomic Position":"19:41725108-41767671(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AXL_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Glesatinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00697632",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AXL",
        "Genomic Position":"19:41725108-41767671(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AXL_unspecified_or_CBL_unspecified_or_DDR2_unspecified_or_KDR_unspecified_or_KIT_unspecified_or_MET_unspecified_or_NTRK1_unspecified_or_NTRK2_unspecified_or_NTRK3_unspecified_or_PDGFRA_unspecified_or_RET_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AXL",
        "Genomic Position":"19:41725108-41767671(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AXL_unspecified_or_CBL_unspecified_or_DDR2_unspecified_or_KDR_unspecified_or_KIT_unspecified_or_MET_unspecified_or_NTRK1_unspecified_or_NTRK2_unspecified_or_NTRK3_unspecified_or_PDGFRA_unspecified_or_RET_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TERT",
        "Genomic Position":"5:1253282-1295162(-) | 5p15.33",
        "CDS Mutation":null,
        "AA Mutation":"TERT_unspecified",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02766270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TERT",
        "Genomic Position":"5:1253282-1295162(-) | 5p15.33",
        "CDS Mutation":null,
        "AA Mutation":"TERT_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous Dendritic Cells vaccine + Radiotherapy + Temozolomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01567202",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TERT",
        "Genomic Position":"5:1253282-1295162(-) | 5p15.33",
        "CDS Mutation":null,
        "AA Mutation":"TERT_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"RZ001",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05595473",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TERT",
        "Genomic Position":"5:1253282-1295162(-) | 5p15.33",
        "CDS Mutation":null,
        "AA Mutation":"TERT_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vx-001",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01935154",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EPS8",
        "Genomic Position":"12:15773096-15942510(-) | 12p12.3",
        "CDS Mutation":null,
        "AA Mutation":"EPS8_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chimeric antigen receptor T cells  + EPS8-specific DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03291444",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"U2AF1",
        "Genomic Position":"21:44513066-44527697(-) | 21q22.3",
        "CDS Mutation":null,
        "AA Mutation":"U2AF1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04147533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"U2AF1",
        "Genomic Position":"21:44513066-44527697(-) | 21q22.3",
        "CDS Mutation":null,
        "AA Mutation":"U2AF1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CA-4948 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04278768",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TNFRSF25",
        "Genomic Position":"1:6521211-6526235(-) | 1p36.31",
        "CDS Mutation":null,
        "AA Mutation":"TNFRSF25_unspecified_(DDR3_unspecified)",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"CYH33 + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04586335",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2L1",
        "Genomic Position":"20:30252255-30310701(-) | 20q11.21",
        "CDS Mutation":null,
        "AA Mutation":"BCL2L1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride + Everolimus + Pegaspargase + Prednisone + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01523977",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2L1",
        "Genomic Position":"20:30252255-30310701(-) | 20q11.21",
        "CDS Mutation":null,
        "AA Mutation":"BCL2L1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00378404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2L1",
        "Genomic Position":"20:30252255-30310701(-) | 20q11.21",
        "CDS Mutation":null,
        "AA Mutation":"BCL2L1_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Paclitaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00176241",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TET2",
        "Genomic Position":"4:106067450-106200973(+) | 4q24",
        "CDS Mutation":"c.137C>T",
        "AA Mutation":"p.P46L",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30848481",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND3",
        "Genomic Position":"6:41902671-41909586(-) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"CCND3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03237390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND3",
        "Genomic Position":"6:41902671-41909586(-) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"CCND3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02187783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND3",
        "Genomic Position":"6:41902671-41909586(-) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"CCND3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04594005",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND3",
        "Genomic Position":"6:41902671-41909586(-) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"CCND3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03310879",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND3",
        "Genomic Position":"6:41902671-41909586(-) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"CCND3_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04393285",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TEK",
        "Genomic Position":"9:27109147-27230173(+) | 9p21.2",
        "CDS Mutation":null,
        "AA Mutation":"TEK_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tegavivint",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04851119",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT1",
        "Genomic Position":"13:28874489-29069232(-) | 13q12.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT1_unspecified_(VEGFR1_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT1",
        "Genomic Position":"13:28874489-29069232(-) | 13q12.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT1_unspecified_or_FLT4_unspecified_or_KDR_unspecified_or_KIT_unspecified_or_PDGFRA_unspecified_or_PDGFRB_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pazopanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02029001",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT1",
        "Genomic Position":"13:28874489-29069232(-) | 13q12.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT1_unspecified_(VEGFR1_unspecified)",
        "Disease":"meninges | meningioma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01125046",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT1",
        "Genomic Position":"13:28874489-29069232(-) | 13q12.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT1_unspecified_(VEGFR1_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT1",
        "Genomic Position":"13:28874489-29069232(-) | 13q12.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT1_unspecified_(VEGFR1_unspecified)_or_FLT4_unspecified_(VEGFR3_unspecified)_or_KDR_unspecfied_(VEGFR2_unspecfied)",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03297606",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT1",
        "Genomic Position":"13:28874489-29069232(-) | 13q12.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT1_unspecified_(VEGFR1_unspecified)",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01831726",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT1",
        "Genomic Position":"13:28874489-29069232(-) | 13q12.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT1_unspecified_(VEGFR1_unspecified)",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04004975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT1",
        "Genomic Position":"13:28874489-29069232(-) | 13q12.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT1_unspecified_(VEGFR1_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified_and_FLT3_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin + Midostaurin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03900949",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Gemtuzumab Ozogamicin + Ivuxolimab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03390296",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lintuzumab-Ac225 + Spironolactone + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03867682",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Lintuzumab-Ac225 + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03932318",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Azacitidine + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03390296",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemtuzumab Ozogamicin + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04070768",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Cytarabine + Fludarabine + Gemtuzumab Ozogamicin + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05183035",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IMGN779",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02674763",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gelonin + Lintuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00038051",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Lintuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00528333",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lintuzumab-Y90",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00002890",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine or Decitabine + Vadastuximab talirine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01902329",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AVE9633",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00543972",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Azacitidine + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03390296",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemtuzumab Ozogamicin + Zosuquidar",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00233909",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Gemtuzumab Ozogamicin + Idarubicin + Vorinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01039363",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD33-targeted CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03126864",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00044733",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vadastuximab talirine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01902329",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemtuzumab Ozogamicin + Glasdebig",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03390296",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Fludarabine + QN-023a",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05601466",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lintuzumab-Ac225",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT00672165",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Functionally enhanced CD33 CAR-T Cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04835519",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemtuzumab Ozogamicin + VOR33",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04849910",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Filgrastim + Gemtuzumab Ozogamicin + Idarubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01698879",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-CD33 CAR-NK cells",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02944162",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Fludarabine + Gemtuzumab Ozogamicin + Idarubicin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00909168",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00460447",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03737955",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lintuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00283114",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CPX-351 + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04915612",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00372593",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00091234",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CLL1, CD33 and\/or CD123-targeted CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04010877",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PRGN-3006",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03927261",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Azacitidine + Ivuxolimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03390296",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Busulfan + Cyclophosphamide + Gemtuzumab Ozogamicin + Methotrexate + Mycophenolate mofetil + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00669890",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD33\/CLL1 targeted CAR-NK cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05215015",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Muc1\/CLL1\/CD33\/CD38\/CD56\/CD123-targeted CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03222674",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Gemtuzumab Ozogamicin + Idarubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01698879",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ivuxolimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03390296",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemtuzumab Ozogamicin + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04207190",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD33-targeted CAR-T cells + Cyclophosphamide + Fludarabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03971799",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00927498",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Filgrastim + Lintuzumab-Bi213",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00014495",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CPX-351 + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03672539",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD33\/CLL1 targeted CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05467254",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lintuzumab-Ac225",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02998047",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD33-targeted CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02958397",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GTB-3550 TriKE",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03214666",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD33-targeted CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05445765",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CART33",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02799680",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Etoposide + Fludarabine + QN-023a",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05665075",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic stem cell transplantation + Busulfan + Cyclophosphamide + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02221310",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD33-targeted CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05672147",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD33\/CLL1 targeted CAR-T cells + Cyclophosphamide + Fludarabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05248685",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD33\/CLL1 targeted CAR-T cells + Cyclophosphamide + Fludarabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05016063",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-CD33 CAR-NK cells + Cyclophosphamide + Fludarabine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT05008575",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GEM333",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03516760",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD33,CD38,CD56,CD123,CD117,CD133,CD34 or Mucl-targeted CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03473457",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cladribine + Cytarabine + Filgrastim + Lintuzumab-Ac225 + Mitoxantrone hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03441048",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SC-DARIC33",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05105152",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD33",
        "Genomic Position":"19:51728354-51743271(+) | 19q13.41",
        "CDS Mutation":null,
        "AA Mutation":"CD33_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD33-targeted CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05473221",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TNFRSF8",
        "Genomic Position":"1:12123434-12204264(+) | 1p36.22",
        "CDS Mutation":null,
        "AA Mutation":"TNFRSF8_unspecified_(CD30_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | peripheral T cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Brentuximab vedotin + Cyclophosphamide + Doxorubicin hydrochloride + Prednisone",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01777152",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TNFAIP3",
        "Genomic Position":"6:138188581-138204449(+) | 6q23.3",
        "CDS Mutation":null,
        "AA Mutation":"TNFAIP3_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous bone marrow transplantation + Chemotherapy + Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02443077",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IRAK1",
        "Genomic Position":"X:153275951-153285431(-) | Xq28",
        "CDS Mutation":null,
        "AA Mutation":"IRAK1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pacritinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03601819",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYOD1",
        "Genomic Position":"11:17741115-17743678(+) | 11p15.1",
        "CDS Mutation":null,
        "AA Mutation":"MYOD1_unspecified_or_TP53_unspecified",
        "Disease":"soft tissue | rhabdomyosarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Dactinomycin + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05304585",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTPN11",
        "Genomic Position":"12:112856718-112947717(+) | 12q24.13",
        "CDS Mutation":null,
        "AA Mutation":"PTPN11_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04147533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTPN11",
        "Genomic Position":"12:112856718-112947717(+) | 12q24.13",
        "CDS Mutation":null,
        "AA Mutation":"PTPN11_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03784014",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTPN11",
        "Genomic Position":"12:112856718-112947717(+) | 12q24.13",
        "CDS Mutation":null,
        "AA Mutation":"PTPN11_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | juvenile myelomonocytic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Etanercept",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00509600",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTPN11",
        "Genomic Position":"12:112856718-112947717(+) | 12q24.13",
        "CDS Mutation":null,
        "AA Mutation":"PTPN11_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myelomonocytic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cobimetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04409639",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL6",
        "Genomic Position":"3:187439165-187463515(-) | 3q27.3",
        "CDS Mutation":null,
        "AA Mutation":"BCL6_unspecified_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous Hematopoietic Stem Cell Transplantation + Carmustine + Cytarabine + Etoposide + Ibrutinib + Melphalan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02443077",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL6",
        "Genomic Position":"3:187439165-187463515(-) | 3q27.3",
        "CDS Mutation":null,
        "AA Mutation":"BCL6_unspecified_and_MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | B cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ARQ 531",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03162536",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"JAK3",
        "Genomic Position":"19:17935595-17958841(-) | 19p13.11",
        "CDS Mutation":null,
        "AA Mutation":"JAK3_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pacritinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03601819",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYC",
        "Genomic Position":"8:128748330-128753674(+) | 8q24.21",
        "CDS Mutation":null,
        "AA Mutation":"MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fimepinostat + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01742988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYC",
        "Genomic Position":"8:128748330-128753674(+) | 8q24.21",
        "CDS Mutation":null,
        "AA Mutation":"MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous Hematopoietic Stem Cell Transplantation + Carmustine + Cytarabine + Etoposide + Ibrutinib + Melphalan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02443077",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYC",
        "Genomic Position":"8:128748330-128753674(+) | 8q24.21",
        "CDS Mutation":null,
        "AA Mutation":"MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fimepinostat + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01742988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYC",
        "Genomic Position":"8:128748330-128753674(+) | 8q24.21",
        "CDS Mutation":null,
        "AA Mutation":"MYC_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fimepinostat",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01742988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MYC",
        "Genomic Position":"8:128748330-128753674(+) | 8q24.21",
        "CDS Mutation":null,
        "AA Mutation":"MYC_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TCF7L2",
        "Genomic Position":"10:114710009-114927437(+) | 10q25.2-q25.3",
        "CDS Mutation":null,
        "AA Mutation":"TCF7L2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02352844",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TCF7L2",
        "Genomic Position":"10:114710009-114927437(+) | 10q25.2-q25.3",
        "CDS Mutation":null,
        "AA Mutation":"TCF7L2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Onatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04518137",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TCF7L2",
        "Genomic Position":"10:114710009-114927437(+) | 10q25.2-q25.3",
        "CDS Mutation":null,
        "AA Mutation":"TCF7L2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Telaglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03872427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MTAP",
        "Genomic Position":"9:21802542-21867077(+) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"MTAP_deletion",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AG-270",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03435250",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MTAP",
        "Genomic Position":"9:21802542-21867077(+) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"MTAP_deletion",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AG-270 + Gemcitabine + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03435250",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MTAP",
        "Genomic Position":"9:21802542-21867077(+) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"MTAP_deletion",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AG-270 + Docetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03435250",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CB",
        "Genomic Position":"3:138372860-138553594(-) | 3q22.3",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1067V",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25982275",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR2",
        "Genomic Position":"14:64699806-64761078(-) | 14q23.2-q23.3",
        "CDS Mutation":null,
        "AA Mutation":"ESR2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Estradiol",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03941730",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR2",
        "Genomic Position":"14:64699806-64761078(-) | 14q23.2-q23.3",
        "CDS Mutation":null,
        "AA Mutation":"ESR2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Estradiol",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01083641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR2",
        "Genomic Position":"14:64699806-64761078(-) | 14q23.2-q23.3",
        "CDS Mutation":null,
        "AA Mutation":"ESR2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tamoxifen",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02062489",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBFB",
        "Genomic Position":"16:67063148-67134925(+) | 16q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CBFB-MYH11_fusion_or_RUNX1-RUNX1T1_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idarubicin + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05404516",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBFB",
        "Genomic Position":"16:67063148-67134925(+) | 16q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CBFB-MYH11_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02450877",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBFB",
        "Genomic Position":"16:67063148-67134925(+) | 16q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CBFB-MYH11_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Topotecan + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00588991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBFB",
        "Genomic Position":"16:67063148-67134925(+) | 16q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CBFB-MYH11_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Topotecan + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00588991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBFB",
        "Genomic Position":"16:67063148-67134925(+) | 16q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CBFB-MYH11_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01139970",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBFB",
        "Genomic Position":"16:67063148-67134925(+) | 16q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CBFB-MYH11_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Fludarabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02926586",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBFB",
        "Genomic Position":"16:67063148-67134925(+) | 16q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CBFB-MYH11_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Belinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00351975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK2",
        "Genomic Position":"12:56360553-56366568(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK2_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04393285",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R1",
        "Genomic Position":"5:67511548-67597649(+) | 5q13.1",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Miransertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02476955",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R1",
        "Genomic Position":"5:67511548-67597649(+) | 5q13.1",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R1_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TQB3525",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04836663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R1",
        "Genomic Position":"5:67511548-67597649(+) | 5q13.1",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anastrozole + Miransertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02476955",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R1",
        "Genomic Position":"5:67511548-67597649(+) | 5q13.1",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R1_unspecified",
        "Disease":"cervix | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TQB3525",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04836663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R1",
        "Genomic Position":"5:67511548-67597649(+) | 5q13.1",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Miransertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02476955",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3R1",
        "Genomic Position":"5:67511548-67597649(+) | 5q13.1",
        "CDS Mutation":null,
        "AA Mutation":"PIK3R1_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TQB3525",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04836663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"POU2F3",
        "Genomic Position":"11:120107349-120190653(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"POU2F3_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PARP1",
        "Genomic Position":"1:226548392-226595774(-) | 1q42.12",
        "CDS Mutation":null,
        "AA Mutation":"PARP1_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03784014",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ASXL1",
        "Genomic Position":"20:30946155-31027122(+) | 20q11.21",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"haematopoietic_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32399015",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ELOC",
        "Genomic Position":"8:74857354-74884522(-) | 8q21.11",
        "CDS Mutation":null,
        "AA Mutation":"ELOC_unspecified_or_EPAS1_unspecified_or_FH_unspecified_or_SDHA_unspecified_or_SDHAF2_unspecified_or_SDHB_unspecified_or_SDHC_unspecified_or_SDHD_unspecified_or_VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DFF332",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04895748",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ELOC",
        "Genomic Position":"8:74857354-74884522(-) | 8q21.11",
        "CDS Mutation":null,
        "AA Mutation":"ELOC_unspecified_or_EPAS1_unspecified_or_FH_unspecified_or_SDHA_unspecified_or_SDHAF2_unspecified_or_SDHB_unspecified_or_SDHC_unspecified_or_SDHD_unspecified_or_VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DFF332 + Spartalizumab + Taminadenant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04895748",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ELOC",
        "Genomic Position":"8:74857354-74884522(-) | 8q21.11",
        "CDS Mutation":null,
        "AA Mutation":"ELOC_unspecified_or_EPAS1_unspecified_or_FH_unspecified_or_SDHA_unspecified_or_SDHAF2_unspecified_or_SDHB_unspecified_or_SDHC_unspecified_or_SDHD_unspecified_or_VHL_unspecified",
        "Disease":"kidney | carcinoma | renal cell carcinoma unclassified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DFF332 + Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04895748",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLLT3",
        "Genomic Position":"9:20341663-20622542(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"MLLT3-KMT2A_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Belinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00351975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLLT3",
        "Genomic Position":"9:20341663-20622542(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"MLLT3-KMT2A_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Topotecan + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00588991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MLLT3",
        "Genomic Position":"9:20341663-20622542(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"MLLT3-KMT2A_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Topotecan + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00588991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PPP2R2A",
        "Genomic Position":"8:26150732-26228402(+) | 8p21.2",
        "CDS Mutation":null,
        "AA Mutation":"PPP2R2A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PPP2R2A",
        "Genomic Position":"8:26150732-26228402(+) | 8p21.2",
        "CDS Mutation":null,
        "AA Mutation":"PPP2R2A_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RECQL5",
        "Genomic Position":"17:73622934-73663269(-) | 17q25",
        "CDS Mutation":null,
        "AA Mutation":"RECQL5_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51",
        "Genomic Position":"15:40987372-41023791(+) | 15q15.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD51_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCE",
        "Genomic Position":"6:35420138-35434880(+) | 6p21.31",
        "CDS Mutation":null,
        "AA Mutation":"FANCE_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD52",
        "Genomic Position":"12:1021243-1058888(-) | 12p13.33",
        "CDS Mutation":null,
        "AA Mutation":"RAD52_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDCD1",
        "Genomic Position":"2:242792033-242801060(-) | 2q37.3",
        "CDS Mutation":null,
        "AA Mutation":"PDCD1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02950220",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDCD1",
        "Genomic Position":"2:242792033-242801060(-) | 2q37.3",
        "CDS Mutation":null,
        "AA Mutation":"PDCD1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05169437",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDCD1",
        "Genomic Position":"2:242792033-242801060(-) | 2q37.3",
        "CDS Mutation":null,
        "AA Mutation":"PDCD1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04423185",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WWTR1",
        "Genomic Position":"3:149235022-149421060(-) | 3q25.1",
        "CDS Mutation":null,
        "AA Mutation":"WWTR1_fusions_or_YAP1_fusions",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IAG933",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04857372",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WWTR1",
        "Genomic Position":"3:149235022-149421060(-) | 3q25.1",
        "CDS Mutation":null,
        "AA Mutation":"WWTR1_fusions_or_YAP1_fusions",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IK-930",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05228015",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SYK",
        "Genomic Position":"9:93564069-93660831(+) | 9q22.2",
        "CDS Mutation":null,
        "AA Mutation":"SYK_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Lintuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00997243",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2B",
        "Genomic Position":"9:22002902-22009362(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2B_unspecified",
        "Disease":"bone | chordoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03110744",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2B",
        "Genomic Position":"9:22002902-22009362(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2B_unspecified",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04074785",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2B",
        "Genomic Position":"9:22002902-22009362(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2B_unspecified",
        "Disease":"central nervous system | glioma | oligodendroglioma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02530320",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2B",
        "Genomic Position":"9:22002902-22009362(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2B_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + LY3214996",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04391595",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2B",
        "Genomic Position":"9:22002902-22009362(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2B_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abiraterone acetate + Prednisone + TQB3616",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05156450",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TACSTD2",
        "Genomic Position":"1:59041099-59043166(-) | 1p32.1",
        "CDS Mutation":null,
        "AA Mutation":"TACSTD2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05332561",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB4",
        "Genomic Position":"2:212240446-213403565(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"ERBB4_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lapatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01264081",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB4",
        "Genomic Position":"2:212240446-213403565(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"ERBB4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Neratinib + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03065387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB4",
        "Genomic Position":"2:212240446-213403565(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"ERBB4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Neratinib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03065387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB4",
        "Genomic Position":"2:212240446-213403565(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"ERBB4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus + Neratinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03065387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB4",
        "Genomic Position":"2:212240446-213403565(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"ERBB4_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Varlitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03499626",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIAA1549",
        "Genomic Position":"7:138522270-138666064(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"KIAA1549-BRAF_fusion_COSF588",
        "Disease":"central nervous system | glioma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03363217",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"LRP6",
        "Genomic Position":"12:12268959-12419746(-) | 12p13.2",
        "CDS Mutation":null,
        "AA Mutation":"LRP6_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tegavivint",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04851119",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RELA",
        "Genomic Position":"11:65421067-65430565(-) | 11q13.1",
        "CDS Mutation":null,
        "AA Mutation":"RELA_fusions",
        "Disease":"central nervous system | primitive neuroectodermal tumour-medulloblastoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Filgrastim + Gemcitabine + Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03434262",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GSK3B",
        "Genomic Position":"3:119545533-119812513(-) | 3q13.33",
        "CDS Mutation":null,
        "AA Mutation":"GSK3B_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tegavivint",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04851119",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DAXX",
        "Genomic Position":"6:33286335-33290791(-) | 6p21.32",
        "CDS Mutation":null,
        "AA Mutation":"DAXX_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"M4344",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02278250",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TYK2",
        "Genomic Position":"19:10461209-10491352(-) | 19p13.2",
        "CDS Mutation":null,
        "AA Mutation":"TYK2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pacritinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03601819",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"LGR5",
        "Genomic Position":"12:71833550-71980090(+) | 12q21.1",
        "CDS Mutation":null,
        "AA Mutation":"LGR5_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tegavivint",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04851119",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGF1",
        "Genomic Position":"5:141971743-142000907(-) | 5q31.3",
        "CDS Mutation":null,
        "AA Mutation":"FGF1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGF1",
        "Genomic Position":"5:141971743-142000907(-) | 5q31.3",
        "CDS Mutation":null,
        "AA Mutation":"FGF1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGF1",
        "Genomic Position":"5:141971743-142000907(-) | 5q31.3",
        "CDS Mutation":null,
        "AA Mutation":"FGF1_unspecified",
        "Disease":"soft tissue | sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Futibatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03784014",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V550L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C552F",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V550M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.1648G>C",
        "AA Mutation":"p.V550L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.1648G>T",
        "AA Mutation":"p.V550L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.1654T>C",
        "AA Mutation":"p.C552R",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.1648G>A",
        "AA Mutation":"p.V550M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCA",
        "Genomic Position":"16:89803957-89883054(-) | 16q24.3",
        "CDS Mutation":null,
        "AA Mutation":"FANCA_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCA",
        "Genomic Position":"16:89803957-89883054(-) | 16q24.3",
        "CDS Mutation":null,
        "AA Mutation":"FANCA_unspecified_or_FANCB_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCG_unspecified_or_FANCI_unspecified_or_FANCJ_unspecified_or_FANCL_unspecified_or_FANCM_unspecified_or_FANCN_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04550494",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCA",
        "Genomic Position":"16:89803957-89883054(-) | 16q24.3",
        "CDS Mutation":null,
        "AA Mutation":"FANCA_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MSR1",
        "Genomic Position":"8:15966940-16050224(-) | 8p22",
        "CDS Mutation":null,
        "AA Mutation":"MSR1_unspecified",
        "Disease":"soft tissue | gastrointestinal stromal tumour | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Spartalizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03609424",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ARID1A",
        "Genomic Position":"1:27022524-27108595(+) | 1p36.11",
        "CDS Mutation":null,
        "AA Mutation":"ARID1A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576444",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ARID1A",
        "Genomic Position":"1:27022524-27108595(+) | 1p36.11",
        "CDS Mutation":null,
        "AA Mutation":"ARID1A_unspecified_or_ATM_unspecified_or_ATRX_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_BLM_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_FAM175A_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCG_unspecified_or_FANCL_unspecified_or_KMT2B_unspecified_or_MRE11A_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51_unspecified_or_RAD51B_unspecified_or_SLX4_unspecified_or_WRN_unspecified_or_XRCC1_unspecified",
        "Disease":"gastrointestinal tract (site indeterminate) | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab + Stereotactic Body Radiation Therapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05379972",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ARID1A",
        "Genomic Position":"1:27022524-27108595(+) | 1p36.11",
        "CDS Mutation":null,
        "AA Mutation":"ARID1A_unspecified_or_ARID1B_unspecified_or_ARID2_unspecified_or_ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BAP1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCD2_unspecified_or_MRN11A_unspecified_or_PALB2_unspecified_or_RAD50_unspecified_or_RAD51_unspecified_or_RAD54B_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04633902",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ARID1A",
        "Genomic Position":"1:27022524-27108595(+) | 1p36.11",
        "CDS Mutation":null,
        "AA Mutation":"ARID1A_unspecified_or_ATM_unspecified_or_ATR_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_EMSY_unspecified_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PTEN_unspecified_or_RAD51_unspecified",
        "Disease":"biliary tract | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04042831",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ARID1A",
        "Genomic Position":"1:27022524-27108595(+) | 1p36.11",
        "CDS Mutation":null,
        "AA Mutation":"ARID1A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"M4344",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02278250",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ARID1A",
        "Genomic Position":"1:27022524-27108595(+) | 1p36.11",
        "CDS Mutation":null,
        "AA Mutation":"ARID1A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ARID1A",
        "Genomic Position":"1:27022524-27108595(+) | 1p36.11",
        "CDS Mutation":null,
        "AA Mutation":"ARID1A_unspecified_or_ATM_unspecified_or_ATR_unspecified_or_BRIP1_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_CDK12_unspecified_or_CHK1_unspecified_or_CHK2_unspecified_or_IDH1_unspecified_or_IDH2_unspecified_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD50_unspecified_or_RAD51_unspecified_or_RAD51B_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_RAD54L_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04550494",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ARID1A",
        "Genomic Position":"1:27022524-27108595(+) | 1p36.11",
        "CDS Mutation":null,
        "AA Mutation":"ARID1A_unspecified_or_ATM_unspecified_or_ATRX_unspecified_or_DAXX_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tuvusertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04170153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ARID1A",
        "Genomic Position":"1:27022524-27108595(+) | 1p36.11",
        "CDS Mutation":null,
        "AA Mutation":"ARID1A_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FOLR1",
        "Genomic Position":"11:71901258-71907342(+) | 11q13.4",
        "CDS Mutation":null,
        "AA Mutation":"FOLR1_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Mirvetuximab Soravtansine",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT04296890",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCNE2",
        "Genomic Position":"8:95891998-95908906(-) | 8q22.1",
        "CDS Mutation":null,
        "AA Mutation":"CCNE2_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04393285",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CREBBP",
        "Genomic Position":"16:3775055-3930727(-) | 16p13.3",
        "CDS Mutation":null,
        "AA Mutation":"CREBBP_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | peripheral T cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride + Prednisone + Tucidinostat + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04480099",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AXIN2",
        "Genomic Position":"17:63524681-63557765(-) | 17q24.1",
        "CDS Mutation":null,
        "AA Mutation":"AXIN2_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tegavivint",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04851119",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCL",
        "Genomic Position":"2:58386382-58468485(-) | 2p16.1",
        "CDS Mutation":null,
        "AA Mutation":"FANCL_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCL",
        "Genomic Position":"2:58386382-58468485(-) | 2p16.1",
        "CDS Mutation":null,
        "AA Mutation":"FANCL_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCL",
        "Genomic Position":"2:58386382-58468485(-) | 2p16.1",
        "CDS Mutation":null,
        "AA Mutation":"FANCL_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD79B",
        "Genomic Position":"17:62006100-62009696(-) | 17q23.3",
        "CDS Mutation":null,
        "AA Mutation":"CD79B_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04994626",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD79B",
        "Genomic Position":"17:62006100-62009696(-) | 17q23.3",
        "CDS Mutation":null,
        "AA Mutation":"CD79B_unspecified_or_MYD88_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Mivavotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05319028",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EP300",
        "Genomic Position":"22:41487790-41576081(+) | 22q13.2",
        "CDS Mutation":null,
        "AA Mutation":"EP300_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | peripheral T cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride + Prednisone + Tucidinostat + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04480099",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PGR",
        "Genomic Position":"11:100900355-101001255(-) | 11q22.1",
        "CDS Mutation":null,
        "AA Mutation":"PGR_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib + Docetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02171741",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"APC",
        "Genomic Position":"5:112043218-112181936(+) | 5q22.2",
        "CDS Mutation":null,
        "AA Mutation":"APC_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04853043",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"APC",
        "Genomic Position":"5:112043218-112181936(+) | 5q22.2",
        "CDS Mutation":null,
        "AA Mutation":"APC_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fluorouracil + Midostaurin + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01282502",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"APC",
        "Genomic Position":"5:112043218-112181936(+) | 5q22.2",
        "CDS Mutation":null,
        "AA Mutation":"APC_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Encorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03839342",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"APC",
        "Genomic Position":"5:112043218-112181936(+) | 5q22.2",
        "CDS Mutation":null,
        "AA Mutation":"APC_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tegavivint",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04851119",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"APC",
        "Genomic Position":"5:112043218-112181936(+) | 5q22.2",
        "CDS Mutation":null,
        "AA Mutation":"APC_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TVB2640",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02980029",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"APC",
        "Genomic Position":"5:112043218-112181936(+) | 5q22.2",
        "CDS Mutation":null,
        "AA Mutation":"APC_unspecified",
        "Disease":"soft tissue | desmoid tumour-fibromatosis | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nirogacestat",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01981551",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"APC",
        "Genomic Position":"5:112043218-112181936(+) | 5q22.2",
        "CDS Mutation":null,
        "AA Mutation":"APC_unspecified",
        "Disease":"soft tissue | desmoid tumour-fibromatosis | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nirogacestat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04195399",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCI",
        "Genomic Position":"15:89787198-89860360(+) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"FANCI_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATR",
        "Genomic Position":"3:142168079-142297668(-) | 3q23",
        "CDS Mutation":null,
        "AA Mutation":"ATR_unspecified",
        "Disease":"urinary tract | papilloma | typical",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00462943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATR",
        "Genomic Position":"3:142168079-142297668(-) | 3q23",
        "CDS Mutation":null,
        "AA Mutation":"ATR_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK2_unspecified_or_ERCC3_unspecified_or_FAM175A_unspecified_or_FANCA_unspecified_or_GEN1_unspecified_or_HDAC2_unspecified_or_MRE11_unspecified_or_NBN_unspecified_or_MLH3_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PALB2_unspecified_or_PMS2_unspecified_or_RAD51_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03012321",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMARCB1",
        "Genomic Position":"22:24129161-24176703(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"SMARCB1_unspecified",
        "Disease":"soft tissue | epithelioid sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02601950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMARCB1",
        "Genomic Position":"22:24129161-24176703(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"SMARCB1_unspecified",
        "Disease":"soft tissue | synovial sarcoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tazemetostat hydrobromide",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02601950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBL",
        "Genomic Position":"11:119076752-119178859(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"CBL_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04147533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBL",
        "Genomic Position":"11:119076752-119178859(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"CBL_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myelomonocytic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03722407",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBL",
        "Genomic Position":"11:119076752-119178859(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"CBL_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myelomonocytic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cobimetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04409639",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBL",
        "Genomic Position":"11:119076752-119178859(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"CBL_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBL",
        "Genomic Position":"11:119076752-119178859(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"CBL_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBL",
        "Genomic Position":"11:119076752-119178859(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"CBL_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBL",
        "Genomic Position":"11:119076752-119178859(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"CBL_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBL",
        "Genomic Position":"11:119076752-119178859(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"CBL_unspecified",
        "Disease":"NS | malignant melanoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GSK2636771 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03131908",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBL",
        "Genomic Position":"11:119076752-119178859(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"CBL_Exon8_or_CBL_Exon9",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Quizartinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04493138",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"IL6R",
        "Genomic Position":"1:154377669-154441926(+) | 1q21.3",
        "CDS Mutation":null,
        "AA Mutation":"1q21_amplification_(IL6R,_MCL1,_ILF2,_BCL9,_CKS1B)",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Dexamethasone + Doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00872521",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_e14a2_(b3a2)_COSF1755",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03516279",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00028847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02973711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01751425",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_e13a2_(b2a2)_COSF1757",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03610971",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03654768",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03610971",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03654768",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00054431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD45RA+ T cell depleted peripheral blood stem cells + Cyclophosphamide + Filgrastim + Fludarabine + Melphalan + Radiotherapy + Rituximab + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02960646",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogeneic hematopoietic stem cell transplantation + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00244829",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Nilotinib + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03654768",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00022490",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00015834",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + PR1 leukemia peptide vaccine + Peginterferon alfa-2b + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00415857",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + PR1 leukemia peptide vaccine + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00415857",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00006052",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"GM-K562 cell vaccine + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00363649",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"BCR-ABL-derived peptide vaccine + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00267085",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Dexrazoxane + Filgrastim + Hydrocortisone + Ifosfamide + Imatinib + Leucovorin calcium + Mercaptopurine + Methotrexate + Pegaspargase + Prednisolone + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03007147",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00081133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Cytarabine + Idarubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00023920",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Zoledronic acid",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00210119",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00287105",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00384228",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01279473",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00481052",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00129740",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00514969",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00006053",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Omacetaxine mepesuccinate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00114959",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00376467",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04838041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03578367",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03906292",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic lymphocytes + Cyclosporine + Dasatinib + Fludarabine + Hematopoietic Stem Cell Transplant + Imatinib + Mycophenolate mofetil + Nilotinib + Peripheral blood stem cell transplantation  + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00036738",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03267186",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous Hematopoietic Stem Cell Transplantation + Cyclophosphamide + Cytarabine + Etoposide + Filgrastim + Imatinib + Leucovorin calcium + Methotrexate + Tacrolimus + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00039377",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Dexamethasone + Imatinib + Mesna + Methotrexate + Sargramostim + Vincristine sulphate + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00038610",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Lonafarnib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00047502",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Dexamethasone + Imatinib + Methotrexate + Prednisone + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03589326",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Oblimersen sodium",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00049192",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00053248",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01279473",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03516279",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03906292",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03610971",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03654768",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00006475",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00510926",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00644878",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01077544",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Peginterferon alfa-2b",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00146913",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00511303",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic stem cell transplantation + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Dexrazoxane + Etoposide + Filgrastim + Hydrocortisone + Ifosfamide + Imatinib + Leucovorin calcium + Mercaptopurine + Methotrexate + Pegaspargase + Prednisone + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03007147",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01274351",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05143840",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00048672",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Hematopoietic Stem Cell Transplant + Imatinib + Methotrexate + Mitoxantrone hydrochloride + Prednisone",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00458848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Etoposide + Leucovorin calcium + Methotrexate + Nilotinib + Prednisolone + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00844298",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00702403",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Busulfan + Clofarabine + Cyclophosphamide + Filgrastim + Fludarabine + Melphalan + Mycophenolate mofetil + Radiotherapy + Rituximab + Tacrolimus + Umbilical cord blood transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03096782",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogeneic hematopoietic stem cell transplantation + Cytarabine + Dexamethasone + Imatinib + Mitoxantrone hydrochloride + Nilotinib + Prednisone",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01025505",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05604755",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00219765",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogeneic natural killer cell line NK-92 + Anti-thymocyte globulin + Busulfan + Clofarabine + Cyclophosphamide + Fludarabine + Melphalan + Radiotherapy + Rituximab + Umbilical cord blood transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02727803",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00093639",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT01774630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entinostat + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01383447",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Cytarabine + Dexamethasone + Doxorubicin hydrochloride + Methotrexate + Pegaspargase + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01769209",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab + Cyclophosphamide + Cytarabine + Inotuzumab Ozogamicin + Mercaptopurine + Methotrexate + Prednisone + Rituximab + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01371630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Human MHC non-restricted cytotoxic T-cell line TALL-104 + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00415909",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01222013",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01528085",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00384228",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Clofarabine + Melphalan + Rituximab + Thiotepa + ?\/?+ T-lymphocyte depleted hematopoietic stem cell transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03615105",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Busulfan + Fludarabine + Melphalan + Rituximab + ?\/?+ T-lymphocyte depleted hematopoietic stem cell transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03615105",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Etoposide + Filgrastim + Imatinib + Mercaptopurine + Methotrexate + Prednisone + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01491763",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Dexrazoxane + Imatinib + Leucovorin calcium + Mercaptopurine + Methotrexate + Pegaspargase + Prednisone + Thioguanine + Vincristine sulphate + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03007147",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Dexamethasone + Vorinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01312818",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Cyclophosphamide + Hematopoietic Stem Cell Transplant + Radiotherapy + Rituximab + Thiotepa + ?\/?+ T-lymphocyte depleted hematopoietic stem cell transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03615105",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01445080",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Dexamethasone + Idarubicin + Imatinib + Methotrexate + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00199186",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Dexamethasone + Leucovorin calcium + Mesna + Methotrexate + Nilotinib + Prednisone + Rituximab + Vincristine + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01670084",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Cytarabine liposome + Dasatinib + Daunorubicin + Etoposide + Hydrocortisone + Leucovorin calcium + Methotrexate + Pegaspargase + Prednisone + Rituximab + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02043587",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00154349",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Bortezomib + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02877082",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03610971",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Interferon alpha",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00015847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01690065",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01914484",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00171223",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Imatinib + Methotrexate + Prednisolone + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00130195",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00055874",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03942094",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02108951",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00264160",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Daunorubicin + Imatinib + Prednisone + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00015860",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00445822",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Dexamethasone + Imatinib + Mercaptopurine + Methotrexate + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01376427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00388895",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01061177",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Lenalidomide + Melphalan + Mycophenolate mofetil + Natural killer cell immunotherapy + Radiotherapy + Rituximab + Tacrolimus + Umbilical cord blood transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01619761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Interferon alpha",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00390897",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02546674",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT01368523",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01206088",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01819389",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02389920",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00171158",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02917720",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01275196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Peginterferon alfa-2b + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00050531",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00769327",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00845221",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Etoposide + Mercaptopurine + Methotrexate + Pegaspargase + Rituximab + Vincristine sulphate + Vindesine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02881086",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib + PEG-interferon alfa-2a",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02201459",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00219726",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01043874",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00802841",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01227577",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01254188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00809211",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00171249",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01221376",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01092741",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00219752",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01400074",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01535391",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Hydroxyurea + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03515018",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00786812",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00006343",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00030394",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05413915",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02174445",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02129062",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib + Peginterferon alfa-2b",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01657604",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02086487",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00004932",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Imatinib + Peginterferon alfa-2b + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00763763",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab + Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02997761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04688983",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01562847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03454503",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Imatinib + Melphalan + Mercaptopurine + Methotrexate + Pegaspargase + Rituximab + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01085617",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00302016",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01316250",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02204722",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03332511",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02272777",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab + Bortezomib + Cytarabine + Dexamethasone + Doxorubicin hydrochloride + Hydrocortisone + Methotrexate + Palbociclib + Pembrolizumab + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03515200",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Methotrexate + Prednisone + Rituximab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04872790",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Dexamethasone + Doxorubicin hydrochloride + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04996160",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00022737",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00519090",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib + Cytarabine + Dasatinib + Dexamethasone + Doxorubicin hydrochloride + Hydrocortisone + Methotrexate + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03515200",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Dexamethasone + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02494882",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00333840",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Navtemadlin + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04835584",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02081378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Panobinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00686218",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"GM-K562 cell vaccine + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00301093",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02225574",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00471497",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Tanespimycin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00066326",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01077544",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02253277",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alvocidib + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00064285",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02081378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Temsirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00101088",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acetaminophen + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00428909",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01702064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00661180",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | blast phase chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00445822",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + PEG-proline-interferon alpha-2b",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01933906",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axitinib + Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02782403",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00040105",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib + Sonidegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01456676",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | blast phase chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00514969",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00109707",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01844765",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Interferon alpha-2B",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00045422",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04070443",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Pioglitazone",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02888964",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Valproic acid",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01011998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00081133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00023881",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bortezomib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00511069",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Busulfan + Donor lymphocyte infusion + Fludarabine + Hematopoietic Stem Cell Transplant + Imatinib + Methotrexate + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00499889",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03193281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogeneic hematopoietic stem cell transplantation + Busulfan + Cyclophosphamide + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01003054",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Hydroxychloroquine + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01227135",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Pioglitazone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02687425",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib + PEG-interferon alfa-2a",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02001818",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Pioglitazone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04883125",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Hydroxyurea + Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02480608",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib + Peginterferon alfa-2b",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01866553",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nilotinib + PEG-interferon alfa-2a",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01294618",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00123487",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00982488",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Ponatinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04188405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00978731",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclosporine + Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01426334",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib + Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02081378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00660920",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00306202",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic stem cell transplantation + Ipilimumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01822509",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Ketoconazole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05638763",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Navtemadlin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04835584",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Aspirin + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04160546",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Peginterferon alfa-2b",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01725204",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00064233",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib + Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03906292",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Decitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01498445",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Peginterferon alfa-2b",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01872442",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00345826",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03895671",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Flumatinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05433532",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00298987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03516279",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Glasdegib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04655391",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04501614",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04554459",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01207440",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04475731",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01570868",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00320190",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03934372",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01460693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic stem cell transplantation + Ipilimumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00060372",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00316953",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04591431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00070499",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02689440",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02819804",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01650805",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00103701",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib + Dasatinib + Prednisone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03595917",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05701215",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"ASTX727 + Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05007873",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00777036",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cladribine + Cytarabine + Gilteritinib + Idarubicin + Midostaurin + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02115295",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Mitoxantrone hydrochloride + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01004497",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02467270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01030718",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00254423",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00123474",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01593254",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00306202",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00481247",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic stem cell transplantation + Dasatinib + Dexamethasone + Inotuzumab Ozogamicin + Methotrexate + Ponatinib + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04747912",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olverembatinib + Prednisone + Venetoclax + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05594784",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | blast phase chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03895671",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Vorinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00816283",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab + Dasatinib + Prednisone",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02143414",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allopurinol sodium + Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Etoposide + Methotrexate + Mitoxantrone hydrochloride + Pegaspargase + Sulphamethoxazole + Trimethoprim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00940524",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogeneic hematopoietic stem cell transplantation + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Etoposide + Mercaptopurine + Methotrexate + Mitoxantrone hydrochloride + Prednisone + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02523976",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01207440",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Tozasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00500006",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02011945",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00103844",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Tozasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00500006",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00101816",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04845035",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00101647",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00982488",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04722848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab + Dexamethasone + Methotrexate + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04530565",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04688983",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00482703",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02268370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02888990",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Methotrexate + Prednisone + Vincristine + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00390793",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04233346",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01667133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic stem cell transplantation + Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01310010",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00123487",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02627677",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01464411",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01802450",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03216070",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04155411",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00362466",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Prednisone + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05026229",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Dexamethasone + Methotrexate + Prednisone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02690922",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Mercaptopurine + Methotrexate + Pegaspargase + Prednisone + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03117751",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04845035",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asparaginase + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Etoposide + Filgrastim + Hydrocortisone sodium succinate + Ifosfamide + Leucovorin calcium + Mercaptopurine + Methotrexate + Methylprednisolone acetate + Pegaspargase + Prednisone + Radiotherapy + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00720109",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab + Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02744768",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab  + Cytarabine + Methotrexate + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03263572",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Dexamethasone + Ponatinib + Vincristine sulphate + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01424982",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Etoposide + Mercaptopurine + Methotrexate + Vincristine sulphate + Vindesine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01724879",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Dexamethasone + Methotrexate + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01641107",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic stem cell transplantation + Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Etoposide + Filgrastim + Leucovorin calcium + Methotrexate + Methylprednisolone acetate + Peripheral blood stem cell transplantation  + Prednisone + Radiotherapy + Sirolimus + Tacrolimus + Vincristine sulphate + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00792948",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Methotrexate + Prednisone",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00391989",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab + Chemotherapy + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03147612",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03934372",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Etoposide + Hematopoietic Stem Cell Transplant + Hydrocortisone + Mercaptopurine + Methotrexate + Ponatinib + Prednisone + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02776605",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Idelalisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03742323",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Ponatinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03576547",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00345826",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00103701",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib + Dasatinib + Prednisone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03595917",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00101595",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alemtuzumab + Cyclosporine + Fludarabine + Mycophenolate mofetil + Peripheral blood stem cell transplantation + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00118352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01256398",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00895297",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab + Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04688983",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00866736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00101660",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03625388",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00337454",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00101595",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00529763",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Peginterferon alfa-2b",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02975115",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00852566",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01660906",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01460160",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Vorinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00816283",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04925141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02398825",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01916785",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00112775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00298987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01746836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04233346",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"BMS-833923 + Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01357655",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"BMS-833923 + Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01218477",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03807479",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03079505",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PEG-interferon alfa-2a",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02381379",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01511289",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Flumatinib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT04375683",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bafetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00352677",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Flumatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04677439",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olverembatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05311943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PEG-interferon alfa-2a",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02736721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03459534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Flumatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05367765",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytokine-induced killer cells",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00815321",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02228382",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03314974",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Flumatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04681820",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Melphalan + Mycophenolate mofetil + Radiotherapy + Sirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03192397",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03333486",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nogapendekin alfa",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01885897",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00042003",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogeneic hematopoietic stem cell transplantation + CD34-enriched PBSCT + CD45RA-depleted PBSCT + Cyclophosphamide + Fludarabine + Methotrexate + Radiotherapy + Tacrolimus + Thiotepa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02220985",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Flumatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05353205",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD8-depleted donor lymphocyte infusion",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00038818",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Cyclosporine + Fludarabine + Peripheral blood stem cell transplantation ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03602898",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Fludarabine + Peripheral blood stem cell transplantation + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03602898",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogeneic hematopoietic stem cell transplantation + Anti-thymocyte globulin + Busulfan + Cyclophosphamide + Fludarabine + Methotrexate + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00787761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogeneic hematopoietic stem cell transplantation + CD34-enriched PBSCT + CD45RA-depleted PBSCT + Cyclophosphamide + Fludarabine + Mycophenolate mofetil + Radiotherapy + Tacrolimus + Thiotepa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02220985",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bone marrow transplantation + Cyclophosphamide + Fludarabine + Mycophenolate mofetil + Natural killer cell immunotherapy + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00789776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00006092",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogeneic hematopoietic stem cell transplantation + CD34-enriched PBSCT + CD45RA-depleted PBSCT + Cyclophosphamide + Fludarabine + Mycophenolate mofetil + Tacrolimus + Thiotepa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02220985",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02546375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03314974",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00005618",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Hematopoietic Stem Cell Transplant + Melphalan + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03128359",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib + Belinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02381548",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Cyclosporine + Methotrexate + Peripheral blood stem cell transplantation ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03602898",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05456191",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic lymphocytes",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00068718",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Omacetaxine mepesuccinate",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00006364",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Omacetaxine mepesuccinate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00462943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Fludarabine + Mycophenolate mofetil + Radiotherapy + Sirolimus + Umbilical cord blood transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02722668",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous heat-shock protein 70 peptide vaccine AG-858",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00058747",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00574873",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Cyclophosphamide + Methotrexate + Peripheral blood stem cell transplantation  + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03602898",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Omacetaxine mepesuccinate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00003694",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Peginterferon alfa-2b",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00037882",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PEG-proline-interferon alpha-2b",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03117816",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclosporine + Fludarabine + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy + Sirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01251575",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00041990",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cyclosporine + Filgrastim + Fludarabine + Hematopoietic Stem Cell Transplant + Melphalan + Mycophenolate mofetil + Radiotherapy + Sirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04195633",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Inecalcitol",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02949570",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fludarabine + Triapine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00381550",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Methotrexate + Peripheral blood stem cell transplantation  + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03602898",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04971226",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00072579 ",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04948333",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Omacetaxine mepesuccinate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00004933",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1 mRNA transfected autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00965224",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"p.DOM-WT1-126 + p.DOM-WT1-37",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01334060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00072579",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04666259",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Cyclophosphamide + Cyclosporine + Methotrexate + Peripheral blood stem cell transplantation + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03602898",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Cyclophosphamide + Cytokine-treated Veto Cells + Fludarabine + Peripheral blood stem cell transplantation  + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03622788",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TGRX-678",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05434312",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cyclosporine + Hematopoietic Stem Cell Transplant + Sirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03246906",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclosporine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Sirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03246906",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Hematopoietic Stem Cell Transplant + Methotrexate + Tacrolimus + Vorinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01789255",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Interferon alpha + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00003561",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Belinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00351975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02458014",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Omacetaxine mepesuccinate + Recombinant interferon alpha-2a",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00003239",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD19 targeting CAR-T cells + CD22 targeting CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04788472",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MLN2480",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02484430",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Flumatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04739826",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Tacrolimus + Thiotepa",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02861417",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic lymphocytes + Cyclosporine + Mycophenolate mofetil + Pentostatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00096161",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Filgrastim + Fludarabine + Melphalan + Mycophenolate mofetil + Spanlecortemlocel + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03674411",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic bone marrow transplantation + Busulfan + Cyclophosphamide + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00004181",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclosporine + Fludarabine + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00119340",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic lymphocytes + Cyclosporine + Fludarabine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00003145",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Fludarabine + Radiotherapy + Thiotepa + Umbilical cord blood transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04083170",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sargramostim + bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00466726",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD8+ and CD4+ donor memory T cells-expressing HA1-specific TCR + Fludarabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03326921",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-PR1\/HLA-A2 monoclonal antibody Hu8F4",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02530034",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Hematopoietic Stem Cell Transplant + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01822509",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib + Inotuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02311998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02861417",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"7-hydroxystaurosporine + Perifosine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00301938",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"EphB4-HSA Fusion Protein + Vincristine sulfate liposome",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03519984",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PF-114",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02885766",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Danusertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00335868",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib + PEG-proline-interferon alpha-2b",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03831776",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + SCH 900776",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00907517",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogeneic CD56-positive CD3-negative natural killer cells + Busulfan + Fludarabine + Hematopoietic Stem Cell Transplant + Interleukin-2",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01823198",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ixabepilone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00030108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Flumatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02511340",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous T-cell transfer + Carmustine + Cyclophosphamide + Etoposide + Filgrastim + Gemcitabine + Melphalan + Peripheral blood stem cell transplantation + Recombinant interferon alpha-2a + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00003727",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vodobatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02629692",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic stem cell transplantation + Anti-thymocyte globulin + Busulfan + Filgrastim + Fludarabine + Interleukin-2 + Methotrexate + Natural killer cell immunotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01390402",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Succimer ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03630991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic bone marrow transplantation + Cyclophosphamide + Long-wave ultra-violet light + Psoralen + Radiotherapy + Thiotepa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00005092",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Methotrexate + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy + Tacrolimus + Thiotepa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02220985",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Fludarabine + mPEG-R-crisantaspase",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04526795",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fludarabine + Hematopoietic Stem Cell Transplant + Methotrexate + Peripheral blood stem cell transplantation  + Radiotherapy + T cell depleted hematopoietic stem cell transplantation + Tacrolimus + Thiotepa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01858740",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Flumatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01503502",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panobinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00723203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Recombinant interleukin-7 + Umbilical cord blood transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03941769",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Edetate calcium disodium",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03630991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Arsenic trioxide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00006091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783_or_SRC_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03297606",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Inotuzumab Ozogamicin + Olverembatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05603156",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogeneic hematopoietic stem cell transplantation + Blinatumomab + Dexamethasone + Methotrexate + Tyrosine Kinase Inhibitor",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04329325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Filgrastim + Fludarabine + Mycophenolate mofetil + Radiotherapy + Spanlecortemlocel + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03674411",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Omacetaxine mepesuccinate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02078960",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic stem cell transplantation + Bone marrow transplantation + Cyclophosphamide + Fludarabine + Melphalan + Mycophenolate mofetil + Natural killer cell immunotherapy + Peripheral blood stem cell transplantation  + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01904136",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Eicosapentaenoic acid + Tyrosine Kinase Inhibitor",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04006847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"bcr-abl peptide vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00428077",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bafetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00352677",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02422719",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Flumatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05071482",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT00261846",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fludarabine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy + Sirolimus + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00105001",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Flotetuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03739606",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"QS21 + bcr-abl peptide vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00004052",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fludarabine + Treosulfan + Umbilical cord blood transplant",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00796068",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cyclosporine + Double-unit umbilical cord blood transplantation + Fludarabine + Mycophenolate mofetil + Radiotherapy + Thiotepa + Umbilical cord blood transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00719888",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Melphalan + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03128359",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic NK cells + Cyclophosphamide + Filgrastim + Fludarabine + Melphalan + Mesna + Mycophenolate mofetil + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05115630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00811070",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BP1001 + Cytarabine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01159028",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02130557",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"XL228",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00464113",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04258943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03106779",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | blast phase chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Flumatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02511340",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Etoposide + Hematopoietic Stem Cell Transplant + Lorazepam + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00619879",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02445742",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03205267",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib + Tyrosine Kinase Inhibitor",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04216563",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PEG-interferon alfa-2a",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01392170",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04795427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01903733",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04925479",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"XL228",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00464113",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic stem cell transplantation + Cyclophosphamide + Cytarabine + Filgrastim + Fludarabine + Methotrexate + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00013533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PRI-724 ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01606579",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + EphB4-HSA Fusion Protein",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03519984",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05143840",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03128359",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Filgrastim + Fludarabine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01028716",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogeneic CMV-specific CTLs",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01475058",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Pioglitazone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02767063",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclosporine + Fludarabine + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy + Sirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01231412",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT1, BCR\/ABL PR1 peptide-loaded autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02543749",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Peginterferon alfa-2b",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03547154",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Realgar-Indigo naturalis formulation",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01755325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dactolisib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01756118",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Cyclosporine + Fludarabine + Melphalan + Mycophenolate mofetil + Peripheral blood stem cell transplantation + Thiotepa",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02707393",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Natural killer cell immunotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02185781",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02210858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Dexamethasone + Dexrazoxane + Leucovorin calcium + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03020030",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Epratuzumab-cys-tesirine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03698552",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Inotuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03610438",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03512405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olverembatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04260022",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD19 targeting CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05535855",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asparaginase + Autologous Hematopoietic Stem Cell Transplantation + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Mitoxantrone hydrochloride + Prednisone + Teniposide + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00526305",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01903733",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02000427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00560794",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bendamustine + Cyclophosphamide + Mycophenolate mofetil + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04943757",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Mercaptopurine + Methotrexate + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01190930",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic T cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Melphalan + Mercaptopurine + Methotrexate + Nelarabine + Pegaspargase + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01085617",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01139970",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Troxacitabine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00012259",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclophosphamide + Filgrastim + LN NEO virus transduced PBSCs + Peripheral blood stem cell transplantation + Radiotherapy + Recombinant interferon alpha-2a",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00005986",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Busulfan + Cyclosporine + Fludarabine + Methotrexate + Peripheral blood stem cell transplantation",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00027924",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05384587",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous bone marrow transplantation + Recombinant interferon alpha-2a + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00011934",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AT9283",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01431664",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic lymphocytes + Anti-thymocyte globulin + Busulfan + Cyclophosphamide + Filgrastim + Fludarabine + Methotrexate + Mycophenolate mofetil + Peripheral blood stem cell transplantation + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00295997",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclosporine + Fludarabine + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00075478",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02807883",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Filgrastim + Peripheral blood stem cell transplantation + Radiotherapy + Recombinant interferon alpha-2a",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00005984",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anti-thymocyte globulin + Cyclosporine + Fludarabine + Melphalan + Methylprednisolone acetate + Mycophenolate mofetil + Peripheral blood stem cell transplantation",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00008307",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogeneic hematopoietic stem cell transplantation + Cytarabine + Daunorubicin + Etoposide + Leucovorin calcium + Methotrexate + Prednisolone + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00618501",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cyclosporine + Filgrastim + Fludarabine + Mycophenolate mofetil + Radiotherapy + Umbilical cord blood transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00309842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib + Inotuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02311998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carmustine + Cyclophosphamide + Cytarabine + Dactinomycin + Mercaptopurine + Methotrexate + Mitoxantrone hydrochloride + Pegaspargase + Prednisone + Sargramostim + Vincristine sulphate + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00002766",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lonafarnib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00038597",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00261846",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04793399",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KDS-1001",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04808115",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02810990",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olverembatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04126681",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pioglitazone + Tyrosine Kinase Inhibitor",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02730195",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00022451",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panobinostat",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00451035",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Panobinostat",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00449761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Glasdegib + Ivosidenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04655391",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gilteritinib + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04655391",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enasidenib + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04655391",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALT-803 + Natural killer cell immunotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02890758",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Zileuton",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01130688",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HS-10382",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05367700",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04655391",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Olverembatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05376852",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tanespimycin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00100997",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Zileuton",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02047149",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HSP70",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00030303",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HSP70",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00027144",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Peginterferon alfa-2b",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00303290",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Irinotecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00053144",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Topotecan + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00217646",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Topotecan + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00217646",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bone marrow transplantation + Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02638467",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Filgrastim + Fludarabine + KDS-1001 + Melphalan + Mesna + Mycophenolate mofetil + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05115630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic T cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01139970",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Omacetaxine mepesuccinate",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asciminib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02081378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olverembatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04260022",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03128411",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01602952",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCR",
        "Genomic Position":"22:23522397-23660224(+) | 22q11.23",
        "CDS Mutation":null,
        "AA Mutation":"BCR-ABL_?:?_COSF1783",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bosutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02906696",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BAX",
        "Genomic Position":"19:49458186-49465055(+) | 19q13.33",
        "CDS Mutation":null,
        "AA Mutation":"BAX_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00378404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BAX",
        "Genomic Position":"19:49458186-49465055(+) | 19q13.33",
        "CDS Mutation":null,
        "AA Mutation":"BAX_unspecified",
        "Disease":"ovary | carcinoma | mixed carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bryostatin + Cisplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00006942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BAX",
        "Genomic Position":"19:49458186-49465055(+) | 19q13.33",
        "CDS Mutation":null,
        "AA Mutation":"BAX_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine + Paclitaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00176241",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND2",
        "Genomic Position":"12:4382938-4414516(+) | 12p13.32",
        "CDS Mutation":null,
        "AA Mutation":"CCND2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03310879",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND2",
        "Genomic Position":"12:4382938-4414516(+) | 12p13.32",
        "CDS Mutation":null,
        "AA Mutation":"CCND2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04594005",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD79A",
        "Genomic Position":"19:42381190-42385439(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"(CD79A_unspecified_or_CD79B_unspecified)_and_MYD88_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04994626",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD79A",
        "Genomic Position":"19:42381190-42385439(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"CD79A_unspecified_or_CD79B_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous bone marrow transplantation + Chemotherapy + Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02443077",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD79A",
        "Genomic Position":"19:42381190-42385439(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"(CD79A_unspecified_or_CD79B_unspecified)_and_MYD88_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acalabrutinib + Cyclophosphamide + Doxorubicin hydrochloride + Prednisone + Vincristine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04604067",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2C",
        "Genomic Position":"1:51426417-51440305(+) | 1p32.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2C_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | plasma cell myeloma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03732703",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2C",
        "Genomic Position":"1:51426417-51440305(+) | 1p32.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2C_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + LY3214996",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04391595",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2C",
        "Genomic Position":"1:51426417-51440305(+) | 1p32.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2C_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abiraterone acetate + Prednisone + TQB3616",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05156450",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EPCAM",
        "Genomic Position":"2:47596287-47614173(+) | 2p21",
        "CDS Mutation":null,
        "AA Mutation":"EPCAM_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KRAS peptide vaccine + poly ICLC",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05013216",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EPCAM",
        "Genomic Position":"2:47596287-47614173(+) | 2p21",
        "CDS Mutation":null,
        "AA Mutation":"EPCAM_unspecified_or_MLH1_unspecified_or_MSH2_unspecified_or_MSH6_unspecified_or_PMS2_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Aspirin + Atorvastatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04379999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.170T>G",
        "AA Mutation":"p.F57C",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24463458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.103G>A",
        "AA Mutation":"p.V35M",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.373T>A",
        "AA Mutation":"p.C125S",
        "Disease":"malignant_melanoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.374G>C",
        "AA Mutation":"p.C125S",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25452114",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.376A>G",
        "AA Mutation":"p.N126D",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.179A>C",
        "AA Mutation":"p.Q60P",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265154",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Q60P",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25705882",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.136C>T",
        "AA Mutation":"p.L46F",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24265153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V215E",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"PD0325901",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22402123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K2",
        "Genomic Position":"19:4090319-4124126(-) | 19p13.3",
        "CDS Mutation":"c.619G>A",
        "AA Mutation":"p.E207K",
        "Disease":"malignant_melanoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Dabrafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25452114",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"XRCC3",
        "Genomic Position":"14:104163955-104178441(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"XRCC3_unspecified",
        "Disease":"large intestine | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trifluridine and tipiracil hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04166604",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NBN",
        "Genomic Position":"8:90945564-90996944(-) | 8q21.3",
        "CDS Mutation":null,
        "AA Mutation":"NBN_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NBN",
        "Genomic Position":"8:90945564-90996944(-) | 8q21.3",
        "CDS Mutation":null,
        "AA Mutation":"NBN_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04336943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NBN",
        "Genomic Position":"8:90945564-90996944(-) | 8q21.3",
        "CDS Mutation":null,
        "AA Mutation":"NBN_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NBN",
        "Genomic Position":"8:90945564-90996944(-) | 8q21.3",
        "CDS Mutation":null,
        "AA Mutation":"NBN_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CARD11",
        "Genomic Position":"7:2945775-3083579(-) | 7p22.2",
        "CDS Mutation":null,
        "AA Mutation":"CARD11_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | diffuse large B cell lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous bone marrow transplantation + Chemotherapy + Ibrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02443077",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCNE1",
        "Genomic Position":"19:30302805-30315215(+) | 19q12",
        "CDS Mutation":null,
        "AA Mutation":"CCNE1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05252416",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCNE1",
        "Genomic Position":"19:30302805-30315215(+) | 19q12",
        "CDS Mutation":null,
        "AA Mutation":"CCNE1_unspecified_and_TP53_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azenosertib + Bevacizumab + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05431582",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCNE1",
        "Genomic Position":"19:30302805-30315215(+) | 19q12",
        "CDS Mutation":null,
        "AA Mutation":"CCNE1_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05252416",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCNE1",
        "Genomic Position":"19:30302805-30315215(+) | 19q12",
        "CDS Mutation":null,
        "AA Mutation":"CCNE1_unspecified",
        "Disease":"ovary | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05252416",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCNE1",
        "Genomic Position":"19:30302805-30315215(+) | 19q12",
        "CDS Mutation":null,
        "AA Mutation":"CCNE1_unspecified_and_TP53_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azenosertib + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05431582",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCNE1",
        "Genomic Position":"19:30302805-30315215(+) | 19q12",
        "CDS Mutation":null,
        "AA Mutation":"CCNE1_unspecified_or_FBXW7_unspecified_or_MYC_unspecified_or_RB1_unspecified_",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Prexasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02873975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCNE1",
        "Genomic Position":"19:30302805-30315215(+) | 19q12",
        "CDS Mutation":null,
        "AA Mutation":"CCNE1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"INX-315",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05735080",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCNE1",
        "Genomic Position":"19:30302805-30315215(+) | 19q12",
        "CDS Mutation":null,
        "AA Mutation":"CCNE1_unspecified",
        "Disease":"endometrium | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04393285",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCNE1",
        "Genomic Position":"19:30302805-30315215(+) | 19q12",
        "CDS Mutation":null,
        "AA Mutation":"CCNE1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCNE1",
        "Genomic Position":"19:30302805-30315215(+) | 19q12",
        "CDS Mutation":null,
        "AA Mutation":"CCNE1_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Prexasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02873975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BIRC3",
        "Genomic Position":"11:102188226-102208465(+) | 11q22.2",
        "CDS Mutation":null,
        "AA Mutation":"BIRC3_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02232386",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"LATS1",
        "Genomic Position":"6:149979289-150039392(-) | 6q25.1",
        "CDS Mutation":null,
        "AA Mutation":"LATS1_unspecified_or_LATS2_unspecified_or_NF2_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IAG933",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04857372",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NOTCH1",
        "Genomic Position":"9:139388896-139440314(-) | 9q34.3",
        "CDS Mutation":null,
        "AA Mutation":"NOTCH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Rituximab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02232386",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NOTCH1",
        "Genomic Position":"9:139388896-139440314(-) | 9q34.3",
        "CDS Mutation":null,
        "AA Mutation":"NOTCH1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acalabrutinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02337829",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NOTCH1",
        "Genomic Position":"9:139388896-139440314(-) | 9q34.3",
        "CDS Mutation":null,
        "AA Mutation":"NOTCH1_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ginsenoside Rg3 capsule + Pirarubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02724358",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NOTCH1",
        "Genomic Position":"9:139388896-139440314(-) | 9q34.3",
        "CDS Mutation":null,
        "AA Mutation":"NOTCH1_unspecified_or_NOTCH2_unspecified_or_NOTCH3_unspecified_or_NOTCH4_unspecified",
        "Disease":"salivary gland | carcinoma | adenoid cystic carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Osugacestat",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03691207",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NOTCH1",
        "Genomic Position":"9:139388896-139440314(-) | 9q34.3",
        "CDS Mutation":null,
        "AA Mutation":"NOTCH1_unspecified",
        "Disease":"upper aerodigestive tract | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bimiralisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03740100",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCC",
        "Genomic Position":"9:97861336-98079984(-) | 9q22.32",
        "CDS Mutation":null,
        "AA Mutation":"FANCC_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PMS1",
        "Genomic Position":"2:190649107-190742355(+) | 2q32.2",
        "CDS Mutation":null,
        "AA Mutation":"PMS1_unspecified",
        "Disease":"pancreas | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KRAS peptide vaccine + poly ICLC",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05013216",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PMS1",
        "Genomic Position":"2:190649107-190742355(+) | 2q32.2",
        "CDS Mutation":null,
        "AA Mutation":"PMS1_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04104893",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SRSF2",
        "Genomic Position":"17:74730197-74733415(-) | 17q25.2",
        "CDS Mutation":null,
        "AA Mutation":"SRSF2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myelomonocytic leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03722407",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TYRO3",
        "Genomic Position":"15:41851232-41871526(+) | 15q15.1",
        "CDS Mutation":null,
        "AA Mutation":"TYRO3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sapanisertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TYRO3",
        "Genomic Position":"15:41851232-41871526(+) | 15q15.1",
        "CDS Mutation":null,
        "AA Mutation":"TYRO3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04185831",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TYRO3",
        "Genomic Position":"15:41851232-41871526(+) | 15q15.1",
        "CDS Mutation":null,
        "AA Mutation":"TYRO3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02352844",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCM",
        "Genomic Position":"14:45605150-45670090(+) | 14q21.2",
        "CDS Mutation":null,
        "AA Mutation":"FANCM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCM",
        "Genomic Position":"14:45605150-45670090(+) | 14q21.2",
        "CDS Mutation":null,
        "AA Mutation":"FANCM_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ITK",
        "Genomic Position":"5:156607837-156682201(+) | 5q33.3",
        "CDS Mutation":null,
        "AA Mutation":"ITK-SYK_fusion",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | peripheral T cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cerdulatinib ",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04021082",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PLCG2",
        "Genomic Position":"16:81812863-81991899(+) | 16q24.1",
        "CDS Mutation":null,
        "AA Mutation":"PLCG2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02950220",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PLCG2",
        "Genomic Position":"16:81812863-81991899(+) | 16q24.1",
        "CDS Mutation":null,
        "AA Mutation":"PLCG2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + LY3214996",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04043845",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PLCG2",
        "Genomic Position":"16:81812863-81991899(+) | 16q24.1",
        "CDS Mutation":null,
        "AA Mutation":"PLCG2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ibrutinib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03128879",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PLCG2",
        "Genomic Position":"16:81812863-81991899(+) | 16q24.1",
        "CDS Mutation":null,
        "AA Mutation":"PLCG2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | chronic lymphocytic leukaemia-small lymphocytic lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acalabrutinib + Obinutuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04505254",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PLCG2",
        "Genomic Position":"16:81812863-81991899(+) | 16q24.1",
        "CDS Mutation":null,
        "AA Mutation":"PLCG2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | mantle cell lymphoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Acalabrutinib + CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn\/mem-enriched T-lymphocytes",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04484012",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NECTIN4",
        "Genomic Position":"1:161040785-161059389(-) | 1q23.3",
        "CDS Mutation":null,
        "AA Mutation":"NECTIN4_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enfortumab vedotin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05097599",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RECQL",
        "Genomic Position":"12:21621845-21654527(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"RECQL_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MTL-CEBPA",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04105335",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idarubicin + Pravastatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01831232",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00927498",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Omacetaxine mepesuccinate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04415008",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"liver | NS | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MTL-CEBPA",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02716012",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified_or_DNMT3A_unspecified_or_FLT3_unspecified_or_KMT2A_unspecified_or_NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Gemtuzumab Ozogamicin",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02473146",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idarubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01296178",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04051996",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Idarubicin + Lenalidomide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01132586",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01546038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified_or_FLT3_unspecified_or_KMT2A_unspecified_or_NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Clofarabine + Cytarabine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00932412",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CEBPA",
        "Genomic Position":"19:33790840-33793470(-) | 19q13.11",
        "CDS Mutation":null,
        "AA Mutation":"CEBPA_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Decitabine + Glasdegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02400281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"LAG3",
        "Genomic Position":"12:6881686-6887619(+) | 12p13.31",
        "CDS Mutation":null,
        "AA Mutation":"LAG3_unspecified",
        "Disease":"soft tissue | gastrointestinal stromal tumour | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Spartalizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03609424",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"LAG3",
        "Genomic Position":"12:6881686-6887619(+) | 12p13.31",
        "CDS Mutation":null,
        "AA Mutation":"LAG3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Relatimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02465060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FOLH1",
        "Genomic Position":"11:49168187-49230222(-) | 11p11.12",
        "CDS Mutation":null,
        "AA Mutation":"FOLH1_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Best supportive care + Lutetium Lu 177 vipivotide tetraxetan",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03511664",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABRAXAS1",
        "Genomic Position":"4:84382092-84406334(-) | 4q21.23",
        "CDS Mutation":null,
        "AA Mutation":"ABRAXAS1_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04336943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABRAXAS1",
        "Genomic Position":"4:84382092-84406334(-) | 4q21.23",
        "CDS Mutation":null,
        "AA Mutation":"ABRAXAS1_unspecified_or_ATM_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_CHEK2_unspecified_or_GEN1_unspecified_or_MRE11A_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04336943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ABRAXAS1",
        "Genomic Position":"4:84382092-84406334(-) | 4q21.23",
        "CDS Mutation":null,
        "AA Mutation":"ABRAXAS1_unspecified_or_ARID1A_unspecified_or_ATM_unspecified_or_ATR_unspecified_or_ATRX_unspecified_or_BRIP1_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_BLM_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_CDK2_unspecified_or_CDK4_unspecified_or_ERCC_unspecified_or_FEN1_unspecified_or_IDH1_unspecified_or_IDH2_unspecified_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_POLD1_unspecified_or_PRKDC_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51_unspecified_or_RAD52_unspecified_or_RPA1_unspecified_or_SLX4_unspecified_or_WRN_unspecified_or_XRCC_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03207347",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51C",
        "Genomic Position":"17:56769934-56811703(+) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RAD51C_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51C",
        "Genomic Position":"17:56769934-56811703(+) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RAD51C_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04336943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51C",
        "Genomic Position":"17:56769934-56811703(+) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RAD51C_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03718091",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51C",
        "Genomic Position":"17:56769934-56811703(+) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RAD51C_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51C",
        "Genomic Position":"17:56769934-56811703(+) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RAD51C_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Berzosertib + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04826341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51C",
        "Genomic Position":"17:56769934-56811703(+) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RAD51C_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51C",
        "Genomic Position":"17:56769934-56811703(+) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RAD51C_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GLI1",
        "Genomic Position":"12:57853921-57866045(+) | 12q13.3",
        "CDS Mutation":null,
        "AA Mutation":"GLI1_unspecified_or_GLI2_unspecified_or_PTCH1_unspecified_or_SMO_unspecified_or_SUFU_unspecified___",
        "Disease":"skin | carcinoma | basal cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Buparlisib + Sonidegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02303041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2D",
        "Genomic Position":"12:49412758-49449107(-) | 12q13.12",
        "CDS Mutation":null,
        "AA Mutation":"KMT2D_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | peripheral T cell lymphoma unspecified",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Doxorubicin hydrochloride + Prednisone + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04480099",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCORL1",
        "Genomic Position":"X:129139164-129192058(+) | Xq26.1",
        "CDS Mutation":null,
        "AA Mutation":"BCORL1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gilteritinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03013998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ETV6",
        "Genomic Position":"12:11802788-12048336(+) | 12p13.2",
        "CDS Mutation":null,
        "AA Mutation":"ETV6_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":0,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02159040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ETV6",
        "Genomic Position":"12:11802788-12048336(+) | 12p13.2",
        "CDS Mutation":null,
        "AA Mutation":"ETV6_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":0,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Deferasirox",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02159040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ETV6",
        "Genomic Position":"12:11802788-12048336(+) | 12p13.2",
        "CDS Mutation":null,
        "AA Mutation":"ETV6-PDGFRB_fusion",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | myelodysplastic syndrome",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00276926",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ETV6",
        "Genomic Position":"12:11802788-12048336(+) | 12p13.2",
        "CDS Mutation":null,
        "AA Mutation":"ETV6_unspecified_or_NTRK1_unspecified_or_NTRK2_unspecified_or_NTRK3_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02637687",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ETV6",
        "Genomic Position":"12:11802788-12048336(+) | 12p13.2",
        "CDS Mutation":null,
        "AA Mutation":"ETV6-NTRK3_fusion",
        "Disease":"salivary gland | carcinoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"t(v;11q23.3)_(KMT2A)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Sorafenib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04752527",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Venetoclax + Ziftomenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05735184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + DS-1594b + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04752163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + DS-1594b + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04752163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)_or_NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + JNJ-75276617 + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05453903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)_or_NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"JNJ-75276617 + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05453903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_MLLT3_fusion_(MLL_AF9_fusion)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02450877",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)_or_NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + JNJ-75276617",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05521087",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CD19 targeting CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04276870",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pinometostat",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01684150",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Filgrastim + Fludarabine + KDS-1001 + Melphalan + Mesna + Mycophenolate mofetil + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05115630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_MLLT3_fusion_(MLL_AF9_fusion)",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03709719",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic B cell leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab + Hematopoietic Stem Cell Transplant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05029531",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asparaginase + Busulfan + Cyclophosphamide + Cytarabine + Gemtuzumab Ozogamicin + Mitoxantrone hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01407757",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entospletinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03013998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Pinometostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03724084",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Asparaginase + Cytarabine + Daunorubicin + Etoposide + Gemtuzumab Ozogamicin + Mitoxantrone hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00372593",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)_or_NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Daunorubicin + Etoposide + Pegaspargase + Prednisone + Revumenib + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05326516",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)_or_NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Fludarabine + Revumenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05326516",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin hydrochloride + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03020030",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pinometostat",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02141828",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Daunorubicin + Ziftomenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05735184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Lestaurtinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00557193",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DS-1594b + Mini-HCVD",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04752163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | acute lymphoblastic leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Leucovorin calcium + Mercaptopurine + Methotrexate + Pegaspargase + Prednisolone + Thioguanine + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02828358",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DS-1594b",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04752163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)_or_NPM1_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + JNJ-75276617",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05453903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Entospletinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03013998",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"KO 539",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04067336",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Allogenic NK cells + Cyclophosphamide + Filgrastim + Fludarabine + Melphalan + Mesna + Mycophenolate mofetil + Radiotherapy + Tacrolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05115630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02768792",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Blinatumomab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05327894",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute myeloid leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine + Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03513484",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cytarabine + Hydrocortisone sodium succinate + Revumenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05761171",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Antifungals + DSP-5336",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04988555",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"JNJ-75276617",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04811560",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pinometostat",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02141828",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Revumenib",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT04065399",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KMT2A",
        "Genomic Position":"11:118307205-118397539(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"KMT2A_unspecified_(MLL_unspecified)",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | acute leukaemia",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Calaspargase pegol-mknl + Cytarabine + Fludarabine + Hydrocortisone sodium succinate + Methotrexate + Pegaspargase + Prednisolone + Prednisone + Revumenib + Vincristine sulphate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05761171",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WRN",
        "Genomic Position":"8:30891317-31031285(+) | 8p12",
        "CDS Mutation":null,
        "AA Mutation":"WRN_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WRN",
        "Genomic Position":"8:30891317-31031285(+) | 8p12",
        "CDS Mutation":null,
        "AA Mutation":"WRN_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CUE-102",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05360680",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WRN",
        "Genomic Position":"8:30891317-31031285(+) | 8p12",
        "CDS Mutation":null,
        "AA Mutation":"WRN_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT4",
        "Genomic Position":"5:180028506-180076624(-) | 5q35.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT4_unspecified_(VEGFR3_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT4",
        "Genomic Position":"5:180028506-180076624(-) | 5q35.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT4_unspecified_(VEGFR3_unspecified)",
        "Disease":"central nervous system | glioma | astrocytoma Grade IV",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04004975",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT4",
        "Genomic Position":"5:180028506-180076624(-) | 5q35.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT4_unspecified_(VEGFR3_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RPA1",
        "Genomic Position":"17:1733278-1802848(+) | 17p13.3",
        "CDS Mutation":null,
        "AA Mutation":"RPA1_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"GEN1",
        "Genomic Position":"2:17935414-17966632(+) | 2p24.2",
        "CDS Mutation":null,
        "AA Mutation":"GEN1_unspecified",
        "Disease":"prostate | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04336943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BLM",
        "Genomic Position":"15:91260558-91358692(+) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"BLM_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BLM",
        "Genomic Position":"15:91260558-91358692(+) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"BLM_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DHH",
        "Genomic Position":"12:49483204-49488602(-) | 12q13.12",
        "CDS Mutation":null,
        "AA Mutation":"DHH_unspecified_or_IHH_unspecified_or_SHH_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05159245",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RECQL4",
        "Genomic Position":"8:145736667-145743210(-) | 8q24.3",
        "CDS Mutation":null,
        "AA Mutation":"RECQL4_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCG",
        "Genomic Position":"9:35073835-35080013(-) | 9p13.3",
        "CDS Mutation":null,
        "AA Mutation":"FANCG_unspecified",
        "Disease":"NS | other | neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04985721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FOXL2",
        "Genomic Position":"3:138663066-138665982(-) | 3q22.3",
        "CDS Mutation":null,
        "AA Mutation":"FOXL2_C134W",
        "Disease":"ovary | sex cord-stromal tumour | granulosa cell tumour",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ketoconazole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01584297",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ZRSR2",
        "Genomic Position":"X:15808595-15841383(+) | Xp22.2",
        "CDS Mutation":null,
        "AA Mutation":"ZRSR2_unspecified",
        "Disease":"haematopoietic and lymphoid tissue | haematopoietic neoplasm | chronic myeloid leukaemia",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Imatinib + Nilotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04147533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SLFN11",
        "Genomic Position":"17:33677324-33700639(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"SLFN11_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KEAP1",
        "Genomic Position":"19:10596796-10614417(-) | 19p13.2",
        "CDS Mutation":null,
        "AA Mutation":"KEAP1_unspecified",
        "Disease":"NS | neoplasm | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Telaglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03872427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KEAP1",
        "Genomic Position":"19:10596796-10614417(-) | 19p13.2",
        "CDS Mutation":null,
        "AA Mutation":"KEAP1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed + Telaglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04265534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KEAP1",
        "Genomic Position":"19:10596796-10614417(-) | 19p13.2",
        "CDS Mutation":null,
        "AA Mutation":"KEAP1_unspecified_or_STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KEAP1",
        "Genomic Position":"19:10596796-10614417(-) | 19p13.2",
        "CDS Mutation":null,
        "AA Mutation":"KEAP1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sirpiglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04471415",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SIGLEC1",
        "Genomic Position":"20:3667617-3687775(-) | 20p13",
        "CDS Mutation":null,
        "AA Mutation":"SIGLEC1_unspecified",
        "Disease":"soft tissue | gastrointestinal stromal tumour | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Imatinib + Spartalizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03609424",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TFE3",
        "Genomic Position":"X:48886242-48901012(-) | Xp11.23",
        "CDS Mutation":null,
        "AA Mutation":"TFE3_unspecified",
        "Disease":"soft tissue | alveolar soft part sarcoma | NS",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01524926",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CNNM2",
        "Genomic Position":"10:104678050-104849978(+) | 10q24.32",
        "CDS Mutation":"c.*12611G>A",
        "AA Mutation":"p.?",
        "Disease":"lymphoid_neoplasm",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Purine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23377281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AC058822.1",
        "Genomic Position":" | ",
        "CDS Mutation":"c.1805A>T",
        "AA Mutation":"p.D602V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15685537",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AC058822.1",
        "Genomic Position":" | ",
        "CDS Mutation":"c.1805A>T",
        "AA Mutation":"p.D602V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20568982",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AC058822.1",
        "Genomic Position":" | ",
        "CDS Mutation":"c.1805A>T",
        "AA Mutation":"p.D602V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28768491",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AC058822.1",
        "Genomic Position":" | ",
        "CDS Mutation":"c.1805A>T",
        "AA Mutation":"p.D602V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:14645423",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AC058822.1",
        "Genomic Position":" | ",
        "CDS Mutation":"c.1805A>T",
        "AA Mutation":"p.D602V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Imatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:12949711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AC058822.1",
        "Genomic Position":" | ",
        "CDS Mutation":"c.1805A>T",
        "AA Mutation":"p.D602V",
        "Disease":"gastrointestinal_stromal_tumour",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Crenolanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28768491",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"LRP1B",
        "Genomic Position":"2:140988992-142889270(-) | 2q22.1-q22.2",
        "CDS Mutation":"c.3561T>G",
        "AA Mutation":"p.C1187W",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30848481",
        "source_db":"COSMIC"
    }
]